organophosphonates has been researched along with HIV Coinfection in 1594 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 47 (2.95) | 18.2507 |
| 2000's | 688 (43.16) | 29.6817 |
| 2010's | 851 (53.39) | 24.3611 |
| 2020's | 8 (0.50) | 2.80 |
| Authors | Studies |
|---|---|
| Kent, KM; Oliyai, R; Yang, T | 1 |
| Choudhary, MC; Mellors, JW | 1 |
| Alfaro, EM; Arazo, P; Arellano, JP; Arribas, JR; Bachiller, P; Buzón, L; Del Amo, J; Díaz de Santiago, A; Díaz-Brito, V; García Del Toro, M; García-Albéniz, X; Garcinuño, MA; Gómez-Sirvent, JL; Guerra, JM; Hernán, MA; Hernández-Torres, A; Hita, C; Martínez de Salazar, P; Masiá, M; Morales, M; Moreno, S; Muñoz, L; Polo, R; Rial-Crestelo, D; Santos, J; Sanz, J; Terán, C | 1 |
| De Clercq, E | 7 |
| Abbara, A; Armstrong-James, D; Awad, Z; Campbell, V; Chand, M; Chiu, C; Cooke, G; Davies, C; Davies, EP; Davies, F; Dhanji, S; ElHaddad, A; Gilchrist, M; Gómez, CHM; Kumar, V; Mora-Peris, B; Muir, D; Osman, S; Peters, J; Rampling, T; Randell, P; Rimmer, S; Smart, C; Stafford, A; Sun, K; Swaine, T; Waddington, CS; Warrell, CE | 1 |
| Baeten, JM; Bekker, LG; Cohen, MS; Corey, L; Delany-Moretlwe, S; Donnell, D; Edupuganti, S; Gao, F; Gray, G; Hanscom, B; Hosseinipour, M; Hughes, JP; Mgodi, N; Rees, H | 1 |
| Geant, PY; Mathé, C; Périgaud, C; Uttaro, JP | 1 |
| Asmuth, DM; Baeten, JM; Brainard, DM; Brunetta, JM; Carter, C; Cox, S; Das, M; Ebrahimi, R; Gilson, R; Henry, K; Kintu, A; Kronborg, G; Ogbuagu, O; Podzamczer, D; Ruane, PJ; Salazar, LC; Shao, Y; Spinner, CD; Whitlock, G; Wohl, D | 1 |
| Castagna, A; Chiappetta, S; Galli, L; Lazzarin, A; Nozza, S; Poli, A; Ripa, M; Rovelli, C; Spagnuolo, V; Tambussi, G | 1 |
| Boffito, M; Lamorde, M; Pozniak, A; Watkins, M | 1 |
| Donahue Carlson, R; Frisch, MB; Haaland, RE; Kraft, CS; Martin, A; Mehta, CC; Ofotokun, I; Patel, AS; Pau, CP; Read, TD; Sheth, AN | 1 |
| Bensouda, S; Cone, RA; Date, AA; Ensign, LM; Fuchs, EJ; Gumber, S; Hanes, J; Hendrix, C; Hoang, T; Marzinke, M; Ortiz, JO; Rohan, L; Villinger, F; Xiao, P; Young, TW | 1 |
| Naing, C; Poovorawan, Y; Tong, KS | 1 |
| DeJesus, E; DiNubile, MJ; Leavitt, R; Lennox, JL; Miller, M; Nguyen, BY; Rockstroh, JK; Rodgers, AJ; Saag, MS; Sklar, P; Teppler, H; Walker, ML; Wan, H; Yazdanpanah, Y | 1 |
| Adams, JL; Corbett, AH; Dumond, JB; Forrest, A; Jennings, SH; Kashuba, AD; Kendrick, RL; Malone, S; Patterson, KB; Prince, HM; Sykes, C; Wang, R; White, N | 1 |
| Bayonne Kombo, ES; Gathse, A | 1 |
| Brady, JJ; Brinkman, K; Cotter, AG; Furrer, H; Fux, CA; Mallon, PW; Reiss, P; Sabin, CA; Vrouenraets, SM; Wit, FW | 1 |
| Plosker, GL | 1 |
| Barrail-Tran, A; Descamps, D; Duval, X; Goujard, C; Mentré, F; Nembot, G; Panhard, X; Parienti, JJ; Taburet, AM; Vigan, M; Vrijens, B | 1 |
| Ackers, ML; Buchbinder, SP; Chillag, KL; Collins, BM; Grant, RM; Grohskopf, LA; Gvetadze, R; Liu, AY; Mayer, KH; Oʼhara, B; Pathak, SR; Paxton, LA; Rose, CE; Thompson, M | 1 |
| Gatanaga, H; Kikuchi, Y; Komatsu, H; Nishijima, T; Oka, S; Shimbo, T; Takano, M; Tanuma, J; Teruya, K; Tsukada, K | 1 |
| Bangsberg, DR; Karim, QA; Mansoor, LE; Matthews, LT; Sibeko, S; Yende-Zuma, N | 1 |
| Abdool Karim, Q; Abdool Karim, SS; Altfeld, M; Carr, WH; Douek, DC; Naranbhai, V; Ndungʼu, T; Roque, A; Samsunder, N; Sandler, NG | 1 |
| Ackers, M; Buchbinder, SP; Chillag, K; Colfax, G; Collins, B; Grohskopf, L; Gvetadze, R; Liu, AY; Mayer, K; Oʼhara, B; Pathak, S; Paxton, L; Thompson, M; Vittinghoff, E | 1 |
| Gatanaga, H; Hayashida, T; Oka, S; Tanuma, J | 1 |
| de la Torre, J; del Arco, A; Olalla, J; Pombo, M; Prada, JL; Urdiales, D | 1 |
| Baeten, JM; Grant, R | 1 |
| Broderick, E; Hotta, MT; Wyatt, CM | 1 |
| Baltussen, R; Boucher, CA; Nichols, BE; Nouwen, JL; Sloot, PM; Thuma, PE; van de Vijver, DA; van de Wijgert, J; van Dijk, JH | 1 |
| Chateau, ML; Denton, PW; Garcia, JV; McGowan, I; Swanson, MD | 1 |
| Cahn, P; Sued, O | 1 |
| Andrade-Villanueva, J; Antunes, F; Arastéh, K; Callebaut, C; Cheng, AK; Chetchotisakd, P; DeJesus, E; Fehr, J; Gallant, JE; Koenig, E; Liu, Y; Moyle, G; Rhee, MS; Rizzardini, G; Szwarcberg, J; Zhong, L | 1 |
| Endo, T; Fujii, T; Gatanaga, H; Higasa, S; Horiba, M; Ishisaka, M; Kaneda, S; Kikuchi, Y; Koibuchi, T; Komatsu, H; Matsushita, S; Mitsuya, H; Naito, T; Nishijima, T; Oka, S; Tachikawa, N; Takada, K; Takano, M; Tanabe, Y; Tateyama, M; Uchiumi, H; Ueda, M; Yamamoto, M; Yokomaku, Y; Yoshida, M | 1 |
| Choo, HW; Davis, J; Fang, J; Hansson, AG; Langdon, G; Layton, G; Tawadrous, M; Vourvahis, M | 1 |
| Andrew, P; Ayudhya, RK; Carballo-Dieguez, A; Cranston, RD; Dai, JY; Hladik, F; Hoesley, C; Janocko, L; Mayer, K; McGowan, I; Piper, J | 1 |
| Arnett, DK; Bagchi, S; Chi, BH; Heimburger, DC; Kabagambe, EK; Kiage, JN; Koethe, JR; Nyirenda, CK; Wellons, MF | 1 |
| Angeletti, C; Antonucci, G; Armignacco, O; Cassola, G; De Stefano, G; Girardi, E; Grossi, P; Mazzotta, F; Orani, A; Pagano, G; Petrosillo, N; Puoti, M; Sagnelli, C; Sagnelli, E | 1 |
| Andrasik, M; Broder, G; Fuchs, JD; Grove, D; Hammer, S; Karuna, ST; Koblin, B; Madenwald, T; Mayer, K; Sherwat, A; Sobieszczyk, ME | 1 |
| Ball, C; Chaowanachan, T; Krogstad, E; Woodrow, KA | 1 |
| Bedogni, G; Cococcioni, L; Fabiano, V; Giacomet, V; Mora, S; Stucchi, S; Viganò, A; Zuccotti, GV | 1 |
| Anglaret, X; Bohoussou, F; Carrou, JL; Danel, C; Eholie, SP; Gabillard, D; Konan, R; Moh, R; Ouattara, E; Peytavin, G | 1 |
| Aguilar, A; De La Torre, J; Del Arco, A; García-Alegría, J; Olalla, J; Pombo, M; Prada, JL; Ruiz-Mateas, F; Urdiales, D | 1 |
| Antinori, A; Bansi, L; Boumis, E; Callegaro, A; Ceccherini-Silberstein, F; Dunn, D; Fearnhill, E; Forbici, F; Francisci, D; Maggiolo, F; Mussini, C; Nicastri, E; Palamara, G; Perno, CF; Sabin, C; Santoro, MM; Zazzi, M; Zoncada, A | 1 |
| Aguilera, A; Barreiro, P; del Romero, J; Mena, A; Pedreira, J; Plaza, Z; Poveda, E; Rodriguez, C; Sierra-Enguita, R; Soriano, V; Tomé, S; Vispo, E | 1 |
| Mayer, KH; Morrow, KM; Operario, D; Underhill, K | 1 |
| Brache, V; Callahan, M; Cochon, L; Cohen, JA; Foster, J; Schwartz, J | 1 |
| Albert, J; Brun-Vezinet, F; Gatell, JM; Gupta, RK; Nachega, JB; Sönnerborg, A; Wainberg, MA | 1 |
| Aghokeng, A; Belec, L; Bertagnolio, S; Bunupuradah, T; Burda, S; Cane, P; Cappelli, G; Charpentier, C; Dagnra, AY; de Wit, TF; Deshpande, AK; El-Katib, Z; Eshleman, SH; Fleury, HJ; Fokam, J; Ford, N; Gody, JC; Hamers, RL; Hawkins, CA; Holmes, S; Hosseinipour, MC; Jordan, MR; Kanki, PJ; Katzenstein, D; Koyalta, DD; Kumwenda, JJ; Lallemant, M; Lynen, L; Manosuthi, W; Marconi, VC; Margot, NA; Moussa, S; Ndung'u, T; Ngo-Giang-Huong, N; Nyambi, PN; Orrell, C; Peeters, M; Rhee, SY; Ruxrungtham, K; Schapiro, JM; Schuurman, R; Shafer, RW; Sigaloff, KC; Sirivichayakul, S; Smith, D; Stevens, W; Tang, MW; van Zyl, GU; Wallis, CL; Zolfo, M | 1 |
| Charalambous, S; Churchyard, GJ; Grant, AD; Hoffmann, CJ; Lewis, JJ; Velen, K | 1 |
| Kanjanabuch, T; Suankratay, C; Woratanarat, K | 1 |
| Funk, EK; Heytens, L; Kohli, A; Kottilil, S; Kwan, R; Masur, H; Nelson, A; Polis, MA; Shaffer, A; Shivakumar, B; Sneller, M | 1 |
| Baldelli, F; Belfiori, B; Bonora, S; Conti, V; Falcinelli, E; Francisci, D; Giannini, S; Gresele, P; Guglielmini, G; Malincarne, L; Mezzasoma, A; Petito, E; Sebastiano, M | 1 |
| Bekker, LG; Kaplan, R; Lawn, SD; Njuguna, C; Orrell, C; Wood, R | 1 |
| Dodds, S; Lange, MM; Rogers, W | 1 |
| Abgrall, S; Antinori, A; Cavassini, M; Costagliola, D; Crane, HM; Gill, MJ; Gomez Sirvent, JL; Guest, JL; Ingle, SM; Manzardo, C; May, MT; Mercie, P; Mugavero, MJ; Phillips, A; Reekie, J; Reiss, P; Saag, MS; Samji, H; Stephan, C; Sterling, TR; Sterne, JA; Tate, J; Wasmuth, JC | 1 |
| Gatanaga, H; Kikuchi, Y; Komatsu, H; Nishijima, T; Oka, S; Tanuma, J; Teruya, K; Tsukada, K | 1 |
| Folayan, MO; Haire, B; Hankins, C; McCormack, S; Ramjee, G; Sugarman, J; Warren, M | 1 |
| Fowler, S; Senn, H; Sharma, M; Tan, DH; Wilton, J | 1 |
| Arends, JE; Feuth, T; Hoepelman, AI; van Baarle, D | 1 |
| Casado, JL; Del Palacio, M; Moreno, A; Moreno, S; Safont, P; Wikman, P | 1 |
| Chaisson, RE; Charalambous, S; Churchyard, GJ; Fielding, KL; Grant, AD; Hoffmann, CJ; Hunt, G; Johnson, JA; Johnston, V; Ledwaba, J; Li, JF; Morris, L | 1 |
| Baeten, JM; Haberer, JE; Liu, AY; Sista, N | 1 |
| Chen, YQ; Donnell, D; Fleming, TR; Hughes, JP; Wang, L | 1 |
| Mayer, KH; Sugarman, J | 1 |
| Baxter, C; Karim, QA; Karim, SA | 2 |
| Karim, SS | 1 |
| Chiamwongpaet, S; Choopanya, K; Chuachoowong, R; Curlin, ME; Gvetadze, RJ; Hendrix, CW; Kitisin, P; Kittimunkong, S; Leethochawalit, M; Martin, M; McNicholl, JM; Mock, PA; Natrujirote, P; Paxton, LA; Sangkum, U; Suntharasamai, P; Vanichseni, S | 1 |
| Asselineau, J; Bonnet, F; Chêne, G; Dauchy, FA; Déti, E; Duffau, P; Gerard, Y; Lazaro, E; Morlat, P; Neau, D; Vandenhende, MA; Vivot, A | 1 |
| Belavic, JM | 1 |
| Puthanakit, T; Siberry, GK | 1 |
| Mendes-Correa, MC; Núñez, M | 1 |
| Ciarrocca, K; De Rossi, SS; Jackson, LL | 1 |
| Acosta, EP; Andrade, A; Campbell, T; Cillo, AR; Daar, ES; Feinberg, J; Flexner, C; Jacobson, JM; Kuritzkes, DR; Lederman, M; Lu, D; Mellors, JW; Rosenkranz, SL | 1 |
| Berger, D; Bredeek, UF; Callebaut, C; DeJesus, E; Fordyce, MW; Markowitz, M; Ramanathan, S; Rhee, MS; Ruane, PJ; Yale, K; Zhong, L | 1 |
| Cao, Y; Cui, Q; Han, Y; Li, T; Li, Y; Song, X; Xie, J; Zhang, L; Zhu, T | 1 |
| Allavena, C; Bach-Ngohou, K; Billaud, E; Dejoie, T; Fakhouri, F; Raffi, F; Reliquet, V; Sécher, S | 1 |
| Boot, J; Boucher, CA; Burger, DM; Fanoy, EB; Op de Coul, EL; Rump, BO; van Agtmael, MA; van de Vijver, DA | 1 |
| Boeke, AJ; Heijnen, AM | 1 |
| Hsu, P; Lucey, JM; Ziegler, JB | 1 |
| Hassoun, G; Kedem, E; Mugrabi, F; Pollack, S; Shahar, E | 1 |
| Benko, E; Blazkova, J; Casazza, JP; Chun, TW; Costiniuk, CT; Fauci, AS; Hallahan, CW; Kandel, G; Kaul, R; Kim, CJ; Koup, RA; Kovacs, C; Moir, S; Murray, D; Ostrowski, M; Shawn Justement, J | 1 |
| Gormley, RH; Kovarik, CL; Rosenbach, M; Wanat, KA | 1 |
| Foisy, MM; Hills-Nieminen, C; Hughes, C; Joffe, AM; Singh, AE | 1 |
| Bani-Sadr, F; de Vries-Sluijs, T; Dunn, D; Gilson, R; Jain, MK; Kuzushita, N; Mauss, S; Nüesch, R; Núñez, M; Peters, M; Pillay, D; Price, H; Reiberger, T; Stephan, C; Tan, L | 1 |
| Schrier, PB; Shah, HH; Spiegel, LR | 1 |
| Cauda, R; Digiambenedetto, S; Fabbiani, M; Fortuna, S; Lisi, L; Navarra, P; Ragazzoni, E | 1 |
| Botes, ME; Hamers, RL; Hoepelman, AI; Ive, P; Rinke de Wit, TF; Sigaloff, KC; Siwale, M; Stevens, WS; Wallis, CL; Zaaijer, HL | 1 |
| Arribas, JR; Compston, J; Domingo, P; Gartland, M; Granier, C; Moyle, GJ; Orkin, C; Pearce, H; Sedani, S; Stellbrink, HJ | 1 |
| Coombes, AG; Dang, NT; Harrich, D; Sivakumaran, H | 1 |
| Barreiro, P; Poveda, E; Soriano, V; Vispo, E | 1 |
| Bailly, F; Brochier, C; Cotte, L; Le Pogam, MA; Maynard, M; Miailhes, P; Okon, JB; Pradat, P; Trolliet, P; Zoulim, F | 1 |
| Badiou, S; Chatron, M; Cournil, A; Cristol, JP; Guiller, E; Peyriere, H; Psomas, C; Reynes, J | 1 |
| Echenique, IA; Rich, JD | 1 |
| Abbas, UL; Boucher, CA; Cambiano, V; Eaton, JW; Glaubius, R; Hallett, TB; Lythgoe, K; Mellors, J; Nichols, BE; Phillips, A; Sigaloff, KC; van de Vijver, DA | 1 |
| Saguil, A | 1 |
| Berhanu, R; Fox, MP; Long, L; Maskew, M; Sanne, I; Shearer, K | 1 |
| Feucht, N; Hadeler, J; Lanzl, I; Loos, D; Schmid, RM; Schwerdtfeger, C; Spinner, CD | 1 |
| Endo, T; Fujii, T; Gatanaga, H; Horiba, M; Itoda, I; Koga, M; Komatsu, H; Mitsuya, H; Miyakawa, T; Naito, T; Nishijima, T; Oka, S; Shimbo, T; Takada, K; Tanabe, Y; Tei, M; Yamamoto, M | 1 |
| Ahmed-Jushuf, I; Arumainayagam, J; Carlin, EM; Chandramani, S; Das, S; Ghanem, M; Kumari, B; Pammi, M; Riddell, L | 1 |
| Gulholm, T; Jamani, S; Poynten, IM; Templeton, DJ | 1 |
| Bertz, R; Bifano, M; Grasela, D; Hartstra, J; Hwang, C; Kandoussi, H; Oosterhuis, B; Sevinsky, H; Tiessen, R; Velinova-Donga, M | 1 |
| Benalycherif, A; Charpentier, C; Delaporte, E; Diallo, MB; Eymard-Duvernay, S; Girard, PM; Guèye, NF; Koulla-Shiro, S; Landman, R; Le Moing, V; Ngolle, M; Peytavin, G; Sow, PS | 1 |
| Dorrell, L; Duncan, S; Sherrard, J; Shine, B; Wainwright, E | 1 |
| Boyd, A; Brichler, S; Chevallier-Queyron, P; Delaugerre, C; Girard, PM; Gordien, E; Lacombe, K; Maylin, S; Miailhes, P; Scholtès, C | 1 |
| Feldt-Rasmussen, B; Gerstoft, J; Helleberg, M; Kronborg, G; Larsen, CS; Obel, N; Pedersen, C; Pedersen, G; Rasch, MG | 1 |
| Emel, L; Eshleman, SH; Fowler, MG; George, K; Herron, C; Hudelson, SE; Joao, E; Kearney, B; Kreitchmann, R; Kumwenda, N; Mirochnick, M; Mofenson, L; Nielsen-Saines, K; Parsons, T; Pinto, J; Richardson, P; Santos, B; Sato, P; Taha, T | 1 |
| Amann, K; Bickel, M; Brodt, HR; Buettner, M; Geiger, H; Gute, P; Haberl, A; Jung, O; Khaykin, P; Lutz, T; Schmidt, K; Stephan, C | 1 |
| Rosenberg, K | 1 |
| Arnoczy, G; Campbell, T; Fichtenbaum, CJ; Ha, B; Hicks, C; Koletar, S; Massengale, K; McComsey, GA; Sax, P; Stein, JH; Taiwo, B; Tebas, P; Walsh, K; Wohl, DA | 1 |
| Baker, A; Bethel, J; Flynn, PM; Gordon, CM; Havens, PL; Hazra, R; Kapogiannis, BG; Kiser, JJ; Liu, N; Lujan-Zilbermann, J; Mulligan, K; Pan, CG; Rutledge, B; Stephensen, CB; Van Loan, MD; Wilson, CM; Woodhouse, LR | 2 |
| Carr, A; Ingersoll, A; McAllister, J; McNulty, A; Read, P; Tong, WW | 1 |
| Bonadies, G; Borgia, G; Borrelli, F; Buonomo, AR; Carleo, MA; Gentile, I; Portella, G | 1 |
| Yongfeng, Y; Zhiliang, H | 1 |
| Cole, SR; Hudgens, MG | 1 |
| Hoffman, IF; Latkin, CA; Miller, WC; Shoptaw, S; Strathdee, SA | 1 |
| Craig, AP; Gray, R; Jansson, J; Wilson, DP | 1 |
| Choopanya, K; Martin, M; Mock, PA; Sangkum, U; Suntharasamai, P; Vanichseni, S | 1 |
| Brockman, MA; Brumme, ZL; Chopera, DR; Goodier, S; Karim, QA; Karim, SA; Kuang, XT; Mann, JK; Martin, E; Mwimanzi, P; Naranbhai, V; Ndabambi, N; Ndung'u, T; Omarjee, S; Williamson, C | 1 |
| Arai, M; Satoh, M; Tanaka, H; Tomoda, Y; Wada, T; Yago, K | 1 |
| Assoumou, L; Bentata, M; Costagliola, D; Katlama, C; Kolta, S; Roux, C; Rozenberg, S; Simon, A; Viard, JP | 1 |
| Gao, Y; Katz, DF | 1 |
| Aldir, I; Horta, A; Serrado, M | 1 |
| Bender, BS | 1 |
| Bulterys, M; Ellington, S; Kourtis, AP; Legardy-Williams, J; Wang, L | 1 |
| Churchill, DR; Fitzgerald, N; Gilleece, Y; Hughes, DJ; Konig, M; Moore-Moffatt, R; Sran, H; Webb, A | 1 |
| Bansi-Matharu, L; Bibby, D; Bulteel, N; Churchill, D; Dunn, D; Hill, T; Nelson, M; Sabin, C | 1 |
| Baeten, JM; Bangsberg, DR; Campbell, J; Celum, C; Donnell, D; Haberer, JE; Katabira, E; Kidoguchi, L; Krows, M; Psaros, C; Ronald, A; Safren, SA; Thomas, KK; Tumwesigye, E; Wangisi, J; Ware, NC | 1 |
| Danjuma, MI; Khoo, S; Mohamad-Fadzillah, NH | 1 |
| Cattaneo, D; Clementi, E; Giacomet, V; Manfredini, V; Nannini, P; Ramponi, G; Viganò, A; Zuccotti, GV | 1 |
| Albrecht, H; Almond, S; Baril, JG; Belonosova, E; Brennan, C; Domingo, P; Gatell, JM; Jaeger, H; Min, S; Quiros-Roldan, E; Raffi, F | 1 |
| Bahemuka, U; Bangsberg, DR; Barin, B; Bwanika, AN; Chetty, P; Fast, P; Haberer, JE; Kamali, A; Katende, D; Kibengo, FM; Mark, D; Priddy, FH; Rooney, JF; Ruzagira, E | 1 |
| Amico, KR; Buchbinder, S; Gilmore, HJ; Goicochea, P; Grant, R; Koester, KA; Liu, A; Lubensky, D; McMahan, V; Vargas, L | 1 |
| Bekker, LG; Kamkuemah, M; Kaplan, R; Myer, L | 1 |
| Beyrer, C; Chariyalertsak, C; Chariyalertsak, S; Guadamuz, T; Kawichai, S; Saokhieo, P; Suwanvanichkij, V; Wongthanee, A; Yang, D; Yotruean, K | 1 |
| Buyze, J; Lynen, L; Phirum, L; Thai, S; van Griensven, J | 1 |
| Bado, G; Hema, A; Kaboré, FN; Kamboulé, EB; Poda, GE; Sawadogo, AB; Soré, I; Zoungrana, J | 1 |
| Cheng, A; Custodio, JM; Hepner, M; Kearney, BP; Ling, KH; Ramanathan, S; Yin, X | 1 |
| Graber, P; Kalbermatter, S; Kiss, D; Koenig, KF; Menter, T | 1 |
| Aoki, M; Desai, DV; Kodama, EN; Maeda, K; Mitsuya, H; Nakata, H | 1 |
| Jabłonowska, E; Piekarska, A; Wójcik, K | 1 |
| Lundgren, JD; Mocroft, A; Ryom, L | 1 |
| Estrada, V; Portilla, J | 1 |
| Brennan, AT; Fox, MP; Ive, P; Long, L; Maskew, M; Sanne, I; Shearer, K | 1 |
| Anastos, K; Bacchetti, P; Baxi, SM; Cohen, M; Gandhi, M; Gange, SJ; Greenblatt, RM; Huang, Y; Minkoff, H; Scherzer, R; Shlipak, MG; Young, M | 1 |
| Dubé, MP; Gupta, SK; Liu, Z; Mi, D; Moe, SM | 1 |
| Boulle, A; Chi, BH; Chimbetete, C; Egger, M; Fox, MP; Gerber, F; Gsponer, T; Hoffmann, CJ; Orrell, C; Prozesky, H; Rohr, J; Wandeler, G; Zwahlen, M | 1 |
| Calvez, V; Charpentier, C; Descamps, D; Flandre, P; Fofana, D; Fourati, S; Lambert-Niclot, S; Marcelin, AG; Masquelier, B; Morand-Joubert, L; Soulie, C; Storto, A; Wirden, M | 1 |
| Baldelli, S; Castagnoli, L; Cattaneo, D; Clementi, E; Fucile, S; Galli, M; Gervasoni, C; Landonio, S; Meraviglia, P; Riva, A; Rizzardini, G | 1 |
| Perry, CM | 2 |
| Brooks, JT; Chirwa, LI; Henderson, FL; Johnson, JA; Li, JF; Matlhaba, O; Niska, RW; Paxton, LA; Rose, CE; Segolodi, TM; Thigpen, MC | 1 |
| Amico, KR; Buchbinder, SP; Glidden, DV; Grant, RM; Kallas, EG; Liu, AY; Marcus, JL; Mayer, KH; McMahan, V; Montoya-Herrera, O; Pilotto, J | 1 |
| Andrade, A; Chan, ES; Clagett, B; Daar, E; Feinberg, J; Funderburg, NT; Jacobson, JM; Kuritzkes, D; Lederman, MM; Lu, D; Mellors, J; Pilch-Cooper, HA; Rodriguez, B; Rosenkranz, SL | 1 |
| Brynda, J; Cihlár, T; de Jong, D; Grantz Šašková, K; Konvalinka, J; Kozíšek, M; Nijhuis, M; Rezáová, P; Stray, K; van Maarseveen, NM | 1 |
| Abdool Karim, Q; Abdool Karim, SS; Bruno, D; Garrett, NJ; Martens, C; Mullis, CE; Porcella, SF; Quinn, TC; Redd, AD; Sheward, D; Wendel, SK; Werner, L; Williamson, C | 1 |
| Rahman, SM; Vaidya, NK; Zou, X | 1 |
| Baeten, JM; Bukusi, E; Campbell, JD; Celum, C; Donnell, D; Kahle, EM; Mugo, N; Mujugira, A; Murnane, PM; Tappero, J; Thomas, KK | 1 |
| Agrahari, V; Ezoulin, MJ; Meng, J; Youan, BB; Zhang, T | 1 |
| Cox, AP; Delany-Moretlwe, S; Foss, AM; Heise, L; Mertenskoetter, T; Meyer-Rath, G; Rees, H; Terris-Prestholt, F; Vickerman, P; Watts, CH | 1 |
| Cattaneo, D; Fucile, S; Gervasoni, C; Milazzo, L; Pezzani, D | 1 |
| Anderson, PL; Bacchetti, P; Buchbinder, SP; Gandhi, M; Goggin, K; Grant, R; Greenblatt, RM; Huang, Y; Jin, C; Liu, AY; Stojanovski, K; Yang, Q | 1 |
| Abdool Karim, Q; Abdool Karim, SS; Heneine, W; Hunt, G; Johnson, JA; Kashuba, AD; Li, JF; Morris, L; Naranbhai, V; Passmore, JA; Sibeko, S; Wei, X; Werner, L | 1 |
| Currier, J; Hogg, E; Hosseinipour, M; Hughes, MD; Lockman, S; Mulenga, L; Mwafongo, A; Nkanaunena, K; Samaneka, W; Siika, A; Zheng, Y | 1 |
| Ananworanich, J; Bowonwattanuwong, C; Bunupuradah, T; Hirschel, B; Jirajariyavej, S; Klinbuayaem, V; Mahanontharit, A; Munsakul, W; Ruxrungtham, K; Sophonphan, J | 1 |
| Dufrene, SL; Li, J; Okulicz, JF | 1 |
| Chamnanphon, M; Jantararoungtong, T; Koomdee, N; Manosuthi, W; Prommas, S; Puangpetch, A; Santon, S; Sukasem, C | 1 |
| Bekker, LG; Burns, DN; Chariyalertsak, S; Glidden, DV; Grant, RM; Guanira, JV; Kallás, EG; Lama, JR; Liu, AY; Mayer, KH; McMahan, V; Mulligan, K; Schechter, M; Solomon, MM; Veloso, VG | 1 |
| Boswell, S; Crane, HM; Eron, JJ; Geng, E; Kim, HN; Kitahata, MM; Martin, J; Mathews, WC; Moore, R; Mugavero, M; Overton, ET; Rodriguez, B; Rodriguez, CV; Saag, MS; Thio, CL; Van Rompaey, S | 1 |
| Anderson, S; Doncel, GF; Thurman, AR | 1 |
| Agut, H; Boutolleau, D; Burrel, S; Caumes, E; Epelboin, L; Katlama, C; Regnier, S; Seang, S; Valantin, MA; Voujon, D | 1 |
| DeGrosky, M; Farajallah, A; Hardy, H; McGrath, D; Moyle, GJ | 1 |
| Bao, Y; Currier, J; Hogg, E; Hughes, MD; Lockman, S; Moses, A; Sawe, F; Shaffer, D | 1 |
| Alam, S; Dinello, D; Israr, M; Jia, R; Kishel, J; Meyers, C; Mitchell, D | 1 |
| Bosch, ME; Burger, DM; Ezinga, M; van der Ven, AJ; Wetzels, JF | 1 |
| Calmy, A; Chi, BH; Davies, MA; Keiser, O; Mulenga, L; Musonda, P; Mwango, A; Mweemba, A; Stringer, JS; Vinikoor, MJ; Wandeler, G | 1 |
| Estrella, MM; Moosa, MR; Nachega, JB | 1 |
| Campbell, LJ; Chadwick, D; Fisher, M; Gilson, R; Hamzah, L; Hay, P; Hill, T; Johnson, M; Jones, R; Jose, S; Leen, C; Nelson, M; Nitsch, D; Post, FA; Sabin, CA; Walsh, J | 1 |
| Hong, JH; Shen, GH | 1 |
| Brennan, AT; Fox, MP; Long, L; Maskew, M; Sanne, I; Shearer, K | 1 |
| Buchbinder, S; Cohan, D; Cohen, S; Follansbee, S; Liu, A; Sachdev, D; Weber, S | 1 |
| Amorosa, VK; Chang, KM; De La Torre, P; Frank, I; Gross, R; Hafkin, JS; Kostman, JR; Lo Re, V; Localio, AR; Mounzer, K; Osborn, MK; Stern, JJ | 1 |
| Bandera, A; Crivellaro, C; Gori, A; Guerra, L; Mangioni, D; Messa, C; Muscatello, A; Squillace, N | 1 |
| Boyd, A; Delaugerre, C; Girard, PM; Gozlan, J; Lacombe, K; Maylin, S; Simon, F | 1 |
| Blum, JD; Kiser, JJ; MacBrayne, CE | 1 |
| Gengiah, TN; Karim, QA; Karim, SS; Kashuba, AD; Mansoor, LE; Naidoo, A; Upfold, M; Yende-Zuma, N | 1 |
| Awio, P; Dunn, DT; Gilks, CF; Goodall, RL; Kaleebu, P; Kityo, C; Munderi, P; Ndembi, N; Nkurunziza, P; Pattery, T; Pillay, D; van Cauwenberge, A | 1 |
| Abdool Karim, Q; Abdool Karim, SS; Frohlich, JA; Grobler, AC; Maarschalk, S; Madlala, B; Mansoor, LE; Mngadi, KT; Ngcobo, N | 1 |
| Amico, KR; Cornman, DH; Fisher, J; Fisher, WA; Karim, QA; Karim, SS; Macqueen, KM; Madlala, B; Mansoor, LE; Ngcobo, N; Werner, L | 1 |
| McGowan, I | 2 |
| Battegay, M; Bernasconi, E; Bucher, HC; Calmy, A; Cavassini, M; Furrer, H; Fux, CA; Vernazza, P; Wang, Q; Weber, R; Young, J | 1 |
| Adesoye, A; Chen, CY; Danavall, D; Easley, K; Evans-Strickfaden, T; Gatcliffe, C; Haaland, R; Hart, C; Lupo, LD; Martin, A; Ofotokun, I; Omondi, MW; Pau, CP; Sheth, AN | 1 |
| Abdool Karim, Q; Abdool Karim, SS; Baxter, C; Grobler, A; MacQueen, KM; Madlala, BT; Mansoor, LE; Yende-Zuma, N | 1 |
| Moyo, C; Vinikoor, MJ | 1 |
| Karim, QA; Karim, SA; MacQueen, KM; Majola, N; Succop, S; Taylor, D; van Loggerenberg, F; Weaver, MA | 1 |
| Anderson, AM; Ebrahimi, R; Flaherty, JF; Fortin, C; Fralich, T; Graham, H; Gupta, SK; Kalayjian, RC; Rachlis, A; Scharen-Guivel, V; Wyatt, CM | 1 |
| Behrens, G; Bosse, M; Chuck, SK; Cohen, C; DeMorin, J; Elion, RA; Mills, A; Nelson, M; Orkin, C; Rijnders, B; Rimsky, L; Stevens, M; Thorpe, D; Vanveggel, S; White, K; Zhong, L | 1 |
| Betancor, G; Gómez-Puertas, P; Martínez, MA; Mendieta, J; Menéndez-Arias, L; Nevot, M | 1 |
| Chiamwongpaet, S; Choopanya, K; Curlin, ME; Gvetadze, RJ; Kittimunkong, S; Leethochawalit, M; Martin, M; McNicholl, JM; Mock, PA; Paxton, LA; Sangkum, U; Suntharasamai, P; Vanichseni, S; Worrajittanon, D | 1 |
| Hsiao, CB; Ma, Q; Sawyer, JR | 1 |
| Bele, V; Bhagani, S; Dabhade, D; Johnson, M; Joshi, K; Makane, A; Pujari, SN; Smith, C; Youle, M | 1 |
| Amin, J; Cooper, DA; Cordery, DV; Emery, S; Haskelberg, H; Kelleher, AD | 1 |
| Iyer, HS; Larson, BA; Long, L; McCoy, K; Moyo, C; Rosen, S; Scott, CA | 1 |
| Balzarini, J; Flynn, ÁS; Hinsinger, K; McGuigan, C; Pertusati, F; Powell, N; Tristram, A | 1 |
| Akil, A; Cost, M; Devlin, B; Rohan, LC | 1 |
| Aberg, JA; Hollabaugh, K; Kang, M; Koletar, SL; Pham, V; Smurzynski, M; Wu, K | 1 |
| Holmes, DT; Jiang, SY; Kendler, DL; Saeedi, R | 1 |
| Fonjungo, PN; Hart, C; Henderson, FL; Niska, R; Paxton, LA; Rose, CE; Segolodi, TM; Turner, KT; Zeh, C | 1 |
| Chimbwandira, FM; Chirwa, Z; Crampin, AC; Dasgupta, AN; Glynn, JR; Jahn, A; Katundu, C; Kayange, M; Koole, O; Price, AJ; Saul, JL; Zaba, B | 1 |
| Abdool Karim, Q; Abdool Karim, SS; Dellar, RC; Grobler, A; Humphries, H; Luthuli, L; Mansoor, LE; Ntombela, F; Werner, L | 1 |
| Allworth, A; Amin, J; Carr, A; Ebeling, PR; Emery, S; Haskelberg, H; Pocock, N | 1 |
| Arnold, V; Barcellos, NT; Brites, C; Chêne, G; De Castro, N; Delaugerre, C; Fagard, C; Grinsztejn, B; Madruga, JV; Molina, JM; Morgado, M; Patey, O; Pilotto, JH; Santini-Oliveira, M; Santos, BR; Veloso, VG; Vorsatz, C | 1 |
| Rijnders, BJ; Rokx, C; Verbon, A | 1 |
| Abdel-Mohsen, M; Anderson, PL; Atchison, R; Bentley, LG; Buchbinder, S; Eden, C; Glidden, DV; Grant, RM; Guanira, JV; Javier, J; Li, P; Liegler, T; McMahan, V; Mehrotra, M; Schmidt, T; Wong, JK | 1 |
| Boyd, A; Delaugerre, C; Girard, PM; Gozlan, J; Lacombe, K; Maylin, S; Peytavin, G; Zoulim, F | 1 |
| Cardoso, SW; Demeter, LM; Godfrey, C; Infante, R; Johnson, VA; Moran, LE; Sanchez, J; Smeaton, LM; Vogler, MA; Wright, RL | 1 |
| Coppola, N; Filippini, P; Martini, S; Pisaturo, M; Sagnelli, C; Sagnelli, E | 1 |
| Ayala-Sims, VA; Fulco, PP | 1 |
| Baeten, JM; Bangsberg, DR; Brantley, J; Bumpus, NN; Celum, C; Donnell, D; Haberer, JE; Hendrix, C; Mugo, N; Mujugira, A; Ndase, P | 1 |
| Manosuthi, W; Nilkamhang, S; Sukasem, C; Sungkanuparph, S; Thongyen, S | 1 |
| Domingo, JC; Domingo, P; Gallego-Escuredo, JM; Giralt, M; Gutierrez, Mdel M; Lamarca, K; Mateo, MG; Torres, F; Vidal, F; Villarroya, F; Villarroya, J | 1 |
| Chima-Okereke, C; Sivaprakasam, V | 1 |
| Henderson, H; Kruse, L; Stover, K | 1 |
| Boucherie, C; Breton, G; Bugault, F; Chakrabarti, LA; Chêne, G; Cumont, MC; Lortholary, O; Patey, O; Richert, L; Roussillon, C | 1 |
| Barthe, Y; Bouix, C; Cacoub, P; Carrat, F; Lascoux-Combe, C; Lebossé, F; Maynard-Muet, M; Miailhes, P; Piroth, L; Pol, S; Rey, D; Sogni, P; Zoulim, F | 1 |
| Antonopoulou, S; Chini, M; Demopoulos, CA; Fragopoulou, E; Gargalianos, P; Lazanas, MC; Mangafas, N; Papakonstantinou, VD; Psarra, K; Stamatakis, GM; Tsogas, N; Tsoupras, AB | 1 |
| Coombes, AG; Dang, NT; Davis-Poynter, N; Harrich, D; Shaw, PN; Sivakumaran, H | 1 |
| Banhegyi, D; De Wit, S; Grarup, J; Kirk, O; Lundgren, JD; Mocroft, A; Phillips, AN; Rakhmanova, A; Reiss, P; Ristola, M | 1 |
| Allavena, C; André-Garnier, E; Billaud, E; Bonnet, B; Bouchez, S; Bouquié, R; Boutoille, D; Dailly, E; Pineau, S; Raffi, F; Raveleau, A; Reliquet, V | 1 |
| Debyser, Z; Schrijvers, R | 2 |
| Arribas, JR; Di Perri, G; Ebrahimi, R; Gathe, J; Nguyen, T; Pialoux, G; Piontkowsky, D; Reynes, J; Tebas, P; White, K | 1 |
| Antela, A; Domingo, P; Garner, W; Girard, PM; Guyer, B; Henry, K; Markowitz, M; Mills, A; Nguyen, T; Piontkowsky, D; Pozniak, A; Stellbrink, HJ; White, K | 1 |
| Deeks, SG; Estrella, MM; Gandhi, M; Grunfeld, C; Peralta, CA; Scherzer, R; Shlipak, MG; Tien, PC | 1 |
| Chariyalertsak, S; Fernandez, T; Glidden, DV; Grant, RM; Guanira, JV; Liu, AY; Mayer, KH; McMahan, VM; Solomon, MM | 1 |
| Abe, M; Hiasa, Y; Hirooka, M; Ikeda, Y; Koizumi, Y; Kumagi, T; Matsuura, B; Ochi, H; Tada, F; Takada, K; Tokumoto, Y; Watanabe, T | 1 |
| Baum, MM; Brooks, AA; Butkyavichene, I; Dinh, CT; Lopez, G; Martin, A; Moss, JA; Smith, JM; Smith, TJ; Srinivasan, P | 1 |
| Asmelash, A; Currier, J; Hughes, MD; Kaloustian, KW; Lockman, S; Ogwu, A; Salata, R; Sawe, F; Shaffer, D; Zheng, Y | 1 |
| Dashti-Khavidaki, S; Jafari, A; Khalili, H | 1 |
| Baeten, JM; Celum, C; Donnell, D; Fife, KH; Hendrix, CW; Hong, T; Morrow, RA; Mujugira, A; Nakku-Joloba, E; Thomas, KK | 1 |
| Ananworanich, J; Bunupuradah, T; Keadpudsa, S; Prasitsuebsai, W; Puthanakit, T; Sahakijpicharn, T; Srimuan, A; Techasaensiri, C; Thammajaruk, N | 1 |
| Chau, JJ; Giancola, MA; Keller, SB; King, HL; Little, SJ; Rodriguez, DA; Smith, DM; Young, JA | 1 |
| Abebe, KZ; Dezzutti, CS; Friend, DR; Li, J; McGowan, IM; Rohan, LC; Russo, J; Wang, L | 1 |
| Clumeck, N; Delforge, M; Ilunga, J; Kabeya, K; Kadiebwe, D; Kapend, L; Kasamba, E; Matanda, S; Milolo, C; Mwamba, C; Necsoi, C; Vaira, D | 1 |
| Gürtler, LG | 1 |
| De Castro, N; Delaugerre, C; Flandre, P; Gallien, S; Molina, JM; Nguyen, N | 1 |
| Bosco, O; Cruciani, M; Malena, M; Mengoli, C; Moyle, G; Parisi, SG; Serpelloni, G | 1 |
| Agashe, H; Akil, A; Devlin, B; Dezzutti, CS; Hillier, SL; Moncla, BJ; Rohan, LC; Shi, Y; Uranker, K | 1 |
| Ballow, C; Battegay, M; Elgadi, M; Feifel, U; Fuhr, R; Girlich, B; Haschke, M; Kort, J; Lang, B; Li, Y; Sabo, JP; Schobelock, M | 1 |
| Agot, K; Ambia, J; Corneli, AL; Kashuba, AD; Lemons, A; Lombaard, J; Malahleha, M; Parker, C; Taylor, D; Van Damme, L; Wang, M | 1 |
| Andrade-Fuentes, K; Gaytan-Martínez, J; López-De León, JI; Manjarrez-Téllez, B; Mata-Marín, JA; Ramírez, JL | 1 |
| Allavena, C; Antinori, A; Arribas, JR; Babiker, AG; Chêne, G; Delfraissy, JF; George, EC; Grarup, J; Hudson, F; Jansson, PO; Molina, JM; Pozniak, A; Raffi, F; Richert, L; Saillard, J; Schwimmer, C; Van Leeuwen, R; Vella, S; Wallet, C | 1 |
| Akkina, R; Kashuba, ADM; LeCureux, J; Remling-Mulder, L; Sykes, C; Veselinovic, M; Yang, KH | 1 |
| Barreiro, P; Fernández-Montero, JV; Labarga, P; Mendoza, Cd; Sierra-Enguita, R; Soriano, V; Vispo, E | 1 |
| Amiel, C; Chas, J; Guessant, S; Hamidi, M; Kherallah, K; Lebrette, MG; Lependeven, C; Pialoux, G; Schneider, V | 1 |
| Daar, ES; Gupta, SK; Ha, B; Kitch, D; McComsey, GA; Melbourne, K; Sax, PE; Tierney, C; Wyatt, CM | 1 |
| Baeten, JM; Bangsberg, DR; Celum, C; Cohen, CR; Heffron, R; Hendrix, CW; Matthews, LT; Mugo, NR | 1 |
| Baldeyrou, M; Batard, ML; Bernard-Henry, C; Cheneau, C; de Mautort, E; Fafi-Kremer, S; Gantner, P; Muret, P; Partisani, M; Priester, M; Reinhart, S; Rey, D | 1 |
| Bonjoch, A; Clotet, B; Domingo, P; Echeverría, P; Escrig, R; Gutiérrez, M; Mateo, G; Negredo, E; Pérez-Álvarez, N; Puig, J | 1 |
| Agot, K; Ahmed, K; Corneli, AL; Deese, J; Kapiga, S; Kashuba, A; Lombaard, J; Manongi, R; Taylor, D; Van Damme, L; Wang, M | 1 |
| Bedimo, RJ; Castanon, R; Cutrell, J; Drechsler, H; Farukhi, I; Jain, M; Li, X; Maalouf, NM; Tebas, P; Zhang, S | 1 |
| Camejo, RR; Cuffe, R; Gilchrist, KA; Lim, JW; Nichols, G; Patel, DA; Pulgar, S; Snedecor, SJ; Stephens, J; Sudharshan, L; Tang, WY | 1 |
| Boettiger, DC; Chaiwarith, R; Heng Sim, BL; Kamarulzaman, A; Kantipong, P; Kiertiburanakul, S; Kumarasamy, N; Law, MG; Lee, MP; Pham, TT; Phanuphak, P; Saphonn, V; Van Nguyen, K | 1 |
| Greeff, OB; Hurrell, T; Khwitshana, AK | 1 |
| Carnovale, C; Chiacchio, MA; Giofrè, SV; Macchi, B; Monciino, G; Romeo, R; Sanfilippo, C | 1 |
| Aiestarán, A; Bonet, J; Bonjoch, A; Clotet, B; Echeverría, P; Juega, J; Negredo, E; Pérez, V; Pérez-Alvarez, N; Puig, J; Romero, R | 1 |
| Abdool-Karim, Q; Abdool-Karim, SS; Garrett, NJ; Gray, C; Morris, L; Naicker, N; Naranbhai, V; Samsunder, N; Sibeko, S; Werner, L; Williamson, C | 1 |
| Aurpibul, L; Puthanakit, T | 1 |
| Aoki, T; Gatanaga, H; Honda, H; Kawasaki, Y; Kikuchi, Y; Kinai, E; Mizushima, D; Nishijima, T; Oka, S; Tanaka, N; Tanuma, J; Teruya, K; Tsukada, K; Watanabe, K; Yazaki, H | 1 |
| Baeten, JM; Bukusi, EA; Celum, C; Heffron, R; Mugo, NR; Mujugira, A; Were, EO | 1 |
| Boucher, CA; Langebeek, N; Mudrikova, T; Nijhuis, M; Pingen, M; Richter, C; van Laarhoven, A; Wensing, AM | 1 |
| Brun-Vezinet, F; Costagliola, D; Mokhtari, S; Poizot-Martin, I; Potard, V; Pradier, C; Rey, D; Rozenbaum, W | 1 |
| Aweeka, F; Baugh, BP; Benson, CA; Brown, TT; Cohn, SE; Currier, JS; Fichtenbaum, CJ; Godfrey, C; Haas, DW; Koletar, SL; Kuritzkes, DR; Landovitz, RJ; Leavitt, RY; Lennox, JL; McComsey, GA; Na, LH; Ofotokun, I; Patterson, KB; Presti, RM; Ribaudo, HJ; Rooney, JF; Sagar, M; Seekins, D | 1 |
| Karim, QA; Karim, SS; MacQueen, KM; Majola, N; Succop, SM; van Loggerenberg, F | 1 |
| Buchbinder, S | 1 |
| Baeten, JM; Bangsberg, D; Bukusi, EA; Campbell, JD; Celum, C; Cohen, CR; Coombs, RW; Donnell, D; Farquhar, C; Fife, KH; Frenkel, L; Haberer, JE; Hendrix, C; John-Stewart, G; Katabira, E; Kiarie, J; Kidoguchi, L; Marzinke, MA; Mugo, NR; Ndase, P; Ronald, A; Tappero, JW; Thomas, KK; Tumwesigye, E; Wangisi, J; Were, E | 1 |
| Boyd, A; Fonquernie, L; Girard, PM; Meynard, JL; Morand-Joubert, L; Surgers, L; Valin, N; Viala, C | 1 |
| Deeks, ED | 1 |
| Guo, F; Li, T; Lin, Q; Shao, H; Sun, P; Tian, J; Xu, Y; Yu, W; Zhou, X | 1 |
| Almond, S; Arasteh, K; Brennan, C; Brinson, C; Cuffe, RL; Eron, J; Górgolas, M; Granier, C; Nichols, WG; Pappa, K; Rachlis, A; Raffi, F; Walmsley, S | 1 |
| Agot, K; Ahmed, K; Corneli, A; Lombaard, J; Van Damme, L; Wang, M | 1 |
| Mistry, N; Oakeshott, P; Sereboe, L | 1 |
| Freeling, JP; Ho, RJ; Koehn, J; Shu, C; Sun, J | 1 |
| Bekker, LG; Kamkuemah, M; Kaplan, R; Little, F; Myer, L | 1 |
| Deese, J; Hubacher, D; Otunga, S; Steiner, MJ; Todd, CS; Van Damme, L; Wang, M | 1 |
| Abram, ME; Andrade-Villanueva, JF; Beraud, C; Cheng, AK; Fisher, M; Graham, H; Liu, Y; Post, FA; Rhee, MS; Szwarcberg, J; Winston, J | 1 |
| Bam, R; Cihlar, T; Dahlin, A; de la Cruz, M; Flaherty, J; Giacomini, KM; Gupta, SK; Ray, AS; Scharen-Guivel, V; Wittwer, M; Woo, JM | 1 |
| Archer, DF; Doncel, GF; Jacot, TA; Kashuba, AD; Nelson, A; Thurman, A | 1 |
| Bacon, O; Blue, RW; Buchbinder, S; Castro, JG; Chege, W; Cohen, SE; Coleman, ME; Doblecki-Lewis, S; Elion, R; Estrada, Y; Feaster, DJ; Kolber, MA; Liu, AY; Matheson, T; Philip, SS; Postle, BS; Trainor, N; Vittinghoff, E | 1 |
| Cohen, MS; Emerson, CW; Fedoriw, Y; Geller, EJ; Kashuba, AD; Nelson, JA; Nicol, MR; Patterson, KB; Prince, HM; Sykes, C | 1 |
| Abdel-Mohsen, M; Agingu, W; Ahmed, K; Bentley, G; Crucitti, T; Damme, LV; De Baetselier, I; Deese, J; Defechereux, P; Fransen, K; Grant, RM; Kashuba, AD; Liegler, T; Taylor, D | 1 |
| Huang, J; Huang, S; Lassman, C; Lum, EL | 1 |
| Abdool Karim, Q; Abdool Karim, SS; Baxter, C; Dawood, H; Dlamini, S; Frohlich, JA; Gengiah, TN; Grobler, A; Mansoor, LE; Mngadi, KT; Montague, C; Mvandaba, N; Nkomonde, N; Samsunder, N | 1 |
| Katz, MH | 1 |
| Baeten, JM; Celum, C; Donnell, D; Kiarie, J; Mugo, NR; Mugwanya, KK; Ronald, A; Tappero, J; Wyatt, C | 1 |
| De Baetselier, I; Deese, J; Lombaard, J; Malahleha, M; Mandala, J; Manongi, R; Nanda, K; Owino, F; Taylor, D; Van Damme, L; Wang, M | 1 |
| Fisher, M; Raffe, S | 1 |
| Cressey, TR; Harrison, L; Jourdain, G; Kamkon, J; Lallemant, M; Le Coeur, S; Luekamlung, N; Ngo-Giang-Huong, N; Nilmanat, A; Owen, A; Sirirungsi, W; Tawon, Y; Thongpaen, S; Urien, S | 1 |
| Back, DJ; Burger, D; Lamorde, M; Schapiro, JM | 1 |
| Baeten, JM; Celum, C; Donnell, D; Frenkel, L; Hendrix, CW; Lehman, DA; Marzinke, MA; Matsen, FA; Mbara, G; McCoy, CO; Mugo, NR; Ndase, P; Overbaugh, J; Peterson, D; Thomas, KK; Weis, JF | 1 |
| Callahan, R; Kapiga, S; Malahleha, M; Mandala, J; Nanda, K; Ogada, T; Taylor, D; Van Damme, L | 1 |
| Havens, PL; Hazra, R | 1 |
| Andreatta, KN; Da Silva, MT; De Aquino, MZ; De Carvalho, AP; Della Negra, M; Graham, B; Liu, YP; Pinto, JA; Quirk, EK | 1 |
| Carney, EF | 1 |
| Barth, RE; Bauer, MP; Hoepelman, AI; Reiss, P; Schoffelen, AF; Smit, C; van Lelyveld, SF; Vogt, L | 1 |
| Chirenje, ZM; Dai, JY; Ganesh, S; Gomez, K; Grossman, C; Hendrix, CW; Hillier, SL; Marrazzo, JM; Marzinke, MA; Mâsse, B; McGowan, IM; Mgodi, N; Mkhize, B; Nair, G; Nakabiito, C; Noguchi, L; Palanee, T; Parikh, UM; Piper, J; Ramjee, G; Richardson, BA; Rooney, J; Schwartz, JL; Taljaard, M; van der Straten, A; Watts, H | 1 |
| Saag, MS | 1 |
| Bronze, M; Carmona, SC; Letsoalo, E; Lukhwareni, A; Papathanasopoulos, MA; Skhosana, L; Steegen, K; Stevens, WS | 1 |
| Mayor, S | 1 |
| Cherian, AO; Mitra, S; Priscilla, R; Rajeev, K; Rajkumar, S; Sauradeep, S | 1 |
| Rijnders, BJ; Rokx, C; Van der Ende, ME | 1 |
| Gatanaga, H; Kawasaki, Y; Nishijima, T; Oka, S; Tanaka, N | 1 |
| Abdool Karim, SS; Eshleman, SH; Garrett, N; Karim, QA; Laeyendecker, O; Longosz, AF; Naranbhai, V; Nason, M; Quinn, TC; Redd, AD | 1 |
| Aurpibul, L; Chokephaibulkit, K; Cressey, TR; Phongsamart, W; Sirisanthana, V; Sricharoenchai, S; Sudjaritruk, T; Wittawatmongkol, O | 1 |
| Arterburn, S; Castaño, E; Cheng, AK; Chuck, SL; Church, J; Deville, J; Enejosa, JV; Estripeaut, D; Gaur, A; Rathore, M; Rhee, MS; Saez-Llorens, X; White, K | 1 |
| Agot, K; Ahmed, K; Corneli, AL; Malamatsho, F; McKenna, K; Odhiambo, J; Perry, B; Skhosana, J; Van Damme, L | 1 |
| Mayer, KH | 2 |
| Bader, J; Glass, TR; Klimkait, T; Labhardt, ND; Lejone, TI; Puga, D; Ringera, I | 1 |
| Bae-Harboe, YS; Mahalingam, M; Marszalek, RM; Masterpol, K | 1 |
| Harirforoosh, S; Moorman, JP; Murrell, DE | 1 |
| De La Mata, FJ; Gómez, R; Jiménez, JL; Muñoz-Fernández, MÁ; Sánchez-Rodríguez, J; Sepúlveda-Crespo, D; Serramía, MJ | 1 |
| Callebaut, C; Cao, H; Cheng, A; Crofoot, G; Custodio, J; Das, M; Flamm, JA; Gathe, J; Liu, HC; Martin, H; McCallister, S; McDonald, C; Mills, A; Saag, M; Scribner, A; Shalit, P; Shamblaw, D; Thomas, A; Yan, M | 1 |
| Amin, J; Belloso, W; Carey, D; Cooper, DA; Crabtree-Ramirez, B; Emery, S; Foulkes, S; Jessen, H; Kumar, S; Lee, MP; Losso, M; Mohapi, L; Phanupak, P; Puls, R; Winston, A | 1 |
| Chaipung, B; Chiamwongpaet, S; Choopanya, K; Curlin, ME; Gvetadze, RJ; Kittimunkong, S; Leethochawalit, M; Martin, M; McNicholl, JM; Mock, PA; Paxton, LA; Sangkum, U; Suntharasamai, P; Vanichseni, S | 1 |
| Baeten, JM; Wyatt, C | 1 |
| Andrade-Villanueva, J; Callebaut, C; Cao, H; Cheng, AK; Crofoot, G; Custodio, JM; DeJesus, E; Fordyce, MW; Koenig, E; Martin, H; McCallister, S; Molina, JM; Oka, S; Plummer, A; Podzamczer, D; Post, F; Pozniak, A; Saag, M; Sax, PE; Thompson, M; Trottier, B; Wohl, D; Yin, MT; Zhong, L | 1 |
| Bogoch, II; Siemieniuk, RA | 1 |
| Barré-Sinoussi, F; Bekker, LG; Beyrer, C; Pozniak, A | 1 |
| Stone, L | 1 |
| Balasubramanian, R; Bangsberg, DR; Ertel, K; Haberer, JE; Hankinson, SE; Kintu, A; Tumwesigye, E | 1 |
| Epelboin, S; Flores, J; Luton, D; Mabileau, G; Mandelbrot, L; Matheron, S; Patrat, C; Schwarzinger, M; Yazdanpanah, Y | 1 |
| Antela, A; Esteban, H; Estébanez, M; Mariño, A; Moreno, S; Navarro, J; Pasquau, J; Perez-Molina, JA; Riera, M; Rivero, A; Rubio, R; Santos, J; Sanz-Moreno, J; Suárez-Lozano, I; Troya, J | 1 |
| Destache, CJ; Fan, W; Kang, G; Li, Q; Li, Y; Lu, W; Tso, FY; Wood, C; Yuan, Z | 1 |
| Abdool Karim, SS; Gengiah, TN; Karim, QA; Kashuba, AD; Werner, L; White, NR; Yang, KH | 1 |
| Abram, ME; Andrade-Villanueva, JF; Antunes, F; Arastéh, K; Cao, H; Chetchotisakd, P; DeJesus, E; Fehr, J; Gallant, JE; Koenig, E; Liu, HC; Rizzardini, G; Szwarcberg, J | 1 |
| Zhang, XQ | 1 |
| Abdool Karim, Q; Abdool Karim, SS; Baxter, C; Gengiah, TN; Grobler, AC; Kashuba, A; Kharsany, AB; Mansoor, LE; Mindel, A; Samsunder, N; Werner, L | 1 |
| Tobin, SC | 1 |
| Loignon, M; Toma, E | 1 |
| Álvarez-Gallego, M; Arribas, JR; Beato, MJ; Bernardino, JI; Díaz-Almirón, M; Feíto, M; Feltes, R; González-García, J; Herranz, P; Pérez-Molina, JA; Sendagorta, E; Yllescas, M | 1 |
| Botelho-Nevers, E; Frésard, A; Gagneux-Brunon, A; Lucht, F | 1 |
| Capitant, C; Chas, J; Chidiac, C; Demoulin, B; Lorente, N; Meyer, L; Molina, JM; Mora, M; Préau, M; Rojas Castro, D; Sagaon-Teyssier, L; Spire, B; Suzan-Monti, M | 1 |
| Boyd, MA; Cooper, DA | 1 |
| Goryaeva, MP; Gulyaeva, SS; Minaeva, SV; Moshkovich, GF; Tichonova, EV; Varlova, LW | 1 |
| Beraud, G; Chagneau-Derrode, C; Garcia, M; Godet, C; Le Moal, G; Roblot, F | 1 |
| Terrault, NA | 1 |
| Hatz, C; Letang, E; Mapesi, H; Ramírez, A; Tanner, M | 1 |
| Battle, S; Closson, EF; Denson, D; Herbst, JH; Holman, J; Landers, S; Mansergh, G; Mimiaga, MJ; Pitts, N | 1 |
| Gilson, R; Nugent, D | 1 |
| Ambrosioni, J; Miró, JM; Mosquera, MM | 1 |
| Barreiro, P; García-Gascó, P; González-Pardo, G; Jiménez-Nácher, I; Maida, I; Morello, J; Parra, A; Rodríguez-Nóvoa, S; Soriano, V; Vispo, E | 1 |
| Cantrell, RA; Chi, BH; Chintu, N; Kankasa, C; Kruse, G; Mbewe, F; Sinkala, M; Smith, PJ; Stringer, EM; Stringer, JS | 1 |
| Brown, AJ; Lewis, FI; Miller, MD; Murray, RJ | 1 |
| de Groot-Mijnes, JD; Rothova, A; Schneider, M | 1 |
| Calabresi, A; Carosi, G; Cologni, G; Costarelli, S; Lapadula, G; Puoti, M; Quiros-Roldan, E; Tirelli, V; Torti, C; Zaltron, S | 1 |
| Abel, K; Bischofberger, N; Brignolo, LL; Cihlar, T; Durand-Gasselin, L; Jerome, C; Kearney, BP; Marthas, ML; Moore, J; Ray, AS; Reiser, H; Spinner, A; Van Rompay, KK | 1 |
| Bläckberg, J; Duberg, AS; Fischler, B; Friman, S; Karlström, O; Lindh, M; Norkrans, G; Reichard, O; Sangfeldt, P; Söderström, A; Sönnerborg, A; Uhnoo, I; Weiland, O; Wejstål, R; Wiström, J | 1 |
| Borroto-Esoda, K; Feng, JY; Goodman, D; Kutty, N; Ly, JK; Margot, NA; Miller, MD; Myrick, F; Svarovskaia, ES; Wang, R; White, KL | 1 |
| Ray, AS; Rhodes, GR; Wright, MR | 1 |
| Breidinger, SA; Chen, J; Friedman, EJ; Gottesdiener, KM; Iwamoto, M; Kost, JT; Lasseter, KC; Stek, JE; Stone, JA; Teppler, H; Wagner, JA; Wenning, LA | 1 |
| Baietto, L; Bonora, S; D'Avolio, A; Di Perri, G; Gonzalez de Requena, D; Sciandra, M; Siccardi, M | 1 |
| Cortes, C; Domingo, P; Ferrer, E; Gatell, JM; Gutierrez, M; Leon, A; Niubo, J; Pedrol, E; Podzamczer, D; Puig, T; Sanchez, P; Veloso, S | 1 |
| Dezzutti, CS; Hladik, F | 1 |
| Cotter, BR; Currier, JS; Dubé, MP; Fichtenbaum, CJ; Gerschenson, M; Komarow, L; Mitchell, CK; Murphy, RL; Parker, RA; Squires, K; Stein, JH; Torriani, FJ | 1 |
| Amin, J; Avihingsanon, A; Bowden, S; Cooper, DA; Dore, GJ; Lewin, SR; Locarnini, S; Marks, P; Matthews, GV; Petcharapirat, P; Rerknimitr, R; Ruxrungtham, K; Sasadeusz, J | 1 |
| Pozniak, A | 1 |
| Crane, HM; Harrington, RD; Kestenbaum, B; Kitahata, MM | 2 |
| Arribas, JR; Gallant, JE | 1 |
| Carrington, M; Davis, B; Duh, FM; Jean-Pierre, P; La Roche, M; Markowitz, M; Mehandru, S; Mohri, H; Poles, M; Prada, N | 1 |
| Boelle, PY; Bonnard, P; Boyd, A; Girard, PM; Gozlan, J; Lacombe, K; Lascoux-Combe, C; Miailhes, P; Molina, JM; Serfaty, L; Zoulim, F | 1 |
| Hsu, R; Lanier, ER; Oie, KL; Pappa, KA; Ross, LL; Rouse, EG | 1 |
| Morrow, JS; Redfield, RR | 1 |
| Freedberg, KA; Losina, E; Sax, PE; Schackman, BR; Scott, CA; Walensky, RP | 1 |
| Baldelli, F; De Socio, GV; Minga, P; Rosignoli, D; Simonetti, S; Tomassini, GM | 1 |
| Chen, SS; Cheng, AK; DeJesus, E; Enejosa, JV; Gallant, JE; Pozniak, AL; Winston, JA | 1 |
| del Arco, A; Gálvez, MC; Gutiérrez-Ravé, V; Hidalgo, C; Lozano, F; Muñoz, L; Palacios, R; Ríos, MJ; Rivero, A; Santos, J | 1 |
| Barreiro, P; Collado, A; de Los Santos Gil, I; González-Serrano, M; Hernández-Burruezo, JJ; López-Cortés, LF; López-Ruz, MA; Macías, J; Martín-Rico, P; Merino, D; Mira, JA; Muñoz, L; Pineda, JA; Ríos-Villegas, MJ; Rivero, A; Soriano, V; Torres-Tortosa, M; Tural, C; Viciana, P | 1 |
| Bele, V; Dravid, A; Gupte, N; Joshi, K; Pujari, S | 1 |
| Hogben, M; Liddon, N | 1 |
| Deray, G; Hawkins, T; Szczech, L; Winston, J; Wyatt, C; Young, B | 1 |
| Hayes, E; Mondy, K; Nurutdinova, D; Onen, NF; Overton, ET | 1 |
| Amani-Bosse, C; Arrivé, E; Blanche, S; Dabis, F; Ekouévi, DK; Gray, G; Hirt, D; Kone, M; Leang, SK; McIntyre, J; Nerrienet, E; Rey, E; Tréluyer, JM; Urien, S | 1 |
| Amengual, JE; Gardner, LB; Ibrahim, S; Zhang, X | 1 |
| Guhl, C; Heinz, W; Klinker, H; Langmann, P; Leyh, M; Schirmer, D; Weissbrich, B; Winzer, R | 1 |
| Kuhlmann, B | 1 |
| Gerondelis, P; Irlbeck, DM; Lanier, E; Parkin, N; Ross, LL; Rouse, E; St Clair, MH; Trinh, L; Underwood, MR | 1 |
| Allavena, C; Calvez, V; Chavanet, P; Diemer, M; Duong, M; Hoen, B; Hoizey, G; Lang, JM; May, T; Meyer, P; Peytavin, G; Rey, D; Schmit, JL; Schmitt, MP; Spire, B | 1 |
| Abecasis, AB; Camacho, R; Deforche, K; Libin, P; Theys, K; Vandamme, AM; Vercauteren, J | 1 |
| Calza, L; Manfredi, R | 2 |
| Benhamou, Y; Dominguez, S; Duvivier, C; Ingiliz, P; Katlama, C; Poynard, T; Thibault, V; Valantin, MA | 1 |
| Akumatey, B; Chen, PL; Clarke, EE; Guest, G; Johnson, L; MacQueen, KM; Shattuck, D | 1 |
| Kasahara, K; Konishi, M; Maeda, K; Mikasa, K; Nakagawa, C; Uno, K; Yonekawa, S; Yoshimoto, E | 1 |
| Burgisser, P; Cavassini, M; Giulieri, SG; Günthard, HF; Knoepfel, SA; Metzner, KJ; Rauch, P; Yerly, S | 1 |
| Cappelli, G; Esposito, R; Giovanardi, C; Guaraldi, G; Orlando, G; Palella, F; Ravera, F; Roverato, A; Squillace, N | 1 |
| Chatelut, E; Jaafar, A; Malard, L; Massip, P; Séronie-Vivien, S; Tack, I | 1 |
| Amini-Bavil-Olyaee, S; Lutz, T; Sheldon, J; Tacke, F; Trautwein, C | 1 |
| Calleja, JL; Peñas, B | 1 |
| Barreiro, P; García-Samaniego, J; Martín-Carbonero, L | 1 |
| Arrivé, E; Avit, D; Blanche, S; Coffié, P; Dabis, F; Ekouévi, DK; Hirt, D; Lalsab, S; Leang, SK; McIntyre, J; Nerrienet, E; Rey, E; Tréluyer, JM; Urien, S | 1 |
| Barry, SM; Fischetti, L; Hope, TJ; Shattock, RJ | 1 |
| Avihingsanon, A; Bowden, S; Dore, GJ; Lewin, SR; Locarnini, SA; Marks, P; Matthews, G; Perelson, AS; Ribeiro, RM; Ruxrungtham, K | 1 |
| Acosta, EP; King, JR; Long, MC | 1 |
| Parienti, JJ | 3 |
| Okoromah, CA; Okwundu, CI | 1 |
| Arrifin, N; Audsley, J; Ayres, A; Bartholomeusz, A; Crowe, SM; Lewin, SR; Locarnini, SA; Mijch, A; Sasadeusz, J; Yuen, LK | 1 |
| Kaplan, BS; Meyers, KE; Rutstein, RM; Shah, SS; Steenhoff, AP; Wood, SM | 1 |
| Freedberg, KA; Losina, E; Paltiel, AD; Sax, PE; Schackman, BR; Scott, CA; Seage, GR; Sloan, CE; Walensky, RP; Wang, B | 1 |
| Bernasconi, E; Bucher, HC; Cavassini, M; Elzi, L; Furrer, H; Fux, CA; Hirschel, B; Opravil, M; Rauch, A; Simcock, M; Vernazza, P | 1 |
| Azanza, JR; García Quetglas, E; Gómez-Giu, A; Sádaba, B | 1 |
| Mallolas, J | 2 |
| Fiorante, S; Pulido, F | 1 |
| Arribas López, JR; Bernardino de la Serna, JI; Mora Rillo, M | 1 |
| Portilla, J | 1 |
| López Bernaldo de Quirós, JC | 1 |
| Barreiro, P; Soriano, V; Tuma, P; Vispo, E | 1 |
| Barril Cuadrado, G; de Los Santos Gil, I | 1 |
| Miralles Alvarez, C | 1 |
| Willyard, C | 1 |
| Aharchi, F; Beets, G; De Smedt, G; Hoetelmans, RM; Kakuda, TN; Peeters, MP; Schöller-Gyüre, M; Vandermeulen, K; Woodfall, BJ | 1 |
| Boyd, K; Butler, K; Cliff, D; Doerholt, K; Gibb, D; Judd, A; Lyall, H; Menson, E; Riordan, A | 1 |
| Alvarez-Uria, G; Ratcliffe, L; Vilar, J | 1 |
| Moreno, V; Valencia, ME | 1 |
| Anton, P; Cranage, M; Herrera, C; McGowan, I; Shattock, RJ | 1 |
| Albalater, M; Barreiro, P; Blanco, F; Labarga, P; Martin-Carbonero, L; Medrano, J; Moreno, V; Rivas, P; Rodriguez-Novoa, S; Solera, C; Soriano, V; Vispo, E | 1 |
| Aslangul, E; Caillat-Vigneron, N; Le Jeunne, C; Perrot, S; Szwebel, T | 1 |
| Albrecht, H | 1 |
| Ayen, R; Clotet, B; Grassi, J; Levi, M; Negredo, E; Pruvost, A; Puig, J; Théodoro, F | 1 |
| Gills Ray, VL; Lee, H; Silkiss, RZ | 1 |
| Ahmed, A; Babrzadeh, F; Egholm, M; Gharizadeh, B; Hanczaruk, B; Holmes, SP; Liu, T; Margeridon-Thermet, S; Shafer, RW; Shahriar, R; Shulman, NS; Simen, BB; Wang, C | 1 |
| Arrivé, E; Avit, D; Blanche, S; Chaix, ML; Coffie, PA; Dabis, F; Diallo, A; Ekouévi, DK; Gray, G; Kruy Leang, S; McIntyre, J; N'Dri-Yoman, T; Nerrienet, E; Rouzioux, C; Srey, VH | 1 |
| Belsey, E; Berzins, B; Chen, D; Choi, J; da Silva, B; Gerschenson, M; Kim, C; Libutti, DE; McComsey, GA; Murphy, RL; Shore, J; Taiwo, B; Weinstein, J | 1 |
| Alvarez, S; Brumble, LM; Dwyer, JP; Irizarry-Alvarado, JM; Mendez, JC | 1 |
| Atta, MG; Fine, DM | 1 |
| Curran, A; Ribera Pascuet, E | 1 |
| Levenson, E | 1 |
| Dejesus, E; Ebrahimi, R; Ecker, J; Farajallah, A; Flaherty, JF; Maa, JF; McColl, D; Morales-Ramirez, JO; Reilly, K; Seekins, D; Sloan, L; Ward, DJ; Young, B | 1 |
| Hanabusa, H; Kinai, E | 2 |
| Arnaiz, JA; Arranz, JA; Arribas, JR; Barragán, P; Barrufet, P; Blanco, JL; Casas, E; Clotet, B; Cosín, J; Cruceta, A; Curran, A; Dalmau, D; Ferrer, E; Gatell, JM; González, A; Gutiérrez, F; Knobel, H; Llibre, JM; Loncá, M; Mallolas, J; Martínez, E; Miró, JM; Pich, J; Podzamczer, D; Ribera, E; Roca, V; Sanz, J; Segura, F | 1 |
| Albalater, M; Back, D; Cuenca, L; Egan, D; González-Pardo, G; Khoo, S; Labarga, P; Morello, J; Owen, A; Rodríguez-Nóvoa, S; Soriano, V | 1 |
| Cabié, A; Chêne, G; Girard, PM; Katlama, C; Mercié, P; Michelet, C; Monchecourt, F; Morand-Joubert, L; Pétour, P; Trylesinski, A; Verdon, R | 1 |
| Calmy, A; Ford, N; Mills, E | 1 |
| Colebunders, R; Lynen, L; van Griensven, J | 1 |
| Brenchley, J; Buckler-White, A; Igarashi, T; Kubo, M; Lafont, B; Lee, W; Martin, MA; Nishimura, Y; Shingai, M | 1 |
| Borroto-Esoda, K; Harris, J; Lansdon, EB; Miller, MD; O'Neal, W; Svarovskaia, ES; Wakeford, C; Waters, JM; White, KL | 1 |
| Beijnen, JH; Huitema, AD; Jansen, RS; Mulder, JW; Smits, PH; Ter Heine, R; van Gorp, EC; Wagenaar, JF | 1 |
| Cope, D; Iskander, E; Mikhail, N | 1 |
| Dauer, B; Gute, P; Khaykin, P; Klauke, S; Staszewski, S; Stephan, C; Stuermer, M | 1 |
| Callahan, MM; Mauck, CK; Poindexter, A; Schwartz, JL; Wheeless, A | 1 |
| Yoganathan, K | 1 |
| Atkins, M; Fisher, M; Gilleece, Y; Grover, D; Mandalia, S; Murungi, A; Nelson, M; Tan, LK | 1 |
| Foster, C; Gibb, DM; Lyall, H; Olmscheid, B; Pearce, G; Zhang, S | 1 |
| Connolly, JO; Copas, A; Edwards, SG; Hall, AM; Johnson, MA; Madge, S; Nair, D; Williams, IG; Woodward, CL | 1 |
| Hughes, B | 1 |
| Benn, P; Cartledge, J; Edwards, SG; Linney, A; Moyle, G; Reilly, G; Ruff, C; Sabin, CA; Sauret-Jackson, V | 1 |
| Arasteh, K; Ebrahimi, R; Fenske, S; Freiwald, M; Gallo, L; Kuhlmann, B; Mertenskoetter, T; Ranneberg, R; Weitner, L | 1 |
| Bellos, N; Fine, D; Kumar, PN; Lackey, P; Patel, P; Shaefer, MS; Sloan, L; Smith, KY; Sutherland-Phillips, DH; Vavro, C; Wannamaker, P; Yau, L | 1 |
| Ebrahimi, R; Ewan, J; Fisher, M; Kingston, M; Liu, H; Moyle, GJ; Orkin, C; Reilly, G; Shahmanesh, M; Wilkins, E | 1 |
| Cohen, C; Dejesus, E; Elion, R; Gathe, JC; Ha, B; Hsu, RK; Lanier, R; Paulsen, D; Redfield, RR; Ross, L; Yau, L | 1 |
| Brooks, JT; Buchacz, K; Moorman, A; Wood, KC; Young, B | 1 |
| Andrade, A; Eshleman, SH; Flanigan, T; Flexner, C; Gross, R; Hogg, E; Lalama, C; Mildvan, D; Reisler, R; Rosenkranz, S; Salomon, N; Santana, J; Tierney, C; Wiggins, I | 1 |
| Roehr, B | 2 |
| Andreotti, M; Antonelli, G; Ceccarelli, G; d'Ettorre, G; Massetti, P; Mastroianni, CM; Rizza, C; Turriziani, O; Vella, S; Vullo, V | 1 |
| Ainsworth, J; Anderson, J; Bansi, L; Dunn, D; Easterbrook, P; Fisher, M; Gazzard, B; Gilson, R; Gompels, M; Hill, T; Johnson, M; Leen, C; Orkin, C; Phillips, A; Pillay, D; Sabin, C; Walsh, J | 1 |
| Carballo-Diéguez, A; Gai, F; Hoffman, S; Mantell, JE; Morrow, KM; Rosen, RK | 1 |
| Cheng, AK; Enejosa, J; Margot, NA; McColl, DJ; Miller, MD | 1 |
| Barnard, RJ; Berger, DS; DeJesus, E; DiNubile, MJ; Lazzarin, A; Leavitt, R; Lennox, JL; Madruga, JV; Miller, MD; Nguyen, BY; Pollard, RB; Rodgers, AJ; Sklar, P; Williams-Diaz, A; Xu, X; Zhao, J | 1 |
| Bourgeois, A; Calmy, A; Ciaffi, L; Delaporte, E; Ducos, J; Kouanfack, C; Koulla-Shiro, S; Laurent, C; Mougnutou, R; Mpoudi-Ngolé, E; Nkoué, N | 1 |
| Cauda, R; Cicconi, P; Corsi, P; De Luca, A; Di Giambenedetto, S; Ladisa, N; Lapadula, G; Manca, N; Nasta, P; Paraninfo, G; Prosperi, M; Torti, C; Trezzi, M; Zazzi, M | 1 |
| Abeli, C; Bonfanti, P; Gianelli, E; Giuntini, R; Grosso, C; Madeddu, G; Marconi, P; Martinelli, C; Palvarini, L; Pellicano, G; Penco, G; Quirino, T; Ricci, E; Vichi, F | 1 |
| Gallant, JE; Moore, RD | 1 |
| Galegov, GA | 2 |
| Barreiro, P; Fernández, JV; Labarga, P; Medrano, J; Soriano, V; Tuma, P; Vispo, E | 1 |
| Chetchotisakd, P | 1 |
| Beltrame, A; Bozzano, F; Cenderello, G; Costa, P; De Maria, A; Di Biagio, A; Fenoglio, D; Ferrea, G; Pagano, G | 1 |
| Sankawa, Y | 1 |
| Warpakowski, A | 1 |
| Bickel, M; Bodtländer, A; Gute, P; Klauke, S; Knecht, GK; Kurowski, M; Lutz, T; Stephan, C; von Hentig, N | 1 |
| Chetty, K; Connolly, JO; Edwards, SG; Hall, AM; Lapsley, M; O'Farrell, S; Unwin, RJ; Williams, IG | 1 |
| Hill, A; Sawyer, W | 1 |
| Cavassini, M; Hayoz, D; Mazzolai, L; Periard, D; Widmeier, A; Yerly, P | 1 |
| Boccafoglio, F; Concia, E; Gottardi, M; Lanzafame, M; Lattuada, E; Soldani, F | 1 |
| Bersoff-Matcha, S; Blank, J; Chang, J; Horberg, M; Hurley, L; Klein, D; Quesenberry, C; Silverberg, M; Tang, B; Towner, W | 1 |
| Labarga, P; Rodriguez-Novoa, S; Soriano, V | 1 |
| Amin, J; Baker, D; Bloch, M; Carr, A; Cooper, DA; Emery, S; Martin, A | 2 |
| Reiss, P | 1 |
| Bangsberg, DR | 1 |
| Bonora, S; Calcagno, A; D'Avolio, A; Lanzafame, M; Penco, G; Perri, GD; Tettoni, MC | 1 |
| Andrews, M; Condoluci, DV; Luber, AD; Olson, K; Pakes, GE; Pappa, KA; Peloquin, CA; Slowinski, PD | 1 |
| Aldrovandi, GM; Cantrell, RA; Chi, BH; Chintu, N; Ellis, GM; Frenkel, LM; Mbewe, F; Nakamura, K; Sinkala, M; Stringer, EM; Stringer, JS; Warrier, R | 1 |
| Battegay, M; Calmy, A; de Wolf, F; Hirschel, B; Hogg, RS; Lange, JM; Lima, VD; Montaner, JS; Nguyen, A; Reiss, P; Vallier, N; Wit, FW; Yip, B | 1 |
| Amuron, B; Birungi, J; Bunnell, R; Coutinho, A; Foster, S; Grosskurth, H; Jaffar, S; Kyomuhangi, R; Levin, J; Mermin, J; Nabiryo, C; Namara, G; Ndembi, N; Opio, A; Tappero, JW | 1 |
| Blanzat, M; Caminade, AM; Majoral, JP; Moog, C; Pérez-Anes, A; Rico-Lattes, I; Stefaniu, C; Turrin, CO | 1 |
| Collier, AC; Daar, ES; Farajallah, A; Fischl, MA; Geiseler, PJ; Godfrey, C; Ha, B; Jahed, NC; Johnson, VA; Katzenstein, D; Koletar, SL; Mollan, K; Myers, L; Peeples, L; Rooney, JF; Sax, PE; Tierney, C; Woodward, WC | 1 |
| Bonnet, F; Dabis, F; Déti, EK; Dupon, M; Lawson-Ayayi, S; Malvy, D; Morlat, P; Neau, D; Pellegrin, JL; Tchamgoué, S; Thiébaut, R | 1 |
| Abaine, D; Aber, M; Ahimbisibwe, F; Akao, J; Akuma, S; Amuron, B; Amurwon, J; Angweng, E; Anywar, W; Atwiine, D; Atwiine, S; Awio, P; Babiker, A; Babiker, AG; Bafana, T; Bagaya, L; Bahendeka, S; Bakeinyaga, GT; Barungi, G; Bassett, M; Bohannon, J; Boocock, K; Borok, M; Bray, D; Breckenridge, A; Bulaya-Tembo, R; Buluma, E; Burke, A; Burke, C; Byakwaga, H; Byamukama, A; Byaruhanga, R; Chakonza, L; Chidziva, E; Chigwedere, E; Chimanzi, J; Chimbetete, C; Chirairo, H; Chirara, M; Chirema, O; Chitsungo, S; Chivhunga, T; Coutinho, A; Darbyshire, JH; Drasiku, A; Dunn, D; Enzama, R; Etukoit, B; Fadhiru, K; Ferrier, A; Florence, A; Foster, S; Gazzard, B; Generous, L; Gibb, DM; Gilks, C; Gilks, CF; Goodall, R; Grosskurth, H; Grundy, C; Haguma, W; Hakim, J; Hill, C; Hughes, P; Jamu, A; Jangano, M; Jones, S; Kabanda, J; Kabuye, G; Kagina, G; Kajungu, D; Kaleebu, P; Kambungu, A; Kankunda, R; Karungi, J; Kasirye, R; Katabira, E; Katabira, H; Katundu, P; Khauka, P; Kigozi, J; Kikaire, B; Kityo, C; Komugyena, J; Kulume, R; Kusiima, A; Kyomugisha, H; Labeja, O; Lara, AM; Latif, A; Levin, J; Lubwama, E; Lutwama, F; Lyagoba, F; Machingura, I; Machingura, J; Makota, S; Mambule, I; Mapinge, F; Mapuchere, C; Massa, R; Matenga, J; Matongo, M; Maweni, C; Mawora, A; McCormick, A; McLaren, A; Mdege, N; Moyo, K; Muchabaiwa, L; Mudzingwa, S; Mufuka-Kapuya, C; Muganzi, A; Mugisha, A; Mugurungi, O; Mugyenyi, P; Muhweezi, D; Muhwezi, A; Mukiibi, S; Mukose, A; Mulindwa, G; Mulindwa, M; Munderi, P; Murungi, S; Musana, H; Musoro, G; Mutowo, J; Mutsai, S; Muvirimi, C; Muyingo, S; Muzambi, M; Mwebesa, D; Mwesigwa, P; Nabankema, E; Nabongo, P; Naidoo, B; Nairuba, R; Nakahima, W; Nakazibwe, M; Nakiyingi, J; Nalumenya, R; Namale, L; Namara, W; Namata, I; Namazzi, A; Namuli, T; Namyalo, M; Nanfuka, A; Nanfuka, R; Nassuna, G; Ndembi, N; Newland, C; Ngorima, N; Nimwesiga, E; Nsibambi, D; Nyachwo, L; Nyiraguhirwa, D; Ochai, R; Ojiambo, H; Ojiambo, W; Oketta, F; Omony, W; Otim, T; Oyugi, J; Palfreeman, A; Pascoe, M; Pearce, G; Peto, L; Peto, T; Phiri, M; Pillay, D; Pozniak, A; Puddephatt, C; Rahim, S; Rauchenberger, M; Reid, A; Robertson, V; Ronald, A; Rooney, J; Ruberantwari, A; Rutikarayo, N; Sabiiti, J; Sadik, F; Sematala, F; Serwadda, D; Sheehan, S; Simango, M; Smith, M; Snowden, W; Spencer-Drake, C; Spyer, M; Ssali, F; Steens, JM; Svovanapasis, P; Takubwa, J; Taylor, K; Taziwa, F; Tinago, G; Todd, J; Tugume, S; Tukamushaba, J; Tumukunde, D; Tumusiime, C; Twijukye, C; Vere, L; Waita, R; Wakholi, BN; Walker, AS; Walusimbi, J; Wangati, K; Wanyama, J; Wapakhabulo, AC; Warambwa, C; Warara, R; Wavamunno, P; Weller, I; Whitworth, J; Wilkes, H; Winogron, D; Yirrell, D; Zalwango, A; Zalwango, E; Zawedde, C; Zengeza, E | 1 |
| Cohen, C; DeJesus, E; Elion, R; Gerondelis, P; Ha, B; Horton, J; Lanier, ER; Ross, LL; Rouse, E | 1 |
| Bolton-Moore, C; Chi, BH; Chintu, N; Giganti, M; Mulenga, LB; Mulenga, PL; Mwaba, P; Mwango, A; Reid, SE; Sheneberger, R; Stringer, EM; Stringer, JS; Tambatamba-Chapula, B | 1 |
| Barragán, P; Casamitjana, R; Deulofeu, R; Gatell, JM; Gutiérrez, F; Larrousse, M; Loncá, M; Mallolas, J; Martínez, E; Pérez, I; Pich, J; Podzamczer, D | 1 |
| Moore, K; Radzio, J; Sluis-Cremer, N; Sonza, S; Tachedjian, G | 1 |
| Gervain, J; Horváth, G; Hunyady, B; Makara, M; Pár, A; Szalay, F; Telegdy, L; Tornai, I | 1 |
| Boothby, M; Gathercole, LL; McGee, KC; McTernan, PG; Nightingale, P; Shahmanesh, M; Shojaee-Moradie, F; Tomlinson, JW; Umpleby, AM | 1 |
| Cheshenko, N; Fakioglu, E; Herold, BC; Keller, MJ; Mesquita, PM; Wilson, SS | 1 |
| Absalon, J; Andrade-Villanueva, J; Chetchotisakd, P; Corral, J; David, N; Echevarria, J; Lataillade, M; Mancini, M; McGrath, D; Molina, JM; Moyle, G; Percival, L; Wirtz, V; Yang, R | 1 |
| Bender, MA; Flanigan, T; Freedberg, KA; Kumarasamy, N; Lu, Z; Mayer, KH; Schackman, BR; Scott, CA; Walensky, RP; Wang, B | 1 |
| Aubron-Olivier, C; Bittar, R; Bollens, D; Bonnefont-Rousselot, D; Costagliola, D; de Truchis, P; Giral, P; Katlama, C; Pétour, P; Slama, L; Valantin, MA | 1 |
| Battegay, M; Bernasconi, E; Cavassini, M; Elzi, L; Furrer, H; Hirschel, B; Ledergerber, B; Marzolini, C; Vernazza, P; Weber, R | 1 |
| Altice, FL; Springer, SA | 1 |
| Bateman, C | 3 |
| Bi, L; Daar, ES; Diamond, C; Flaherty, J; Goicoechea, M; Ha, B; Haubrich, R; Jain, S; Kemper, C; Louie, S; Richman, D; Sun, S | 1 |
| Baraboutis, IG; Georgiou, O; Kotsianopoulou, M; Papastamopoulos, V; Samarkos, M; Skoutelis, AT; Vrionis, E | 1 |
| Dinsmore, WW; Donnelly, CM; Emerson, CR; Quinn, KJ | 1 |
| Burty, C; Christian, B; May, T; Penalba, C; Prazuck, T; Rabaud, C; Salmon-Ceron, D; Truchetet, F; Yazdanpanah, Y | 1 |
| Denton, PW; Estes, JD; Garcia, JV; Krisko, JF; Kwak, YT; Martinez-Torres, F; Mathias, M; Payne, DA; Powell, DA; Zou, W | 1 |
| Calvez, V; Grant, PM; Marcelin, AG; Nevins, AB; Taylor, J; Wirden, M; Zolopa, AR | 1 |
| Bruzzone, B; Colao, G; De Silvestri, A; Di Biagio, A; Di Pietro, M; Maserati, R; Re, MC; Tinelli, C; Uglietti, A; Zazzi, M | 1 |
| Boyd, KL; Butler, K; Dunn, D; Gibb, DM; Judd, A; Lyall, H; Riordan, A; Sharland, M; Shingadia, D; Stöhr, W | 1 |
| Flux, K; Gholam, P; Hartmann, M; Hueter, E; Weberschock, T | 1 |
| Dejesus, E; Ebrahimi, R; Ecker, J; Esker, S; Farajallah, A; Flaherty, JF; Grimm, K; Hodder, SL; Mounzer, K | 1 |
| Airoldi, M; Cossarizza, A; De Biasi, S; Gibellini, L; Maggiolo, F; Mussini, C; Nasi, M; Pinti, M; Ravasio, V; Roat, E; Suter, F | 1 |
| de Mendoza, C; Labarga, P; Medrano, J; Morello, J; Poveda, E; Rodriguez-Novoa, S; Seclen, E; Soriano, V; Vispo, E | 1 |
| Carr, A; van Agtmael, MA; Wever, K | 1 |
| Flandre, P | 1 |
| Dutta, A; Edwards, MS; Schwarzwald, HL | 1 |
| Landman, GW; Soonawala, D | 1 |
| Albalate, M; Barreiro, P; Bonora, S; D'avolio, A; Di Perri, G; Labarga, P; Rodríguez-Nóvoa, S; Siccardi, M; Solera, C; Soriano, V; Vispo, E | 1 |
| Brown, LB; Eron, JJ; Hosseinipour, MC; Kumwenda, JJ; Mhango, B; Mzinganjira, D; Phiri, S; van Oosterhout, JJ; Weigel, R | 1 |
| DeJesus, E; Fischl, MA; Horton, JH; Lancaster, CT; Pakes, GE; Pappa, KA; Ross, LL; Smith, KY; Weinberg, WG | 1 |
| Khandazhinskaya, A; Matyugina, E; Shirokova, E | 1 |
| Alvarez, E; Labarga, P; Rodriguez-Nóvoa, S; Soriano, V | 1 |
| Back, D; Dickinson, L; Erlwein, OW; Garvey, L; Latch, N; Mackie, NE; McClure, MO; Scullard, G; Walsh, J; Winston, A | 1 |
| Benhamou, Y; Izzedine, H; Peytavin, G; Schneider, L; Thibault, V; Valantin, MA | 1 |
| Branco, T; Cavassini, M; Domingo, P; Fisher, M; Givens, N; Khuong-Josses, MA; Lim, ML; Moyle, GJ; Norden, AG; Pearce, HC; Podzamczer, D; Post, FA; Rieger, A; Stellbrink, HJ; Vavro, C | 1 |
| Almond, MR; Buckheit, RW; Hartman, T; Keilholz, L; Lampert, BM; Lanier, ER; Mankowski, MK; Osterling, MC; Painter, GR; Ptak, RG | 1 |
| Floridia, M; Manconi, PE; Ortu, F; Weimer, LE | 1 |
| Absalon, J; Malan, N; Mancini, M; McGrath, D; Su, J; Wirtz, V; Yang, R | 1 |
| Sax, PE | 4 |
| Aberg, JA; Alston-Smith, B; Glesby, MJ; Gupta, SK; Jones, L; Kitch, D; Mellors, JW; Moran, L; Rooney, JF; Tungsiripat, M | 1 |
| Behrens, G; Ho, NA; Schmidt, RE | 1 |
| Barahona, I; Brodine, S; Crum-Cianflone, N; Ganesan, A; Medina, S; Riddle, M; Teneza-Mora, N | 1 |
| Barnas, D; Bazmi, H; Bixby, C; Jemsek, J; Koontz, D; Mellors, JW | 1 |
| Freedberg, KA; Loubiere, S; Meiners, C; Sloan, C; Yazdanpanah, Y | 1 |
| Galau, NH; Moore, S; Myint, MM | 1 |
| Johnson, LM; Mack, N; MacQueen, KM; Moffett, J; Robinson, ET | 1 |
| Chambers, MG; Earnshaw, SR; Farkouh, RA; Kauf, TL; Maroudas, P; Watson, ME | 1 |
| Anzidei, G; Baroncelli, S; Cauda, R; Cusato, M; De Luca, A; Fantoni, M; Floridia, M; Pinnetti, C; Regazzi, M; Tamburrini, E; Tozzi, V; Villani, P | 1 |
| Bansi, L; Campbell, LJ; Cheserem, E; Hendry, BM; Ibrahim, F; Naftalin, C; Post, FA; Roe, J; Sabin, C | 1 |
| Cohen, J | 7 |
| Abdool Karim, Q; Abdool Karim, SS; Arulappan, N; Baxter, C; Frohlich, JA; Gengiah, TN; Grobler, AC; Kharsany, AB; Maarschalk, S; Mansoor, LE; Mlisana, KP; Mlotshwa, M; Morris, L; Omar, Z; Sibeko, S; Taylor, D | 1 |
| Bosch, M; Brouwer, AM; Burger, D; Dofferhoff, T; Keuter, M; Koopmans, PP; van der Ven, A; van Luin, M | 1 |
| Carr, A; Richardson, R; Sinn, K | 1 |
| Gianini, RJ; Gomes-Gouvêa, MS; Leite, OM; Locarnini, S; Martins, LG; Mendes-Correa, MC; Pinho, JR; Santana, RA; Silva, MH; Sitnik, R; Uip, DE; Yuen, L | 1 |
| Bacchetti, P; Biggs, ML; Currier, JS; Delaney, JA; Grunfeld, C; Kronmal, RA; O'leary, D; Polak, JF; Scherzer, R; Shliplak, MG; Tien, PC; Wanke, C | 1 |
| Bano, G; Copas, AJ; Gedela, K; Hay, PE; Pakianathan, MR; Rosenvinge, MM; Sadiq, ST; Sheehy, CA; Wilkinson, A | 1 |
| Branch, AD; Childs, KE; Constable, C; Dieterich, DT; Fishman, SL; Gutierrez, JA; Mullen, MP; Wyatt, CM | 1 |
| Bernstein, B; Cohen, D; da Silva, B; Fredrick, L; González-García, J; Johnson, M; Naylor, C; Sloan, L | 1 |
| Cooper, RD; Keiser, P; Naicker, S; Smith, N; Tonelli, M; Wiebe, N | 1 |
| Baleta, A | 2 |
| German, P; Hui, J; Kearney, BP; Warren, D; West, S | 1 |
| Curto, J; Niubo, J; Podzamczer, D; Tiraboschi, JM | 1 |
| Cates, W | 1 |
| DeJesus, E; Kakuda, TN; Lalezari, JP; Osiyemi, OO; Ruane, PJ; Ryan, R; Witek, J | 1 |
| Benabdelmoumen, G; Bouvet, E; Christian, B; Muller, P; Peyrouse, E; Prazuck, T; Quertainmont, Y; Rabaud, C; Tosini, W | 1 |
| Alcaro, S; Alteri, C; Antinori, A; Artese, A; Balzarini, J; Ceccherini-Silberstein, F; Costa, G; Forbici, F; Narciso, P; Perno, CF; Santoro, MM; Schols, D; Svicher, V; Tommasi, C; Van Laethem, K; Zaccarelli, M | 1 |
| Cacoub, P; Carrat, F; Goderel, I; Lacombe, K; Loustau-Ratti, V; Miailhes, P; Morlat, P; Piroth, L; Pol, S; Rami, A; Rey, D; Rosenthal, E; Sene, D | 1 |
| de Man, RA; de Vries-Sluijs, TE; Hansen, BE; Hoepelman, AI; Janssen, HL; Mulder, JW; Pas, SD; Prins, JM; Reijnders, JG; Richter, C; Schutten, M; van der Ende, ME; Zaaijer, HL | 1 |
| D'Agati, VD; Herlitz, LC; Markowitz, GS; Mohan, S; Radhakrishnan, J; Stokes, MB | 1 |
| Mohammadi, D | 1 |
| Arrivé, E; Avit, D; Blanche, S; Chaix, ML; Dabis, F; Ekouévi, DK; Gray, G; Kruy, LS; McIntyre, J; Nerrienet, E; Rouzioux, C; Say, L | 1 |
| Carr, A; Hoy, J | 1 |
| Arribas, JR; Compston, J; Gerstoft, J; Hughes, S; Lambert, J; Lazzarin, A; Leather, D; Orkin, C; Pearce, H; Rizzardini, G; Sprenger, HG; Stellbrink, HJ; Sture, G; Van Wijngaerden, E; Zucchi, P | 1 |
| Aba, YT; Aoussi, EF; Bissagnene, E; Eholié, SP; Ehui, E; Kadio, A; Kakou, AR; Kassi, A; Ondounda, M; Ouattara, I; Tanon, A | 1 |
| Avihingsanon, A; Bowden, S; Chang, JJ; Dore, GJ; Kerr, S; Lange, J; Lewin, SR; Matthews, GV; Napissanant, N; Piyawat, K; Ruxrungtham, K | 1 |
| Boucher, CA; van de Vijver, DA | 1 |
| McCoy, SI; Padian, NS; Watts, CH | 1 |
| De Beaudrap, P; Delaporte, E; Diallo, MB; Diouf, A; Etard, JF; Girard, PM; Guèye, NF; Kane, CT; Landman, R; Ndiaye, I; Sow, PS | 1 |
| Allegri, R; Amadasi, S; Carosi, G; Cristini, G; Gatti, F; Izzo, I; Mendeni, M; Motta, D; Paraninfo, G; Quiros-Roldan, E; Torti, C | 1 |
| Murphy, B; Romanelli, F | 1 |
| De Terlizzi, F; Parodi, A; Rosso, R; Torrisi, C; Vignolo, M; Viscoli, C | 1 |
| Corbett, C; De Smedt, G; Hoetelmans, RM; Kakuda, TN; Leopold, L; Nijs, S; Peeters, MP; Schöller-Gyüre, M; Snoeck, E; Vingerhoets, J; Vis, P; Wade, JR; Woodfall, BJ | 1 |
| Addad, N; Ariën, KK; Augustijns, P; Bourlet, T; Brouwers, J; Delezay, O; Gali, Y; Hamzeh-Cognasse, H; Pozzetto, B; Vanham, G | 1 |
| Rutherford, GW; Siegfried, N; Spaulding, A | 1 |
| Alston-Smith, B; Asmelash, A; Atwine, D; Chipato, T; Conradie, F; Currier, JS; Eshleman, S; Hakim, J; Hogg, E; Hosseinipour, MC; Hughes, MD; Kanyama, C; Lockman, S; McIntyre, J; Mellors, JW; Mngqibisa, R; Mohapi, L; Purcelle-Smith, E; Rahim, S; Rooney, J; Salata, RA; Sawe, F; Schooley, RT; Shaffer, D; Siika, A; Stringer, E; Walawander, A; Wools-Kaloustian, K; Zheng, Y | 1 |
| Arrivé, E; Avit, D; Benaboud, S; Blanche, S; Dabis, F; Ekouévi, DK; Gray, G; Hirt, D; McIntyre, J; Nerrienet, E; Rey, E; Sim, KL; Tréluyer, JM; Urien, S | 1 |
| Anton, P; Becker, S; Burns, D; DeGruttola, V; Fletcher, CV; McGowan, I; Veronese, F; Zwerski, S | 1 |
| Bonacini, M | 1 |
| Asensi, V; Miró, JM; Rodríguez-Guardado, A; Tuset, M | 1 |
| Bonnard, P; Boyd, A; Girard, PM; Lacombe, K; Lascoux-Combe, C; Lasnier, E; Meynard, JL; Miailhes, P; Molina, JM; Wendum, D | 1 |
| Anglaret, X; Attia, A; Chenal, H; Danel, C; Eholié, S; Gabillard, D; Messou, E; N'Dri-Yoman, T; Polneau, S; Seyler, C; Toni, T; Wakasugi, N | 1 |
| Cerini, C; Fabiano, V; Giacomet, V; Mora, S; Pivetti, V; Puzzovio, M; Viganò, A; Zamproni, I; Zuccotti, GV | 1 |
| Bonjoch, A; Clotet, B; del Rio, L; di Gregorio, S; Estany, C; Figueras, M; Gómez, G; Negredo, E; Perez-Alvarez, N; Puig, J; Rosales, J | 1 |
| Bangsberg, DR; Deeks, SG; Monk, A; Ragland, K | 1 |
| Batard, ML; Martinot, M; Roth, B; Springinsfeld, G; Tortel, MC | 1 |
| Bénet, T; Billioud, C; Boibieux, A; Brochier, C; Chevallier, M; Cotte, L; Ferry, T; Miailhes, P; Scoazec, JY; Vanhems, P; Zoulim, F | 1 |
| Bowonwatanuwong, C; Chaisiri, K; Kasettratat, N; Kiertiburanakul, S | 1 |
| Figueras, C; Fortuny, C; Garcia, L; Martín-Nalda, A; Melendo, S; Mellado, MJ; Navarro, ML; Noguera-Julian, A; Soler-Palacín, P; Uriona, S | 1 |
| Perazella, MA | 1 |
| Deeks, ED; Perry, CM | 1 |
| Michael, NL | 1 |
| Amico, KR; Anderson, PL; Bekker, LG; Buchbinder, SP; Burns, DN; Bushman, LR; Casapía, M; Chariyalertsak, S; Defechereux, P; Fernández, T; Ganoza, C; Glidden, DV; Goicochea, P; Grant, RM; Guanira-Carranza, JV; Hance, RJ; Jaffe, HS; Kallás, EG; Lama, JR; Lee, J; Liu, AY; Martinez, AI; Mayer, KH; McConnell, JJ; McMahan, V; Montoya-Herrera, O; Mulligan, K; Postle, B; Ramirez-Cardich, ME; Rooney, JF; Schechter, M; Vargas, L; Veloso, VG; Wang, F; Zheng, JH | 1 |
| Benhamou, Y; Pais, R | 1 |
| Anderson, PL; Gardner, EM; Grant, RM; Kiser, JJ; Meditz, A; Rower, JE | 1 |
| Bracciale, L; Cauda, R; De Luca, A; Di Cristo, V; Di Giambenedetto, S; Doino, M; Fabbiani, M; Farina, S; Sidella, L | 1 |
| Ariën, KK; Vanham, G | 1 |
| Back, DJ; Boffito, M; Jackson, AG; Mandalia, S; Moyle, GJ; Randell, PA; Taylor, J; Tjia, JF | 1 |
| Kaul, R; Raboud, JM; Tan, DH; Walmsley, SL | 1 |
| Borroto-Esoda, K; Goodman, DD; Margot, NA; McColl, DJ; Miller, MD; Svarovskaia, ES; Zhong, L; Zhou, Y | 1 |
| Bygrave, H; Ford, N; Goemaere, E; Hilderbrand, K; Jouquet, G; Kranzer, K; Makakole, L; Triviño, L; van Cutsem, G; Vlahakis, N | 1 |
| Burleson, D; Gayton, JC; Laughlin, RT; Polenakovik, H | 1 |
| Martin, L | 1 |
| Mallet, V; Pol, S; Vallet-Pichard, A | 1 |
| Cooper, RD; Tonelli, M | 1 |
| Abdool Karim, SS; Baxter, C | 2 |
| de Silva, T; Weiss, RA | 1 |
| Wainberg, MA | 1 |
| Van Damme, L; Vermund, SH | 1 |
| Arulappan, N; Gengiah, T; Karim, QA; Karim, SS; Kharsany, AB; Luthuli, LR; Mlisana, KP; Naidoo, K; Omar, Z; Yende, N | 1 |
| Babusis, D; Durand-Gasselin, L; Flaherty, JF; Hawkins, T; Ray, AS; Reddy, YS; Veikley, W | 1 |
| Basar, M; Best, BM; Burchett, SK; Capparelli, EV; Hawkins, E; Hu, C; Mirochnick, M; Read, JS; Rossi, SS; Smith, E; Stek, AM | 1 |
| Chen, J; Cho, S; Cohen, HW; Diament, EC; Fazzari, MJ; Hendrix, CW; Herold, BC; Kalyoussef, S; Keller, MJ; Lee, AC; Louissaint, N; Madan, RP; Mesquita, PM; Shust, G; Soto-Torres, L; Torres, NM | 1 |
| Mayer, KH; Myers, GM | 1 |
| Bentley, TG; Broder, MS; Chang, EY; Juday, T; Uy, J | 1 |
| Alivanis, P; Aperis, G; Arvanitis, A; Paliouras, C; Zervos, A | 1 |
| Collette, DC; Zechel, MA | 1 |
| García, N; Gutiérrez, F; Jarrin, I; Masiá, M; Padilla, S; Tormo, C | 1 |
| Arribas, JR; Hill, A; Moecklinghoff, C; Pulido, F; Van Delft, Y | 1 |
| de Béthune, MP; De Meyer, S; Dierynck, I; Lathouwers, E; Lavreys, L; Picchio, G; Van de Casteele, T | 1 |
| Campbell, LJ; Hamzah, L; Post, FA | 1 |
| Bracciale, L; Cauda, R; D'Avino, A; De Luca, A; Di Giambenedetto, S; Doino, M; Fabbiani, M; Marzocchetti, A; Navarra, P | 1 |
| León, E; Lozano de León-Naranjo, F; Pérez-Rivera, AÁ; Sáez, P | 1 |
| Driscoll, M; Erickson, C; Gaspari, A | 1 |
| Baldelli, F; Floridia, M; Francisci, D; Martinelli, L; Masini, G; Weimer, LE; Zazzi, M | 1 |
| Kaptur, PE; Mertenskoetter, T | 1 |
| Beadsworth, MB; Pennell, A; Phillips, M; Ratcliffe, L; Vilar, FJ | 1 |
| Aboh, S; Bosivert, N; Duke, N | 1 |
| Chimsuntorn, S; Lueangniyomkul, A; Mankatitham, W; Manosuthi, W; Nilkamhang, S; Sungkanuparph, S; Suntisuklappon, B; Tantanathip, P; Thongyen, S | 1 |
| Arulappan, N; Baxter, C; Frohlich, JA; Gengiah, TN; Grobler, A; Karim, QA; Karim, SS; Kharsany, AB; Maarschalk, S; Mansoor, LE; Mlisana, KP; Mlotshwa, M; Omar, Z; Samsunder, N; Sibeko, S; Yende, N | 1 |
| Darin, KM; Gerzenshtein, L; O'Donnell, EP; Palella, FJ; Postelnick, MJ; Scarsi, KK | 1 |
| Gruters, RA; Luider, TM; Meesters, RJ; Scheuer, RD; van der Ende, ME; van Kampen, JJ | 1 |
| Calmy, A; Hirschel, B; Schiffer, V | 1 |
| Chuck, SL; Cohen, C; DeJesus, E; Elion, R; Kearney, BP; Liu, HC; Ramanathan, S; Rashbaum, B; Ruane, P; Shamblaw, D; Warren, DR; Yale, K | 1 |
| Kuijper, A; Mudrikova, T; Rookmaker, MB | 1 |
| Connolly, JO; Hall, AM; Hendry, BM; Nitsch, D | 1 |
| Alukda, D; Sturgis, T; Youan, BC | 1 |
| Desire, N; Katlama, C; Stitou, H; Thibault, V; Tubiana, R; Valantin, MA | 1 |
| Calza, L; Colangeli, V; Manfredi, R; Piergentili, B; Tedeschi, S; Trapani, F; Viale, P | 1 |
| French, P; Pittrof, R; Sauer, U | 1 |
| Underhill, K | 1 |
| Malgarini, RB; Pimpinella, G | 1 |
| Lafuente-Lafuente, C; Roques, P; Sellier, PO | 1 |
| Lee, DH; Vielemeyer, O | 1 |
| Cooper, V; Ewan, J; Fisher, M; Horne, R; Liu, HC; Moyle, GJ; Reilly, G | 1 |
| Barry, AC; Chu, H; Eron, JJ; Ferrari, G; Fiscus, SA; Gay, CL; Hicks, CB; Kerkau, M; Kuruc, JD; Margolis, DM; Mayo, AJ; McGee, KS; Mfalila, CK; Sebastian, J | 1 |
| Balzarini, J; Dittmann, E; Férir, G; Huskens, D; Kehr, JC; Markovitz, DM; Schols, D; Swanson, MD; Van Damme, EJ; Vermeire, K | 1 |
| Chan, DJ; Jeganathan, S; Maruszak, H; Smith, DE | 1 |
| Choi, AI; Deeks, SG; Li, Y; Shlipak, MG; Vittinghoff, E; Weekley, CC | 1 |
| Gracey, D; MacLeod, C; McKenzie, P; Post, J | 1 |
| Andrade-Villanueva, J; Cairns, V; Clotet, B; de Rossi, L; Domingo, P; Gellermann, HJ; Podzamczer, D; Reiss, P; Rockstroh, JK; Soriano, V; Taylor, S | 1 |
| Aung, W; Cong, ME; García-Lerma, JG; Hanson, DL; Heneine, W; Holder, A; Kersh, E; Kuklenyik, S; Lee, WA; Lin, CY; Luo, W; Martin, A; Mitchell, J; Pau, CP; Ray, AS; Rooney, JF; Youngpairoj, AS; Zheng, Q | 1 |
| Bedogni, G; Caprio, C; Cerini, C; di Nello, F; Giacomet, V; Manfredini, V; Penagini, F; Viganò, A; Zuccotti, GV | 1 |
| Bonnet, F; Cazanave, C; Dabis, F; Dauchy, FA; de La Faille, R; Dupon, M; Greib, C; Lawson-Ayayi, S; Mehsen, N; Miremont-Salamé, G; Rigothier, C | 1 |
| Andrade-Villanueva, J; Antunes, F; Arastéh, K; de Rossi, L; Di Perri, G; Domingo, P; Gellermann, H; Lutz, T; Migrone, H; Opravil, M; Podzamczer, D; Soriano, V; Taylor, S | 1 |
| Bronsveld, W; Haverkort, ME; Huitema, AD; Lips, P; Slieker, WA; ter Heine, R; van der Spek, BW | 1 |
| Stephenson, J | 1 |
| Appella, E; Denton, PW; Estes, JD; Fleming, E; Gallay, P; Garcia, JV; Kay, MS; Krisko, JF; Kwak, YT; Lu, M; Martinez-Torres, F; Othieno, F; Payne, DA; Powell, DA; Wahl, A; Welch, BD; Zein, S; Zou, W | 1 |
| Wepner, U | 1 |
| Daar, ES; Ha, B; Jahed, NC; Kitch, D; McComsey, GA; Melbourne, K; Myers, L; Sax, PE; Tebas, P; Tierney, C | 1 |
| Albalater, M; Back, DJ; Bonora, S; Di Perri, G; Hopper-Borge, E; Khoo, S; Labarga, P; Liptrott, NJ; Owen, A; Pirmohamed, M; Pushpakom, SP; Rodríguez-Nóvoa, S; Soriano, V | 1 |
| Colby-Germinario, SP; Schachter, JR; Schader, SM; Wainberg, MA; Xu, H | 1 |
| Brennan, A; Evans, D; Fox, M; Ive, P; Maotoe, T; Maskew, M; Naicker, S; Sanne, I | 1 |
| Blanche, S; Dollfus, C; Firtion, G; Foissac, F; Hirt, D; Laurent, C; Treluyer, JM; Urien, S | 1 |
| Bedimo, RJ; Drechsler, H; Tebas, P; Vidiella, G; Westfall, AO | 1 |
| Abdool Karim, SS; Gouws, E; Karim, QA; Williams, BG | 1 |
| Cotter, AG; Powderly, WG | 1 |
| Hakim, JG; Katsidzira, L | 1 |
| Acosta, EP; Britto, P; Carey, V; Graham, B; Hazra, R; Jean-Philippe, P; King, JR; Wiznia, A; Yogev, R | 1 |
| Barragán, P; Bonet, R; Curran, A; Gatell, JM; Knobel, H; Loncá, M; Martínez, E; Negredo, E; Ordoñez-Llanos, J; Podzamczer, D; Ribera, E; Saumoy, M | 1 |
| Athmann, C; Berger, F; Filmann, N; Hegener, P; Henke, J; Herrmann, E; Hueppe, D; Mauss, S; Schmutz, G | 1 |
| Meng, J; Sturgis, TF; Youan, BB | 1 |
| Chimsuntorn, S; Manosuthi, W; Nilkamhang, S; Prasithsirikul, W; Sungkanuparph, S; Tantanathip, P | 1 |
| Koole, O; Lynen, L; Sopheak, T; van Griensven, J; Verpooten, GA | 1 |
| Chan, K; Cooper, C; Hogg, RS; Klein, MB; Loutfy, MR; Machouf, N; Montaner, JS; Raboud, J; Rourke, SB; Tan, DH; Tsoukas, C; Walmsley, S | 1 |
| Bonasso, M; Bonora, S; Calcagno, A; D'Avolio, A; Di Perri, G; Imperiale, D; Romito, A; Rostagno, R; Simiele, M; Tettoni, MC | 1 |
| Akimoto, T; Hamano, Y; Iwazu, Y; Kusano, E; Miki, T; Muto, S; Numata, A; Otani, N; Saito, O; Sugase, T; Takemoto, F; Toshima, M; Ueda, Y | 1 |
| Beadle, JR; Hostetler, KY; Hwu, JB; Prichard, MN; Schooley, RT; Valiaeva, N; Wyles, DL | 1 |
| Farajallah, A; McGrath, D; Sheppard, L; Uy, J; Wirtz, V; Yang, R | 1 |
| Sturgis, TF; Youan, BB; Zhang, T | 1 |
| Andrei, G; Balzarini, J; Hocková, D; Holý, A; Snoeck, R | 1 |
| Bouldouyre, MA; Molina, JM; Pavie, J; Pillebout, E; Scemla, A; Verine, J | 1 |
| Hosseini, SH; Kohler, JJ | 1 |
| Ellis, RM; Hood, AF; Mohr, MR; Oldfield, EC | 1 |
| Debyser, Z; Desimmie, BA; Schrijvers, R | 1 |
| Karim, QA; Karim, SS; Kashuba, AD; Werner, L | 1 |
| Bygrave, H; Cleary, S; Ford, N; Gadot, L; Goemaere, E; Hilderbrand, K; Jouquet, G; Kranzer, K; Lee, J; Makakole, L; Trivino, L; Vlahakis, N | 1 |
| Bertz, R; Boffito, M; Child, M; Chung, E; Kashuba, A; Mahnke, L; Patterson, K; Tebas, P; Wang, X; Wu, Y; Zhang, J; Zhu, L | 1 |
| Karim, QA; Karim, SS | 2 |
| Chau, Q; Fessel, WJ; Leong, D | 1 |
| Burlacu, R; de Lastours, V; Fonsart, J; Gourmel, B; Molina, JM | 1 |
| Lane, JM; Rebolledo, BJ; Unnanuntana, A | 1 |
| Aoki, T; Gatanaga, H; Honda, H; Honda, M; Kikuchi, Y; Kinai, E; Komatsu, H; Nishijima, T; Oka, S; Tanuma, J; Teruya, K; Tsukada, K; Watanabe, K; Yazaki, H | 1 |
| Bruzzone, B; Callegaro, AP; Di Biagio, A; Maggiolo, F; Nulvesu, L; Rosso, R; Taramasso, L; Viscoli, C | 1 |
| Kazazis, C | 1 |
| Gatanaga, H; Kikuchi, Y; Nagata, N; Nishijima, T; Oka, S; Teruya, K; Tsukada, K; Watanabe, K | 1 |
| Chuck, SL; Cohen, C; Elion, R; Gathe, J; Hawkins, T; Kearney, BP; Liu, HC; Mathias, AA; Shalit, P; Warren, DR | 1 |
| Allavena, C; Dejesus, E; Fernandez Garcia, E; Fisher, M; Hardy, WD; Jackson, AG; Jayaweera, DT; Katlama, C; Mauss, S; Moyle, GJ; Raffi, F; Reiss, P; Slama, L; van Eeden, A; Vrouenraets, SM; Wit, FW | 1 |
| Ammassari, A; Castagna, A; Delaugerre, C; Ghosn, J; Medrano, J; Molina, JM; Pavie, J; Porcher, R; Rusconi, S; Torti, C; Valin, N | 1 |
| Cocohoba, J; Gruta, C; John, MD; Lao, CK | 1 |
| Holodniy, M; Schirmer, P; Winters, M | 1 |
| Balazs, AB; Baltimore, D; Dekel, E; Kim, JT; Mayo, A; Milo, R; Sigal, A | 1 |
| Baldelli, F; Belfiori, B; Falcinelli, E; Fierro, T; Francisci, D; Gresele, P; Petito, E | 1 |
| Bolton-Moore, C; Chi, BH; Chintu, NT; Giganti, MJ; Moyo, C; Mulenga, LB; Mwango, A; Schuttner, L; Sheneberger, R; Sikazwe, I; Stringer, EM; Stringer, JS | 1 |
| Benaboud, S; Blanche, S; Bouazza, N; Foissac, F; Frange, P; Hirt, D; Rey, E; Tréluyer, JM; Urien, S | 1 |
| Vermund, SH | 1 |
| Abeling, NG; Brinkman, K; Furrer, H; Fux, CA; Garcia, EF; Hoek, FJ; Krediet, RT; Reiss, P; Vrouenraets, SM; Wit, FW | 1 |
| Kohli, R; Mehendale, S; Tolley, EE; Tsui, S; Weaver, MA | 1 |
| Bardeguez, A; Cotter, A; Fiscus, SA; Flynn, PM; Heckman, B; Huang, S; Jean-Philippe, P; Kearney, B; Mirochnick, M; Mofenson, LM; Purswani, M; Robbins, B; Rodman, J; Rooney, JF; Shapiro, DE; Thorpe, E; Van Rompay, KK; Watts, DH | 1 |
| Hull, MW; Montaner, JS | 1 |
| Budhathoki, C; Collier, AC; Daar, ES; Farajallah, A; Feinberg, J; Fischl, MA; Godfrey, C; Ha, B; Jahed, NC; Katzenstein, D; Mollan, K; Murphy, RL; Myers, L; Rooney, JF; Sax, PE; Tashima, K; Tierney, C; Woodward, WC | 1 |
| Hitomi, S; Kiyasu, Y; Koganemaru, H | 1 |
| Dejesus, E; Dinubile, MJ; Lazzarin, A; Leavitt, R; Lennox, JL; Nguyen, BY; Rockstroh, JK; Rodgers, AJ; Saag, MS; Sklar, P; Teppler, H; Walker, ML; Wan, H; Xu, X; Zhao, J | 1 |
| da Silva, AC; Gianini, RJ; Gomes-Gouvea, MS; Guastini, CF; Leite, AG; Martins, LG; Mendes-Correa, MC; Pinho, JR; Silva, MH; Uip, DE | 1 |
| Abraham, B; Bélec, L; Charpentier, C; Dandy, M; De Dieu Longo, J; Grésenguet, G; Matta, M; Mbelesso, P; Moussa, S; Péré, H | 1 |
| Razonable, RR | 1 |
| Bando, H; Kasai, D; Kushida, H; Kuwahara, T; Nishida, Y; Ogawa, Y; Shirasaka, T; Taniguchi, T; Uehira, T; Watanabe, D; Yagura, H; Yajima, K; Yonemoto, H; Yoshino, M | 1 |
| Chiamwongpaet, S; Choopanya, K; Chuachoowong, R; Kittimunkong, S; Leethochawalit, M; Martin, M; McNicholl, JM; Mock, PA; Paxton, L; Sangkum, U; Suntharasamai, P; van Griensven, F; Vanichseni, S | 1 |
| Frederiksen, CA; Langdahl, BL; Laursen, AL; Melchjorsen, J; Nielsen, US; Rasmussen, TA; Tolstrup, M; Østergaard, L | 1 |
| Allen, P; Kashuba, A; Nuttall, J; Roberts, J; Romano, J; Wang, R; White, N | 1 |
| Albini, L; Bellagamba, R; Calabresi, A; Cesana, BM; Fezza, R; Focà, E; Gotti, D; Guaraldi, G; Izzo, I; Lapadula, G; Maggi, P; Manili, L; Motta, D; Narciso, P; Quiros-Roldan, E; Sighinolfi, L; Torti, C | 1 |
| Baeten, JM; Barnes, L; Bukusi, E; Campbell, JD; Celum, C; Cohen, CR; Coombs, RW; Donnell, D; Farquhar, C; Fife, KH; Ingram, C; John-Stewart, G; Katabira, E; Kiarie, J; Kidoguchi, L; Krows, M; Lingappa, JR; Morrison, S; Mugo, NR; Mujugira, A; Ndase, P; Ondrejcek, L; Panteleeff, D; Revall, J; Ronald, A; Shah, H; Tappero, JW; Tumwesigye, E; Wangisi, J; Were, E | 1 |
| Krakower, D; Mayer, KH | 2 |
| Agarwal, R; Dubé, MP; Gupta, SK; Mather, KJ; Shen, C | 1 |
| Esser, S; Gölz, J; Haberl, A; Körber, A; Lazzarin, A; Mulcahy, F; Staszewski, S; Teofilo, E; Vera, J | 1 |
| Gibb, DM; Gilks, CF; Grosskurth, H; Hakim, J; Kityo, C; Mambule, I; Munderi, P; Reid, A; Ssali, F; Stöhr, W; Walker, AS | 1 |
| Brown, TT; Labbato, D; McComsey, GA; Ross, AC; Storer, N | 1 |
| Hoffmann, C; Schewe, CK; Stellbrink, HJ; Weitner, L | 1 |
| Antonopoulou, S; Chini, M; Demopoulos, CA; Fragopoulou, E; Gargalianos, P; Lazanas, MC; Mangafas, N; Papakonstantinou, VD; Tsogas, N; Tsoupras, AB | 1 |
| Hong, JH; Kim, E; Li, H; Yoo, JC | 1 |
| Clercq, ED | 1 |
| Furrer, H; Rauch, A; Wandeler, G | 1 |
| Keller, SB; Smith, DM | 1 |
| Dobard, C; García-Lerma, JG; Hanson, DL; Heneine, W; Holder, A; Kuklenyik, Z; Lipscomb, J; Martin, A; Novembre, FJ; Pau, CP; Sharma, S; Smith, J | 1 |
| Aboulker, JP; Andreo, C; Capitant, C; Carrieri, MP; Cook, E; Fugon, L; Le Gall, JM; Lorente, N; Molina, JM; Spire, B | 1 |
| Kohli, R; Marlow, HM; Mehendale, S; Tolley, EE; Weaver, MA | 1 |
| Berger, RE | 2 |
| Branger, M; Collin, G; Fraqueiro, G; Gervais, A; Hamet, G; Lada, O; Marcellin, P; Martinot-Peignoux, M; Matheron, S; Moucari, R; Peytavin, G; Roquebert, B | 1 |
| Caro-Vega, Y; Crabtree-Ramírez, B; López-Martínez, A; O'Brien, NM; Sierra-Madero, J | 1 |
| Pletz, MW; Schleenvoigt, BT; Stallmach, A | 1 |
| Bertz, R; Child, M; Eley, T; Farajallah, A; Krystal, M; Liao, S; McGrath, D; Molina, JM; Persson, A; Sevinsky, H; Xu, X; Zhang, J; Zhu, L | 1 |
| Chipato, T; Cole, SR; Currier, JS; D'Amico, R; Eron, JJ; Hosseinipour, M; Hughes, MD; Lockman, S; McCarthy, JS; Meshnick, SR; Poole, C; Porter, KA; Salata, R; Sawe, FK; Shaffer, D; Siika, A; Skinner-Adams, TS; Stringer, E; Zheng, Y | 1 |
| Benaboud, S; Bouazza, N; Chappuy, H; Firtion, G; Foissac, F; Hirt, D; Launay, O; Pannier, E; Rey, E; Tréluyer, JM; Urien, S | 1 |
| Baum, MM; Butkyavichene, I; Clark, MR; Friend, DR; Gilman, J; Kennedy, S; Kopin, E; Malone, AM; Moss, JA; Motamedi, M; Nguyen, C; Smith, TJ; Vincent, KL | 1 |
| Colby-Germinario, SP; Ibanescu, RI; Moisi, D; Oliveira, M; Schader, SM; Wainberg, MA | 1 |
| Angarano, G; Bellacosa, C; Graziano, G; Maggi, P; Montinaro, V; Pietanza, S; Strippoli, GF; Volpe, A | 1 |
| Lampiris, HW | 1 |
| Cooper, DA; Duncombe, C; Emery, S; Gill, JM; Kerr, SJ; Li, PC; Puls, R; Taylor-Robinson, SD; Winston, A | 1 |
| Cane, PA; Crook, AM; Delpech, V; Dolling, D; Dunn, D; Fearnhill, E; Hill, T; Phillips, AN; Pillay, D; Shepherd, J | 1 |
| Back, DJ; Else, LJ; Khoo, SH; Taylor, S | 1 |
| Cellini, M; Gabiano, C; Giacomet, V; Manfredini, V; Mora, S; Puzzovio, M; Salvini, F; Stucchi, S; Tamburrini, E; Viganò, A; Zuccotti, GV | 1 |
| Clauss, M; Desta, Z; Deuter-Reinhard, M; Green, L; Gupta, SK; Kim, C; Taylor, BM | 1 |
| Baeten, JM; Celum, C | 2 |
| Cohen, MS; Jenkins, AJ; Kashuba, AD; Kraft, E; Patterson, KB; Prince, HA; Rooney, JF; Shaheen, NJ | 1 |
| Camp, R; Connick, E; Daar, ES; Degruttola, V; Del Rio, C; Fiscus, SA; Hare, CB; Hogan, CM; Kallungal, B; Little, S; Macatangay, B; Markowitz, M; Morton, T; Sun, X; Tashima, KT | 1 |
| Conway, B; Tossonian, H | 1 |
| Boyd, A; Delaugerre, C; Girard, PM; Lacombe, K; Lavocat, F; Maylin, S; Simon, F; Zoulim, F | 1 |
| Bugeja, A; Gupta, A; Kirpalani, D | 1 |
| Aoki, T; Gatanaga, H; Honda, H; Honda, M; Kikuchi, Y; Kinai, E; Komatsu, H; Nishijima, T; Oka, S; Shimbo, T; Tanuma, J; Teruya, K; Tsukada, K; Watanabe, K; Yazaki, H | 1 |
| Balzarini, J; Schols, D | 1 |
| Gelman, M; Grasso, C; Mayer, KH; Mimiaga, MJ | 1 |
| Baeten, JM; Bangsberg, DR; Celum, CL; Haberer, JE; Kintu, A; Psaros, C; Safren, S; Tumwesigye, E; Ware, NC; Wyatt, MA | 1 |
| Branger, M; Collin, G; Fraqueiro, G; Gervais, A; Lada, O; Leclerc, L; Marcellin, P; Martinot-Peignoux, M; Matheron, S; Moucari, R; Peytavin, G; Roquebert, B | 1 |
| Baker, A; Bethel, J; Flynn, PM; Havens, PL; Hazra, R; Kapogiannis, BG; Liu, N; Lujan-Zilbermann, J; Mulligan, K; Pan, CG; Rutledge, B; Stephensen, CB; Van Loan, MD; Wilson, CM; Woodhouse, LR | 1 |
| Amodio, D; Baldassari, S; Bernardi, S; Cotugno, N; Palma, P; Pontrelli, G; Tchidjou, HK; Zangari, P | 1 |
| Choi, J; Gerschenson, M; Harrill, D; Libutti, D; McComsey, GA; O'Riordan, M; Rowe, D; Storer, N | 1 |
| Ando, M; Nitta, K; Tsuchiya, K | 1 |
| Celum, CL | 1 |
| Al-Daghri, NM; Boothby, M; Das, S; Gathercole, LL; Harte, AL; McGee, KC; McTernan, PG; Nightingale, P; Shahmanesh, M; Shojaee-Moradie, F; Tomlinson, JW; Tripathi, G; Umpleby, AM | 1 |
| Baker, J; Brooks, JT; Bush, T; Conley, L; Hammer, J; Henry, K; Kojic, E; Overton, T; Patel, P | 1 |
| Bedimo, R; Drechsler, H; Maalouf, NM; Tebas, P; Zhang, S | 1 |
| Arterburn, S; Cheng, AK; Chuck, SL; da Silva, MT; de Aquino, MZ; de Carvalho, AP; Della Negra, M; Enejosa, JV; Liu, YP; Pinto, J; Rhee, MS; White, K | 1 |
| Fernando, M; Gracey, DM; Post, JJ; White, CP; Ziegler, J | 1 |
| Adams, JL; Kashuba, AD | 1 |
| Ramjee, G | 1 |
| Choi, AI; Deeks, SG; Estrella, M; Grunfeld, C; Li, Y; Scherzer, R; Shlipak, MG | 1 |
| Fessel, WJ; Israelski, D; Kagan, R; Kaufman, D; Melikian, GL; Rhee, SY; Robbins, GK; Shafer, RW; Taylor, J; Towner, W; Troia-Cancio, PV; Zolopa, A | 1 |
| Boyd, A; Delaugerre, C; Girard, PM; Gozlan, J; Lacombe, K; Lascoux-Combe, C; Lassel, L; Lavocat, F; Maylin, S; Miailhes, P; Zoulim, F | 1 |
| Bangsberg, DR; Haberer, JE; Van Damme, L; van der Straten, A | 1 |
| Okwundu, CI; Omeje, I | 2 |
| Amoroso, A; Edozien, A; Etienne-Mesubi, M; Hossain, MB; Obiefune, M; Ojoo, S; Redfield, RR; Sheneberger, R; Stafford, K | 1 |
| Bando, H; Hirota, K; Koizumi, Y; Kuwahara, T; Nishida, Y; Otera, H; Shirasaka, T; Tominari, S; Uehira, T; Watanabe, D; Yagura, H; Yajima, K; Yonemoto, H; Yoshino, M | 1 |
| Hakim, JG; Kuritzkes, DR; Sanne, I | 1 |
| Kanki, PJ; Shafer, RW; Tang, MW | 1 |
| Bork, K; Cames, C; Cournil, A; Coutherut, J; Delaporte, E; Diouf, A; Eymard-Duvernay, S; Moquet, C; Ngom Gueye, NF; Sow, PS; Taverne, B | 1 |
| Abdool Karim, Q; Abdool Karim, S; Altfeld, M; Mkhwanazi, NP; Mureithi, MW; Naranbhai, V; Ndung'u, T; Poole, D; Reddy, S; Sibeko, S; Werner, L | 1 |
| Fidler, S; Fisher, M; McCormack, S | 1 |
| Fernandez, VA; Reiser, IW; Spitalewitz, S; Thomas, DB | 1 |
| Agu, KA; Akpoigbe, KJ; Badru, T; Chabikuli, O; Eluwa, GI; Hamelmann, C | 1 |
| Aubron-Olivier, C; Calvez, V; Charpentier, C; Descamps, D; Katlama, C; Landman, R; Marcelin, AG; Simon, A; Valantin, MA; Wirden, M; Yeni, P | 1 |
| Barragan, P; Crespo, M; Curran, A; Falco, V; Gatell, JM; Imaz, A; Lonca, M; Martinez, E; Martinez, M; Podzamczer, D; Ribera, E; Vidal-Sicart, S | 1 |
| DiMeglio, LA; Griner, R; Hazra, R; Jacobson, DL; Kacanek, D; Mendez, H; Miller, T; Mofenson, LM; Rich, KC; Seage, GR; Siberry, GK; Tassiopoulos, K; Watts, DH; Williams, PL | 1 |
| Friend, DR | 1 |
| Bao, R; Cao, Y; Chen, Y; Han, C; He, B; Jiang, S; Li, L; Li, Y; Shi, W; Sun, Y; Yan, H; Yang, J; Yang, Y; Zhang, X; Zhang, Y; Zhong, M; Zhou, D | 1 |
| Heneine, W; Kashuba, A | 1 |
| Abdool Karim, SS; Baxter, C; Gengiah, TN; Kharsany, AB; Mansoor, LE | 1 |
| Clark, MR; Friend, DR | 1 |
| Battegay, M; Bernasconi, E; Bucher, HC; Calmy, A; Cavassini, M; Furrer, H; Fux, CA; Schäfer, J; Vernazza, P; Weber, R; Young, J | 1 |
| Akil, A; Clark, MR; Cost, M; Dezzutti, CS; Friend, DR; Rohan, LC | 1 |
| Clark, MR; Friend, DR; Major, I; Malcolm, RK; Mc Conville, C; Woolfson, AD | 1 |
| Islam, FM; Jansson, J; Wilson, DP; Wu, J | 1 |
| Brinkman, K; Furrer, H; Fux, CA; Garcia, EF; Hoek, FJ; Krediet, RT; Reiss, P; van Straalen, JP; Vrouenraets, SM; Wit, FW | 1 |
| Lee, WM; Tujios, SR | 1 |
| Herold, BC; Huber, AM; Kiser, PF; Mesquita, PM; Rastogi, R; Segarra, TJ; Teller, RS; Torres, NM | 1 |
| Bekker, LG; Freedberg, KA; Losina, E; Mayer, KH; Paltiel, AD; Park, JE; Scott, CA; Seage, GR; Walensky, RP; Wood, R | 1 |
| Birn, H; Erlandsen, EJ; Jensen, D; Langdahl, BL; Laursen, AL; Nielsen, US; Rasmussen, TA; Tolstrup, M; Østergaard, L | 1 |
| Aguilar-Bernier, M; Del Boz, J; Fernández-Morano, T; Fúnez-Liébana, R | 1 |
| Bookstaver, PB; Bryant, JE; Millisor, VE; Rokas, KE; Shamroe, CL; Sutton, SS; Weissman, SB | 1 |
| Anzala, O; Bangsberg, D; Barin, B; Chetty, P; Fast, P; Haberer, JE; Mark, D; Mugo, P; Mutua, G; Priddy, FH; Rooney, JF; Sanders, E | 1 |
| Naggie, S; Sulkowski, MS | 1 |
| Carnovale, C; Chiacchio, U; Frezza, C; Giofrè, SV; Macchi, B; Marino-Merlo, F; Pistarà, V; Romeo, G; Romeo, R | 1 |
| Bräu, N; Chang, MH; Fung, HB; Monteagudo-Chu, MO | 1 |
| Abrahams, MR; Anderson, J; Arney, L; Bandawe, G; Goodier, S; Karim, QA; Karim, SS; Naranbhai, V; Sibeko, S; Swanstrom, R; Treurnicht, F; Valley-Omar, Z; Werner, L; Williamson, C | 1 |
| Marchand, C | 1 |
| Cost, M; Dezzutti, CS; Friend, D; Lynam, JD; Rohan, LC; Shetler, C; Uranker, K; Wang, L | 1 |
| Bulterys, M; Kuhn, L | 1 |
| Ang, BC; Teoh, SC | 1 |
| Bhyrapuneni, G; Kandikere, V; Komarneni, P; Muddana, N; Mudigonda, K; Mukkanti, K; Nirogi, R; Saralaya, R | 1 |
| Edelman, EJ; Gordon, K; Justice, AC; Rodriguez-Barradas, MC | 1 |
| Chidziva, E; Gibb, DM; Gilks, CF; Grosskurth, H; Hakim, J; Kizito, H; Kyomugisha, H; Munderi, P; Musoke, P; Nalumenya, R; Nathoo, K; Russell, EC; Spyer, M; Tumukunde, D; Walker, AS; Zalwango, E | 1 |
| Baum, MM; Butkyavichene, I; Clark, MR; Friend, DR; Gilman, J; Kennedy, S; Kopin, E; Malone, AM; Moss, JA; Nguyen, C; Smith, TJ | 1 |
| Alonso-Villaverde, C; Aragonès, G; Beltrán-Debón, R; Camps, J; Fernández-Sender, L; Joven, J; Pardo-Reche, P; Rodríguez-Gallego, E; Rull, A | 1 |
| Buscher, A; Giordano, TP; Hartman, C; Kallen, MA | 1 |
| Haire, B; Jordens, CF; Kaldor, J | 1 |
| Engsig, FN; Feldt-Rasmussen, B; Gerstoft, J; Kirk, O; Kronborg, G; Obel, N; Pedersen, C; Rasch, MG | 1 |
| Mwethera, PG; Obiero, J; Wiysonge, CS | 1 |
| Grabczewska, E; Olczak, A | 1 |
| Amin, J; Carr, A; Ebeling, PR; Emery, S; Haskelberg, H; Hoy, JF | 1 |
| Manning, TG | 1 |
| Bobardt, MD; Dezzutti, CS; Esch, T; Gallay, PA; Gunaseelan, S; Maskiewicz, R | 1 |
| Fang, J; Jadhav, PR | 1 |
| Boulle, A; Brennan, A; Chaweza, T; Chimbetete, C; Egger, M; Garone, D; Giddy, J; Hoffmann, CJ; Keiser, O; Mulenga, L; Prozesky, H; Wandeler, G; Wood, R | 1 |
| Cheng, AK; DeJesus, E; Gathe, J; Henry, K; Kearney, BP; Molina, JM; Ramanathan, S; Rockstroh, JK; Szwarcberg, J; Wei, X; White, K; Yale, K | 1 |
| Cheng, AK; Cohen, C; DeJesus, E; Gallant, JE; Kearney, BP; Liu, HC; Mills, A; Quirk, E; Sax, PE; Szwarcberg, J; White, K; Wohl, D; Yale, K; Zhong, L; Zolopa, A | 1 |
| Ducos, J; Kania, D; Kuster, N; Lozano, C; Mondain, AM; Nagot, N; Pageaux, GP; Poinso, A; Reynes, J; Tuaillon, E; Van de Perre, P | 1 |
| Baden, LR; Cohen, MS | 1 |
| Abdool Karim, SS; Gray, GE; Martinson, N | 1 |
| Abebe, D; Brooks, JT; Buliva, E; Chillag, KL; Chirwa, LI; Gvetadze, RJ; Hart, C; Henderson, FL; Hendrix, CW; Johnson, JA; Johnson, S; Kasonde, M; Kebaabetswe, PM; Malotte, CK; Mutanhaurwa, R; Pathak, SR; Paxton, LA; Rose, CE; Segolodi, TM; Smith, DK; Soud, FA; Sukalac, T; Thigpen, MC; Thomas, VT | 1 |
| Agot, K; Ahmed, K; Corneli, A; Crucitti, T; Deese, J; Fransen, K; Grant, R; Kapiga, S; Kashuba, A; Kiernan, H; Kirkendale, S; Lombaard, J; Mak'Oketch, P; Makanda, M; Makatu, SE; Malahleha, M; Mandala, J; Manongi, R; Mastro, TD; Monedi, MC; Nanda, K; Onyango, J; Owino, F; Reblin, I; Saylor, L; Taylor, D; Temu, L; Van Damme, L; Wong, C | 1 |
| Apaka, C; Baeten, JM; Bangsberg, D; Bukusi, EA; Bumpus, NN; Campbell, JD; Celum, C; Cohen, CR; Coombs, RW; Donnell, D; Emmanuel-Ogier, M; Farquhar, C; Fife, KH; Frenkel, L; Gabona, F; Haberer, JE; Haugen, H; Hendrix, C; John-Stewart, G; Kakia, A; Katabira, E; Kiarie, J; Kidoguchi, L; Krows, M; Lingappa, JR; Morrison, S; Mucunguzi, A; Mugo, NR; Mujugira, A; Nakku-Joloba, E; Ndase, P; Ngure, K; Odoyo, J; Ondrejcek, L; Panteleeff, D; Revall, J; Ronald, A; Stevens, WS; Tamooh, H; Tappero, JW; Thomas, KK; Tumwesigye, E; Twesigye, R; Wangisi, J; Were, E | 1 |
| Okoromah, CA; Okwundu, CI; Uthman, OA | 1 |
| Kim, JH; Psevdos, G; Sharp, V | 1 |
| Daly, F | 1 |
| Chianura, L; Errante, I; Moioli, MC; Orcese, C; Orso, M; Puoti, M; Rossotti, R; Schiantarelli, C; Schlacht, I; Travi, G; Vigo, B; Villa, MR; Volonterio, A | 1 |
| Duwal, S; Schütte, C; von Kleist, M | 1 |
| Bruzzone, B; Caligiuri, P; Di Biagio, A; Giacobbe, DR; Mikulska, M; Taramasso, L; Viscoli, C | 1 |
| Abdool Karim, Q; Abdool Karim, SS; Altfeld, M; Carr, WH; Durgiah, R; Naranbhai, V; Samsunder, N; Sibeko, S | 1 |
| Gibbs, C; Guyer, B; Haddad, M; McColl, DJ; Miller, MD; Su, C | 1 |
| Akinkuotu, A; Chasela, C; Hosseinipour, MC; Jamieson, DJ; Johnson, DC; King, CC; Kourtis, AP; Maliwichi, M; Moses, A; Mwafongo, A; van der Horst, C | 1 |
| Holmes, D | 2 |
| Bartlett, H; Gibson, A; Kelly, MD; Patten, J; Rowling, D | 1 |
| Hall, AM | 1 |
| Aguilera, A; Alcamí, J; Álvarez, M; Anta, L; Betancor, G; Blanco, JL; Caballero, E; Cañizares, A; Clotet, B; Córdoba, J; Dalmau, D; de Mendoza, C; del Romero, J; Galindo, MJ; García, F; Garrido, C; Garriga, C; Gatel, JM; Gómez Sirvent, JL; Gutiérrez, C; Gutiérrez, F; Iribarren, JA; Jaén, A; Leal, M; Llibre, JM; López Aldeguer, J; Manuzza, G; Martínez, MA; Martinez-Picado, J; Menéndez-Arias, L; Miralles, C; Morano, L; Moreno, S; Nevot, M; Ocampo, A; Palomares, JC; Pedreira, J; Peraire, J; Pérez-Elías, MJ; Pérez-Olmeda, M; Pérez-Romero, P; Pineda, JA; Poveda, E; Puertas, MC; Ribera, E; Riera, M; Rodríguez, C; Rodríguez, P; Santos, J; Soriano, V; Viciana, I; Viciana, P; Vidal, C; Vidal, F | 1 |
| Bonjoch, A; Clotet, B; Echeverría, P; Estany, C; Negredo, E; Perez-Alvarez, N; Puig, J | 1 |
| Pommer, P | 1 |
| Attia, S; Bogner, JR; Füeßl, B; Goebel, FD; Kay, L; Lederer, SR; Röder, M; Schlattner, U; Schmid, H; Tokarska-Schlattner, M | 1 |
| Bertagnolio, S; Cambiano, V; Jordan, MR; Lundgren, J; Miners, A; Phillips, AN; Pillay, D; von Wyl, V | 1 |
| Baxter, C; Frolich, J; Grobler, A; Karim, QA; Karim, SS; Kharsany, AB; Maarshalk, S; Mansoor, LE; Miya, N; Mlisana, K; Sibeko, S; Sokal, DC; Yende-Zuma, N | 1 |
| Aaron, E; Cohan, D | 1 |
| Borghi, V; Capetti, A; Cicconi, P; Di Biagio, A; Di Giambenedetto, S; Francisci, D; Giacometti, A; Giannarelli, D; Maggiolo, F; Monno, L; Penco, G; Prinapori, R; Sterrantino, G; Zoncada, A | 1 |
| Grulich, AE; Poynten, IM; Zablotska, I | 1 |
| Szpir, M; Van Damme, L | 1 |
| Lyseng-Williamson, KA; Scott, LJ | 1 |
| Anderson, PL; Bushman, LR; Castillo-Mancilla, JR; Fernandez, C; Gardner, EM; Kiser, JJ; Langness, J; Meditz, A; Predhomme, J; Rower, JE; Zheng, JH | 1 |
| Buckheit, KW; Buckheit, RW; Dezzutti, CS; Gwozdz, G; Mahalingam, A; Shetler, C; Ugaonkar, SR | 1 |
| Gnarini, M; Maserati, R; Uglietti, A; Zanaboni, D | 1 |
| Anton, PA; Bumpus, NN; Carballo-Diéguez, A; Cranston, RD; Cumberland, WG; Dennis, R; Elliott, J; Hendrix, CW; Janocko, L; Ju, C; Kashuba, A; Khanukhova, E; Mauck, C; McGowan, I; Richardson-Harman, N | 1 |
| Fox, PA | 1 |
| Henry, K | 1 |
| Alvarez, A; Calatayud, S; De Pablo, C; Esplugues, JV; Martí-Cabrera, M; Orden, S | 1 |
| Gatanaga, H; Hayashida, T; Higasa, K; Komatsu, H; Nishijima, T; Oka, S; Takano, M; Tsuchiya, K | 1 |
| Du, X; Fu, Q; Kou, H; Li, T; Li, Y; Zhu, Z | 1 |
| Bonovas, S; Hatzakis, A; Nikolopoulos, G; Tsiodras, S | 1 |
| Baeten, J; Celum, C | 1 |
| Hendrix, CW | 1 |
| Herold, BC; Kiser, PF; Mesquita, PM | 1 |
| Hansen, BE; Janssen, HL; Koëter, T; Komuta, M; Rossing, HH; Schouten, JN; Van der Ende, ME; van der Valk, M; Verheij, J | 1 |
| Anderson, PL; Bekker, LG; Buchbinder, S; Bushman, LR; Casapía, M; Chariyalertsak, S; Glidden, DV; Grant, RM; Guanira, JV; Kallás, EG; Lama, JR; Liu, A; Mayer, KH; McMahan, V; Montoya-Herrera, O; Schechter, M; Veloso, VG | 1 |
| Gatanaga, H; Hinoshita, F; Hoshimoto, K; Kikuchi, Y; Nishijima, T; Oka, S; Tasato, D; Teruya, K; Yazaki, H | 1 |
| Cooke, G; Courtney, AP; Hickson, M; Klassen, K; Martineau, AR; Wilkinson, RJ | 1 |
| Borderi, M; Calza, L; Colangeli, V; Di Bari, MA; Magistrelli, E; Manfredi, R; Salvadori, C; Trapani, F; Viale, P | 1 |
| Ananworanich, J; Bhakeecheep, S; Bowonwattanuwong, C; Bunupuradah, T; Chetchotisakd, P; Hirschel, B; Jirajariyavej, S; Klinbuayaem, V; Mahanontharit, A; Munsakul, W; Prasithsirikul, W; Ruxrungtham, K; Sophonphan, J; Valcour, V | 1 |
| Bocchiola, B; Cahua, T; Castagna, A; Danise, A; Galli, L; Gianotti, N; Lazzarin, A; Maillard, M; Panzini, P; Pazzi, A; Salpietro, S; Zandonà, D | 1 |
| Albright, TH; Chandra, N; Clark, JT; Clark, MR; Doncel, GF; Fabian, J; Friend, DR; Johnson, TJ; Kiser, PF; McCabe, RT; Nebeker, JS; Tuitupou, AL | 1 |
| Colbert, JA | 1 |
| Abecasis, AB; Camacho, RJ; Snoeck, J; Theys, K; Vandamme, AM; Vercauteren, J | 1 |
| Bonfanti, P; Carenzi, L; di Biagio, A; Madeddu, G; Martinelli, C; Menzaghi, B; Mura, MS; Orofino, G; Parruti, G; Ricci, E | 1 |
| Acosta, EP; Baheti, G; Fletcher, CV; King, JR | 1 |
| Amin, J; Cooper, DA; Cordery, DV; Emery, S; Kelleher, AD; Martin, A | 1 |
| Barrail-Tran, A; Descamps, D; Duval, X; Goujard, C; Mentré, F; Nembot, G; Panhard, X; Savic, RM; Taburet, AM; Verstuyft, C; Vrijens, B | 1 |
| Crowther, NJ; Dickens, C; Dix-Peek, T; Duarte, R; Fox, MP; Ive, P; John, MA; Macphail, P; Maskew, M; Menezes, CN; Raal, F; Sanne, I; Van Amsterdam, D | 1 |
| Ceppi, C; Cua, E; De Salvador, F; Dellamonica, P; Durant, J; Esnault, V; Fafin, C; Mondain, V; Moranne, O; Perbost, I; Pradier, C; Pugliese, P; Rahelinirina, V; Roger, PM; Rosenthal, E | 1 |
| Aarnoutse, RE; Boeree, MJ; Burger, DM; Fillekes, Q; Kibiki, GS; Kisanga, ER; Kisonga, RM; Mleoh, L; Mtabho, CM; Ndaro, A; Semvua, HH; van den Boogaard, J; van der Ven, A | 1 |
| Grabmeier-Pfistershammer, K; Kosi, L; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Rieger, A; Strassl, R | 1 |
| Cohen, MS; Dumond, JB; Forrest, A; Garonzik, SM; Kashuba, AD; Kendrick, RN; Nicol, MR; Patterson, KB | 1 |
| Hayashi, T; Ikeda, H; Ishida, T; Kunimoto, Y; Miyamoto, A; Nakata, H; Noda, N; Okazaki, M; Shinomura, Y; Takahashi, S; Touda, N; Yasui, H | 1 |
| Raphael, MC | 1 |
| Chen, BA; Gandham, S; Gomez, K; Guddera, V; Hendrix, CW; Hoesley, C; Justman, J; Minnis, AM; Nakabiito, C; Patterson, K; Richardson, BA; Salata, R; Soto-Torres, L | 1 |
| Ananworanich, J; Bhakeecheep, S; Bowonwatanuwong, C; Bunupuradah, T; Chetchotisakd, P; Hirschel, B; Jirajariyavej, S; Kantipong, P; Kerr, SJ; Klinbuayaem, V; Munsakul, W; Prasithsirikul, W; Ruxrungtham, K; Sophonphan, J; Sungkanuparph, S | 1 |
| Fätkenheuer, G; Kümmerle, T | 1 |
| Adams, JL; Crucitti, T; De Baetselier, I; Fransen, K; Kashuba, AD; Menezes, P; Patterson, KB; Prince, HM; Sykes, C; Van Damme, L | 1 |
| Chateau, M; Garcia, JV; Swanson, MD | 1 |
| Beck, EJ; Brettle, R; Gazzard, B; Gompels, M; Johnson, M; Mandalia, S; Pozniak, A; Sangha, R; Schwenk, A; Taylor, S; Walsh, J; Wilkins, E; Williams, I; Youle, M | 1 |
| Klibanov, OM; Olin, JL; Spooner, LM | 1 |
| Baril, JG; Dufresne, S; Laprise, C; Trottier, H | 1 |
| Cabie, A; Charpentier, C; Chene, G; Colin de Verdiere, N; Descamps, D; Fagard, C; Grondin, C; Joly, V; Raffi, F; Tabuteau, S; Yazdanpanah, Y; Yeni, P | 1 |
| Burger, DM; Colbers, AP; Giaquinto, C; Gingelmaier, A; Hawkins, DA; Ivanovic, J; Kabeya, K; Moltó, J; Rockstroh, JK; Sadiq, ST; Taylor, GP; Weizsäcker, K; Wyen, C | 1 |
| Abecasis, AB; Camacho, RJ; Clotet, B; De Luca, A; Grossman, Z; Schülter, E; Snoeck, J; Sönnerborg, A; Struck, D; Theys, K; Torti, C; Vandamme, AM; Vercauteren, J; Zazzi, M | 1 |
| Blevins, S; Dumond, JB; Eron, JJ; Floris-Moore, M; Hudgens, MG; Kashuba, AD; Massengale, K; Pittard, D; Ragan, D; Richardson, A; Walsh, K; Wang, R; Wohl, DA | 1 |
| Craig, C; Fätkenheuer, G; Heera, J; Leal, M; McFadyen, L; Mildvan, D; Mills, A; Podzamczer, D; Portsmouth, S; Rinehart, AR; Than, S; Valdez, H; Valluri, SR; Vourvahis, M | 1 |
| Collier, AC; Daar, ES; Fichtenbaum, CJ; Fink, H; Gerschenson, M; Kosmiski, L; Libutti, DE; McComsey, GA; O'Riordan, M; Santana, JL; Sax, PE | 1 |
| Ananworanich, J; Chomchey, N; Gerschenson, M; Hongchookiat, P; Jadwattanakul, T; Kerr, SJ; Kim, JH; Mathajittiphun, P; Phanuphak, N; Phanuphak, P; Pinyakorn, S; Praihirunyakit, P; Rungrojrat, P; Shikuma, C; Teeratakulpisarn, N; Valcour, V | 1 |
| Bisi, L; Borghi, V; Cossarizza, A; Manzini, L; Mussini, C | 1 |
| Hussar, DA; Martinez, LN | 1 |
| Breeze, S | 1 |
| Morrow, T | 1 |
| Basse, CD; Dia, NM; Dieng, AB; Diop, BM; Diop, SA; Fortes-Déguénonvo, L; Manga, NM; Ndaw, G; Ndour, CT; Seydi, M; Soumaré, M; Sow, PS | 1 |
| Chernoff, MC; Hazra, R; Kopp, JB; Mofenson, LM; Patel, K; Purswani, M; Scott, GB; Seage, GR; Siberry, GK; Van Dyke, RB | 1 |
| Abraham, AG; Anastos, K; Benning, L; Burian, P; Cohen, M; Gandhi, M; Oboho, I; Sharma, A; Szczech, L; Young, M | 1 |
| Lueangniyomkul, A; Mankatitham, W; Manosuthi, S; Manosuthi, W; Nilkamhang, S; Sukasem, C; Sungkanuparph, S; Thongyen, S | 1 |
| Daucher, M; Davey, RT; Kohli, A; Kottilil, S; Masur, H; Sarin, SK; Sherman, AC; Trehanpati, N | 1 |
| Aral, SO; Cates, W | 1 |
| Agrahari, V; Murowchick, JB; Oyler, NA; Youan, BB; Zhang, C; Zhang, T | 1 |
| Ammara, A; Back, D; Boffito, M; Gazzard, B; Jackson, A; Mohabeer, M; Moyle, G; Tjia, J; Watson, V | 1 |
| Bolland, MJ; Grey, A | 1 |
| Paxton, LA; Rose, CE; Thigpen, MC | 1 |
| Colebunders, R; Kenyon, C | 1 |
| Corneli, A; Van Damme, L | 1 |
| Cannizzaro, MV; Chimenti, S; Chiricozzi, A; Giunta, A; Nisticò, SP; Saraceno, R | 1 |
| Alvarez, ML; Arterburn, S; Berenguer, J; Clotet, B; Curran, A; Estrada, V; Ferrer, P; Larrousse, M; Martínez, E; Negredo, E; Pulido, F; Ribera, E; Rubio, R; Sanz, J | 1 |
| Cattaneo, D; Galli, M; Gervasoni, C; Landonio, S; Meraviglia, P; Riva, A; Rizzardini, G | 1 |
| Armishaw, J; Cameron, PU; Chuah, J; Cooper, DA; Crowe, SM; Fairley, C; Gouillou, M; Hearps, A; Koelsch, KK; Leeansyah, E; Lewin, SR; Liu, JP; Pierce, AB; Smit, de V; Solomon, A; Spelman, T; Tennakoon, S; Velayudham, P | 1 |
| Chan, PA; Huang, A; Kantor, R | 1 |
| Avihingsanon, A; Bowden, S; Dore, GJ; Finlayson, R; Hoy, JF; Lewin, SR; Littlejohn, M; Locarnini, S; Matthews, GV; Revill, PA; Ruxrungtham, K; Sasadeusz, J; Saulynas, M; Seaberg, EC; Thio, CL | 1 |
| Freedberg, KA; Nakamura, YM; Paltiel, AD; Pei, PP; Sax, PE; Schackman, BR; Walensky, RP; Weinstein, MC | 1 |
| Cooper, DA; Craig, C; Goodrich, J; Kaplan, R; Lazzarin, A; Mori, J; Pozniak, A; Pulik, P; Tawadrous, M; Valdez, H; Vernazza, P; Wang, C; Weil, E | 1 |
| Abram, M; Cheng, AK; DeJesus, E; Fordyce, MW; Gathe, J; Henry, K; Molina, JM; Plummer, A; Ramanathan, S; Rockstroh, JK; Szwarcberg, J; Wei, X | 1 |
| Bock, P; Fidler, S | 1 |
| Parks, L | 1 |
| Calvez, V; Charpentier, C; Descamps, D; Flandre, P; Fofana, DB; Fourati, S; Lambert-Niclot, S; Marcelin, AG; Masquelier, B; Morand-Joubert, L; Soulié, C; Storto, A; Visseaux, B; Wirden, M | 1 |
| Benson, P; Bredeek, UF; Brinson, C; Campo, R; Dau, L; DeJesus, E; Flaherty, J; Fralich, T; Guyer, B; Henry, K; Khanlou, H; Logue, K; Piontkowsky, D; Wang, H; White, K | 1 |
| Nathan, M | 1 |
| Atta, MG; Stokes, MB | 1 |
| Corbett, CE; Dong, H; Kovacic, D; Qayyum, S; Sohail, S; Thornton, C; Waters, B | 1 |
| Cannizzaro, C; Chen, X; Desai, MC; Lansdon, EB; Parrish, J; Tong, L; Wang, M; Xu, L; Zheng, X | 1 |
| Bershteyn, A; Eckhoff, PA | 1 |
| Bigliano, P; Bonora, S; Bramato, C; Calcagno, A; D'Avolio, A; Di Perri, G; Gonzalez de Requena, D; Libanore, V; Motta, I; Orofino, G; Orsucci, E; Salassa, B; Simiele, M; Tettoni, MC | 1 |
| Bumpus, NN; Chen, BA; Gandham, S; Gomez, K; Guddera, V; Hendrix, CW; Hoesley, C; Justman, J; Minnis, AM; Nakabiito, C; Patterson, K; Richardson, BA; Salata, R; Soto-Torres, L | 1 |
| Cheng, AK; Cohen, C; DeJesus, E; Gallant, JE; Liu, HC; Mills, A; Plummer, A; Rhee, MS; Sax, PE; Szwarcberg, J; White, KL; Wohl, D; Zolopa, A | 1 |
| Best, BM; Burchett, SK; Byroads, M; Caparelli, E; Cressey, TR; Hawkins, E; Kreitchmann, R; Mirochnick, M; Rossi, S; Shapiro, DE; Smith, E; Stek, A; Wang, J; Watts, DH | 1 |
| Feinberg, J | 3 |
| Gallant, JE | 1 |
| Andersen, J; Barker, DE; Bowen, BC; Clifford, D; Cohen, BA; Donovan Post, MJ; Huang, ML; Kelly, S; Marra, CM; Queen-Baker, J; Rajicic, N; Ruiz, A; Shriver, S | 1 |
| Dusak, BA; Goodwin, SD; Kuritzkes, DR; Rooney, JF; Skowron, G; Squires, KE; Stevens, M; Thompson, MA; Tolson, JM; Yuen, GJ | 1 |
| Prescott, LM | 1 |
| Gazzard, B; Mandalia, S; Pillay, D; Pozniak, A; Winston, A | 1 |
| Shere-Wolfe, KD; Verley, JR | 1 |
| Bates, M; Chappey, C; Hellmann, NS; Maroldo, L; Parkin, N; Petropoulos, CJ | 1 |
| Dieterich, DT | 1 |
| Alcaide, ML; Jayaweera, D; Kolber, M | 1 |
| Díaz, B; González-Lahoz, J; Núñez, M; Pérez-Olmeda, M; Ríos, P; Soriano, V | 1 |
| Aberg, JA; Crippin, J; Kessels, L; Lisker-Melman, M; Powderly, WG; Ristig, MB; Tebas, P | 1 |
| Fung, HB; Piacenti, FJ; Stone, EA | 1 |
| Atkins, M; Barr, A; Bower, M; Fisher, M; Gazzard, B; Matthews, G; Nelson, M; Pillay, D; Portsmouth, S; Stebbing, J | 1 |
| Eagan, L | 1 |
| James, JS | 6 |
| Coca, S; Perazella, MA | 1 |
| Benhamou, Y; Thibault, V; Tubiana, R | 1 |
| Antoniou, T; Park-Wyllie, LY; Tseng, AL | 1 |
| Bray, M; Wright, ME | 1 |
| Bruno, R; Ciappina, V; Filice, G; Puoti, M; Sacchi, P; Zocchetti, C | 1 |
| Créput, C; Gonzalez-Canali, G; Hill, G; Kazatchkine, M; Nochy, D; Piketty, C | 1 |
| Bakshi, KK; Chen, J; Condra, JH; Danovich, RM; DiNubile, MJ; Graham, DJ; Haas, DW; Holder, DJ; Rhodes, RR; Saah, AJ; Shivaprakash, M | 1 |
| Brun, S; Di Mascio, M; Ho, DD; Hogan, C; Hurley, A; Louie, M; Markowitz, M; Perelson, AS; Rooney, J; Ruiz, N; Simon, V; Sun, E | 1 |
| Bourgarit, A; Droz, D; Furco, A; Karras, A; Lafaurie, M; Legendre, C; Martinez, F; Molina, JM; Sereni, D | 1 |
| Grim, SA; Romanelli, F | 1 |
| Cheng, A; Isaacson, E; Margot, NA; McGowan, I; Miller, MD | 1 |
| Beijnen, JH; Crommentuyn, KM; Schellens, JH; Sparidans, RW | 1 |
| Chung, C; Coakley, D; Di Mascio, M; Flaherty, J; Hogan, C; Hurley, A; Lamy, P; Louie, M; Markowitz, M; Padte, N; Perelson, AS; Simon, V | 1 |
| Mallal, S; Nolan, D | 1 |
| Callens, S; Colebunders, R; De Schacht, C; Huyst, V | 1 |
| Vere Hodge, A | 1 |
| Chadapaud, S; Hittinger, G; Jolly, P; Lafeuillade, A; Lambry, V; Philip, G | 1 |
| Bassetti, D; Bassetti, M; Ciravegna, BW; Di Biagio, A; Ferrazin, A; Rosso, R | 1 |
| Chapman, T; McGavin, J; Noble, S | 1 |
| Antoniou, T | 1 |
| Kumar, A | 1 |
| Gross, M | 1 |
| Aymard, G; Fernandez, C; Lechat, P; Sentenac, S; Thuillier, A | 1 |
| Kirian, MA; Pecora Fulco, P | 1 |
| Blanchard, JN; Canas, A; King, K; Lonergan, JT; Wohlfeiler, M | 1 |
| Asensi, V; Barrios, A; Dalmau, D; de Mendoza, C; Domingo, P; Estrada, V; Galindo, MJ; Gálvez, J; Martín-Carbonero, L; Ribera, E; Soriano, V | 1 |
| Becker, SL; Bellos, NC; Berger, D; Cheng, A; Coakley, DF; Miller, MD; Pierone, G; Pozniak, AL; Squires, K; Steinhart, CR; Toole, JJ; Wulfsohn, M | 1 |
| Deresinski, S; Gallant, JE | 1 |
| Crippin, J; Drechsler, H; Lisker-Melman, M; Ristig, M; Tebas, P | 1 |
| Lee, JC; Marosok, RD | 1 |
| Dixit, NM; Perelson, AS | 1 |
| Becker, S; Feinberg, J | 1 |
| Brinkman, K; Frissen, PH; Hoogewerf, M; Regez, RM; Schouten, WE; Weigel, HM | 1 |
| Camino, N; Núñez, M; Puoti, M; Soriano, V | 1 |
| Balis, FM; Blanche, S; Bresson, JL; Coakley, DF; DeCarlo, E; Flaherty, JF; Hazra, R; Kearney, BP; Poblenz, M; Steinberg, SM; Tullio, AN; Worrell, CJ; Yale, K; Zeichner, SL; Zhong, L; Zuckerman, JA | 1 |
| Lai, CL; Poynard, T; Ratziu, V; Yuen, MF | 1 |
| DeChristoforo, R; Penzak, SR | 1 |
| Bagnis, CI; Beaufils, H; Benhamou, Y; Brosgart, C; Deray, G; Hannon, H; Izzedine, H; Poynard, T; Sullivan, M | 1 |
| Cunningham, CK; McKinney, RE | 1 |
| Boyle, BA | 2 |
| Chen, SS; Cheng, A; Lu, B; Margot, N; Miller, MD; Wulfsohn, M; Zhong, L | 1 |
| Chen, JM; Margot, NA; Miller, MD; Naeger, LK; Petropoulos, CJ; Swaminathan, S; White, KL; Wrin, T | 1 |
| Benhamou, Y | 1 |
| Rivkin, AM | 1 |
| Cheng, AK; Cooper, DA; DeJesus, E; Dore, GJ; Lu, B; Miller, MD; Pozniak, AL; Zhong, L | 1 |
| Acosta, EP; Brundage, RC; Fletcher, CV; Gulick, RM; Haubrich, R; Jiang, H; Katzenstein, D | 1 |
| Abrams, EJ; Ainyette, I; Champion, SE; Chiriboga, CA; DiGrado, M; Robinson, LG | 1 |
| Lamba, H; Richardson, D | 1 |
| Carter, M | 1 |
| Gazzard, B; Mandalia, S; Nelson, M; Pillay, D; Pozniak, A; Winston, A | 1 |
| Barrios, A; García-Benayas, T; González-Lahoz, J; Soriano, V | 1 |
| Thio, CL | 1 |
| Ala, A; Dieterich, DT | 1 |
| Earle, KE; Seneviratne, T; Shaker, J; Shoback, D | 1 |
| DeRossi, SS; Laudenbach, J | 1 |
| Burger, D; Clotet, B; Grassi, J; Juan, M; Masmitjà, E; Moltó, J; Negredo, E; Paredes, R; Pruvost, A; Puig, J; Ribera, E; Ruiz, L; Viciana, P | 1 |
| Cheng, A; Deray, G; Hulot, JS; Isnard-Bagnis, C; Izzedine, H; Jais, CK; Launay-Vacher, V; Vittecoq, D | 1 |
| Gutiérrez, F; Masiá, M; Padilla, S; Pascual, J; Ramos, JM | 2 |
| Aboulker, JP; Calvez, V; Chazallon, C; Clavel, F; Gérard, L; Girard, PM; Piketty, C; Taburet, AM; Vincent, I | 1 |
| Agbalika, F; Berezne, A; Oksenhendler, E | 1 |
| Almond, MR; Liotta, DC; Mao, S; Painter, GR | 1 |
| Gerstoft, J; Katzenstein, TL; Kristiansen, TB; Larsen, K; Laursen, AL; Lerbaek, A; Mathiesen, L; Nielsen, C; Nielsen, JO; Nielsen, SD; Obel, N | 1 |
| Domingo, P; Elías, MJ; Guerro, MF; Labarga, P; Llibre, JM; Palacios, R; Ruiz, MI; Santos, J; Terrón, JA | 1 |
| Agher, R; Calvez, V; Dominguez, S; Duvivier, C; Ghosn, J; Katlama, C; Marcelin, AG; Paris, L; Peytavin, G; Tubiana, R; Valantin, MA; Wirden, M | 1 |
| Flaherty, JF; Kearney, BP; Shah, J | 1 |
| Hirschel, B; Pechère, M; Piguet, V; Saurat, JH; Schiffer, V; Toutous-Trellu, L | 1 |
| Berger, A; Brodt, HR; Lennemann, TS; Lutz, T; Mösch, M; Staszewski, S; Stephan, C; Stürmer, M | 1 |
| Stebbing, J; Winston, A | 1 |
| Cheng, AK; Coakley, DF; DeJesus, E; Gallant, JE; Lu, B; Miller, MD; Pozniak, AL; Staszewski, S; Suleiman, JM; Toole, JJ | 1 |
| Bocket, L; Brun-Vézinet, F; Costagliola, D; Descamps, D; Ferré, V; Izopet, J; Masquelier, B; Miller, M; Montès, B; Palmer, P; Peytavin, G; Ruffault, A; Schneider, V; Tamalet, C; Trylesinski, A; Wirden, M | 1 |
| Burger, D; Clotet, B; Galindos, MJ; Gel, S; Miralles, C; Moltó, J; Muñoz-Moreno, JA; Negredo, E; Pedrol, E; Puig, J; Ribera, E; Rodriguez Fumaz, C; Rodríguez, E; Ruiz, L; Viciana, P; Videla, S | 1 |
| Benhamou, Y; Cahour, A; Katlama, C; Lada, O; Poynard, T; Thibault, V | 1 |
| Luber, AD; Ruane, PJ | 1 |
| Bates, M; Chappey, C; Clair, MS; Fisher, R; Lanier, ER; Parkin, N; Ross, L; Tisdale, M | 1 |
| Peraire, J; Ribera, E; Richart, C; Sauleda, S; Saumoy, M; Vea, AM; Vidal, F; Viladés, C | 1 |
| Gerstoft, J; Hansen, AB; Mathiesen, S | 1 |
| Alexandre, M; Breton, G; Duval, X; Leport, C; Peytavin, G; Prie, D; Vildei, JL | 1 |
| Harangozo, CS; Korman, TM; Moyle, M; Veitch, AJ; Woolley, IJ | 1 |
| Benhamou, Y; Bonyhay, L | 1 |
| Bini, T; Bongiovanni, M; Cicconi, P; d'Arminio Monforte, A; Melzi, S; Tordato, F | 1 |
| Fung, HB; Guo, Y | 1 |
| Fulco, PP; Higginson, RT; Kirian, MA | 1 |
| Sterling, RK; Sulkowski, MS | 1 |
| Aguero, J; Corral, A; de Mendoza, C; Gallego, O; Martin-Carbonero, L; Soriano, V | 1 |
| Bresson, JL; Chaix, ML; Ghosn, J; Goujard, C; Katlama, C; Peytavin, G; Rey, E; Rouzioux, C; Tréluyer, JM; Viard, JP | 1 |
| Brun-Vézinet, F; Campa, P; Chêne, G; Collin, G; Damond, F; Delaunay, C; Descamps, D; Matheron, S; Peytavin, G; Taieb, A | 1 |
| Ahmad, K | 1 |
| Blum, MR; Kearney, BP; Rousseau, FS; Stevens, RC | 1 |
| Bani-Sadr, F; Molina, JM; Palmer, P; Scieux, C | 1 |
| Gallant, JE; Pham, PA | 2 |
| Hadziyannis, SJ; Papatheodoridis, GV | 1 |
| Cheng, AK; Coakley, DF; Margot, NA; McColl, DJ; Miller, MD; Wulfsohn, M | 1 |
| Zhou, YH; Zhuang, H | 1 |
| Danta, M; Dusheiko, G | 1 |
| Heseltine, PN; Kagan, RM; Merigan, TC; Winters, MA | 1 |
| Bassetti, D; Bassetti, M; Briozzo, A; Cruciani, M; Di Biagio, A; Ferrazin, A; Gatti, G; Rosso, R | 1 |
| Berg, T; Bergk, A; Mauss, S; Reinke, P; Schürmann, D; van Bömmel, F; Wiedenmann, B; Wünsche, T | 1 |
| Däumer, M; Kaiser, R; Matz, B; Rockstroh, JK; Schewe, CK; Schildgen, O; Vogel, M; Weitner, L | 1 |
| Corral, A; de Mendoza, C; Martín-Carbonero, L; Soriano, V; Valer, L | 1 |
| Boeri, E; Castagna, A; Clementi, M; Fusetti, G; Galli, A; Gianotti, N; Lazzarin, A; Salpietro, S; Seminari, E | 1 |
| Bower, M; Gazzard, B; Jones, R; Mandalia, S; Moyle, G; Nelson, M; Stebbing, J | 1 |
| Back, D; Boffito, M; Di Perri, G; Gazzard, B; Hill, A; Moyle, G; Nelson, M; Pozniak, A; Stainsby-Tron, M; Tomkins, J | 1 |
| Montes, B; Segondy, M | 1 |
| Anderson, PL; Becker, SL; Kakuda, TN | 1 |
| Berger, F; Mauss, S; Schmutz, G | 1 |
| Berger, F; Gatell, J; Hoffmann, C; Holm, S; Kuhlmann, B; Martínez, E; Mauss, S; Milinkovic, A; Schmutz, G | 1 |
| Ananworanich, J; Hill, A; Hirschel, B; Mahanontharit, A; Ruxrungtham, K; Siangphoe, U | 1 |
| Thompson, M | 1 |
| Blanco, JL; Gatell, JM; Laguno, M; León, A; Mallolas, J; Martinez, E; Pumarola, T | 1 |
| Lyseng-Williamson, KA; Plosker, GL; Reynolds, NA | 1 |
| Frantzen, L; Hannedouche, T; Krummel, T; Lalanne, H; Marcellin, L; Moulin, B; Parvez-Braun, L | 1 |
| Bonn, D | 1 |
| Benhamou, Y; Bonacini, M; Brook, G; Cargnel, A; Puoti, M; Rockstroh, J; Soriano, V; Thio, C | 1 |
| Düzgüneş, N; Flasher, D; Konopka, K; Pedroso de Lima, MC; Pretzer, E; Salem, II; Simões, S; Slepushkin, V; Steffan, G | 1 |
| Chaix, ML; Delaugerre, C; Peytavin, G; Roudiere, L; Rouzioux, C; Viard, JP | 1 |
| Bannister, A; Day, SL; Fisher, M; Hankins, M; Leake Date, HA | 1 |
| Cheng, A; Deray, G; Gallant, JE; Hulot, JS; Izzedine, H; Launay-Vacher, V; Staszewski, S; Vittecoq, D | 1 |
| Havlir, DV; Ignacio, CC; Koelsch, KK; Lu, B; Margot, N; Miller, MD; Strain, MC; Wong, JK | 1 |
| Dalmau, D; Ferrer, E; Gatell, JM; Iniguez, D; Knobel, H; Leon, A; Niubo, J; Podzamczer, D; Polo, C; Ruiz, I | 1 |
| Barat, A; Caramelo, C; Egido, J; Guerrero, MF; Justo, P; Melero, R; Müller, G; Ortiz, A; Sanz, A; Strutz, F | 1 |
| Gallant, JE; Keruly, JC; Moore, RD; Parish, MA | 1 |
| Mallal, S; Nolan, D; Reiss, P | 1 |
| Farthing, C; Guyer, B; Khanlou, H; Yeh, V | 1 |
| Barreiro, P; Barrios, A; Blanco, F; Clotet, B; Cooper, D; Domingo, P; Garcia-Benayas, T; Gil, P; Gonzalez-Lahoz, J; Labarga, P; Maida, I; Martín-Carbonero, L; Negredo, E; Núñez, M; Rendón, A; Sambeat, MA; Sánchez-Conde, M; Santos, J; Soriano, V | 1 |
| Coco, J; DeJesus, E; Grinsztejn, B; Johnson, M; Lazzarin, A; Lichtenstein, K; Rightmire, A; Rodriguez, C; Sankoh, S; Wilber, R | 1 |
| Benech, H; Clotet, B; García, E; Grassi, J; Grau, E; Moltó, J; Negredo, E; Pruvost, A; Puig, J; Theodoro, F | 1 |
| Becker, M; Breske, A; Esser, S; Hill, A; Koerber, A; Kopperman, M; Kruse, G; Kurowski, M; Möcklinghoff, C; Ross, B; Stocker, H; Wiehler, H | 1 |
| D'Agostino, C; d'Ettorre, G; Lichtner, M; Massetti, AP; Mastroianni, CM; Vullo, V | 1 |
| Bower, M; Gazzard, B; Mandalia, S; Nelson, M; Tung, MY | 1 |
| Amin, J; Carr, A; Cooper, DA; McAllister, J; Winston, A | 1 |
| Bonmarchand, M; Calvez, V; Conan, F; Kalkias, L; Katlama, C; Kirstetter, M; Marcelin, AG; Paris, L; Simon, A; Tubiana, R; Valantin, MA; Wirden, M | 1 |
| Boelle, PY; Girard, PM; Gozlan, J; Lacombe, K; Serfaty, L; Valleron, AJ; Zoulim, F | 1 |
| Basilico, C; Giola, M; Grossi, P | 1 |
| Bignani, O; Delfraissy, JF; Goujard, C; Harmouche, H; Le Bras, P | 1 |
| Girard, PM; Lacombe, K; Meynard, JL; Pacanowski, J; Trylesinski, A | 1 |
| Claas, EC; Gelinck, LB; Kroon, FP | 1 |
| Boffito, M; Gazzard, B; Hand, J; Maitland, D; Mandalia, S; Moyle, G; Nelson, M | 1 |
| Angel-Moreno-Maroto, A; Hernández-Cabrera, M; Pérez-Arellano, JL; Suárez-Castellano, L | 1 |
| Lange, JM | 1 |
| Mills, EJ; Singh, JA | 1 |
| Clark, N; Guyer, B; Hawkins, T; Kearney, BP; St Claire, RL; Veikley, W | 1 |
| Antoniou, T; Chirhin, S; Gough, K; Govan, V; Loutfy, M; Raboud, J; Rachlis, A; Yoong, D | 1 |
| Brun-Vézinet, F; Collin, G; Delaunay, C; Descamps, D; Flandre, P; Landman, R; Miller, M; Peytavin, G; Trylesinski, A | 1 |
| Gupta, SK | 2 |
| Fine, DM | 1 |
| Brito, MO; Quimby, D | 1 |
| Dupin, N; Jaffray, P; Jullien, V; Krivine, A; Lescoat, A; Lillo-Le Louet, A; Moachon, L; Pons, G; Rey, E; Salmon, D; Tréluyer, JM; Urien, S | 1 |
| Bogner, JR; Crispin, A; Goebel, FD; Jülg, BD | 1 |
| Cánovas, V; Gutiérrez, F; Masiá, M; Orozco, C; Padilla, S | 1 |
| Harris, M; Montaner, JS | 1 |
| Bonjoch, A; Clotet, B; Negredo, E; Paredes, R; Puig, J | 1 |
| Maitland, D; Moyle, GJ; Waters, L | 1 |
| Chadwick, DR; Williams, J | 1 |
| Issa, BG; Parsonage, MJ; Savage, MW; Snowden, N; Wilkins, EG | 1 |
| Barrail, A; Goujard, C; Le Tiec, C; Taburet, AM | 1 |
| Badiou, S; Baillat, V; Cristol, JP; De Boever, CM; Reynes, J; Terrier, N | 1 |
| Biglia, A; Blanco, JL; De Lazzari, E; Gatell, JM; Laguno, M; Larrousse, M; León, A; Lonca, M; Mallolas, J; Martinez, E; Milincovic, A; Pumarola, T | 1 |
| Geerlings, SE; Lange, JM; Prins, JM; van Leth, F | 1 |
| Bulgheroni, E; Cicconi, P; Galli, M; Lo Cicero, M; Rusconi, S; Soster, F; Viganò, O | 1 |
| Agut, H; Allen, G; Astriti, M; Bossi, P; Boutolleau, D; Bricaire, F; Gautheret-Dejean, A; Katlama, C; Seilhean, D; Zeller, V | 1 |
| Buchbinder, S; Cates, W; Clarke, E; Coates, T; Cohen, MS; Delaney, M; Flores, G; Goicochea, P; Gonsalves, G; Grant, RM; Harrington, M; Lama, JR; MacQueen, KM; Moore, JP; Peterson, L; Sanchez, J; Thompson, M; Wainberg, MA | 1 |
| Bartholomeusz, A; Camino, N; Klausen, G; Kuiper, M; Locarnini, S; Lutz, T; Mauss, S; Núñez, M; Rodés, B; Sheldon, J; Soriano, V; Tacke, F | 1 |
| Cawthorne, P; Chua, A; Ford, N; Wilson, D | 1 |
| Ditmore, M | 1 |
| Andrei, G; Balzarini, J; De Clercq, E; Hocková, D; Holý, A; Leyssen, P; Naesens, L; Neyts, J; Pannecouque, C; Snoeck, R; Ying, C | 1 |
| Susman, E | 1 |
| Battegay, M; Cavassini, M; Elzi, L; Furrer, H; Gayet-Ageron, A; Hirschel, B; Karrer, U; Ledergerber, B; Russotti, M; Schmid, P; Speck, RF; Weber, R | 1 |
| Berger, F; Corral, A; Mauss, S; Rockstroh, J; Rodés, B; Schwarze-Zander, C; Sheldon, JA; Soriano, V | 1 |
| Kuritzkes, DR | 1 |
| Berger, DS; Gallant, JE; Johnson, J; Liao, Q; Lim, ML; Rodriguez, AE; Ross, L; Shaefer, MS; Weinberg, WG; Young, B | 1 |
| Bushman, L; Delahunty, T; Fletcher, CV | 1 |
| Berger, A; Bickel, M; Carlebach, A; Klauke, S; Lutz, T; Staszewski, S; Stephan, C; Stuermer, M | 1 |
| Collins, C; Halima, Y | 1 |
| Giacomet, V; Martelli, L; Merlo, M; Mora, S; Sciannamblo, M; Viganò, A | 1 |
| Balis, FM; DeCarlo, E; Flaherty, J; Gafni, RI; Hazra, R; Kearney, BP; Maldarelli, F; Steinberg, SM; Tullio, AN; Worrell, CJ; Yale, K; Zeichner, SL | 1 |
| Asensi, V; Barrios, A; Clotet, B; Domingo, P; Estrada, V; Labarga, P; Morales, D; Negredo, E; Santos, J; Soriano, V | 1 |
| Adam, A; Maserati, R; Schewe, CK; Wassmer, G; Weitner, L | 1 |
| Girault, V | 1 |
| Burger, DM; Droste, JA; Hekster, YA; Kearney, BP | 1 |
| Mills, E | 1 |
| Diaz, RS | 1 |
| de Man, RA; de Vries-Sluijs, TE; Hansen, BE; Osterhaus, AD; van der Eijk, AA; van der Ende, ME | 1 |
| Amin, J; Carr, A; Cooper, DA; Emery, S; Mallon, P; Marriott, D; Winston, A | 1 |
| Arribas, JR; Campo, RE; Cheng, AK; Chuck, S; DeJesus, E; Enejosa, J; Gallant, JE; Gazzard, B; Lu, B; McColl, D; Pozniak, AL; Toole, JJ | 1 |
| Aldrovandi, GM; Beretta, S; Giacomet, V; Luraschi, P; Martelli, L; Merlo, M; Mora, S; Rombolà, G; Viganò, A | 1 |
| Cardellach, F; Casademont, J; Clotet, B; Garrabou, G; Infante, AB; López, S; Miró, O; Negredo, E; Puig, J; Ramos, X; Ruiz, L; Sanjurjo, E | 1 |
| El-Sadr, WM; Eshleman, SH; Gai, F; Hendrix, C; Justman, J; Kwiecien, A; Maslankowski, LA; Mâsse, B; Mayer, KH; Morrow, K; Rooney, JF; Soto-Torres, L | 1 |
| Benhamou, Y; Fleury, H; Katlama, C; Le Teuff, G; Pellegrin, I; Piketty, C; Rozenbaum, W; Trimoulet, P; Trylesinski, A; Urbinelli, R | 1 |
| Coco, J; DeJesus, E; Grinsztejn, B; Johnson, M; Lazzarin, A; Lichtenstein, K; McLaren, C; Odeshoo, L; Rightmire, A; Rodriguez, C; Wirtz, V | 1 |
| Andrade, RA; El Sahly, HM; Hunter, R; Munoz, C; Nnabuife, C; Teeter, L; Zerai, T | 1 |
| Bonjoch, A; Bravo, I; Clotet, B; Heilek-Sneider, GM; Martinez-Picado, J; Moltó, J; Negredo, E; Ruiz, L; Valle, M | 1 |
| Fisher, M; Gazzard, B; Higgs, C; Johnson, M; Mandalia, S; Moyle, G; Nelson, M; Teague, A | 1 |
| Côté, HC; Gadawski, I; Harrigan, PR; Harris, M; Hogg, R; Magil, AB; Montaner, JS; Scarth, BJ; Wang, N; Werb, R; Yip, B; Yu, E; Zalunardo, N | 1 |
| Darder, M; Ford, N | 1 |
| Barreiro, P; Soriano, V | 1 |
| Antinori, A; Bellagamba, R; Bonfigli, S; Boumis, E; Ceccherini-Silberstein, F; Comandini, UV; Concetta Bellocchi, M; D'Arrigo, R; Federico Perno, C; Forbici, F; Lorenzini, P; Marconi, P; Narciso, P; Soldani, F; Tozzi, V; Trotta, MP; Zaccarelli, M | 1 |
| Gazzard, BG | 2 |
| Balestre, E; Boucher, S; Capdepont, S; Dabis, F; Dupon, M; Fleury, H; Masquelier, B; Thiébaut, R | 1 |
| Manfredi, R | 1 |
| Butt, AA | 1 |
| Armon, C; Baker, RK; Holmberg, SD; Moorman, AC; Weidle, PJ; Wood, KC; Young, B | 1 |
| Barreiro, P; Barrios, A; Blanco, F; García-Benayas, T; González-Lahoz, J; Maida, I; Rendón, AL; Rivas, P; Rodríguez-Novóa, S; Soriano, V | 1 |
| Cheng, A; Ebrahimi, R; Kearney, BP; Mittan, A; Ramanathan, S | 1 |
| Aboulker, JP; Calvez, V; Chazallon, C; Clavel, F; Gérard, L; Girard, PM; Madelaine-Chambrin, I; Marcelin, AG; Molina, JM; Piketty, C; Taburet, AM | 1 |
| Andreoni, M; Antinori, A; Bini, T; Bonora, S; Carosi, G; Castagna, A; Di Perri, G; Landonio, S; Merli, S; Nasta, P; Perno, CF; Quirino, T; Tozzi, V; Trotta, MP; Zaccarelli, M | 1 |
| Gottardi, M; Lanzafame, M; Lattuada, E; Rapagna, F; Vento, S | 1 |
| Shepp, DH; Winston, JA | 1 |
| Antunes, F; Chiesi, A; Goebel, FD; Katlama, C; Knysz, B; Ledergerber, B; Lundgren, JD; Mocroft, A; Phillips, AN; Reiss, P | 1 |
| Carr, A | 1 |
| Anderson, PL; Kakuda, TN | 1 |
| Nagy, GS | 1 |
| Hammerstrom, TS; Laessig, KA; Lewis, LL | 1 |
| Alvarez, ML; Domingo, P; Ena, J; Estrada, V; Falcó, V; Moreno, S; Murillas, J; Palacios, R; Santos, J | 1 |
| Amiel, C; Guessant, S; Kara, A; Lebrette, MG; Marechal, Eda S; Pialoux, G; Quercia, R; Renaud, S; Schneider, V; Thevenet, S | 1 |
| Arvieux, C; Dailly, E; Jolliet, P; Perré, P; Raffi, F; Tattevin, P; Tribut, O | 1 |
| Jenny-Avital, ER | 1 |
| Hussain, S; Khayat, A; Rathore, MH; Tolaymat, A | 1 |
| Antela, A; Domingo, P; Llibre, JM; Miralles, C; Moreno, S; Palacios, R; Pérez-Elías, MJ; Sánchez-de la Rosa, R; Santos, J | 1 |
| Forbes, A | 1 |
| Mentré, F; Panhard, X; Piketti, C; Taburet, AM | 1 |
| Cobo, J; Corral, I; García, AM; Quereda, C | 1 |
| Lee, WA; Martin, JC | 1 |
| Cha, AE | 1 |
| Piacenti, FJ | 1 |
| Cirino, CM; Kan, VL | 1 |
| Aldern, KA; Beadle, JR; Ciesla, SL; Hostetler, KY; Wan, WB | 1 |
| Fätkenheuer, G; Lehmann, C; Wyen, C | 1 |
| Alessi, E; Cusini, M; Ghislanzoni, M; Zerboni, R | 1 |
| Croom, KF; Frampton, JE | 1 |
| Gatanaga, H; Genka, I; Honda, M; Kikuchi, Y; Kimura, S; Oka, S; Tachikawa, N; Tanuma, J; Teruya, K; Ueda, A; Yazaki, H | 1 |
| DeCarlo, E; Flaherty, JF; Gafni, RI; Hazra, R; Kearney, BP; Maldarelli, F; Reynolds, JC; Tullio, AN; Worrell, CJ; Yale, K; Zeichner, SL | 1 |
| Cheng, A; Lu, B; Margot, NA; Miller, MD | 1 |
| Baker, RK; Brooks, JT; Buchacz, K; Greenberg, A; Holmberg, SD; Moorman, AC; Tong, T | 1 |
| Shepp, DH; Winston, J | 1 |
| Blaas, S; Glück, T; Salzberger, B; Schneidewind, A | 1 |
| Blanche, S; Delaugerre, C; Jullien, V; Macassa, E; Rouzioux, C; Teglas, JP; Tréluyer, JM; Veber, F | 1 |
| Grant, RM; Levy, V | 1 |
| Alloui, C; Bouhassoune, K; Calboreanu, A; Dény, P; Gordien, E; Legal, F; Podevin, P; Rico-Garcia, M; Salmon-Céron, D; Sogni, P | 1 |
| Grant, RM; Wainberg, MA | 1 |
| Adams, DR; Bashirian, S; Butera, S; Folks, TM; Greenberg, AE; Hudgens, MG; Jackson, E; Janssen, R; Johnson, J; Kim, C; Monsour, M; Otten, RA; Paxton, L; Ramos, A; Rendon, A; Soriano, V; Subbarao, S | 1 |
| Cardellach, F; Casademont, J; Deig, E; Garrabou, G; Infante, AB; López, S; Miró, O; Pedrol, E; Vidal, I | 1 |
| Buggisch, P; Lutgehetmann, M; Petersen, J; Wursthorn, K; Zollner, B | 1 |
| Chen, JM; Chen, X; Cihlar, T; Hatada, M; He, GX; Leavitt, SA; Lee, WA; Liu, X; McDermott, MJ; Mulato, AS; Stray, KM; Swaminathan, S; Yang, ZY | 1 |
| Farthing, C; Khanlou, H | 1 |
| Berg, T; Berger, F; Bruno, R; Carlebach, A; Hoffmann, C; Jaeger, H; Lutz, T; Mauss, S; Nelson, M; Rockstroh, J; Schmutz, G; Schürmann, D; Schwarze-Zander, C; Sheldon, J; Soriano, V; Stoehr, A; von Boemmel, F; Wolf, E | 1 |
| Barreiro, P; Camino, N; Díaz-Pollán, B; González-Lahoz, J; Martín-Carbonero, L; Núñez, M; Ramos, B; Soriano, V | 1 |
| Arribas López, JR; Muñoz de Benito, RM | 1 |
| Laurence, J | 1 |
| Cartledge, J; Churchill, D; Fakoya, A; Hay, P; Johnson, M; Leen, C; Moyle, GJ; Murphy, M; Reilly, G; Sabin, CA; Scullard, G; Wilkins, E | 1 |
| Bernard-Henry, C; Cheneau, C; de Mautort, E; Hess, G; Krebs, M; Lang, JM; Partisani, M; Priester, M; Rey, D | 1 |
| Arribas, JR; Campo, RE; Chen, SS; Cheng, AK; DeJesus, E; Enejosa, J; Gallant, JE; Gazzard, B; McColl, D; Pozniak, AL; Toole, JJ | 1 |
| Alston-Smith, B; Andersen, J; Brosgart, CL; Jacobson, JM; Johnson, VA; Liu, T; Lynch, P; Peters, MG; Pollard, RB; Polsky, B; Rooney, JF; Sherman, KE; Swindells, S | 1 |
| d'Ettorre, G; Mastroianni, CM; Vullo, V | 1 |
| Bongiovanni, M; Tordato, F | 1 |
| Haas, DW; Hulgan, T | 1 |
| Deray, AG; Dominguez, S; Ghosn, J; Goyenvalle, C; Hulot, JS; Izzedine, H; Lechat, P; Valantin, MA; Villard, E | 1 |
| Durantel, S; Girard, PM; Gozlan, J; Lacombe, K; Ollivet, A; Tran, N; Zoulim, F | 1 |
| Bonfanti, P; Carradori, S; De Socio, G; Grosso, C; Madeddu, G; Marconi, P; Melzi, S; Mura, MS; Palvarini, L; Penco, G; Quirino, T; Ricci, E; Rossella, E | 1 |
| Baker, RK; Brooks, JT; Buchacz, K; Chmiel, JS; Moorman, A; Wood, KC; Young, B | 1 |
| Aubron-Olivier, C; Calvez, V; Deray, G; Dominguez, S; Ghosn, J; Izzedine, H; Katlama, C; Ktorza, N; Miller, M; Peytavin, G; Trylesinski, A; Wirden, M | 1 |
| Chi, G; Nair, V; Pommier, Y; Semenova, E | 1 |
| Hester, J; Jain, MK; Lee, WM; Parekh, NK | 1 |
| Cheng, AK; Margot, N; McColl, D; Miller, MD | 1 |
| Barreiro, P; Blanco, F; de Mendoza, C; García-Benayas, T; Gil, P; González-Lahoz, J; Maida, I; Martín-Carbonero, L; Soriano, V | 1 |
| Halima, Y | 1 |
| Best, B; Goicoechea, M | 1 |
| Bogner, JR; Goebel, FD; Jülg, B; Mühlbayer, D; Nelson, PJ; Röling, J; Schlattner, U; Schmid, H; Sternfeld, T; Wallimann, T | 1 |
| Attar, N; Comanor, L; Elkin, C; Jain, MK; Keiser, P; Kipnis, P; Lee, WM; Leung, K; Ocampo, A; White, C | 1 |
| Boucher, S; Fleury, H; Lavignolle-Aurillac, V; Masquelier, B; Neau, D; Ragnaud, JM; Recordon-Pinson, P; Schrive, MH | 1 |
| Gallant, JE; Klotman, PE; Sax, PE | 1 |
| Amoroso, A; Chan-Tack, KM; Kopack, AM; Polk, C | 1 |
| De Munter, P; Schrooten, Y; Van Laethem, K; Van Ranst, M; Van Wijngaerden, E; Vandamme, AM; Verbesselt, R | 1 |
| Bogner, J; Claas, GJ; Goebel, FD; Jülg, B | 1 |
| Ananworanich, J; Chetchotisakd, P; Gayet-Ageron, A; Hirschel, B; Jupimai, T; Le Braz, M; Prasithsirikul, W; Rooney, JF; Ruxrungtham, K; Ubolyam, S | 1 |
| Brew, BJ; Chen, TC; Drake, AK; Li, PC; Loy, CT; Petoumenos, K; Wright, EJ | 1 |
| Cihlar, T; Ray, AS | 1 |
| Chappell, BJ; Margot, NA; Miller, MD | 1 |
| Dore, GJ; Matthews, GV | 1 |
| Mertenskoetter, T; Pearce, G; Ranneberg, B | 1 |
| Gulick, RM; Klingman, KL; Koletar, SL; Kuritzkes, DR; Lalama, CM; Pilcher, CD; Reichman, RC; Ribaudo, HJ; Schackman, BR; Schouten, J; Shikuma, CM; Squires, KE | 1 |
| Antinori, A; Antonucci, F; Barreiro, P; Carosi, G; De Silvestri, A; El Hamad, I; Ladisa, N; Lapadula, G; Maggiolo, F; Mandalia, S; Maserati, R; Migliorino, G; Pierotti, P; Sighinolfi, L; Soriano, V; Suter, F; Torti, C | 1 |
| Benech, H; Da Silva, D; Durand-Gasselin, L; Grassi, J; Pruvost, A | 1 |
| Kagan, RM; Lee, TS; Lewinski, MA; Lloyd, RM; Potts, SJ; Ross, L | 1 |
| Gosling, J | 1 |
| Maggiolo, F; Ripamonti, D; Suter, F | 1 |
| Anastos, K; Cohen, M; Cole, S; Hessol, NA; Justman, J; Kaplan, RC; Lu, D; Shi, Q; Tien, PC; Vigen, C; Young, M | 1 |
| Ambuhl, P; Huber, M; Keusch, G; Moch, H; Moddel, M; Opravil, M; Pfammatter, R; Schmid, S; Varga, Z; Wuthrich, RP | 1 |
| Gripshover, B; Gupta, S; Hammond, SP; Hatano, H; Hu, Z; Kalayjian, RC; Kuritzkes, DR; Smith, D; Whitcomb, J; Wild, M | 1 |
| El Barkil, M; Gagnieu, MC; Guitton, J | 1 |
| Beniowski, M; Gargalianos, P; Gatell, J; Kirk, O; Lundgren, JD; Mocroft, A; Reiss, P; Staszewski, S; Viard, JP; Zilmer, K | 1 |
| Birnkrant, DB; Chan-Tack, KM; Struble, KA; Truffa, MM | 1 |
| Chaix, ML; Correas, JM; Dhalluin-Venier, V; Mallet, VO; Pol, S; Verkarre, V; Viard, JP | 1 |
| Aboulker, JP; Chazallon, C; Gérard, L; Girard, PM; Piketty, C; Taburet, AM | 1 |
| Buclin, T; Colombo, S; Décosterd, L; Furrer, H; Rotger, M; Telenti, A | 1 |
| Cooper, DA; Dore, GJ; Matthews, GV | 1 |
| Antenozzi, S; Hulse, S; Luque, A; Shahzad, U; Smith, B; Tanzman, E; Wang, D | 1 |
| Bischofberger, N; Chen, SS; Clotet, B; Cooper, DA; Curtis, S; Gazzard, B; Katlama, C; Lange, J; Lazzarin, A; Montaner, JS; Nelson, MR; Rooney, JF; Schewe, K; Smith, S; Wyatt, C | 1 |
| Calvez, V; Chaix, ML; Delaugerre, C; Girard, PM; Katlama, C; Marcelin, AG; Morand-Joubert, L; Soulié, C | 1 |
| Baker, DL; Drevets, DA; Greenfield, RA; Lockhart, SM; Rathbun, RC; Salvaggio, MR; Stephens, JR; Vincent, S | 1 |
| Acosta, EP; Jennings, HC; Parks, DA; Taylor, CW | 1 |
| Bonfanti, P; Carradori, S; De Socio, GV; Grosso, C; Landonio, S; Madeddu, G; Marconi, P; Melzi, S; Miccolis, S; Mura, MS; Penco, G; Quirino, T; Ricci, E; Rosella, E | 1 |
| Baker, RK; Brooks, JT; Buchacz, K; Chmiel, J; Moorman, AC; Wood, KC; Young, B | 1 |
| Mellors, JW; Parikh, UM; Sluis-Cremer, N; Zelina, S | 1 |
| Curtis, S; Rooney, JF; Shepp, DH | 1 |
| Christen, A; Furrer, H; Fux, CA; Mohaupt, MG; Zgraggen, S | 1 |
| Celesia, BM; Massimino, SD; Mavilla, S; Mughini, MT; Nunnari, G; Onorante, A; Russo, R | 1 |
| Garcia-Gasco, P; Sheldon, J; Soriano, V | 1 |
| Arnaiz, JA; Blanco, JL; de Lazzari, E; Garrabou, G; Gatell, JM; Laguno, M; Larrousse, M; Leon, A; Lonca, M; López, S; Mallolas, J; Martinez, E; Milinkovic, A; Miró, O; Vidal, S | 1 |
| Anderson, PL; Aquilante, CL; Bushman, LR; Carten, ML; Delahunty, T; Fletcher, CV; King, TM; Kiser, JJ; Wolfe, P | 1 |
| Cascone, A; Colella, G; Di Martino, F; Filippini, A; Filippini, P; Lanza, A; Martini, S; Masiello, A; Pisapia, R | 1 |
| Acosta, EP; Binongo, JN; Chuck, SK; Lennox, JL; Ofotokun, I; Palau, M | 1 |
| Hope, T; Jaffe, HW; Paxton, LA | 1 |
| Clotet, B; Girard, PM; Negredo, E; Neubacher, D; Youle, M | 1 |
| Brim, NM; Cu-Uvin, S; Hu, SL; O'Bell, JW | 1 |
| Beretta, S; Borgonovo, S; Cafarelli, L; Giacomet, V; Martelli, L; Mora, S; Rombolà, G; Viganò, A; Zuccotti, GV | 1 |
| Aldern, KA; Almond, MR; Beadle, JR; De Clercq, E; Hostetler, KY; Korba, BE; Lampert, BM; Neyts, J; Painter, GR; Trost, LC | 1 |
| Ahya, SN; Kanwar, YS; Palella, F; Patel, SM; Zembower, TR | 1 |
| Ball, C; Hawkins, S | 1 |
| Dauer, B; Haberl, A; Harder, S; Klauke, S; Lutz, T; Staszewski, S; von Hentig, N | 1 |
| Bae, AS; Borroto-Esoda, K; Goodman, D; Margot, NA; Miller, MD; Svarovskaia, ES; Waters, JM; Zhong, L | 1 |
| Akumatey, B; Alleman, P; Johnson, L; Lawoyin, T; Macqueen, KM; Nyiama, T | 1 |
| Cabau, J; Gort, A; Planella, R; Roselló, L | 1 |
| Cohen, DE; Golub, SA; Mayer, KH; Rosenthal, L | 1 |
| Daniels, E; Gaglio, PJ; Sterling, R; Tedaldi, E | 1 |
| Ayliffe, U; Dervisevic, S; Garcia-Diaz, A; Geretti, AM; Gilson, R; Johnson, M; Nebbia, G; Smith, C; Tedder, R | 1 |
| Doerr, HW; Staszewski, S; Stürmer, M | 1 |
| Corona, G; Innocenti, F; Sandron, S; Sartor, I; Tirelli, U; Toffoli, G; Vaccher, E | 1 |
| Bridges, AS; Cohen, MS; Corbett, AH; Dumond, JB; Jung, BH; Kashuba, AD; Patterson, KB; Rezk, NL; Stewart, PW; Yeh, RF | 1 |
| Crumpacker, CS; Gilde, LR; Gotuzzo, E; Isaacs, RD; Kovacs, C; Markowitz, M; Mendo, F; Miller, MD; Morales-Ramirez, JO; Nguyen, BY; Prada, G; Ratanasuwan, W; Teppler, H; Wan, H; Wenning, LA | 1 |
| Brenner, BG; Lalonde, R; Micheli, V; Moisi, D; Ntemgwa, M; Oliveira, M; Wainberg, MA | 1 |
| Killingley, B; Pozniak, A | 1 |
| de Silva, TI; Dockrell, DH; Griffin, MD; Post, FA | 1 |
| Abdool Karim, Q; Abdool Karim, SS | 1 |
| Balán, IC; Carballo-Diéguez, A; El-Sadr, W; Gai, F; Hoffman, S; Mantell, JE; Maslankowski, L; Mayer, K; Morrow, K; Rosen, R | 1 |
| Blanchet, F; Duval, X; Essig, M; Gervais, A; Iordache, L; Kaied, FA; Leport, C; Longuet, P; Peytavin, G | 1 |
| Burger, DM; Droste, JA; Lange, JM; Lowe, SH; Prins, JM; Reiss, P; Repping, S; van der Veen, F; van Leeuwen, E | 1 |
| Blanche, S; Dechaux, M; Jullien, V; Papaleo, A; Salomon, R; Veber, F; Warszawski, J | 1 |
| Battegay, M; Bernasconi, E; Bucher, HC; Cavassini, M; Furrer, H; Hasse, B; Hirschel, B; Kaufmann, G; Vernazza, PL; Wolbers, M | 1 |
| Agrofoglio, L; Bénech, H; Negredo, E; Pruvost, A; Théodoro, F | 1 |
| Nelson, R | 1 |
| Chantratitra, W; Kiertiburanakul, S; Manosuthi, W; Sungkanuparph, S | 1 |
| Arribas, JR; Campo, RE; Chen, SS; Cheng, AK; Dejesus, E; Enejosa, J; Gallant, JE; Gazzard, B; Holmes, CB; McColl, D; Pozniak, AL; Toole, JJ | 1 |
| Aldrovandi, GM; Cantrell, RA; Chi, BH; Chintu, N; Kankasa, C; Kruse, G; Mbewe, F; Safrit, JT; Sinkala, M; Stringer, EM; Stringer, JS | 1 |
| Cunningham, CK; Fletcher, CV; Flynn, PM; Harris, DR; Havens, PL; Kapogiannis, BG; Kiser, JJ; Liu, NX; Major-Wilson, H; Muenz, LR; Viani, RM; Wilson, CM | 1 |
| Colson, P; Henry, M; Solas, C; Tamalet, C; Tomei, C; Villacian, J | 1 |
| Deig, E; Pedrol, E | 1 |
| Abeli, C; Antinori, A; Bongiovanni, M; Capetti, A; Castagna, A; Chiesa, E; Cicconi, P; d'Arminio Monforte, A; de Luca, A; di Biagio, A; Gatti, F; Gianotti, N; Marconi, P; Matti, A; Mussini, C; Nasta, P; Tirelli, V; Torti, C; Zaccarelli, M | 1 |
| Bedini, A; Borghi, V; Esposito, R; Mussini, C; Prati, F; Sabbatini, F | 1 |
| Haefeli, WE; Ketabi-Kiyanvash, N; Storch, CH; Weis, N; Weiss, J | 1 |
| Boojamra, CG; Callebaut, C; Cihlar, T; Gao, Y; Hui, H; Lin, KY; Mackman, RL; Ray, AS; Stray, K; Vela, JE; Zhang, L | 1 |
| Barisoni, L; Hynes, P; McMeeking, A; Rabenou, R; Urbina, A | 1 |
| Chayama, K; Takahashi, S | 1 |
| Chen, J; Cooper, DA; Emery, S; Hazuda, DJ; Kelleher, AD; Law, M; Murray, JM; Nguyen, BY; Teppler, H | 1 |
| Ananworanich, J; Chetchotisakd, P; Hirschel, B; Jupimai, T; Klinbuayam, W; Mahanontharit, A; Nüesch, R; Prasithsirikul, W; Ruxrungtham, K; Srasuebkul, P | 1 |
| Cossarizza, A; Dentone, C; Di Biagio, A; Esposito, R; Ferraresi, R; Mussini, C; Nasi, M; Nemes, E; Pinti, M; Repetto, E; Rosso, R; Viscoli, C | 1 |
| Szczech, LA | 1 |
| Best, B; Diamond, C; Goicoechea, M; Haubrich, R; Jain, S; Kemper, C; Liu, S; Louie, S; Sun, S; Witt, M | 1 |
| Bill, R; Cohen, D; Fisher, A; Grasso, C; Mayer, KH; Mimiaga, MJ; Van Derwarker, R | 1 |
| Guillemi, S; Gutiérrez, S; Harrigan, PR; Jahnke, N; Montaner, JS; Montessori, V | 1 |
| Shacklett, BL | 1 |
| Denton, PW; Estes, JD; Garcia, JV; Haase, AT; Othieno, FA; Payne, D; Powell, DA; Sun, Z; Wege, AK; Wei, BL | 1 |
| Bernasconi, E; Bucher, HC; Cavassini, M; Elzi, L; Furrer, H; Fux, CA; Hirschel, B; Opravil, M; Simcock, M; Vernazza, P; Wolbers, M | 1 |
| Carosi, G; Ceresoli, F; Cologni, G; Cossarizza, A; Costarelli, S; Gargiulo, F; Lapadula, G; Magoni, M; Manca, N; Nasi, M; Nichelatti, M; Pinti, M; Quiros-Roldan, ME; Torti, C | 1 |
| Atta, MG; Fine, DM; Lucas, GM; Perazella, MA | 1 |
| Carballo-Diéguez, A; El-Sadr, WM; Gai, F; Hoffman, S; Mantell, JE; Maslankowski, L; Mayer, KH; Morrow, KM; Rosen, RK | 1 |
| Abel, S; Muirhead, GJ; Ridgway, CE; Russell, D; Whitlock, LA | 1 |
| Ananworanich, J; Côté, HC; Hill, A; Hirschel, B; Jupimai, T; Kerr, SJ; Laopraynak, N; Nuesch, R; Ruxrungtham, K; Saenawat, S | 1 |
| Herrera, L; Moreno, S; Sánchez-de la Rosa, R | 1 |
| Ceccarelli, G; D'Ettorre, G; Massetti, AP; Mastroianni, CM; Vullo, V; Zaffiri, L | 1 |
| Bosch-García, RJ; Fernández-Orland, A; Herrera-Ceballos, E; Tejera-Vaquerizo, A | 1 |
| Gafni, RI; Hazra, R; Purdy, JB; Reynolds, JC; Zeichner, S | 1 |
| Larsen, CS; Lybaek, D | 1 |
| Anderson, PL; Aquilante, CL; Carten, ML; Fletcher, CV; King, TM; Kiser, JJ | 1 |
| Avril, MF; Beaulieu, D; Burnouf, M; Dupin, N; Lacau Saint-Guily, J; Plantier, F; Régnier, S | 1 |
| Bulgin-Coleman, D; Fath, M; Fontaine, L; Kantor, C; Mieras, J; Pierone, G; Shearer, J | 1 |
| Stephan, C | 1 |
| Barreiro, P; Corral, A; de Mendoza, C; Garrido, C; González-Lahoz, J; Jiménez-Nacher, I; Poveda, E; Soriano, V; Zahonero, N | 1 |
| Calabresi, A; Carosi, G; Costarelli, S; Izzo, I; Lapadula, G; Quiros-Roldan, E; Torti, C | 1 |
| Battegay, M; Bernasconi, E; Böni, J; Bürgisser, P; Cavassini, M; Furrer, H; Günthard, HF; Hirschel, B; Klimkait, T; Ledergerber, B; Rickenbach, M; Vernazza, PL; von Wyl, V; Yerly, S | 1 |
| Carolo, G; Concia, E; Gottardi, M; Lanzafame, M; Lattuada, E; Vento, S | 1 |
| González-Mena, A; Guelar-Grimberg, A; Knobel-Freud, H; Vallecillo-Sánchez, G | 1 |
| Castrillo-Bustamante, C; Hernández-Hernández, JL; Vejo-Puente, E; Velasco-Montes, J | 1 |
| Bonjoch, A; Clotet, B; Domingo, P; Galindo, MJ; Iribarren, J; Llibre, JM; Martinez-Picado, J; Negredo, E; Pérez-Alvarez, N; Schapiro, J | 1 |
| Ayen, R; Bellido, R; Cardellach, F; Clotet, B; Garrabou, G; Lòpez, S; Miró, O; Morén, C; Negredo, E; Puig, J | 1 |
| Chen, MS; Cherrington, JM; Foli, A; Gu, Z; Mulato, AS; Salomon, H; Sogocio, KM; Wainberg, MA; Yarchoan, R | 1 |
| Beck, TW; Benveniste, RE; Bischofberger, N; Black, R; Follis, KE; Grant, RF; Sabo, A; Tsai, CC | 1 |
| Cundy, KC; Fisher, PE; Flaherty, J; Hitchcock, MJ; Jaffe, HS; Lalezari, JP; Lietman, PS; Petty, BG; Polis, MA; Wachsman, M | 1 |
| Balzarini, J; De Clercq, E; Georgsson, G; Naesens, L; Pálsson, PA; Thormar, H; Torsteinsdóttir, S | 1 |
| Baird, BF; Davey, RT; Falloon, J; Fisher, PE; Jaffe, HS; Kovacs, JA; Manischewitz, JF; Polis, MA; Spooner, KM; Walker, RE | 1 |
| Barditch-Crovo, P; Collier, AC; Cundy, KC; Ebeling, D; Jaffe, HS; Toole, J; Walker, RE | 1 |
| Cherrington, JM; Drew, WL; Hitchcock, MJ; Lalezari, JP; Miner, R | 1 |
| Ahmed, PS; Brennan, TM; Bridges, CG; Casara, P; Hornsperger, JM; Navé, JF; Taylor, DL; Tyms, AS | 1 |
| Cundy, KC; Fisher, PE; Jaffe, HS; Lietman, PS; Pastelak, A; Petty, BG; Wachsman, M | 1 |
| Danner, SA | 1 |
| Arends, S; Kamp, W; Schokker, J; van Halteren, E | 1 |
| Barditch-Crovo, P; Cundy, KC; Ebeling, D; Hendrix, CW; Jaffe, HS; Lietman, PS; Toole, J | 1 |
| Meadows, KP; Pavia, AT; Rallis, TM; Tyring, SK | 1 |
| Cherrington, JM; Collier, A; Deeks, SG; Drew, WL; Hellmann, N; Jaffe, HS; Kahn, J; Lalezari, J; Lamy, PD; Li, W; Mulato, AS; Pavia, A; Rodrigue, D; Toole, J | 1 |
| Chinn, R; Fisher, M; Gazzard, BG; Healy, J; Nelson, MR; Sadler, M | 1 |
| Agatep, E; Berardi, CJ; Bischofberger, N; Cundy, KC; Dehqanzada, ZA; Lifson, JD; Marthas, ML; Pedersen, NC; Van Rompay, KK; Vasquez, GM | 1 |
| Barditch-Crovo, P; Cundy, KC; Deeks, SG; Hellmann, NS; Hwang, F; Kahn, JO; Lietman, PS; Rooney, JF; Safrin, S | 1 |
| Anton, KE; Cherrington, JM; Lamy, PD; Miller, MD; Mulato, AS | 1 |
| Barditch-Crovo, P; Cundy, KC; Jaffe, HS; Lietman, PS; Petty, BG; Redpath, M; Ruby, A | 1 |
| Crowe, S | 1 |
| Collier, AC; Schwartz, MA | 1 |
| De Clercq, E; Neyts, J | 1 |
| Chopra, KB; Gilson, RJ; Jaffe, HS; Murray-Lyon, IM; Nelson, MR; Newell, AM; Rice, SJ; Tedder, RS; Toole, J; Weller, IV | 1 |
| Au Eong, KG; Beatty, S; Charles, SJ | 1 |
| Angarano, G | 1 |
| Blanchard, S; Burchett, S; Coakley, DF; Culnane, M; Cundy, KC; Fridland, A; Hughes, WT; Purdue, L; Read, JS; Rodman, JH; Shenep, JL; Willoughby, R; Zimmer, B | 1 |
| Brosgart, CL; Israelski, DM; Katzenstein, DA; Miller, MD; Murlidharan, U; Passaro, DJ; Shafer, RW; Shulman, NS; Van Doren, S; Zolopa, AR | 1 |
| Self, SG; Wick, D | 1 |
| Acosta, E; Cheng, H; Fischl, M; Fiscus, SA; Fletcher, CV; Freimuth, W; Gulick, RM; Haubrich, R; Hu, XJ; Katzenstein, D; Lagakos, SW; Mills, C; Pettinelli, C; Snyder, S; Swanstrom, R | 1 |
| Boix, V; Merino, E; Portilla, J; Reus, S; Román, F | 1 |
| Ammassari, A; Antinori, A; Cingolani, A; De Luca, A; Giancola, ML; Govoni, A; Grisetti, S; Monforte, AD; Murri, R; Paglia, MG; Testa, L | 1 |
| Beck, TW; Bischofberger, N; Emau, P; Follis, KE; Morton, WR; Sun, JC; Tran, CA; Tsai, CC | 1 |
| Hogan, PG; Johnson, DW; Kay, TD; McLeod, SE | 1 |
| Acosta, EP; Cheng, H; Fischl, M; Fletcher, CV; Gulick, RM; Haubrich, R; Hu, XJ; Katzenstein, D; Mills, C; Raasch, R; Remmel, RP | 1 |
| Houston, S; Mashinter, L; Roberts, N | 1 |
| Calista, D | 1 |
| Bischofberger, N; Brown, CR; Buckler-White, A; Endo, Y; Hirsch, V; Igarashi, T; Martin, MA; Plishka, R | 1 |
| Hatse, S | 1 |
| Bischofberger, N; Buch, S; Foresman, L; Kumar, A; Lifson, JD; Narayan, O | 1 |
| Crickx, B; Descamps, V; Duval, X; Grossin, M; Leport, C | 1 |
| Cheng, B | 1 |
| Smart, T | 1 |
| Cadman, J | 2 |
| McArthur, J | 1 |
| Schouten, J | 1 |
| Beltrame, A; Carosi, G; Casalini, C; Ciravolo, G; Forleo, MA; Graifemberghi, S; Gulletta, M; Matteelli, A; Tedoldi, S | 1 |
| Bell, A; D'agati, VD; Kambham, N; Markowitz, GS; Tanji, K; Tanji, N | 1 |
| Anton, KE; Cherrington, JM; Fuller, MD; Lamy, PD; Margot, NA; Miller, MD; Mulato, AS | 1 |
| Buckheit, R; Gilbert, H; Margot, N; Miller, M; Palmer, S; Shaw, N | 1 |
| Alston, B; Brosgart, CL; Chaloner, K; Cohn, DL; El-Sadr, WM; Fisher, EJ; Grant, LB; Sampson, J; Schmetter, B | 1 |
| Benhamou, Y; Bochet, M; Brosgart, C; Calvez, V; Fievet, MH; Fry, J; Gibbs, CS; Katlama, C; Namini, H; Poynard, T; Thibault, V; Vig, P | 1 |
| Barditch-Crovo, P; Coakley, DF; Coleman, RL; Collier, A; Deeks, SG; Kahn, JO; Kearney, BP; Lamy, PD; Lietman, PS; McGowan, I; Miller, M; Safrin, S | 1 |
| Gilden, D | 1 |
| Carr, A; Chuah, J; Cooper, DA; Doong, N; French, M; Hoy, J; Hudson, J; Law, M; Mallal, S; Smith, D | 1 |
| Barditch-Crovo, P; Coakley, DF; Collier, A; Deeks, SG; McGowan, I; Miller, M; Smith, A | 1 |
| Huff, B | 1 |
| Schwetz, BA | 1 |
| Thompson, CA | 1 |
| Beretta, R; Cargnel, A; Fasolo, MM; Merli, S; Orlando, G | 1 |
| Pujol, G; Williams, K | 1 |
| Giles, C | 1 |
| Bestman-Smith, J; Boivin, G | 1 |
| Benhamou, Y; Bochet, MV; Bombled, T; Calvez, V; Delaugerre, C; Katlama, C; Marcelin, AG; Peytavin, G; Thibault, V | 1 |
| Polk, B | 1 |
| Cheng, AK; Isaacson, E; Margot, NA; McGowan, I; Miller, MD; Schooley, RT | 1 |
| Beall, G; Berger, D; Chen, SS; Cheng, AK; Isaacson, E; Lampiris, H; Miller, MD; Myers, RA; Ruane, P; Schooley, RT | 1 |
| Huengsberg, M; Palfreeman, A | 1 |
| Di Perri, G; Maiello, A; Quario, M; Racca, D; Sinicco, A; Zeme, DA | 1 |
| Bendele, RA; Richardson, FC | 1 |
| Aberg, JA; Bennett, KK; Bessen, LJ; Brosgart, C; DeGruttola, V; Eron, JJ; Gulick, RM; Hammer, SM; Holohan, MK; Karol, CN; Lewis, RH; Mellors, JW; Mitsuyasu, RT; Rogers, MD; Saah, AJ; Sheiner, L; Vaida, F; Valentine, FT; Wheat, LJ | 1 |
| Balzarini, J; Bergamini, A; Calio, R; De Clercq, E; Milanese, G; Pauwels, R; Perno, CF; Rocchi, G; Yarchoan, R | 1 |
174 review(s) available for organophosphonates and HIV Coinfection
| Article | Year |
|---|---|
Use of cidofovir in a patient with severe mpox and uncontrolled HIV infection.
Topics: Antiviral Agents; Cidofovir; Cytosine; HIV Infections; Humans; Male; Middle Aged; Mpox (monkeypox); Organophosphonates; State Medicine | 2023 |
Antiretroviral dose optimization: the future of efavirenz 400 mg dosing.
Topics: Adenine; Alkynes; Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Dose-Response Relationship, Drug; HIV Infections; Humans; Organophosphonates; Tenofovir; Treatment Outcome | 2017 |
Comparative effectiveness of anti-viral drugs with dual activity for treating hepatitis B and HIV co-infected patients: a network meta-analysis.
Topics: Adenine; Adult; Aged; Antiviral Agents; Coinfection; Emtricitabine; Female; Hepatitis B; Hepatitis B virus; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Network Meta-Analysis; Organophosphonates; Tenofovir; Treatment Outcome; Young Adult | 2018 |
Emtricitabine/tenofovir disoproxil fumarate: a review of its use in HIV-1 pre-exposure prophylaxis.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Patient Acceptance of Health Care; Randomized Controlled Trials as Topic; Safe Sex; Sexual Behavior; Sexuality; Tenofovir | 2013 |
Use of antiretrovirals for HIV prevention: what do we know and what don't we know?
Topics: Adenine; Administration, Oral; Administration, Topical; Anti-HIV Agents; Chemoprevention; Female; HIV Infections; Humans; Male; Medication Adherence; Organophosphonates; Randomized Controlled Trials as Topic; Risk Reduction Behavior; Sexual Behavior; Tenofovir | 2013 |
Preexposure prophylaxis for HIV prevention: where have we been and where are we going?
Topics: Adenine; Administration, Oral; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Emtricitabine; HIV Infections; Humans; Medication Adherence; Organophosphonates; Risk Factors; Tenofovir | 2013 |
Bone health in children and adolescents with perinatal HIV infection.
Topics: Adenine; Adolescent; Anti-HIV Agents; Bone Density; Bone Diseases; Child; HIV Infections; Humans; Organophosphonates; Prevalence; Tenofovir | 2013 |
Viral hepatitis and HIV: update and management.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Antiviral Agents; Coinfection; Drug Therapy, Combination; Guanine; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Organophosphonates; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; Tenofovir | 2013 |
[Pre-exposure prophylaxis for the prevention of sexual HIV transmission; new preventative strategy using tenofovir/emtricitabine].
Topics: Adenine; Anti-HIV Agents; Chemoprevention; Deoxycytidine; Emtricitabine; HIV Infections; Humans; Netherlands; Organophosphonates; Patient Compliance; Risk-Taking; Sexual Behavior; Tenofovir | 2013 |
Suppression of HBV by tenofovir in HBV/HIV coinfected patients: a systematic review and meta-analysis.
Topics: Adenine; Anti-HIV Agents; Coinfection; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Organophosphonates; Tenofovir | 2013 |
Hepatitis B in HIV-infected patients.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Coinfection; Drug Resistance, Viral; Hepatitis B Vaccines; Hepatitis B, Chronic; Hepatitis D; HIV Infections; Humans; Lamivudine; Organophosphonates; Tenofovir | 2013 |
EFV/FTC/TDF-associated hepatotoxicity: a case report and review.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Cyclopropanes; Deoxycytidine; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Liver; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Viral Load | 2013 |
Single-tablet regimens in HIV: does it really make a difference?
Topics: Adenine; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Nitriles; Organophosphonates; Pyrimidines; Quinolones; Reverse Transcriptase Inhibitors; Rilpivirine; Tablets; Tenofovir; Thiazoles | 2014 |
Safety of tenofovir during pregnancy for the mother and fetus: a systematic review.
Topics: Adenine; Animals; Female; Fetal Development; HIV Infections; Humans; Infant, Newborn; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Tenofovir | 2013 |
Antiretroviral therapy, immune suppression and renal impairment in HIV-positive persons.
Topics: Adenine; Anti-Retroviral Agents; HIV Infections; Humans; Immunosuppression Therapy; Kidney Diseases; Organophosphonates; Protease Inhibitors; Tenofovir | 2014 |
[Mechanism of action and pharmacokinetics of rilpivirine].
Topics: Adenine; Adult; Aged; Animals; Anti-HIV Agents; Biological Availability; Child; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Deoxycytidine; Drug Administration Routes; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Emtricitabine; Food-Drug Interactions; Half-Life; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Intestinal Absorption; Molecular Structure; Nanoparticles; Nitriles; Organophosphonates; Proton Pump Inhibitors; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Tenofovir | 2013 |
Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Stribild®): a review of its use in the management of HIV-1 infection in adults.
Topics: Adenine; Anti-HIV Agents; Carbamates; Deoxycytidine; Drug Combinations; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; HIV-1; Humans; Organophosphonates; Quinolones; Tablets; Thiazoles | 2014 |
Systemic preexposure prophylaxis for HIV: translating clinical data to clinical practice.
Topics: Adenine; Anti-HIV Agents; Cost-Benefit Analysis; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Incidence; Medication Adherence; Organophosphonates; Risk Reduction Behavior; Safe Sex; Tenofovir | 2014 |
Effects of hormonal contraception on antiretroviral drug metabolism, pharmacokinetics and pharmacodynamics.
Topics: Adenine; Anti-HIV Agents; Contraception; Contraceptives, Oral, Hormonal; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Deoxycytidine; Drug Interactions; Emtricitabine; Family Planning Services; Female; HIV Infections; HIV-1; Humans; Organophosphonates; Pregnancy; Progestins; Tenofovir; Treatment Outcome | 2014 |
Tenofovir, emtricitabine, and darunavir/ritonavir pharmacokinetics in an HIV-infected patient after Roux-en-Y gastric bypass surgery.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Deoxycytidine; Emtricitabine; Gastric Bypass; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Ritonavir; Sulfonamides; Tenofovir | 2014 |
An overview of antiretroviral pre-exposure prophylaxis of HIV infection.
Topics: Adenine; Anti-HIV Agents; Cyclohexanes; Drug Resistance, Viral; Female; HIV Infections; Humans; Male; Maraviroc; Medication Adherence; Nitriles; Organophosphonates; Pre-Exposure Prophylaxis; Pyridones; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Tenofovir; Triazoles | 2014 |
Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection.
Topics: Adenine; Antiviral Agents; Coinfection; DNA, Viral; Drug Therapy, Combination; Guanine; Hepacivirus; Hepatitis B; Hepatitis B virus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Organophosphonates; Ribavirin; RNA, Viral; Tenofovir; Virus Replication | 2014 |
Tenofovir-induced nephrotoxicity: incidence, mechanism, risk factors, prognosis and proposed agents for prevention.
Topics: Adenine; Animals; Anti-HIV Agents; HIV Infections; Humans; Incidence; Kidney Diseases; Organophosphonates; Reverse Transcriptase Inhibitors; Risk Factors; Tenofovir | 2014 |
Virological efficacy of abacavir: systematic review and meta-analysis.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Emtricitabine; HIV Infections; Humans; Lamivudine; Organophosphonates; Randomized Controlled Trials as Topic; Tenofovir; Treatment Outcome | 2014 |
48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Lipids; Lopinavir; Nitriles; Organophosphonates; Oxazines; Piperazines; Pyridones; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Randomized Controlled Trials as Topic; Rilpivirine; Ritonavir; Tenofovir; Time Factors; Treatment Outcome; Viral Load | 2014 |
Review of tenofovir use in HIV-infected children.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Bone and Bones; Child; Child, Preschool; Drug Utilization; Drug-Related Side Effects and Adverse Reactions; HIV Infections; Humans; Kidney; Organophosphonates; Tenofovir; Young Adult | 2015 |
Microbicides and their potential as a catalyst for multipurpose sexual and reproductive health technologies.
Topics: Adenine; Anti-HIV Agents; Anti-Infective Agents; Female; Gels; HIV Infections; Humans; Male; Organophosphonates; Reproductive Health; Tenofovir; Women's Health | 2014 |
Emtricitabine/rilpivirine/tenofovir disoproxil fumarate single-tablet regimen: a review of its use in HIV infection.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Nitriles; Organophosphonates; Pyrimidines; Rilpivirine; Tablets; Tenofovir | 2014 |
The pharmacokinetics, pharmacodynamics and clinical efficacy of elvitegravir + cobicistat + emtricitabine + tenofovir combination therapy for the treatment of HIV.
Topics: Adenine; Adult; Anti-HIV Agents; Carbamates; Deoxycytidine; Drug Approval; Drug Combinations; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; European Union; HIV Infections; HIV-1; Humans; Organophosphonates; Quinolones; Tablets; Thiazoles | 2015 |
Antiretroviral drugs for prevention of mother-to-child transmission: pharmacologic considerations for a public health approach.
Topics: Adenine; Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Child; Cyclopropanes; Drug Resistance, Viral; Drug Therapy; HIV; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Organophosphonates; Public Health; Tenofovir | 2014 |
Stribild: a review of component characteristics and combination drug efficacy.
Topics: Adenine; Anti-HIV Agents; Carbamates; Deoxycytidine; Drug Combinations; Drug Synergism; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; Humans; Organophosphonates; Quinolones; Thiazoles | 2015 |
[The newest developments of the study on anti-HIV drugs].
Topics: Adenine; Anti-HIV Agents; HIV Infections; Humans; Organophosphates; Organophosphonates; Piperazines; Pyridones; Reverse Transcriptase Inhibitors; Tenofovir | 2015 |
Treatment options for progressive multifocal leukoencephalopathy in HIV-infected persons: current status and future directions.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Cidofovir; Coinfection; Cytarabine; Cytosine; HIV Infections; Humans; Immune Reconstitution Inflammatory Syndrome; Leukoencephalopathy, Progressive Multifocal; Mefloquine; Mianserin; Mirtazapine; Organophosphonates; Ritanserin; Serotonin Antagonists | 2016 |
Where next with preexposure prophylaxis?
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; HIV Infections; Humans; Organophosphonates; Pre-Exposure Prophylaxis; Randomized Controlled Trials as Topic; Tenofovir | 2017 |
Treatment of chronic hepatitis B infection: an update of Swedish recommendations.
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Guanine; Hepatitis B, Chronic; HIV Infections; Humans; Immunocompromised Host; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Cirrhosis; Liver Transplantation; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Sweden; Tenofovir | 2008 |
Tenofovir: what have over 1 million years of patient experience taught us?
Topics: Adenine; Anti-HIV Agents; Clinical Trials as Topic; Drug Resistance, Viral; HIV Infections; Humans; Organophosphonates; Tenofovir | 2008 |
Kidney disease in patients with HIV infection and AIDS.
Topics: Adenine; HIV Infections; Humans; Kidney Diseases; Organophosphonates; Risk Factors; Tenofovir | 2008 |
[Entecavir].
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Clinical Trials as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Liver Cirrhosis; Liver Transplantation; Multicenter Studies as Topic; Organophosphonates; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load; Virus Replication | 2008 |
[Hepatitis B in patients with HIV infection].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Comorbidity; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Guanine; Hepatitis B; Hepatitis B Vaccines; Hepatitis B virus; HIV; HIV Infections; Humans; Interferon-alpha; Lamivudine; Nucleosides; Organophosphonates; Practice Guidelines as Topic; Pyrimidinones; Reverse Transcriptase Inhibitors; Telbivudine; Tenofovir; Thymidine; Virus Replication | 2008 |
Pharmacologic aspects of new antiretroviral drugs.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; Humans; Nitriles; Organophosphonates; Oxazines; Practice Guidelines as Topic; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Sulfonamides | 2009 |
Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals.
Topics: Adenine; Anti-HIV Agents; Female; HIV Infections; Humans; Organophosphonates; Randomized Controlled Trials as Topic; Risk; Tenofovir | 2009 |
Tenofovir-associated nephrotoxicity in two HIV-infected adolescent males.
Topics: Adenine; Adolescent; Age Factors; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Black or African American; Blood Urea Nitrogen; CD4 Lymphocyte Count; Creatinine; Diagnosis, Differential; HIV Infections; Humans; Hypophosphatemia; Infectious Disease Transmission, Vertical; Male; Organophosphonates; Renal Insufficiency; Reverse Transcriptase Inhibitors; Rickets; Risk Factors; Safety; Tenofovir | 2009 |
[Tenofovir: pharmacology and interactions].
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Biological Availability; Biotransformation; Child; Child, Preschool; Deoxyadenine Nucleotides; DNA, Viral; Drug Interactions; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Kidney Diseases; Liver Diseases; Middle Aged; Molecular Structure; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Virus Replication; Young Adult | 2008 |
[Clinical data II. Clinical experience of tenofovir DF in combination with protease inhibitors].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; Cohort Studies; Deoxycytidine; Diabetic Nephropathies; Double-Blind Method; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Emtricitabine; HIV; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; Humans; Kidney Diseases; Multicenter Studies as Topic; Organophosphonates; Randomized Controlled Trials as Topic; Retrospective Studies; Reverse Transcriptase Inhibitors; Salvage Therapy; Tenofovir; Treatment Outcome | 2008 |
[Clinical data I. Clinical experience with tenofovir in combination with nonnucleoside analogue transcriptase inhibitors].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Clinical Trials, Phase III as Topic; Double-Blind Method; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; Humans; Multicenter Studies as Topic; Organophosphonates; Patient Acceptance of Health Care; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2008 |
[Tenofovir as a strategy to avoid or limit adverse effects].
Topics: Adenine; Anemia; Anti-HIV Agents; Antimetabolites; Clinical Trials as Topic; DNA, Mitochondrial; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Glucose Metabolism Disorders; HIV Infections; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Multicenter Studies as Topic; Organophosphonates; Prospective Studies; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir; Thymidine; Zidovudine | 2008 |
[Tenofovir DF in rescue regimens].
Topics: Adenine; Anti-HIV Agents; Antimetabolites; Clinical Trials, Phase III as Topic; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; HIV; HIV Infections; HIV Reverse Transcriptase; Humans; Multicenter Studies as Topic; Mutation; Organophosphonates; Randomized Controlled Trials as Topic; Retrospective Studies; Reverse Transcriptase Inhibitors; Salvage Therapy; Selection, Genetic; Tenofovir; Thymidine; Treatment Failure; Viral Load; Zalcitabine | 2008 |
[Role of tenofovir in HIV and hepatitis C virus coinfection].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Chemical and Drug Induced Liver Injury; Disease Progression; Drug Hypersensitivity; Drug Interactions; Drug Therapy, Combination; Fatty Liver; Glucose Metabolism Disorders; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver; Liver Cirrhosis; Organophosphonates; Reverse Transcriptase Inhibitors; Ribavirin; Tenofovir | 2008 |
[Management of renal toxicity in HIV-positive patients. What to measure, how to measure it and how frequently].
Topics: Adenine; Algorithms; Anti-HIV Agents; beta 2-Microglobulin; Clinical Trials as Topic; Cohort Studies; Creatinine; Drug Monitoring; Female; HIV Infections; Humans; Hypophosphatemia; Incidence; Kidney Diseases; Kidney Function Tests; Kidney Tubules; Male; Organophosphonates; Proteinuria; Reverse Transcriptase Inhibitors; Tenofovir; Time Factors | 2008 |
[Are all analogue combinations equal?].
Topics: Adenine; Anti-HIV Agents; Antimetabolites; Antiretroviral Therapy, Highly Active; Cardiovascular Diseases; Clinical Trials as Topic; Cohort Studies; Drug Interactions; Drug Therapy, Combination; Dyslipidemias; Gastrointestinal Diseases; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Organophosphonates; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Thymidine | 2008 |
[Current role of tenofovir in clinical medicine].
Topics: Adenine; Anti-HIV Agents; Antimetabolites; Antiretroviral Therapy, Highly Active; Chemical and Drug Induced Liver Injury; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Dyslipidemias; Glucose Metabolism Disorders; Hepatitis, Viral, Human; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Liver Diseases; Meta-Analysis as Topic; Organophosphonates; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Retrospective Studies; Reverse Transcriptase Inhibitors; Salvage Therapy; Tenofovir; Thymidine; Viral Load | 2008 |
Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine?
Topics: Adenine; Adult; Africa South of the Sahara; Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Diseases; Child; Child, Preschool; Congenital Abnormalities; Disease Models, Animal; Drug Resistance, Viral; Female; Health Services Accessibility; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Macaca; Mitochondria; Nevirapine; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Tenofovir; Zidovudine | 2009 |
[Highly efficient chemoprophylaxis of perinatal transmission of HIV 1 infection in HIV-infected pregnant women].
Topics: Animals; Anti-HIV Agents; Azides; Clinical Trials as Topic; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Mice; Nevirapine; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Rabbits; Rats; Tablets; Thymidine; Treatment Outcome | 2009 |
The CASTLE study: atazanavir/r versus lopinavir/r in antiretroviral-naive patients.
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Lopinavir; Multicenter Studies as Topic; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Randomized Controlled Trials as Topic; Ritonavir; Tenofovir; Treatment Outcome | 2009 |
Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
Topics: Adenine; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Intention to Treat Analysis; Lamivudine; Male; Organophosphonates; Randomized Controlled Trials as Topic; Regression Analysis; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load | 2009 |
Pharmacogenetics of tenofovir treatment.
Topics: Adenine; Anti-HIV Agents; Anti-Retroviral Agents; HIV Infections; HIV-1; Humans; Kidney Diseases; Kidney Tubules; Multidrug Resistance-Associated Proteins; Organic Anion Transporters; Organophosphonates; Pharmacogenetics; Polymorphism, Genetic; Tenofovir | 2009 |
Anti-HIV therapy with AZT prodrugs: AZT phosphonate derivatives, current state and prospects.
Topics: Animals; HIV Infections; Humans; Organophosphonates; Prodrugs; Zidovudine | 2010 |
Renal toxicity associated with tenofovir use.
Topics: Adenine; Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; Humans; Kidney; Kidney Diseases; Male; Mitochondria; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2010 |
Economic evaluation of ART in resource-limited countries.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cost-Benefit Analysis; Developing Countries; Drug Monitoring; Health Care Costs; HIV Infections; Humans; Organophosphonates; RNA, Viral; Stavudine; Tenofovir; Viral Load | 2010 |
Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients.
Topics: Adenine; Anti-HIV Agents; HIV Infections; Humans; Kidney Diseases; Organophosphonates; Tenofovir | 2010 |
The risk of HIV drug resistance following implementation of pre-exposure prophylaxis.
Topics: Adenine; Animals; Anti-HIV Agents; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HIV; HIV Infections; Humans; Organophosphonates; Risk Assessment; Tenofovir; Viremia | 2010 |
Systemic preexposure prophylaxis for human immunodeficiency virus infection.
Topics: Adenine; Animals; Anti-HIV Agents; Antiviral Agents; Deoxycytidine; Emtricitabine; Female; HIV; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Occupational Exposure; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors; Risk Factors; Risk-Taking; Tenofovir | 2010 |
Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Child; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Lamivudine; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Zidovudine | 2010 |
Efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Atripla®): a review of its use in the management of HIV infection.
Topics: Adenine; Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; Humans; Medication Adherence; Organophosphonates; Oxazines; Patient Satisfaction; Quality of Life; Reverse Transcriptase Inhibitors | 2010 |
Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection.
Topics: Adenine; Chemoprevention; Deoxycytidine; Drug Interactions; Emtricitabine; Female; Food-Drug Interactions; HIV Infections; Humans; Male; Organophosphonates; Tenofovir | 2011 |
[What's new in dermatological treatments?].
Topics: Adenine; Anti-HIV Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Cyclosporine; Dermatofibrosarcoma; Dermatologic Agents; Dermatology; Drug Therapy, Combination; Etanercept; Follow-Up Studies; Gels; HIV Infections; Humans; Imatinib Mesylate; Immunoglobulin G; Immunosuppressive Agents; Ipilimumab; Melanoma; Neoplasm Staging; Organophosphonates; Piperazines; Psoriasis; Pyrimidines; Receptors, Tumor Necrosis Factor; Skin Diseases; Skin Neoplasms; Survival Analysis; Tenofovir; Treatment Outcome; Ustekinumab | 2010 |
The impact of human immunodeficiency virus on viral hepatitis.
Topics: Adenine; Antiviral Agents; Deoxycytidine; Disease Progression; Drug Therapy, Combination; Emtricitabine; Guanine; Hepatitis B; Hepatitis C; Hepatitis Viruses; HIV Infections; Humans; Interferon-alpha; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Telbivudine; Tenofovir; Thymidine | 2011 |
Renal disease associated with antiretroviral therapy in the treatment of HIV.
Topics: Adenine; Anti-Retroviral Agents; Atazanavir Sulfate; HIV Infections; Humans; Indinavir; Kidney Diseases; Oligopeptides; Organophosphonates; Pyridines; Tenofovir | 2011 |
Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings.
Topics: Adenine; Administration, Oral; Anti-HIV Agents; Chemoprevention; Clinical Trials as Topic; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Risk; Tenofovir; United States | 2011 |
Novel treatment of atypical human papillomavirus-associated epithelial hyperplasia with cidofovir.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Anus Neoplasms; Cidofovir; Cytosine; Epithelium; Fatal Outcome; HIV Infections; Humans; Male; Middle Aged; Molecular Structure; Mouth Diseases; Mouth Mucosa; Organophosphonates; Papillomavirus Infections | 2011 |
Update on microbicide research and development - seeking new HIV prevention tools for women.
Topics: Adenine; Administration, Intravaginal; Adult; Africa South of the Sahara; Anti-HIV Agents; Anti-Infective Agents; Clinical Trials as Topic; Cyclohexanes; Drug Discovery; Female; HIV Infections; Humans; Male; Maraviroc; Organophosphonates; Pyridines; Pyrimidines; Tenofovir; Triazoles; Urea | 2011 |
Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence.
Topics: Adenine; Animals; Fanconi Syndrome; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Diseases; Kidney Tubules, Proximal; Organophosphonates; Risk Factors; Tenofovir | 2011 |
The clinical potential of the acyclic (and cyclic) nucleoside phosphonates: the magic of the phosphonate bond.
Topics: Adenine; Antineoplastic Agents; Antiviral Agents; Cidofovir; Cytosine; Guanosine; Hepatitis B; HIV Infections; Humans; Organophosphonates; Prodrugs; Structure-Activity Relationship; Tenofovir | 2011 |
Endocrine complications of human immunodeficiency virus infection: hypogonadism, bone disease and tenofovir-related toxicity.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Diseases; Endocrine System Diseases; HIV; HIV Infections; Humans; Hypogonadism; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2011 |
HIV prevention in southern Africa: why we must reassess our strategies?
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adolescent; Adult; Anti-HIV Agents; Circumcision, Male; Condoms; Condoms, Female; Female; HIV Infections; HIV Seropositivity; Humans; Interdisciplinary Communication; Male; Middle Aged; Organophosphonates; Preventive Medicine; Risk Reduction Behavior; Tenofovir; Young Adult | 2011 |
Antiviral drugs for viruses other than human immunodeficiency virus.
Topics: Acyclovir; Adenine; Amantadine; Antiviral Agents; Comorbidity; Drug Therapy, Combination; Foscarnet; Ganciclovir; Guanine; Hepatitis; Hepatitis B, Chronic; Hepatitis C; Herpesviridae Infections; HIV Infections; Humans; Influenza, Human; Interferons; Lamivudine; Nucleosides; Oligopeptides; Organophosphonates; Oseltamivir; Proline; Protease Inhibitors; Pyrimidinones; Ribavirin; Telbivudine; Thymidine; Valacyclovir; Valganciclovir; Valine; Virus Replication; Zanamivir | 2011 |
Promising prevention approaches: tenofovir gel and prophylactic use of antiretroviral medications.
Topics: Adenine; Anti-HIV Agents; Female; Gels; HIV Infections; Humans; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2011 |
Elvitegravir: a once-daily, boosted, HIV-1 integrase inhibitor.
Topics: Adenine; Carbamates; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Combinations; Drug Interactions; Drug Resistance, Viral; Drug-Related Side Effects and Adverse Reactions; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Organophosphonates; Quinolones; Randomized Controlled Trials as Topic; Thiazoles | 2012 |
Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid).
Topics: Adenine; Adult; Amniotic Fluid; Anti-HIV Agents; Cyclohexanes; Enfuvirtide; Female; Fetal Blood; Fetus; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Maraviroc; Nevirapine; Organophosphonates; Peptide Fragments; Placenta; Pregnancy; Pregnancy Complications, Infectious; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Tenofovir; Triazoles; Viral Load; Zidovudine | 2011 |
Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence.
Topics: Adenine; Administration, Oral; Administration, Topical; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Male; Medication Adherence; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2012 |
How to manage HIV-infected patients with chronic kidney disease in the HAART era.
Topics: Adenine; Albuminuria; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Black People; Cystatin C; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Failure, Chronic; Organophosphonates; Prevalence; Proteinuria; Risk Factors; Tenofovir; Viral Load | 2012 |
Formulation, pharmacokinetics and pharmacodynamics of topical microbicides.
Topics: Adenine; Animals; Anti-HIV Agents; Anti-Infective Agents, Local; Female; HIV; HIV Infections; Humans; Mice; Organophosphonates; Tenofovir; Treatment Outcome; Vaginal Creams, Foams, and Jellies | 2012 |
Microbicides for HIV prevention.
Topics: Adenine; Administration, Intravaginal; Anti-HIV Agents; Anti-Infective Agents, Local; Developing Countries; Drug Delivery Systems; Drug Resistance, Viral; Female; HIV Infections; Humans; Organophosphonates; Tenofovir | 2011 |
WITHDRAWN. Effectiveness and safety of first-line tenofovir + emtricitabine + efavirenz for patients with HIV.
Topics: Adenine; Deoxycytidine; Drug Combinations; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; Humans; Organophosphonates; Oxazines; Reverse Transcriptase Inhibitors | 2012 |
A review of the virological efficacy of the 4 World Health Organization-recommended tenofovir-containing regimens for initial HIV therapy.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Lamivudine; Nevirapine; Organophosphonates; Tenofovir; Treatment Failure; Viral Load; World Health Organization | 2012 |
Drug delivery in multiple indication (multipurpose) prevention technologies: systems to prevent HIV-1 transmission and unintended pregnancies or HSV-2 transmission.
Topics: Adenine; Administration, Intravaginal; Anti-Infective Agents; Antiviral Agents; Biopharmaceutics; Contraception; Disease Transmission, Infectious; Drug Delivery Systems; Female; Herpes Genitalis; Herpesvirus 2, Human; HIV Infections; HIV-1; Humans; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Pregnancy, Unplanned; Tenofovir | 2012 |
Overview of microbicides for the prevention of human immunodeficiency virus.
Topics: Adenine; Anti-HIV Agents; Anti-Infective Agents; Clinical Trials as Topic; Female; HIV; HIV Infections; Humans; Organophosphonates; Tenofovir | 2012 |
HIV prevention by oral preexposure prophylaxis.
Topics: Adenine; Administration, Oral; Animals; Anti-Retroviral Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Female; HIV Infections; HIV Seronegativity; Humans; Male; Mucous Membrane; Organophosphonates; Protein Binding; Rectum; Tenofovir; Vagina; Virus Replication | 2012 |
A drug evaluation of 1% tenofovir gel and tenofovir disoproxil fumarate tablets for the prevention of HIV infection.
Topics: Adenine; Animals; Anti-HIV Agents; Gels; HIV Infections; Humans; Organophosphonates; Reverse Transcriptase Inhibitors; Tablets; Tenofovir | 2012 |
Relative risk of renal disease among people living with HIV: a systematic review and meta-analysis.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Anti-HIV Agents; Anti-Retroviral Agents; Chronic Disease; Female; HIV Infections; Humans; Kidney Diseases; Male; Odds Ratio; Organophosphonates; Survival Rate; Tenofovir | 2012 |
New advances in chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Coinfection; Disease Progression; Drug Resistance, Viral; Female; Guanine; Guidelines as Topic; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis D; HIV Infections; Humans; Interferons; Liver Cirrhosis; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Risk Factors; Tenofovir | 2012 |
Role of raltegravir in HIV-1 management.
Topics: Adenine; Animals; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Tenofovir | 2012 |
Where rilpivirine meets with tenofovir, the start of a new anti-HIV drug combination era.
Topics: Adenine; Animals; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Emtricitabine; Emtricitabine, Rilpivirine, Tenofovir Drug Combination; HIV Infections; HIV-1; Humans; Nitriles; Organophosphonates; Oxazines; Pyrimidines; Rilpivirine; Tenofovir | 2012 |
Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Coinfection; Deoxycytidine; Dideoxynucleosides; Disease Progression; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Emtricitabine; Hepatitis C, Chronic; HIV Infections; Homosexuality, Male; Humans; Interferon-alpha; Lamivudine; Liver Cirrhosis; Liver Diseases; Male; Oligopeptides; Organophosphonates; Polyethylene Glycols; Proline; Pyrrolidinones; Raltegravir Potassium; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Substance Abuse, Intravenous; Tenofovir; Treatment Outcome | 2012 |
Tenofovir: quo vadis anno 2012 (where is it going in the year 2012)?
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2012 |
WITHDRAWN: Effectiveness and safety of first-line tenofovir + emtricitabine + efavirenz for patients with HIV.
Topics: Adenine; Deoxycytidine; Drug Combinations; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; Humans; Organophosphonates; Oxazines; Reverse Transcriptase Inhibitors | 2012 |
Topical microbicides for prevention of sexually transmitted infections.
Topics: Acrylic Resins; Adenine; Administration, Topical; Agaricales; Anti-HIV Agents; Anti-Infective Agents, Local; Cellulose; Female; HIV Infections; Humans; Male; Naphthalenesulfonates; Organophosphonates; Polymers; Seaweed; Sexually Transmitted Diseases; Tenofovir | 2012 |
[HIV preexposure prophylaxis].
Topics: Adenine; Administration, Oral; Animals; Anti-HIV Agents; Chemoprevention; Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; HIV Infections; Humans; Male; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir | 2012 |
Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals.
Topics: Adenine; Administration, Oral; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Male; Organophosphonates; Premedication; Randomized Controlled Trials as Topic; Risk; Risk-Taking; Tenofovir; Unsafe Sex | 2012 |
What primary care providers need to know about preexposure prophylaxis for HIV prevention: a narrative review.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Directive Counseling; Emtricitabine; Evidence-Based Medicine; Heterosexuality; HIV Infections; Homosexuality; Humans; Medication Adherence; Organophosphonates; Primary Health Care; Risk Assessment; Risk-Taking; Sexual Partners; Tenofovir | 2012 |
Combinational therapies for HIV: a focus on EVG/COBI/FTC/TDF.
Topics: Adenine; Anti-HIV Agents; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cobicistat; Deoxycytidine; Drug Combinations; Drug Resistance, Multiple, Viral; Emtricitabine; HIV Infections; Humans; Organophosphonates; Quinolones; Tenofovir; Thiazoles | 2012 |
Update on tenofovir toxicity in the kidney.
Topics: Adenine; Animals; Anti-HIV Agents; Antiviral Agents; Hepatitis B; HIV Infections; Humans; Kidney; Kidney Diseases; Organophosphonates; Risk Factors; Tenofovir | 2013 |
Considerations regarding antiretroviral chemoprophylaxis in MSM.
Topics: Adenine; Administration, Oral; Animals; Anti-HIV Agents; Chemoprevention; Clinical Trials as Topic; Deoxycytidine; Disease Models, Animal; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Leukocytes, Mononuclear; Male; Medication Adherence; Organophosphonates; Plasma; Tenofovir; Treatment Outcome | 2012 |
Current status of topical antiretroviral chemoprophylaxis.
Topics: Adenine; Administration, Intravaginal; Administration, Topical; Anilides; Anti-HIV Agents; Chemoprevention; Clinical Trials, Phase II as Topic; Female; Furans; HIV Infections; Humans; Organophosphonates; Pyrimidines; Tenofovir; Thioamides; Treatment Outcome | 2012 |
Emtricitabine/tenofovir in the treatment of HIV infection: current PK/PD evaluation.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Emtricitabine; HIV Infections; HIV-1; Humans; Organophosphonates; Practice Guidelines as Topic; Tenofovir | 2012 |
Treatment options for anal intraepithelial neoplasia and evidence for their effectiveness.
Topics: Adult; Aminoquinolines; Antimetabolites, Antineoplastic; Antineoplastic Agents; Anus Neoplasms; Cidofovir; Comorbidity; Cytosine; Female; Fluorouracil; Global Health; HIV Infections; Homosexuality, Male; Humans; Imiquimod; Incidence; Male; Organophosphonates; Papillomavirus Infections; Precancerous Conditions; Trichloroacetic Acid | 2012 |
Antiretrovirals for HIV Exposure Prophylaxis.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Emtricitabine; HIV; HIV Infections; Humans; Lamivudine; Occupational Exposure; Organophosphonates; Stavudine; Tenofovir; Zidovudine | 2012 |
Oral antiretroviral chemoprophylaxis: current status.
Topics: Adenine; Administration, Oral; Animals; Anti-HIV Agents; Chemoprevention; Clinical Trials as Topic; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Male; Medication Adherence; Organophosphonates; Tenofovir | 2012 |
The clinical pharmacology of antiretrovirals for HIV prevention.
Topics: Adenine; Administration, Oral; Administration, Topical; Anti-Retroviral Agents; Chemoprevention; Clinical Trials as Topic; Colon; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Organophosphonates; Tenofovir; Vagina | 2012 |
Rectal microbicide development.
Topics: Adenine; Administration, Rectal; Administration, Topical; Anilides; Anti-HIV Agents; Chemoprevention; Clinical Trials, Phase I as Topic; Drug-Related Side Effects and Adverse Reactions; Furans; HIV Infections; Homosexuality, Male; Humans; Male; Organophosphonates; Tenofovir; Thioamides | 2012 |
Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single tablet for HIV-1 infection treatment.
Topics: Adenine; Anti-HIV Agents; Carbamates; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Combinations; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; HIV Integrase Inhibitors; Humans; Organophosphonates; Quinolones; Tablets; Thiazoles; Viral Load | 2012 |
Complete resolution of erythrodermic psoriasis in an HIV and HCV patient unresponsive to antipsoriatic treatments after highly active antiretroviral therapy (Ritonavir, Atazanavir, Emtricitabine, Tenofovir).
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Hepatitis C, Chronic; HIV Infections; Humans; Immunocompromised Host; Male; Middle Aged; Oligopeptides; Organophosphonates; Psoriasis; Pyridines; Ritonavir; Tenofovir; Treatment Outcome | 2012 |
Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection.
Topics: Adenine; Animals; Anti-HIV Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Resistance, Viral; Drug Synergism; Drug Therapy, Combination; Hepatitis B; HIV Infections; HIV-1; Humans; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir | 2002 |
Tenofovir: a nucleotide analog for the management of human immunodeficiency virus infection.
Topics: Adenine; Adenosine Monophosphate; Anti-HIV Agents; Biological Availability; HIV Infections; HIV-1; Humans; Inhibitory Concentration 50; Organophosphonates; Organophosphorus Compounds; Randomized Controlled Trials as Topic; Tenofovir; Treatment Outcome; Viral Load | 2003 |
Progressive vaccinia.
Topics: Antiviral Agents; Cidofovir; Cytosine; HIV Infections; Humans; Methisazone; Organophosphonates; Organophosphorus Compounds; Ribavirin; Vaccination; Vaccinia | 2003 |
Tenofovir disoproxil fumarate.
Topics: Adenine; Animals; Clinical Trials as Topic; HIV Infections; HIV-1; Humans; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2003 |
Thymidine analogue-sparing highly active antiretroviral therapy (HAART).
Topics: Adenine; Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; Dideoxynucleosides; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-Associated Lipodystrophy Syndrome; Humans; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Time Factors | 2003 |
Tenofovir disoproxil fumarate.
Topics: Adenine; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Mutation; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir; Treatment Outcome | 2003 |
Effect of tenofovir on didanosine absorption in patients with HIV.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Area Under Curve; Clinical Trials as Topic; Didanosine; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2003 |
Viral hepatitis B.
Topics: Adenine; Antiviral Agents; Comorbidity; Drug Therapy, Combination; Genotype; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Interferon-alpha; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Viral Load | 2003 |
Newer treatments for HIV in children.
Topics: Adenine; Anti-Bacterial Agents; Anti-HIV Agents; Child; Deoxycytidine; Didanosine; Drug Therapy, Combination; Emtricitabine; Enfuvirtide; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; Humans; Microbial Sensitivity Tests; Organophosphonates; Organophosphorus Compounds; Peptide Fragments; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir | 2004 |
The continuing evolution of HIV therapy.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Cyclopropanes; Delayed-Action Preparations; Deoxycytidine; Didanosine; Dideoxynucleosides; Drug Monitoring; Emtricitabine; Furans; HIV Infections; Humans; Lamivudine; Nevirapine; Oligopeptides; Organophosphates; Organophosphonates; Organophosphorus Compounds; Oxazines; Pyridines; Randomized Controlled Trials as Topic; Stavudine; Sulfonamides; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2003 |
Adefovir dipivoxil in the treatment of chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B, Chronic; HIV Infections; Humans; Liver Transplantation; Organophosphonates; Randomized Controlled Trials as Topic | 2004 |
Management of chronic hepatitis B in the HIV-infected patient.
Topics: Adenine; Algorithms; Antiviral Agents; Clinical Trials as Topic; Decision Trees; Drug Therapy, Combination; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2004 |
Editorial comment: HIV and HBV coinfection--a coming-of-age in treatment strategies.
Topics: Adenine; Antiviral Agents; Comorbidity; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Guanine; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2004 |
Fanconi's syndrome in HIV+ adults: report of three cases and literature review.
Topics: Adenine; Adult; Anti-Retroviral Agents; Bone Density; Calcitriol; Calcium; Fanconi Syndrome; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Phosphates; Tenofovir | 2004 |
Biochemical and mechanistic basis for the activity of nucleoside analogue inhibitors of HIV reverse transcriptase.
Topics: Adenine; Cytidine Triphosphate; Deoxycytidine; Deoxycytidine Monophosphate; Deoxyribonucleotides; Dioxolanes; DNA, Viral; Emtricitabine; HIV Infections; HIV Reverse Transcriptase; Humans; Kinetics; Molecular Structure; Nucleosides; Organophosphonates; Organophosphorus Compounds; Phosphorylation; Protein Binding; Protein Conformation; Purine Nucleosides; Reverse Transcriptase Inhibitors; Substrate Specificity; Tenofovir; Zalcitabine | 2004 |
Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics.
Topics: Adenine; Administration, Oral; Animals; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Interactions; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir | 2004 |
K65R-associated virologic failure in HIV-infected patients receiving tenofovir-containing triple nucleoside/nucleotide reverse transcriptase inhibitor regimens.
Topics: Adenine; Clinical Trials as Topic; Dideoxynucleosides; Drug Interactions; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; Humans; Mutation; Organophosphonates; Prospective Studies; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure | 2004 |
Severe metabolic acidosis and renal failure in an HIV-1 patient receiving tenofovir.
Topics: Acidosis, Lactic; Acute Kidney Injury; Adenine; HIV Infections; Humans; Kidney Function Tests; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Prognosis; Reverse Transcriptase Inhibitors; Risk Assessment; Severity of Illness Index; Tenofovir | 2004 |
Treatment of hepatitis B virus infection in patients coinfected with HIV.
Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; HIV Infections; Humans; Interferon-alpha; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2004 |
Hepatitis C virus in the setting of HIV or hepatitis B virus coinfection.
Topics: Adenine; Antiviral Agents; Comorbidity; Hepacivirus; Hepatitis B virus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Organophosphonates; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Risk Factors | 2004 |
Tenofovir disoproxil fumarate (Viread) for the treatment of HIV infection.
Topics: Adenine; Animals; Clinical Trials as Topic; HIV Infections; Humans; Organophosphonates; Tenofovir | 2003 |
Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection.
Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Drug Approval; Drug Resistance, Viral; Hepatitis B e Antigens; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Organophosphonates | 2004 |
Adefovir dipivoxil: review of a novel acyclic nucleoside analogue.
Topics: Adenine; AIDS-Related Opportunistic Infections; Antiviral Agents; Drug Resistance, Viral; Hepatitis B, Chronic; HIV Infections; Humans; Organophosphonates; Treatment Outcome | 2004 |
Tenofovir disoproxil fumarate: a review of its use in the management of HIV infection.
Topics: Adenine; Area Under Curve; Biological Availability; Double-Blind Method; Drug Interactions; Half-Life; HIV Infections; Humans; Metabolic Clearance Rate; Organophosphonates; Randomized Controlled Trials as Topic; Tenofovir; Tissue Distribution | 2005 |
[Nikavir (phosphazide)--an antiretroviral agent: anti-HIV activity, toxicology, pharmacokinetics and some perspectives of its clinical use].
Topics: Administration, Oral; Animals; Anti-Retroviral Agents; Azides; Capsules; Cell Line; Clinical Trials as Topic; Dogs; Drug Evaluation, Preclinical; HIV Infections; HIV-1; Humans; Lethal Dose 50; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Tablets; Thymidine | 2004 |
Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel.
Topics: Adenine; Antiviral Agents; Comorbidity; Deoxycytidine; Disease Progression; Drug Monitoring; Emtricitabine; Hepatitis B, Chronic; HIV Infections; Humans; Interferon-alpha; Lamivudine; Organophosphonates; Tenofovir | 2005 |
Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics.
Topics: Adenine; Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cardiovascular Diseases; Cyclopropanes; Drug Monitoring; Drug Therapy, Combination; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Kidney Diseases; Lopinavir; Metabolic Syndrome; Nevirapine; Organophosphonates; Oxazines; Pyrimidinones; Risk Factors; Tenofovir | 2005 |
Editorial comment: tenofovir nephrotoxicity--vigilance required.
Topics: Adenine; Fanconi Syndrome; Glycosuria; HIV Infections; Humans; Hypokalemia; Hypophosphatemia; Organophosphonates; Proteinuria; Renal Insufficiency; Reverse Transcriptase Inhibitors; Tenofovir | 2005 |
Fanconi syndrome associated with use of tenofovir in HIV-infected patients: a case report and review of the literature.
Topics: Adenine; Fanconi Syndrome; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2005 |
Management of HIV-infected patients with multidrug-resistant virus.
Topics: Adenine; Anti-HIV Agents; Anti-Retroviral Agents; Atazanavir Sulfate; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Enfuvirtide; HIV Envelope Protein gp41; HIV Infections; HIV-1; Humans; Oligopeptides; Organophosphonates; Peptide Fragments; Pyridines; Pyrones; Randomized Controlled Trials as Topic; Sulfonamides; Tenofovir; Treatment Failure; Viral Load | 2004 |
Tenofovir and didanosine: a dangerous liaison.
Topics: Adenine; Anti-HIV Agents; Didanosine; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Organophosphonates; Tenofovir | 2005 |
Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.
Topics: Adenine; Age Factors; Alkynes; Atazanavir Sulfate; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Liver; Oligopeptides; Organophosphonates; Oxazines; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Sex Factors; Tenofovir | 2005 |
Severe toxicity associated with the combination of tenofovir and didanosine: case report and review.
Topics: Acidosis, Lactic; Acute Disease; Adenine; Anti-HIV Agents; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Liver Failure; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2005 |
[The treatment of HIV infection].
Topics: Adenine; Anti-Retroviral Agents; Carbamates; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Drug Therapy, Combination; Furans; HIV Infections; Humans; Lamivudine; Nevirapine; Organophosphates; Organophosphonates; Risk Factors; Sulfonamides; Tenofovir; Zidovudine | 2005 |
Use of tenofovir disoproxil fumarate and emtricitabine combination in HIV-infected patients.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Organophosphonates; Tenofovir | 2006 |
Perspectives on the development of acyclic nucleotide analogs as antiviral drugs.
Topics: Adenine; Animals; Antiviral Agents; Dogs; Drug Design; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Nucleotides; Organophosphonates; Randomized Controlled Trials as Topic; Tenofovir | 2006 |
Tenofovir disoproxil fumarate for the treatment of HIV infection.
Topics: Adenine; Animals; Drug Administration Schedule; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B; HIV Infections; Humans; Organophosphonates; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir | 2006 |
An update and review of antiretroviral therapy.
Topics: Adenine; Animals; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Carbamates; Clinical Trials as Topic; Deoxycytidine; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Drugs, Investigational; Emtricitabine; Enfuvirtide; Furans; HIV Envelope Protein gp41; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Oligopeptides; Organophosphates; Organophosphonates; Patient Compliance; Peptide Fragments; Pyridines; Pyrones; Reverse Transcriptase Inhibitors; Sulfonamides; Tenofovir | 2006 |
Antiretroviral therapy for hepatitis B virus-HIV-coinfected patients: promises and pitfalls.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Antiviral Agents; Deoxycytidine; Drug Combinations; Emtricitabine; Guanine; Hepatitis B; Hepatitis B virus; HIV Infections; HIV-1; Humans; Lamivudine; Organophosphonates; Preventive Medicine; Tenofovir | 2006 |
Tenofovir disoproxil fumarate-emtricitabine coformulation for once-daily dual NRTI backbone.
Topics: Adenine; Animals; Chemistry, Pharmaceutical; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Emtricitabine; HIV Infections; HIV Reverse Transcriptase; Humans; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2006 |
Evolving simplified treatment strategies for HIV infection: the role of a single-class quadruple-nucleoside/nucleotide regimen of trizivir and tenofovir.
Topics: Adenine; Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; HIV Infections; HIV-1; Humans; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Zidovudine | 2006 |
Tenofovir plus didanosine as Nrti backbone in HIV-infected subjects.
Topics: Adenine; Anti-HIV Agents; Didanosine; Drug Antagonism; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; Humans; Organophosphonates; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Tenofovir | 2006 |
[Renal toxicity in HIV-infected patients receiving HAART including tenofovir].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Interactions; HIV Infections; Humans; Kidney Diseases; Organophosphonates; Tenofovir | 2006 |
Efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed-dose combination: first-line therapy for all?
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Organophosphonates; Oxazines; Reverse Transcriptase Inhibitors; Tenofovir | 2007 |
Renal safety of tenofovir disoproxil fumarate.
Topics: Adenine; Anti-HIV Agents; Clinical Trials as Topic; HIV Infections; Humans; Kidney; Kidney Diseases; Organophosphonates; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir | 2007 |
Treatment of chronic hepatitis B in HIV-infected patients in 2007.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; HIV Infections; Humans; Interferon-alpha; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Telbivudine; Tenofovir; Thymidine | 2007 |
Pre-exposure prophylaxis for HIV infection: what if it works?
Topics: Adenine; Anti-HIV Agents; Attitude of Health Personnel; Drug Administration Schedule; Female; HIV Infections; HIV Seropositivity; Humans; Male; Organophosphonates; Public Health; Risk-Taking; Tenofovir | 2007 |
Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Resistance, Multiple, Viral; HIV Infections; HIV-1; Humans; Lamivudine; Mutation; Organophosphonates; Practice Guidelines as Topic; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure; Treatment Outcome; Viral Load; Zidovudine | 2007 |
The first once-daily single-tablet regimen for the treatment of HIV-infected patients.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Organophosphonates; Reverse Transcriptase Inhibitors; Tablets; Tenofovir; Therapeutic Equivalency | 2007 |
HIV-1 infection and the kidney: an evolving challenge in HIV medicine.
Topics: Acute Disease; Acute Kidney Injury; Adenine; AIDS-Associated Nephropathy; Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Black or African American; Chronic Disease; Comorbidity; Disease Progression; HIV Infections; HIV-1; Humans; Kidney; Kidney Diseases; Kidney Failure, Chronic; Kidney Transplantation; Mice; Mice, Transgenic; Microcirculation; Organophosphonates; Tenofovir; Viral Proteins | 2007 |
Tenofovir gel--the new HIV prevention 'banker'?
Topics: Adenine; Anti-HIV Agents; Clinical Trials, Phase II as Topic; Drug Approval; Female; HIV Infections; Humans; Organophosphonates; Tenofovir; Vaginal Creams, Foams, and Jellies | 2007 |
[Attention-getting sexually transmitted diseases: Hepatitis B].
Topics: Adenine; Adenosine; Antiviral Agents; Comorbidity; Drug Therapy, Combination; Genotype; Guanine; Guanosine; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Sexually Transmitted Diseases, Viral | 2007 |
Kidney biopsy in HIV: beyond HIV-associated nephropathy.
Topics: Acute Disease; Adenine; AIDS-Associated Nephropathy; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biopsy; Comorbidity; Diabetic Nephropathies; Diagnosis, Differential; Female; HIV Infections; Humans; Hypertension; Immune Complex Diseases; Kidney; Kidney Diseases; Kidney Glomerulus; Middle Aged; Nephritis, Interstitial; Organophosphonates; Risk Assessment; Risk Factors; Tenofovir | 2008 |
Experience with tenofovir disoproxil fumarate for antiretroviral therapy.
Topics: Adenine; Adult; Anti-HIV Agents; Anti-Retroviral Agents; Child; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; Humans; Organophosphonates; Randomized Controlled Trials as Topic; Tenofovir; Treatment Outcome | 2008 |
Management of cytomegalovirus disease.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cytosine; Drug Therapy, Combination; Foscarnet; Ganciclovir; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds | 1995 |
New reverse transcriptase inhibitors.
Topics: Adenine; Alkynes; Benzoxazines; Cyclopropanes; Delavirdine; Dideoxynucleosides; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Nevirapine; Organophosphonates; Oxazines; Prodrugs; Reverse Transcriptase Inhibitors; Soman; Uracil | 1999 |
Strategies for second-line antiretroviral therapy in adults with HIV infection.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; HIV; HIV Infections; Humans; Organophosphonates; Oxazines; Reverse Transcriptase Inhibitors; Virus Latency; Virus Replication | 1999 |
Cytomegalovirus retinitis in patients with acquired immune deficiency syndrome.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Cidofovir; Cytomegalovirus Retinitis; Cytosine; Foscarnet; Ganciclovir; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Retinal Detachment | 1999 |
Coming therapies: adefovir.
Topics: Adenine; Antiviral Agents; Drug Resistance, Multiple; HIV Infections; HIV-1; Humans; Organophosphonates; Reverse Transcriptase Inhibitors | 1999 |
The potential place of tenofovir in antiretroviral treatment regimens.
Topics: Adenine; Anti-HIV Agents; Drug Resistance, Viral; HIV; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir | 2001 |
Adefovir dipivoxil. Bis-POM PMEA, GS 0840, GS 840, Piv2PMEA.
Topics: Adenine; Animals; Clinical Trials as Topic; Drug Industry; Hepatitis B, Chronic; HIV Infections; Humans; Organophosphonates | 2002 |
Therapeutic potential of phosphonylmethoxyalkylpurines and -pyrimidines as antiviral agents.
Topics: Adenine; Animals; Antiviral Agents; Cidofovir; Cytosine; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Purines; Pyrimidines; Retroviridae Infections; Virus Diseases | 1990 |
377 trial(s) available for organophosphonates and HIV Coinfection
| Article | Year |
|---|---|
Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo-controlled randomized trial in healthcare workers.
Topics: Adenine; Anti-HIV Agents; COVID-19; COVID-19 Drug Treatment; Deoxycytidine; Double-Blind Method; Emtricitabine; Health Personnel; HIV Infections; Humans; Hydroxychloroquine; Organophosphonates; Pre-Exposure Prophylaxis; SARS-CoV-2; Tenofovir | 2023 |
Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Adenine; Adult; Aged; Alanine; Anti-HIV Agents; Double-Blind Method; Drug Therapy, Combination; Emtricitabine; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Pre-Exposure Prophylaxis; Tenofovir; Treatment Outcome; Young Adult | 2021 |
Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Oxazines; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2013 |
Impact of switching from zidovudine to tenofovir disoproxil fumarate on bone mineral density and markers of bone metabolism in virologically suppressed HIV-1 infected patients; a substudy of the PREPARE study.
Topics: Adenine; Adult; Anti-HIV Agents; Biomarkers; Bone and Bones; Bone Density; Cohort Studies; Down-Regulation; Drug Substitution; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Parathyroid Hormone; Tenofovir; Vitamin D; Zidovudine | 2013 |
Adherence profiles and therapeutic responses of treatment-naive HIV-infected patients starting boosted atazanavir-based therapy in the ANRS 134-COPHAR 3 trial.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Deoxycytidine; Drug Administration Schedule; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Medication Adherence; Middle Aged; Oligopeptides; Organophosphonates; Prospective Studies; Pyridines; Ritonavir; Surveys and Questionnaires; Tenofovir; Viral Load | 2013 |
Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United States.
Topics: Adenine; Adolescent; Anti-HIV Agents; Boston; CD4 Lymphocyte Count; Double-Blind Method; Follow-Up Studies; Georgia; HIV Infections; HIV Seronegativity; Homosexuality, Male; Humans; Hypophosphatemia; Male; Medication Adherence; Middle Aged; Organophosphonates; San Francisco; Tenofovir; Treatment Outcome | 2013 |
Women with pregnancies had lower adherence to 1% tenofovir vaginal gel as HIV preexposure prophylaxis in CAPRISA 004, a phase IIB randomized-controlled trial.
Topics: Adenine; Adult; Anti-HIV Agents; Attitude to Health; Double-Blind Method; Female; HIV Infections; Humans; Medication Adherence; Multivariate Analysis; Odds Ratio; Organophosphonates; Pregnancy; South Africa; Tenofovir; Vaginal Creams, Foams, and Jellies; Young Adult | 2013 |
Neither microbial translocation nor TLR responsiveness are likely explanations for preexisting immune activation in women who subsequently acquired HIV in CAPRISA 004.
Topics: Adenine; Anti-HIV Agents; Bacterial Translocation; Cytokines; Fatty Acid-Binding Proteins; Female; HIV Infections; HIV-1; Humans; Killer Cells, Natural; Lipopolysaccharide Receptors; Lipopolysaccharides; Lymphocyte Activation; Organophosphonates; Tenofovir; Toll-Like Receptor 2; Toll-Like Receptor 4; Toll-Like Receptor 7; Toll-Like Receptor 8; Toll-Like Receptors | 2013 |
Sexual risk behavior among HIV-uninfected men who have sex with men participating in a tenofovir preexposure prophylaxis randomized trial in the United States.
Topics: Adenine; Adolescent; Adult; Amphetamine-Related Disorders; Anti-HIV Agents; Boston; Double-Blind Method; Follow-Up Studies; Georgia; Health Knowledge, Attitudes, Practice; HIV Infections; HIV Seronegativity; Homosexuality, Male; Humans; Male; Middle Aged; Organophosphonates; Risk Assessment; Risk-Taking; San Francisco; Sexual Partners; Tenofovir; Treatment Outcome; Unsafe Sex | 2013 |
Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Cobicistat; Deoxycytidine; Double-Blind Method; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir; Thiazoles; Treatment Outcome; Viral Load | 2013 |
Abacavir/lamivudine versus tenofovir/emtricitabine with atazanavir/ritonavir for treatment-naive Japanese patients with HIV-1 infection: a randomized multicenter trial.
Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; Asian People; Atazanavir Sulfate; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Oligopeptides; Organophosphonates; Pilot Projects; Pyridines; Ritonavir; Tenofovir; Treatment Outcome | 2013 |
Pharmacokinetic interactions between lersivirine and zidovudine, tenofovir disoproxil fumarate/emtricitabine and abacavir/lamivudine.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug Interactions; Emtricitabine; Female; Healthy Volunteers; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Nitriles; Organophosphonates; Pyrazoles; Tenofovir; Young Adult; Zidovudine | 2013 |
A phase 1 randomized, double blind, placebo controlled rectal safety and acceptability study of tenofovir 1% gel (MTN-007).
Topics: Adenine; Administration, Rectal; Adult; Anti-HIV Agents; Double-Blind Method; Female; Gels; HIV Infections; Humans; Intestinal Mucosa; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Organophosphonates; Rectum; Tenofovir; Transcriptome; Young Adult | 2013 |
Intentions to use preexposure prophylaxis among current phase 2B preventive HIV-1 vaccine efficacy trial participants.
Topics: Adenine; Adolescent; Adult; AIDS Vaccines; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Heterosexuality; HIV Infections; Homosexuality, Male; Humans; Intention; Male; Middle Aged; Organophosphonates; Research Design; Surveys and Questionnaires; Tenofovir; Young Adult | 2013 |
Long-term body composition and metabolic changes in HIV-infected children switched from stavudine to tenofovir and from protease inhibitors to efavirenz.
Topics: Absorptiometry, Photon; Adenine; Adolescent; Alkynes; Anti-Retroviral Agents; Benzoxazines; Blood Glucose; Body Composition; Child; Child, Preschool; Cohort Studies; Cyclopropanes; Female; HIV Infections; Humans; Lamivudine; Linear Models; Lipids; Longitudinal Studies; Male; Organophosphonates; Stavudine; Tenofovir | 2013 |
Early upper digestive tract side effects of zidovudine with tenofovir plus emtricitabine in West African adults with high CD4 counts.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cote d'Ivoire; Deoxycytidine; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; Female; Gastrointestinal Diseases; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Tenofovir; Zidovudine | 2013 |
A randomized, comparative safety study of a prefilled plastic and user-filled paper applicator with candidate microbicide tenofovir 1% gel.
Topics: Adenine; Administration, Intravaginal; Adolescent; Adult; Anti-HIV Agents; Cross-Over Studies; Drug Delivery Systems; Female; HIV Infections; Humans; Middle Aged; Organophosphonates; Paper; Patient Acceptance of Health Care; Plastics; Tenofovir; Treatment Outcome; Vaginal Creams, Foams, and Jellies; Young Adult | 2013 |
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Substance Abuse, Intravenous; Tenofovir; Thailand; Treatment Outcome; Young Adult | 2013 |
Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Organophosphonates; Pilot Projects; Prospective Studies; Pyrrolidinones; Raltegravir Potassium; Ritonavir; RNA Stability; RNA, Viral; Tenofovir; Viral Load | 2013 |
Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults.
Topics: Adenine; Adult; Alanine; Anti-Retroviral Agents; Area Under Curve; Dose-Response Relationship, Drug; Fatigue; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nausea; Organophosphates; Organophosphonates; RNA, Viral; Single-Blind Method; Statistics, Nonparametric; Tenofovir; Viral Load; Young Adult | 2013 |
Impact of a tenofovir disoproxil fumarate plus ritonavir-boosted protease inhibitor-based regimen on renal function in HIV-infected individuals: a prospective, multicenter study.
Topics: Adenine; Adult; Anti-HIV Agents; Creatinine; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney; Kidney Diseases; Male; Middle Aged; Organophosphonates; Prospective Studies; Protease Inhibitors; Proteinuria; Ritonavir; Statistics, Nonparametric; Tenofovir | 2013 |
Variability of raltegravir plasma levels in the clinical setting.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; HIV Infections; Humans; Lamivudine; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Tenofovir | 2013 |
96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Bone and Bones; Bone Density; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Kidney; Lamivudine; Male; Organophosphonates; Tenofovir; Time Factors; Treatment Outcome | 2013 |
Switching tenofovir/emtricitabine plus lopinavir/r to raltegravir plus Darunavir/r in patients with suppressed viral load did not result in improvement of renal function but could sustain viral suppression: a randomized multicenter trial.
Topics: Adenine; Adult; Anti-HIV Agents; Darunavir; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Kidney; Kidney Function Tests; Lopinavir; Male; Middle Aged; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Sulfonamides; Tenofovir; Viral Load | 2013 |
Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Carbamates; Coinfection; Cyclopropanes; Drug Interactions; Female; Hepatitis C; HIV Infections; Humans; Imidazoles; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Pyrrolidines; Ritonavir; Tenofovir; Valine; Viral Nonstructural Proteins; Young Adult | 2013 |
Evaluation of four tenofovir-containing regimens as first-line treatments in Cameroon and Senegal: the ANRS 12115 DAYANA Trial.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cameroon; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; HIV Infections; HIV-1; Humans; Male; Medication Adherence; Middle Aged; Organophosphonates; Senegal; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2014 |
Pharmacokinetics and safety of tenofovir in HIV-infected women during labor and their infants during the first week of life.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Drug Administration Schedule; Female; Fetal Blood; HIV Infections; Humans; Infant, Newborn; Labor, Obstetric; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Tenofovir; Young Adult | 2014 |
Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency?
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Calcitriol; Calcium; Double-Blind Method; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Glomerular Filtration Rate; HIV; HIV Infections; Humans; Hypophosphatemia; Male; Organophosphonates; Parathyroid Hormone; Phosphates; Reverse Transcriptase Inhibitors; Tenofovir; Vitamin D Deficiency; Vitamin D-Binding Protein | 2013 |
Raltegravir-emtricitabine-tenofovir as HIV nonoccupational post-exposure prophylaxis in men who have sex with men: safety, tolerability and adherence.
Topics: Adenine; Adult; Anti-HIV Agents; Biomarkers; Creatine Kinase; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Organophosphonates; Prospective Studies; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Tenofovir | 2014 |
Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa.
Topics: Adenine; Adult; Africa, Eastern; Anti-HIV Agents; Cohort Studies; Deoxycytidine; Emtricitabine; Family Characteristics; Female; HIV Infections; HIV Seropositivity; Humans; Male; Medication Adherence; Multivariate Analysis; Organophosphonates; Regression Analysis; Tenofovir | 2013 |
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Dideoxynucleosides; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Kaplan-Meier Estimate; Lamivudine; Male; Organophosphonates; Oxazines; Piperazines; Pyridones; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Tenofovir | 2013 |
Safety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trial.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Male; Organophosphonates; Patient Compliance; Tenofovir; Uganda | 2013 |
Participant experiences and facilitators and barriers to pill use among men who have sex with men in the iPrEx pre-exposure prophylaxis trial in San Francisco.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Antiviral Agents; Deoxycytidine; Double-Blind Method; Emtricitabine; Focus Groups; Health Knowledge, Attitudes, Practice; HIV Infections; HIV-1; Homosexuality, Male; Humans; Interviews as Topic; Male; Medication Adherence; Middle Aged; Organophosphonates; Qualitative Research; Risk Factors; San Francisco; Tenofovir; Young Adult | 2013 |
Effect of food on rilpivirine/emtricitabine/tenofovir disoproxil fumarate, an antiretroviral single-tablet regimen for the treatment of HIV infection.
Topics: Adenine; Adult; Anti-HIV Agents; Cross-Over Studies; Deoxycytidine; Drug Combinations; Emtricitabine; Fasting; Female; Food-Drug Interactions; HIV Infections; Humans; Male; Middle Aged; Nitriles; Organophosphonates; Pyrimidines; Rilpivirine; Tablets; Tenofovir; Young Adult | 2014 |
Effects of switching from efavirenz to raltegravir on endothelial function, bone mineral metabolism, inflammation, and renal function: a randomized, controlled trial.
Topics: Adenine; Adult; Alkaline Phosphatase; Anti-HIV Agents; Biomarkers; Bone and Bones; C-Reactive Protein; Cholesterol; Deoxycytidine; Drug Combinations; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Endothelium, Vascular; Female; HIV Infections; Humans; Indiana; Inflammation; Male; Organophosphonates; Oxazines; Pyrrolidinones; Raltegravir Potassium; Renal Insufficiency; Treatment Outcome; Viral Load | 2013 |
Low body weight in females is a risk factor for increased tenofovir exposure and drug-related adverse events.
Topics: Adenine; Adult; Anti-HIV Agents; Body Weight; Bone Resorption; Female; HIV Infections; Humans; Middle Aged; Organophosphonates; Risk Factors; Tenofovir | 2013 |
Dynamics of immune reconstitution and activation markers in HIV+ treatment-naïve patients treated with raltegravir, tenofovir disoproxil fumarate and emtricitabine.
Topics: Adenine; Adult; Anti-HIV Agents; Biomarkers; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lymphocyte Activation; Male; Middle Aged; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Tenofovir; Young Adult | 2013 |
Limited HIV-1 superinfection in seroconverters from the CAPRISA 004 Microbicide Trial.
Topics: Adenine; Adult; Anti-Infective Agents; Chemoprevention; env Gene Products, Human Immunodeficiency Virus; Female; gag Gene Products, Human Immunodeficiency Virus; HIV Infections; HIV-1; Humans; Incidence; Kenya; Organophosphonates; Sequence Analysis, DNA; South Africa; Superinfection; Tenofovir; Vaginal Creams, Foams, and Jellies; Viral Load; Young Adult | 2014 |
Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals: subgroup analyses from a randomized trial.
Topics: Adenine; Adult; Anti-Retroviral Agents; Chemoprevention; Deoxycytidine; Emtricitabine; Female; Heterosexuality; HIV Infections; HIV-1; Humans; Incidence; Kenya; Male; Organophosphonates; Placebos; Tenofovir; Treatment Outcome; Uganda | 2013 |
Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP).
Topics: Adenine; Administration, Oral; Adult; Demography; Dose-Response Relationship, Drug; Female; Hair; HIV Infections; Humans; Male; Medication Adherence; Organophosphonates; Tenofovir | 2014 |
Sensitive tenofovir resistance screening of HIV-1 from the genital and blood compartments of women with breakthrough infections in the CAPRISA 004 tenofovir gel trial.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Drug Resistance, Viral; Female; Gels; HIV Infections; HIV-1; Humans; Organophosphonates; Polymerase Chain Reaction; South Africa; Tenofovir; Vagina; Vaginal Creams, Foams, and Jellies; Viral Load; Young Adult | 2014 |
Renal events among women treated with tenofovir/emtricitabine in combination with either lopinavir/ritonavir or nevirapine.
Topics: Adenine; Adult; Antiviral Agents; Creatinine; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Kidney Diseases; Lopinavir; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome | 2014 |
HIV-1 genital shedding in HIV-infected patients randomized to second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; Follow-Up Studies; Genitalia; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Organophosphonates; Risk Factors; Ritonavir; Tenofovir; Time Factors; Treatment Outcome; Viral Load; Virus Shedding | 2014 |
Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Chemoprevention; Creatinine; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Kidney; Kidney Function Tests; Male; Metabolic Clearance Rate; Middle Aged; Organophosphonates; Phosphorus; Placebos; Tenofovir; Young Adult | 2014 |
Vitamin D3 supplementation increases fibroblast growth factor-23 in HIV-infected youths treated with tenofovir disoproxil fumarate.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Cholecalciferol; Dietary Supplements; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; HIV Infections; Humans; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Young Adult | 2014 |
Comparison of body composition changes between atazanavir/ritonavir and lopinavir/ritonavir each in combination with tenofovir/emtricitabine in antiretroviral-naïve patients with HIV-1 infection.
Topics: Absorptiometry, Photon; Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Body Composition; Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Lopinavir; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir; Tomography, X-Ray Computed; Young Adult | 2014 |
Cardiovascular disease risk factors in HIV-infected women after initiation of lopinavir/ritonavir- and nevirapine-based antiretroviral therapy in Sub-Saharan Africa: A5208 (OCTANE).
Topics: Adenine; Adult; Africa South of the Sahara; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Blood Pressure; Body Mass Index; Cardiovascular Diseases; CD4-Positive T-Lymphocytes; Cholesterol, HDL; Cholesterol, LDL; Deoxycytidine; Emtricitabine; Endpoint Determination; Female; HIV Infections; HIV-1; Humans; Linear Models; Logistic Models; Lopinavir; Multivariate Analysis; Nevirapine; Organophosphonates; Prospective Studies; Risk Factors; Ritonavir; RNA, Viral; Tenofovir; Triglycerides | 2014 |
Measuring adherence by visual inspection of returned empty gel applicators in the CAPRISA 004 microbicide trial.
Topics: Adenine; Administration, Intravaginal; Adult; Anti-Infective Agents; Coitus; Double-Blind Method; Drug Delivery Systems; Female; Follow-Up Studies; Gels; HIV Infections; Humans; Multivariate Analysis; Organophosphonates; Patient Compliance; Proportional Hazards Models; Rural Population; South Africa; Tenofovir; Urban Population | 2014 |
Phenotypic and genotypic analyses to guide selection of reverse transcriptase inhibitors in second-line HIV therapy following extended virological failure in Uganda.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Inhibitory Concentration 50; Microbial Sensitivity Tests; Organophosphonates; Tenofovir; Uganda; Zidovudine | 2014 |
Impact of an adherence intervention on the effectiveness of tenofovir gel in the CAPRISA 004 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Anti-Infective Agents, Local; Double-Blind Method; Female; Gels; Health Behavior; HIV Infections; Humans; Incidence; Medication Adherence; Models, Psychological; Motivational Interviewing; Organophosphonates; Socioeconomic Factors; South Africa; Tenofovir; Treatment Outcome | 2014 |
Adherence in the CAPRISA 004 tenofovir gel microbicide trial.
Topics: Adenine; Administration, Intravaginal; Adult; Anti-HIV Agents; Anti-Infective Agents, Local; Counseling; Double-Blind Method; Female; Follow-Up Studies; Gels; HIV Infections; HIV-1; Humans; Incidence; Kaplan-Meier Estimate; Medication Adherence; Motivational Interviewing; Organophosphonates; Rural Population; Sexual Behavior; Socioeconomic Factors; South Africa; Tenofovir; Treatment Outcome; Urban Population | 2014 |
Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naïve HIV-1-infected patients with HIV-1 RNA ≤100,000 copies/mL: week 96 pooled ECHO/THRIVE subanalysis.
Topics: Adenine; Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antiviral Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nitriles; Organophosphonates; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; RNA, Viral; Tenofovir; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2014 |
Risk behaviors and risk factors for HIV infection among participants in the Bangkok tenofovir study, an HIV pre-exposure prophylaxis trial among people who inject drugs.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Risk-Taking; Substance-Related Disorders; Tenofovir; Thailand | 2014 |
HLA alleles association with changes in bone mineral density in HIV-1-infected adults changing treatment to tenofovir-emtricitabine or abacavir-lamivudine.
Topics: Adenine; Adult; Alleles; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Density; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; HLA-DQ Antigens; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir | 2014 |
Normal laboratory reference intervals among healthy adults screened for a HIV pre-exposure prophylaxis clinical trial in Botswana.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Botswana; Deoxycytidine; Emtricitabine; Female; Hematologic Tests; HIV Infections; Humans; Male; Organophosphonates; Reference Values; Tenofovir; Young Adult | 2014 |
Hip structural parameters over 96 weeks in HIV-infected adults switching treatment to tenofovir-emtricitabine or abacavir-lamivudine.
Topics: Adenine; Anti-HIV Agents; Bone Density; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug Substitution; Emtricitabine; Female; Hip Joint; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Radiography; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2014 |
Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial.
Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Brazil; Coinfection; Cyclopropanes; Drug Therapy, Combination; Female; France; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Tenofovir; Treatment Outcome; Tuberculosis; Viral Load | 2014 |
Persistent viremia in human immunodeficiency virus/hepatitis B coinfected patients undergoing long-term tenofovir: virological and clinical implications.
Topics: Adenine; Adult; Coinfection; DNA, Viral; Drug Resistance, Viral; Female; Follow-Up Studies; Genotype; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Prospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Viral Load; Viremia; Virus Replication | 2014 |
Combination antiretroviral treatment for women previously treated only in pregnancy: week 24 results of AIDS clinical trials group protocol a5227.
Topics: Adenine; Adult; Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Organophosphonates; Pregnancy; Prospective Studies; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load | 2014 |
HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention.
Topics: Adenine; Adult; Anti-HIV Agents; Biomarkers; Cohort Studies; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Seropositivity; Humans; Male; Medication Adherence; Organophosphonates; Predictive Value of Tests; Proportional Hazards Models; Tenofovir; Young Adult | 2014 |
A 48-week study of fat molecular alterations in HIV naive patients starting tenofovir/emtricitabine with lopinavir/ritonavir or efavirenz.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Gene Expression Regulation; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lopinavir; Organophosphonates; Ritonavir; Subcutaneous Fat; Tenofovir; Transcriptome | 2014 |
Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG study.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Coinfection; Deoxycytidine; Drug Carriers; Emtricitabine; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Interferon-alpha; Lamivudine; Male; Middle Aged; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Tenofovir; Treatment Outcome; Viral Load | 2014 |
Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results o
Topics: Adenine; Adult; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Protease Inhibitors; Quinolones; Ritonavir; Tenofovir; Thiazoles; Viral Load | 2014 |
Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week r
Topics: Adenine; Adult; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Emtricitabine; Female; HIV; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Quinolones; Reverse Transcriptase Inhibitors; Tenofovir; Thiazoles; Viral Load | 2014 |
Syphilis predicts HIV incidence among men and transgender women who have sex with men in a preexposure prophylaxis trial.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; Homosexuality, Male; Humans; Incidence; Male; Middle Aged; Organophosphonates; Placebos; Pre-Exposure Prophylaxis; Prevalence; Syphilis; Tenofovir; Transgender Persons; Treatment Outcome; Young Adult | 2014 |
Predictors of suboptimal CD4 response among women achieving virologic suppression in a randomized antiretroviral treatment trial, Africa.
Topics: Adenine; Adult; Africa; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lopinavir; Nevirapine; Organophosphonates; Ritonavir; Tenofovir; Treatment Outcome | 2014 |
Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial.
Topics: Adenine; Administration, Oral; Adult; Anti-Retroviral Agents; Antiviral Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; Herpes Genitalis; Herpesvirus 2, Human; Heterosexuality; HIV Infections; HIV Seronegativity; HIV-1; Humans; Incidence; Male; Medication Adherence; Organophosphonates; RNA, Viral; Tenofovir | 2014 |
First-line antiretroviral therapy with nevirapine versus lopinavir-ritonavir based regimens in a resource-limited setting.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2014 |
Clinical assessment of potential drug interactions of faldaprevir, a hepatitis C virus protease inhibitor, with darunavir/ritonavir, efavirenz, and tenofovir.
Topics: Adenine; Adult; Alkynes; Aminoisobutyric Acids; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Coinfection; Cyclopropanes; Darunavir; Drug Interactions; Female; Healthy Volunteers; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Leucine; Male; Middle Aged; Oligopeptides; Organophosphonates; Proline; Protease Inhibitors; Quinolines; Ritonavir; Sulfonamides; Tenofovir; Thiazoles; Young Adult | 2014 |
Accuracy of Self-Report and Pill-Count Measures of Adherence in the FEM-PrEP Clinical Trial: Implications for Future HIV-Prevention Trials.
Topics: Adenine; Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; Humans; Interviews as Topic; Kenya; Male; Medication Adherence; Middle Aged; Organophosphonates; Pre-Exposure Prophylaxis; Predictive Value of Tests; Qualitative Research; Self Report; Tenofovir; Treatment Outcome | 2015 |
Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cholesterol, HDL; Cholesterol, LDL; Darunavir; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides; Tenofovir; Treatment Outcome | 2014 |
Changes in proteinuria and albuminuria with initiation of antiretroviral therapy: data from a randomized trial comparing tenofovir disoproxil fumarate/emtricitabine versus abacavir/lamivudine.
Topics: Adenine; Adult; Albuminuria; Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Linear Models; Male; Organophosphonates; Proteinuria; Tenofovir | 2014 |
High medication adherence during periconception periods among HIV-1-uninfected women participating in a clinical trial of antiretroviral pre-exposure prophylaxis.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Cohort Studies; Double-Blind Method; Female; Fertilization; HIV Infections; Humans; Kenya; Medication Adherence; Organophosphonates; Pre-Exposure Prophylaxis; Pregnancy; Pregnancy Complications, Infectious; Proportional Hazards Models; Regression Analysis; Tenofovir; Uganda; Young Adult | 2014 |
Improvement in bone mineral density after switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: two-centre randomized pilot study (OsteoTDF study).
Topics: Adenine; Adult; Anti-HIV Agents; Bone Density; Dideoxynucleosides; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Osteoporosis; Pilot Projects; Tenofovir; Treatment Outcome | 2014 |
FEM-PrEP: adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Logistic Models; Male; Medication Adherence; Multivariate Analysis; Organophosphonates; Risk Factors; Tenofovir; Young Adult | 2014 |
The RADAR study: week 48 safety and efficacy of RAltegravir combined with boosted DARunavir compared to tenofovir/emtricitabine combined with boosted darunavir in antiretroviral-naive patients. Impact on bone health.
Topics: Adenine; Adult; Bone Density; Darunavir; Deoxycytidine; Emtricitabine; HIV Infections; HIV-1; Humans; Middle Aged; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Sulfonamides; Tenofovir | 2014 |
HIV disease progression in seroconvertors from the CAPRISA 004 tenofovir gel pre-exposure prophylaxis trial.
Topics: Adenine; Disease Progression; Female; Gels; HIV Infections; Humans; Organophosphonates; Placebos; Pre-Exposure Prophylaxis; Reverse Transcriptase Inhibitors; Tenofovir; Vagina | 2015 |
Pre-exposure prophylaxis does not affect the fertility of HIV-1-uninfected men.
Topics: Adenine; Adult; Anti-Retroviral Agents; Chemoprevention; Deoxycytidine; Emtricitabine; Female; Fertility; HIV Infections; Humans; Male; Organophosphonates; Placebos; Pre-Exposure Prophylaxis; Pregnancy; Tenofovir | 2014 |
Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.
Topics: Adenine; Adult; Atazanavir Sulfate; Darunavir; Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; RNA, Viral; Sulfonamides; Tenofovir; Therapeutic Equivalency; Viral Load | 2014 |
Trial participation disclosure and gel use behavior in the CAPRISA 004 tenofovir gel trial.
Topics: Adenine; Administration, Intravaginal; Adult; Anti-HIV Agents; Disclosure; Female; Gels; HIV Infections; Humans; Male; Medication Adherence; Organophosphonates; Patient Acceptance of Health Care; Sexual Behavior; Sexual Partners; Tenofovir | 2014 |
Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Double-Blind Method; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Kenya; Male; Organophosphonates; Placebos; Pre-Exposure Prophylaxis; Tenofovir; Treatment Outcome; Uganda | 2014 |
Sino-implant (II)® continuation and effect of concomitant tenofovir disoproxil fumarate-emtricitabine use on plasma levonorgestrel concentrations among women in Bondo, Kenya.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; Contraceptive Agents, Female; Deoxycytidine; Drug Combinations; Drug Implants; Emtricitabine; Female; HIV Infections; Humans; Kenya; Levonorgestrel; Longitudinal Studies; Organophosphonates; Polypharmacy; Prospective Studies; Tenofovir; Young Adult | 2015 |
Drug resistance and plasma viral RNA level after ineffective use of oral pre-exposure prophylaxis in women.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Female; High-Throughput Nucleotide Sequencing; HIV Infections; HIV-1; Humans; Organophosphonates; Plasma; Pre-Exposure Prophylaxis; RNA, Viral; Tenofovir | 2015 |
Assessing the implementation effectiveness and safety of 1% tenofovir gel provision through family planning services in KwaZulu-Natal, South Africa: study protocol for an open-label randomized controlled trial.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Clinical Protocols; Family Planning Services; Female; Gels; Health Services Accessibility; HIV Infections; Humans; Organophosphonates; Program Evaluation; Quality Improvement; Quality Indicators, Health Care; Research Design; Rural Health Services; South Africa; Tenofovir; Time Factors; Treatment Outcome; Urban Health Services; Women's Health Services; Young Adult | 2014 |
Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Kidney Function Tests; Kidney Glomerulus; Male; Medication Adherence; Middle Aged; Organophosphonates; Tenofovir; Young Adult | 2015 |
Liver and renal safety of tenofovir disoproxil fumarate in combination with emtricitabine among African women in a pre-exposure prophylaxis trial.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Anti-HIV Agents; Aspartate Aminotransferases; Black People; Chemical and Drug Induced Liver Injury; Creatinine; Deoxycytidine; Double-Blind Method; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Kidney Diseases; Organophosphonates; Phosphorus; Pre-Exposure Prophylaxis; Reverse Transcriptase Inhibitors; Tenofovir; Young Adult | 2014 |
Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent preexposure prophylaxis.
Topics: Adenine; Anti-HIV Agents; Anti-Retroviral Agents; Deoxycytidine; Double-Blind Method; Drug Resistance, Viral; Emtricitabine; HIV Infections; HIV Seropositivity; HIV-1; Humans; Organophosphonates; Risk; Tenofovir | 2015 |
Long-term efficacy and safety of tenofovir disoproxil fumarate in HIV-1-infected adolescents failing antiretroviral therapy: the final results of study GS-US-104-0321.
Topics: Adenine; Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Density; Child; Double-Blind Method; Drug Resistance, Viral; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Placebos; RNA, Viral; Tenofovir; Treatment Failure; Viral Load | 2015 |
Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Administration, Intravaginal; Administration, Oral; Adolescent; Adult; Africa South of the Sahara; Anti-Retroviral Agents; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Seropositivity; HIV-1; Humans; Medication Adherence; Middle Aged; Organophosphonates; Pre-Exposure Prophylaxis; Surveys and Questionnaires; Tenofovir; Young Adult | 2015 |
A randomized, open-label study of the safety and efficacy of switching stavudine or zidovudine to tenofovir disoproxil fumarate in HIV-1-infected children with virologic suppression.
Topics: Adenine; Adolescent; Anti-HIV Agents; Child; Child, Preschool; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; RNA, Viral; Stavudine; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2015 |
Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; RNA, Viral; Tenofovir | 2015 |
Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Double-Blind Method; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Intention to Treat Analysis; Longitudinal Studies; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2015 |
High Mortality Among Non-HIV-Infected People Who Inject Drugs in Bangkok, Thailand, 2005-2012.
Topics: Accidents, Traffic; Adenine; Adult; Anti-HIV Agents; Cause of Death; Double-Blind Method; Drug Overdose; Female; HIV Infections; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Needle Sharing; Organophosphonates; Pre-Exposure Prophylaxis; Risk-Taking; Substance Abuse, Intravenous; Surveys and Questionnaires; Tenofovir; Thailand | 2015 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Arthralgia; Bone Density; Carbamates; CD4 Lymphocyte Count; Cobicistat; Deoxycytidine; Double-Blind Method; Drug Combinations; Emtricitabine; Female; Headache; HIV Infections; Humans; Kidney; Male; Nausea; Organophosphonates; Quinolones; Respiration Disorders; Sleep Initiation and Maintenance Disorders; Tenofovir; Thiazoles; Treatment Outcome; Viral Load | 2015 |
Sexual Relationships Outside Primary Partnerships and Abstinence Are Associated With Lower Adherence and Adherence Gaps: Data From the Partners PrEP Ancillary Adherence Study.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Male; Medication Adherence; Middle Aged; Organophosphonates; Pre-Exposure Prophylaxis; Sexual Abstinence; Sexual Partners; Tenofovir; Uganda; Young Adult | 2015 |
Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Deoxycytidine; Drug Substitution; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Viral Load; Zidovudine | 2015 |
Genital Tenofovir Concentrations Correlate With Protection Against HIV Infection in the CAPRISA 004 Trial: Importance of Adherence for Microbicide Effectiveness.
Topics: Adenine; Adult; Anti-HIV Agents; Case-Control Studies; Cervix Uteri; Female; Gels; HIV Infections; Humans; Medication Adherence; Organophosphonates; South Africa; Tenofovir; Tissue Distribution; Vagina; Young Adult | 2015 |
Brief Report: Cobicistat Compared With Ritonavir as a Pharmacoenhancer for Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate: Week 144 Results.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Cobicistat; Deoxycytidine; Double-Blind Method; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; RNA, Viral; Tenofovir; Thiazoles; Viral Load | 2015 |
Tenofovir Gel for the Prevention of Herpes Simplex Virus Type 2 Infection.
Topics: Adenine; Administration, Intravaginal; Adult; Double-Blind Method; Female; Follow-Up Studies; Gels; Herpes Genitalis; Herpesvirus 2, Human; HIV Infections; HIV Seronegativity; Humans; Incidence; Kaplan-Meier Estimate; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Young Adult | 2015 |
Topical cidofovir to treat high-grade anal intraepithelial neoplasia in HIV-infected patients: a pilot clinical trial.
Topics: Administration, Topical; Adult; Antiviral Agents; Anus Neoplasms; Biopsy; Carcinoma in Situ; Cidofovir; Cytosine; HIV Infections; Humans; Male; Organophosphonates; Papillomavirus Infections; Pilot Projects; Treatment Outcome | 2016 |
Addition of single-dose tenofovir and emtricitabine to intrapartum nevirapine to reduce perinatal HIV transmission.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nevirapine; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Tenofovir | 2008 |
Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; DNA Mutational Analysis; DNA, Viral; Drug Resistance, Viral; Female; Genotype; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Tenofovir; Time Factors; Treatment Outcome; Virus Replication | 2008 |
Lack of a significant drug interaction between raltegravir and tenofovir.
Topics: Adenine; Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2008 |
Zidovudine/lamivudine/abacavir plus tenofovir in HIV-infected naive patients: a 96-week prospective one-arm pilot study.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Endpoint Determination; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Pilot Projects; Prospective Studies; Spain; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2008 |
Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Brachial Artery; CD4 Lymphocyte Count; Cyclopropanes; Endothelium, Vascular; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Organophosphonates; Prospective Studies; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Tenofovir; Time Factors; Zidovudine | 2008 |
A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; DNA, Viral; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Prospective Studies; Tenofovir; Thailand; Treatment Outcome; Zidovudine | 2008 |
Comparison of the antiviral activity of adefovir and tenofovir on hepatitis B virus in HIV-HBV-coinfected patients.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Proportional Hazards Models; Tenofovir; Treatment Outcome; Viral Load | 2008 |
The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Creatinine; Double-Blind Method; Female; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Phosphorus; Proteinuria; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir; Young Adult; Zidovudine | 2008 |
Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone.
Topics: Adenine; Adult; Anti-HIV Agents; Blood; Cohort Studies; Deoxycytidine; Dideoxynucleosides; Emtricitabine; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Middle Aged; Multivariate Analysis; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Tenofovir; Treatment Outcome; Viral Load | 2008 |
Effectiveness and safety of generic fixed-dose combination of tenofovir/emtricitabine/efavirenz in HIV-1-infected patients in Western India.
Topics: Adenine; Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Drugs, Generic; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Immunosuppression Therapy; India; Male; Middle Aged; Organophosphonates; Prevalence; Tenofovir; Treatment Outcome; Young Adult | 2008 |
Population pharmacokinetics of tenofovir in HIV-1-infected pregnant women and their neonates (ANRS 12109).
Topics: Adenine; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Maternal-Fetal Exchange; Organophosphonates; Population Groups; Pregnancy; Pregnancy Complications, Infectious; Prenatal Exposure Delayed Effects; Tenofovir | 2009 |
High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.
Topics: Adenine; Adult; Amino Acid Substitution; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation, Missense; Nevirapine; Organophosphonates; Tenofovir; Treatment Outcome; Viral Load; Viral Proteins | 2009 |
[Two novel fixed formulations of nucleoside analogues (tenofovir-emtricitabine, and abacavir-lamivudine). Prospective, open study on clinical practice and therapeutic perspectives, in patients naïve and in subjects pre-treated with antiretrovirals].
Topics: Adenine; Adult; Antiviral Agents; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Prospective Studies; Reverse Transcriptase Inhibitors; Tenofovir | 2008 |
Efficacy and safety of adefovir dipivoxil plus pegylated interferon-alpha2a for the treatment of lamivudine-resistant hepatitis B virus infection in HIV-infected patients.
Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Reverse Transcriptase Inhibitors; Treatment Outcome | 2008 |
Changes in sexual risk behavior among participants in a PrEP HIV prevention trial.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Counseling; Double-Blind Method; Female; Ghana; HIV Infections; Humans; Interviews as Topic; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Risk Reduction Behavior; Risk-Taking; Sexual Behavior; Sexual Partners; Surveys and Questionnaires; Tenofovir; Treatment Outcome; Unsafe Sex; Young Adult | 2008 |
Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfected individuals: similar effectiveness of lamivudine, tenofovir, or combination therapy.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biopsy; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B; Hepatitis B virus; HIV Infections; HIV-1; Humans; Immunosuppression Therapy; Lamivudine; Liver; Male; Middle Aged; Models, Biological; Organophosphonates; Prospective Studies; Tenofovir; Viral Load; Young Adult | 2009 |
Assessment of the steady-state pharmacokinetic interaction between etravirine administered as two different formulations and tenofovir disoproxil fumarate in healthy volunteers.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Belgium; Cross-Over Studies; Drug Interactions; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Netherlands; Nitriles; Organophosphonates; Pyridazines; Pyrimidines; Tenofovir; Young Adult | 2009 |
Tenofovir use in human immunodeficiency virus-1-infected children in the United kingdom and Ireland.
Topics: Adenine; Adolescent; Anti-HIV Agents; Child; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; Humans; Ireland; Male; Organophosphonates; Pediatrics; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; United Kingdom | 2009 |
Abacavir/3TC vs. tenofovir/FTC: interim results from ACTG 5202.
Topics: Adenine; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2008 |
Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir.
Topics: Adenine; Adult; Anti-HIV Agents; Area Under Curve; Cross-Sectional Studies; Dideoxynucleosides; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Longitudinal Studies; Lopinavir; Male; Middle Aged; Organophosphonates; Pilot Projects; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome | 2009 |
Tolerance and viral resistance after single-dose nevirapine with tenofovir and emtricitabine to prevent vertical transmission of HIV-1.
Topics: Adenine; Adult; Anti-HIV Agents; Cambodia; Cote d'Ivoire; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; Female; Genotype; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Nevirapine; Organophosphonates; Pregnancy; RNA, Viral; South Africa; Tenofovir; Viral Load | 2009 |
Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Patient Compliance; Tenofovir | 2009 |
A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Spain; Tenofovir; Treatment Failure; Treatment Outcome | 2009 |
A randomized trial of two-drug versus three-drug tenofovir-containing maintenance regimens in virologically controlled HIV-1 patients.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; France; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir; Treatment Outcome; Viral Load | 2009 |
Safety evaluation of 1% tenofovir gel in healthy men.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Cellulose; Circumcision, Male; Gels; Glycerol; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Penis; Phosphates; Propylene Glycols; Reverse Transcriptase Inhibitors; Single-Blind Method; Tenofovir; Treatment Outcome; Young Adult | 2009 |
Improvements in cheek volume in lipoatrophic individuals switching away from thymidine nucleoside reverse transcriptase inhibitors.
Topics: Absorptiometry, Photon; Adenine; Adult; Aged; Body Composition; Cheek; Dideoxynucleosides; Female; HIV Infections; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Male; Middle Aged; Organophosphonates; Quality of Life; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir; Zidovudine | 2009 |
Switch from a ZDV/3TC-based regimen to a completely once daily (QD) regimen of emtricitabine/tenofovir DF fixed dose combination plus a third QD agent (SONETT).
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Emtricitabine; Female; Hemoglobins; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Prospective Studies; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load; Young Adult; Zidovudine | 2009 |
Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cardiovascular Diseases; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Double-Blind Method; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Organophosphonates; Pyrimidinones; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome | 2009 |
A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individuals.
Topics: Adenine; Adipose Tissue; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Emtricitabine; Extremities; Female; HIV Infections; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Lipids; Male; Middle Aged; Organophosphonates; Tenofovir; Young Adult; Zidovudine | 2009 |
Modulation of K65R selection by zidovudine inclusion: analysis of HIV resistance selection in subjects with virologic failure receiving once-daily abacavir/lamivudine/zidovudine and tenofovir DF (study COL40263).
Topics: Adenine; Adult; Amino Acid Substitution; Anti-HIV Agents; Dideoxynucleosides; Drug Administration Schedule; Drug Resistance, Multiple, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Pilot Projects; RNA, Viral; Tenofovir; Treatment Failure; Zidovudine | 2009 |
Modified directly observed antiretroviral therapy compared with self-administered therapy in treatment-naive HIV-1-infected patients: a randomized trial.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Aged; Anti-HIV Agents; Deoxycytidine; Dose-Response Relationship, Drug; Emtricitabine; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Organophosphonates; Pyrimidinones; Retrospective Studies; RNA, Viral; Stavudine; Tenofovir; Treatment Outcome; Young Adult | 2009 |
Covert use, vaginal lubrication, and sexual pleasure: a qualitative study of urban U.S. Women in a vaginal microbicide clinical trial.
Topics: Adenine; Administration, Intravaginal; Adult; Anti-HIV Agents; Anti-Infective Agents, Local; Black or African American; Cohort Studies; Coitus; Female; Heterosexuality; HIV Infections; Humans; Interpersonal Relations; Interviews as Topic; Lubricants; Male; Organophosphonates; Patient Satisfaction; Pleasure; Sexual Behavior; Sexual Partners; Tenofovir; United States; Urban Population; Vagina; Vaginal Creams, Foams, and Jellies | 2010 |
Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naïve subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934.
Topics: Adenine; Alkynes; Amino Acid Substitution; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Genome, Viral; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Mutation, Missense; Organophosphonates; Tenofovir; Treatment Failure; Zidovudine | 2009 |
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.
Topics: Adenine; Adult; Alkynes; Analysis of Variance; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Double-Blind Method; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Prognosis; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Safety; Tenofovir; Treatment Outcome; Viral Load | 2009 |
Raltegravir as effective as efavirenz in 144-week data.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Double-Blind Method; Drug Therapy, Combination; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Tenofovir; Time Factors; Treatment Outcome | 2009 |
[Efficacy and safety of TAM-sparing antiretroviral regimens in naïve HIV-positive patients].
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Hyperinsulinism; Hyperlipidemias; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Prospective Studies; Tenofovir; Thymidine; Treatment Outcome; Young Adult | 2009 |
Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; Female; HIV Infections; HLA-B Antigens; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir; Treatment Outcome; Viral Load | 2009 |
Modified directly observed therapy to improve HIV treatment outcomes: little impact with potent, once-daily therapy in unselected antiretroviral-naïve patients.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Lopinavir; Medication Adherence; Organophosphonates; Pyrimidinones; Ritonavir; Self Administration; Stavudine; Tenofovir; Treatment Outcome | 2009 |
Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Carbamates; Cross-Over Studies; Drug Administration Schedule; Drug Eruptions; Drug Interactions; Drug Therapy, Combination; Female; Furans; HIV Infections; Humans; Male; Middle Aged; Organophosphates; Organophosphonates; Prodrugs; Ritonavir; Sulfonamides; Tenofovir; Young Adult | 2010 |
Intrapartum tenofovir and emtricitabine reduces low-concentration drug resistance selected by single-dose nevirapine for perinatal HIV prevention.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Infectious Disease Transmission, Vertical; Mutation; Nevirapine; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2009 |
Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Community Health Services; Female; HIV; HIV Infections; Home Care Services; Humans; Lamivudine; Male; Nevirapine; Organophosphonates; Stavudine; Tenofovir; Uganda; Zidovudine | 2009 |
Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.
Topics: Adenine; Adolescent; Adult; Analysis of Variance; Anti-HIV Agents; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Double-Blind Method; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Female; Fractures, Bone; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; RNA, Viral; Tenofovir; Therapeutic Equivalency; Time Factors; Treatment Failure; Viral Load; Young Adult | 2009 |
Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Africa; Aged; Anemia; Anti-Retroviral Agents; CD4 Lymphocyte Count; Creatinine; Dideoxynucleosides; Disease Progression; Drug Monitoring; Female; Glomerular Filtration Rate; Hemoglobins; HIV Infections; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Male; Middle Aged; Neutropenia; Neutrophils; Nevirapine; Organophosphonates; RNA, Viral; Tenofovir; Urea; Viral Load; Zidovudine | 2010 |
Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction.
Topics: Adenine; Adult; Anti-HIV Agents; Biomarkers; Cardiovascular Diseases; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lipids; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Viral Load | 2010 |
Adipocyte differentiation, mitochondrial gene expression and fat distribution: differences between zidovudine and tenofovir after 6 months.
Topics: Adenine; Adipocytes; Adipose Tissue; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cell Differentiation; Cyclopropanes; Drug Therapy, Combination; Fatty Acids; Female; Gene Expression; Genes, Mitochondrial; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Male; Mitochondria; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Up-Regulation; Zidovudine | 2009 |
Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lipids; Lopinavir; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2010 |
Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients.
Topics: Adenine; Adult; Anti-HIV Agents; Cholesterol, LDL; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Nucleosides; Organophosphonates; Tenofovir; Triglycerides | 2010 |
Abacavir and tenofovir disoproxil fumarate co-administration results in a nonadditive antiviral effect in HIV-1-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxyguanine Nucleotides; Dideoxynucleosides; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; RNA, Viral; Tenofovir; Treatment Outcome | 2010 |
Long-term efficacy and safety of once-daily nevirapine in combination with tenofovir and emtricitabine in the treatment of HIV-infected patients: a 72-week prospective multicenter study (TENOR-trial).
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nevirapine; Organophosphonates; Prospective Studies; Tenofovir; Treatment Outcome | 2009 |
Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF.
Topics: Adenine; Adolescent; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Patient Compliance; Patient Preference; Puerto Rico; Quality of Life; Reverse Transcriptase Inhibitors; Severity of Illness Index; Tablets; Tenofovir; Treatment Outcome; United States; Young Adult | 2010 |
Mitochondrial changes during D-drug-containing once-daily therapy in HIV-positive treatment-naive patients.
Topics: Adenine; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cross-Sectional Studies; Cyclopropanes; Didanosine; Dideoxynucleosides; DNA, Mitochondrial; Drug Administration Schedule; Female; HIV; HIV Infections; Humans; Lamivudine; Male; Mitochondria; Organophosphonates; Reverse Transcriptase Inhibitors; RNA; RNA, Mitochondrial; Tenofovir | 2010 |
Impact of low abundance HIV variants on response to ritonavir-boosted atazanavir or fosamprenavir given once daily with tenofovir/emtricitabine in antiretroviral-naive HIV-infected patients.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Atazanavir Sulfate; Carbamates; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Emtricitabine; Furans; Genetic Variation; HIV Infections; HIV-1; Humans; Middle Aged; Oligopeptides; Organophosphates; Organophosphonates; Pyridines; Ritonavir; RNA, Viral; Sequence Analysis, RNA; Sulfonamides; Tenofovir; Treatment Failure | 2010 |
The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Darunavir; Deoxycytidine; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Tenofovir; Treatment Outcome; Young Adult | 2010 |
Tenofovir/emtricitabine combination results in lower bone-mineral density.
Topics: Adenine; Anti-HIV Agents; Bone Density; Deoxycytidine; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Organophosphonates; Tenofovir; Treatment Outcome | 2010 |
Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study.
Topics: Adenine; Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; beta 2-Microglobulin; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Kidney; Lamivudine; Male; Middle Aged; Organophosphonates; Retinol-Binding Proteins; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2010 |
Gastrointestinal tolerability and quality of life in antiretroviral-naive HIV-1-infected patients: data from the CASTLE study.
Topics: Adenine; Adult; Aged; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; Gastrointestinal Diseases; HIV Infections; HIV-1; Humans; Irritable Bowel Syndrome; Lopinavir; Male; Medication Adherence; Middle Aged; Oligopeptides; Organophosphonates; Prospective Studies; Pyridines; Pyrimidinones; Quality of Life; Ritonavir; Surveys and Questionnaires; Tenofovir; Young Adult | 2010 |
A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cholesterol; Dyslipidemias; Epidemiologic Methods; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Pilot Projects; Tenofovir; Young Adult | 2010 |
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
Topics: Adenine; Administration, Intravaginal; Adolescent; Adult; Anti-HIV Agents; Anti-Infective Agents, Local; Double-Blind Method; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Incidence; Organophosphonates; Patient Compliance; Pregnancy; Pregnancy Outcome; Rural Population; Sexual Behavior; South Africa; Tenofovir; Urban Population; Vaginal Creams, Foams, and Jellies; Viral Load; Young Adult | 2010 |
Short communication: Comparable safety and efficacy with once-daily versus twice-daily dosing of lopinavir/ritonavir tablets with emtricitabine + tenofovir DF in antiretroviral-naïve, HIV type 1-infected subjects: 96 week final results of the randomized t
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Lopinavir; Organophosphonates; Pyrimidinones; Ritonavir; Tenofovir | 2010 |
Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV.
Topics: Adenine; Administration, Oral; Adult; Anti-HIV Agents; Biological Availability; Deoxycytidine; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; Humans; Male; Organophosphonates; Plasma; Quinolones; Tablets; Tenofovir | 2010 |
Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults.
Topics: Adenine; Adult; Anti-HIV Agents; Darunavir; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Male; Nitriles; Organophosphonates; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Tenofovir; Treatment Outcome | 2010 |
Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus.
Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; CD4 Lymphocyte Count; DNA, Viral; Drug Resistance, Viral; Female; Follow-Up Studies; Guanine; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Kaplan-Meier Estimate; Kidney; Male; Middle Aged; Organophosphonates; Prospective Studies; Tenofovir; Time Factors; Virus Replication | 2010 |
Maternal and nenonatal tenofovir and emtricitabine to prevent vertical transmission of HIV-1: tolerance and resistance.
Topics: Adenine; Adult; Antiviral Agents; Cambodia; Cote d'Ivoire; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; Genotype; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Organophosphonates; Pregnancy; RNA, Viral; South Africa; Tenofovir; Viral Load | 2010 |
Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study.
Topics: Absorptiometry, Photon; Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Bone and Bones; Bone Density; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Europe; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir; Young Adult | 2010 |
Efficacy of tenofovir disoproxil fumarate/emtricitabine compared with emtricitabine alone in antiretroviral-naive HIV-HBV coinfection in Thailand.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Deoxycytidine; DNA, Viral; Emtricitabine; Female; Hepatitis B, Chronic; HIV Infections; Humans; Male; Organophosphonates; Prospective Studies; Tenofovir; Thailand | 2010 |
Pharmacokinetics and pharmacodynamics of the non-nucleoside reverse-transcriptase inhibitor etravirine in treatment-experienced HIV-1-infected patients.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Aged; Darunavir; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Nitriles; Organophosphonates; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2010 |
Antiretroviral therapies in women after single-dose nevirapine exposure.
Topics: Adenine; Adult; Anti-HIV Agents; Anti-Retroviral Agents; CD4 Lymphocyte Count; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Vertical; Kaplan-Meier Estimate; Linear Models; Lopinavir; Nevirapine; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Pyrimidinones; Ritonavir; Statistics, Nonparametric; Tenofovir; Treatment Failure; Young Adult | 2010 |
Population pharmacokinetics of nevirapine in HIV-1-infected pregnant women and their neonates.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Infant, Newborn; Nevirapine; Organophosphonates; Pregnancy; Tenofovir; Treatment Outcome; Young Adult; Zidovudine | 2011 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Follow-Up Studies; HIV; HIV Antibodies; HIV Infections; HIV Seropositivity; Homosexuality, Male; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Nausea; Organophosphonates; Patient Compliance; RNA, Viral; Tenofovir; Transsexualism; Young Adult | 2010 |
Effect of boosted fosamprenavir or lopinavir-based combinations on whole-body insulin sensitivity and lipids in treatment-naive HIV-type-1-positive men.
Topics: Adenine; Adipose Tissue; Adult; Anti-HIV Agents; Blood Glucose; Carbamates; Confidence Intervals; Drug Administration Schedule; Drug Combinations; Dyslipidemias; Furans; HIV Infections; HIV-1; Humans; Insulin; Insulin Resistance; Lamivudine; Lipids; Lopinavir; Male; Organophosphates; Organophosphonates; Pyrimidinones; Ritonavir; Sulfonamides; Tenofovir | 2010 |
Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapy.
Topics: Adenine; Adult; Alkynes; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Organophosphonates; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Tenofovir; Treatment Failure; Viral Load | 2011 |
Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men.
Topics: Adenine; Antiviral Agents; Deoxycytidine; Double-Blind Method; Drug Therapy, Combination; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Organophosphonates; Tenofovir; Unsafe Sex | 2011 |
Co-enrollment in multiple HIV prevention trials - experiences from the CAPRISA 004 Tenofovir gel trial.
Topics: Adenine; Adult; Africa South of the Sahara; Anti-HIV Agents; Clinical Trials, Phase II as Topic; Female; Gels; HIV Infections; Humans; Organophosphonates; Patient Participation; Patient Selection; Randomized Controlled Trials as Topic; Self Report; Tenofovir; Young Adult | 2011 |
Intracellular nucleotide levels during coadministration of tenofovir disoproxil fumarate and didanosine in HIV-1-infected patients.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Chromatography, Liquid; Deoxyadenine Nucleotides; Deoxyguanine Nucleotides; Didanosine; Dideoxynucleotides; Female; HIV Infections; Humans; Male; Middle Aged; Nucleotides; Organophosphonates; Tandem Mass Spectrometry; Tenofovir; Young Adult | 2011 |
Atazanavir pharmacokinetics with and without tenofovir during pregnancy.
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infectious Disease Transmission, Vertical; Oligopeptides; Organophosphonates; Postpartum Period; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimester, Third; Prospective Studies; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome | 2011 |
A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel.
Topics: Adenine; Adult; Anti-HIV Agents; Biomarkers; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Genitalia, Female; HIV Infections; Humans; Immunity, Mucosal; Mucous Membrane; Organophosphonates; Semen; Tenofovir; Vaginal Douching; Young Adult | 2011 |
Early changes in inflammatory and pro-thrombotic biomarkers in patients initiating antiretroviral therapy with abacavir or tenofovir.
Topics: Adenine; Adult; Anti-HIV Agents; Biomarkers; C-Reactive Protein; Coagulants; Dideoxynucleosides; Female; HIV Infections; Humans; Inflammation Mediators; Interleukin-6; Longitudinal Studies; Male; Middle Aged; Organophosphonates; Plasminogen Activator Inhibitor 1; Tenofovir; Thrombosis; Vascular Cell Adhesion Molecule-1 | 2011 |
Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis.
Topics: Adenine; Adult; Anti-HIV Agents; Darunavir; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; Genetic Association Studies; HIV Infections; HIV-1; Humans; Lopinavir; Male; Mutation; Organophosphonates; Polymorphism, Genetic; Pyrimidinones; Ritonavir; RNA, Viral; Sulfonamides; Tenofovir; Treatment Failure; Viral Load | 2011 |
Tenofovir discontinuation could predispose to urolithiasis in atazanavir-treated patients.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Male; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Urolithiasis | 2011 |
Initial results reported on raltegravir once-daily dosing.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV Integrase Inhibitors; Humans; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Tenofovir; Treatment Outcome | 2011 |
Metabolic benefits of switching to tenofovir/lamivudine after long-term use of stavudine/lamivudine in NNRTI-based antiretroviral regimens: a prospective study.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Female; HIV Infections; Humans; Lamivudine; Lipid Metabolism; Male; Middle Aged; Organophosphonates; Prospective Studies; Stavudine; Tenofovir; Treatment Outcome | 2011 |
Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial.
Topics: Adenine; Administration, Intravaginal; Adolescent; Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Organophosphonates; Patient Selection; Prevalence; Reverse Transcriptase Inhibitors; Risk Assessment; Risk Factors; Rural Population; Sex Factors; Sexual Behavior; South Africa; Tenofovir; Treatment Outcome; Urban Population; Vaginal Creams, Foams, and Jellies; Women's Health; Young Adult | 2011 |
Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Cobicistat; Cyclopropanes; Deoxycytidine; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Patient Compliance; Patient Selection; Quinolones; Tenofovir; Thiazoles; Treatment Outcome | 2011 |
Beliefs about antiretroviral therapy, treatment adherence and quality of life in a 48-week randomised study of continuation of zidovudine/lamivudine or switch to tenofovir DF/emtricitabine, each with efavirenz.
Topics: Adenine; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Combinations; Drug Substitution; Drug Therapy, Combination; Emtricitabine; Female; Health Knowledge, Attitudes, Practice; HIV Infections; HIV-1; Humans; Lamivudine; Male; Medication Adherence; Middle Aged; Organophosphonates; Quality of Life; Tenofovir; Treatment Outcome; Young Adult; Zidovudine | 2011 |
Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study).
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; Deoxycytidine; Drug Therapy, Combination; Dyslipidemias; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lipids; Male; Nevirapine; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir; Viral Load | 2011 |
Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Cardiovascular Diseases; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nevirapine; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome | 2011 |
Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG
Topics: Absorptiometry, Photon; Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Bone Density; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; Fractures, Bone; HIV Infections; Humans; Intention to Treat Analysis; Lamivudine; Male; Middle Aged; Oligopeptides; Organophosphonates; Osteoporosis; Pyridines; Risk Factors; Ritonavir; Tenofovir; Viral Load | 2011 |
Steady-state pharmacokinetics of tenofovir-based regimens in HIV-infected pediatric patients.
Topics: Adenine; Adolescent; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Child; Cyclopropanes; Drug Administration Schedule; Female; HIV Infections; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir | 2011 |
Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovir.
Topics: Adenine; Adult; Anti-HIV Agents; Cardiovascular Diseases; Cholesterol, LDL; Clinical Protocols; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lipoproteins; Lipoproteins, LDL; Male; Middle Aged; Organophosphonates; Phospholipases A2; Reverse Transcriptase Inhibitors; Tenofovir | 2011 |
Treatment of advanced HIV disease in antiretroviral-naïve HIV-1-infected patients receiving once-daily atazanavir/ritonavir or twice-daily lopinavir/ritonavir, each in combination with tenofovir disoproxil fumarate and emtricitabine.
Topics: Adenine; Adult; Aged; Antiviral Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Organophosphonates; Prospective Studies; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome; Young Adult | 2011 |
Effects of the H2-receptor antagonist famotidine on the pharmacokinetics of atazanavir-ritonavir with or without tenofovir in HIV-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Cohort Studies; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Famotidine; Female; Histamine H2 Antagonists; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir; Viral Load | 2011 |
Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Carbamates; CD4 Lymphocyte Count; Cobicistat; Deoxycytidine; Double-Blind Method; Drug Administration Schedule; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; RNA, Viral; Tenofovir; Thiazoles; Treatment Outcome | 2011 |
Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients.
Topics: Adenine; Adult; Atazanavir Sulfate; Deoxycytidine; Drug Administration Schedule; Dyslipidemias; Emtricitabine; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Diseases; Male; Oligopeptides; Organophosphonates; Pyridines; Saquinavir; Tenofovir; Treatment Outcome | 2011 |
Predicting product adherence in a topical microbicide safety trial in Pune, India.
Topics: Adenine; Adolescent; Adult; Anti-Infective Agents; Anti-Infective Agents, Local; Condoms; Female; HIV Infections; Humans; India; Medication Adherence; Middle Aged; Organophosphonates; Predictive Value of Tests; Prospective Studies; Risk Reduction Behavior; Sexual Partners; Social Support; Socioeconomic Factors; Tenofovir; Young Adult | 2012 |
Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Infant; Infectious Disease Transmission, Vertical; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Young Adult | 2011 |
Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Double-Blind Method; Emtricitabine; Female; HIV; HIV Infections; Humans; Kaplan-Meier Estimate; Lamivudine; Male; Middle Aged; Organophosphonates; RNA, Viral; Tenofovir; Viral Load | 2011 |
Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK.
Topics: Absorptiometry, Photon; Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load | 2011 |
Virological response and resistance profiles after 24 months of first-line antiretroviral treatment in adults living in Bangui, Central African Republic.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Central African Republic; DNA Fingerprinting; Drug Resistance, Viral; Female; Genetic Variation; Health Services Accessibility; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Medication Adherence; Oligopeptides; Organophosphonates; Prospective Studies; Pyridines; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Viral Load; Young Adult; Zidovudine | 2012 |
Enrollment characteristics and risk behaviors of injection drug users participating in the Bangkok Tenofovir Study, Thailand.
Topics: Adenine; Administration, Oral; Adult; AIDS Vaccines; Communicable Disease Control; Double-Blind Method; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Placebos; Risk; Risk-Taking; Substance Abuse, Intravenous; Tenofovir; Thailand | 2011 |
Evaluation of cardiovascular biomarkers in HIV-infected patients switching to abacavir or tenofovir based therapy.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biomarkers; Cardiovascular Diseases; Deoxycytidine; Dideoxynucleosides; E-Selectin; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Plasma; Tenofovir; Vascular Cell Adhesion Molecule-1 | 2011 |
A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naive HIV-infected patients after tenofovir/emtricitabine in combination with atazanavir/ritonavir or efavirenz.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Creatinine; Cyclopropanes; Cystatin C; Deoxycytidine; Emtricitabine; Female; Glomerular Filtration Rate; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Organophosphonates; Pilot Projects; Pyridines; Ritonavir; Tenofovir | 2012 |
Characteristics of HIV-1 serodiscordant couples enrolled in a clinical trial of antiretroviral pre-exposure prophylaxis for HIV-1 prevention.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Cohort Studies; Deoxycytidine; Emtricitabine; Female; Heterosexuality; HIV Infections; HIV Seronegativity; HIV Seropositivity; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Risk-Taking; Sexual Behavior; Tenofovir; Young Adult | 2011 |
Glomerular dysfunction and associated risk factors over 4-5 years following antiretroviral therapy initiation in Africa.
Topics: Adenine; Adult; Africa; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Creatinine; Dideoxynucleosides; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Diseases; Kidney Glomerulus; Lamivudine; Male; Nevirapine; Organophosphonates; Risk Factors; Tenofovir; Time Factors; Zidovudine | 2011 |
Predictors of limb fat gain in HIV positive patients following a change to tenofovir-emtricitabine or abacavir-lamivudine.
Topics: Adenine; Adipose Tissue; Adult; Biomarkers; Body Fat Distribution; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Extremities; HIV Infections; Humans; Lamivudine; Middle Aged; Organophosphonates; Predictive Value of Tests; Tenofovir | 2011 |
Changes in condom use during a microbicide clinical trial in Pune, India.
Topics: Adenine; Adult; Anti-HIV Agents; Cohort Studies; Condoms; Counseling; Female; Follow-Up Studies; Gels; Health Knowledge, Attitudes, Practice; HIV Infections; Humans; India; Male; Middle Aged; Odds Ratio; Organophosphonates; Risk Factors; Risk Reduction Behavior; Sex Distribution; Sexual Behavior; Sexual Partners; Surveys and Questionnaires; Tenofovir; Young Adult | 2012 |
Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir | 2012 |
HIV-1 protease inhibitors and clinical malaria: a secondary analysis of the AIDS Clinical Trials Group A5208 study.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Incidence; Lopinavir; Malaria; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome | 2012 |
Dynamics of cognitive change in HIV-infected individuals commencing three different initial antiretroviral regimens: a randomized, controlled study.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cognition; Cognition Disorders; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir; Zidovudine | 2012 |
The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Organophosphonates; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load | 2012 |
Raltegravir, tenofovir DF, and emtricitabine for postexposure prophylaxis to prevent the sexual transmission of HIV: safety, tolerability, and adherence.
Topics: Adenine; Adult; Anti-HIV Agents; Boston; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Patient Compliance; Post-Exposure Prophylaxis; Pyrrolidinones; Raltegravir Potassium; Tenofovir; Young Adult | 2012 |
What's love got to do with it? Explaining adherence to oral antiretroviral pre-exposure prophylaxis for HIV-serodiscordant couples.
Topics: Adenine; Administration, Oral; Adult; Anti-HIV Agents; Attitude to Health; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV Seronegativity; HIV Seropositivity; Humans; Interpersonal Relations; Male; Medication Adherence; Middle Aged; Organophosphonates; Sexual Partners; Tenofovir; Uganda; Young Adult | 2012 |
Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: a randomized, placebo-controlled trial.
Topics: Adenine; Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cholecalciferol; Double-Blind Method; Drug Interactions; Female; HIV Infections; Humans; Male; Multicenter Studies as Topic; Organophosphonates; Parathyroid Hormone; Placebos; Tenofovir; Vitamins; Young Adult | 2012 |
Mitochondrial function, inflammation, fat and bone in HIV lipoatrophy: randomized study of uridine supplementation or switch to tenofovir.
Topics: Adenine; Adipocytes; Adipose Tissue; Adult; Anti-HIV Agents; Apoptosis; Bone Density; DNA, Mitochondrial; Female; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Inflammation; Male; Middle Aged; Mitochondria; Organophosphonates; Reverse Transcriptase Inhibitors; RNA; RNA, Mitochondrial; Tenofovir; Uridine; Viral Load | 2012 |
Evidence for a shift to anaerobic metabolism in adipose tissue in efavirenz-containing regimens for HIV with different nucleoside backbones.
Topics: Adenine; Adipose Tissue; Adult; Alkynes; Anaerobiosis; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Electron Transport Complex IV; Female; Gene Expression Regulation; HIV Infections; HIV-1; Humans; Ion Channels; Lipogenesis; Male; Middle Aged; Mitochondrial Proteins; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Uncoupling Protein 2; Zidovudine | 2012 |
A randomized study of tenofovir disoproxil fumarate in treatment-experienced HIV-1 infected adolescents.
Topics: Adenine; Adolescent; Anti-HIV Agents; Child; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Treatment Outcome; Viremia | 2012 |
Treatment outcomes of recommended first-line antiretroviral regimens in resource-limited clinics.
Topics: Adenine; Adult; Age Factors; Anti-HIV Agents; CD4 Lymphocyte Count; Cross-Sectional Studies; Deoxycytidine; Developing Countries; Drug Costs; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Organophosphonates; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2012 |
Changes in body composition and mitochondrial DNA in HIV-1-infected patients switching to fixed-dose abacavir/lamivudine or tenofovir/emtricitabine: a substudy of the BICOMBO trial.
Topics: Adenine; Adult; Anti-HIV Agents; Body Composition; Bone Density; Deoxycytidine; Dideoxynucleosides; DNA, Mitochondrial; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir | 2012 |
A comparison of measured and estimated glomerular filtration rate in successfully treated HIV-patients with preserved renal function.
Topics: Adenine; Adult; Anti-HIV Agents; Body Mass Index; Deoxycytidine; Emtricitabine; Female; Glomerular Filtration Rate; HIV Infections; Humans; Lamivudine; Linear Models; Male; Middle Aged; Netherlands; Organophosphonates; Pilot Projects; Research Design; Statistics, Nonparametric; Tenofovir; Treatment Outcome; Zidovudine | 2012 |
Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial.
Topics: Adenine; Adult; Alkaline Phosphatase; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biomarkers; Bone and Bones; Bone Density; Creatinine; Cystatin C; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Kidney; Kidney Function Tests; Lamivudine; Male; Middle Aged; Organophosphonates; Osteocalcin; Tenofovir; Time Factors; Treatment Outcome | 2012 |
Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Homosexuality, Male; Humans; Kenya; Male; Middle Aged; Organophosphonates; Patient Compliance; Sex Workers; Tenofovir | 2012 |
CAPRISA 004 tenofovir microbicide trial: no impact of tenofovir gel on the HIV transmission bottleneck.
Topics: Adenine; Anti-HIV Agents; Anti-Infective Agents, Local; Cervix Uteri; Cohort Studies; Female; Gels; HIV Infections; HIV-1; Humans; Mucous Membrane; Organophosphonates; Tenofovir | 2012 |
Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial.
Topics: Abortion, Spontaneous; Adenine; Adult; Anti-HIV Agents; Body Height; Body Weight; Breast Feeding; Burns; Cause of Death; Child, Preschool; Congenital Abnormalities; Drug Combinations; Female; Follow-Up Studies; Fractures, Bone; Growth; HIV Infections; HIV Seropositivity; Humans; Infant; Infant Mortality; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Male; Measles; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Prevalence; Respiratory Tract Infections; Tenofovir; Uganda; Zidovudine; Zimbabwe | 2012 |
Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine.
Topics: Absorptiometry, Photon; Adenine; Adult; Bone Density; Bone Remodeling; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2012 |
From in vitro EC₅₀ to in vivo dose-response for antiretrovirals using an HIV disease model. Part I: a framework.
Topics: Adenine; Anti-HIV Agents; Cyclohexanes; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Inhibitory Concentration 50; Male; Maraviroc; Models, Biological; Nitriles; Organophosphonates; Oxazines; Piperazines; Pyridazines; Pyridones; Pyrimidines; RNA, Viral; Tenofovir; Triazoles | 2012 |
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Cobicistat; Deoxycytidine; Double-Blind Method; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Quinolones; Ritonavir; Tenofovir; Thiazoles | 2012 |
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cobicistat; Cyclopropanes; Deoxycytidine; Double-Blind Method; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Quinolones; Tenofovir; Thiazoles | 2012 |
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Bone Density; Contraception Behavior; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Seropositivity; HIV-1; HIV-2; Humans; Kaplan-Meier Estimate; Male; Organophosphonates; Proportional Hazards Models; RNA, Viral; Sexual Behavior; Tenofovir; Viral Load; Young Adult | 2012 |
Preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Anti-Retroviral Agents; Case-Control Studies; Deoxycytidine; Double-Blind Method; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV Seropositivity; HIV-1; Humans; Incidence; Kaplan-Meier Estimate; Medication Adherence; Organophosphonates; Risk-Taking; RNA, Viral; Sexual Behavior; Tenofovir; Treatment Failure; Viral Load; Young Adult | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Blind Method; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Female; Heterosexuality; HIV Infections; HIV Seropositivity; HIV-1; Humans; Incidence; Male; Middle Aged; Organophosphonates; Pregnancy; RNA, Viral; Sexual Behavior; Tenofovir; Young Adult | 2012 |
Tenofovir use and renal insufficiency among pregnant and general adult population of HIV-infected, ART-naïve individuals in Lilongwe, Malawi.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Body Mass Index; CD4 Lymphocyte Count; Creatinine; Cyclopropanes; Drug Combinations; Female; HIV Infections; Humans; Lamivudine; Malawi; Male; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Renal Insufficiency; Tenofovir | 2012 |
Safety of tenofovir gel, a vaginal microbicide, in South African women: results of the CAPRISA 004 Trial.
Topics: Adenine; Administration, Intravaginal; Anti-HIV Agents; Anti-Infective Agents, Local; Bone and Bones; Female; Follow-Up Studies; Gastrointestinal Tract; HIV Infections; Humans; Kidney; Organophosphonates; South Africa; Tenofovir; Vaginal Creams, Foams, and Jellies | 2013 |
RMP-02/MTN-006: A phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate.
Topics: Adenine; Administration, Oral; Administration, Rectal; Adult; Aged; Anti-HIV Agents; Double-Blind Method; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Patient Satisfaction; Rectum; Tenofovir; Treatment Outcome; United States; Vaginal Creams, Foams, and Jellies | 2012 |
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Organophosphonates; Tenofovir | 2012 |
Neurocognitive impairment in patients randomized to second-line lopinavir/ritonavir-based antiretroviral therapy vs. lopinavir/ritonavir monotherapy.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Cognition Disorders; Depression; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Viral Load | 2012 |
Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients.
Topics: Adenine; Adult; Aged; Alleles; Atazanavir Sulfate; Cytochrome P-450 CYP3A; Deoxycytidine; Drug Interactions; Drug Therapy, Combination; Emtricitabine; Female; Genotype; HIV Infections; HIV Protease Inhibitors; Humans; Male; Medication Adherence; Middle Aged; Models, Biological; Nonlinear Dynamics; Oligopeptides; Organophosphonates; Pharmacogenetics; Pyridines; Ritonavir; Tenofovir; Young Adult | 2012 |
The early effects of stavudine compared with tenofovir on adipocyte gene expression, mitochondrial DNA copy number and metabolic parameters in South African HIV-infected patients: a randomized trial.
Topics: Adenine; Adipocytes; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biomarkers; DNA Copy Number Variations; DNA, Mitochondrial; Dose-Response Relationship, Drug; Female; Gene Expression Profiling; Glucose; HIV Infections; Humans; Inflammation; Lipid Metabolism; Male; Middle Aged; Organophosphonates; Prospective Studies; Reverse Transcriptase Inhibitors; South Africa; Stavudine; Tenofovir | 2013 |
Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Ethambutol; Female; HIV Infections; Humans; Isoniazid; Male; Organophosphonates; Oxazines; Pyrazinamide; Reverse Transcriptase Inhibitors; Rifampin; Treatment Outcome; Tuberculosis, Pulmonary | 2013 |
Pharmacokinetic modelling of efavirenz, atazanavir, lamivudine and tenofovir in the female genital tract of HIV-infected pre-menopausal women.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Female; Genitalia, Female; HIV Infections; Humans; Lamivudine; Models, Biological; Oligopeptides; Organophosphonates; Premenopause; Pyridines; Reverse Transcriptase Inhibitors; Tenofovir | 2012 |
Adherence and acceptability in MTN 001: a randomized cross-over trial of daily oral and topical tenofovir for HIV prevention in women.
Topics: Adenine; Administration, Oral; Administration, Topical; Adolescent; Adult; Anti-HIV Agents; Cross-Over Studies; Female; HIV Infections; Humans; Medication Adherence; Middle Aged; Organophosphonates; Patient Acceptance of Health Care; Patient Preference; Sexual Partners; South Africa; Tenofovir; Uganda; United States; Vaginal Creams, Foams, and Jellies | 2013 |
A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study.
Topics: Adenine; Adult; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Male; Organophosphonates; Ritonavir; Tenofovir | 2012 |
Intensification of antiretroviral therapy through addition of enfuvirtide in naive HIV-1-infected patients with severe immunosuppression does not improve immunological response: results of a randomized multicenter trial (ANRS 130 Apollo).
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cyclopropanes; Deoxycytidine; Drug Combinations; Emtricitabine; Enfuvirtide; Female; HIV Envelope Protein gp41; HIV Infections; HIV-1; Humans; Immune Tolerance; Lopinavir; Male; Organophosphonates; Peptide Fragments; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load | 2013 |
The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Europe; Female; Fetal Blood; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Vertical; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimester, Third; Tenofovir; Viral Load; Young Adult | 2013 |
Raltegravir pharmacokinetics in treatment-naive patients is not influenced by race: results from the raltegravir early therapy in African-Americans living with HIV (REAL) study.
Topics: Adenine; Adult; Black or African American; Body Mass Index; CD4 Lymphocyte Count; Deoxycytidine; Drug Administration Schedule; Emtricitabine; Female; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; Humans; Male; Middle Aged; Organophosphonates; Pyrrolidinones; Racial Groups; Raltegravir Potassium; Tenofovir; Viral Load; White People | 2013 |
Maraviroc once-daily nucleoside analog-sparing regimen in treatment-naive patients: randomized, open-label pilot study.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cyclohexanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Oligopeptides; Organophosphonates; Pilot Projects; Pyridines; Ritonavir; RNA, Viral; Tenofovir; Triazoles; Viral Load; Young Adult | 2013 |
Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202.
Topics: Adenine; Adipose Tissue; Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; DNA, Mitochondrial; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Male; Mitochondria; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome | 2013 |
A 72-week randomized study of the safety and efficacy of a stavudine to zidovudine switch at 24 weeks compared to zidovudine or tenofovir disoproxil fumarate when given with lamivudine and nevirapine.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Diet; Drug Administration Schedule; Drug Substitution; Female; Glomerular Filtration Rate; Hemoglobins; HIV Infections; Humans; Lamivudine; Male; Nevirapine; Organophosphonates; Peripheral Nervous System Diseases; Stavudine; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2012 |
Augmentation of hepatitis B virus-specific cellular immunity with programmed death receptor-1/programmed death receptor-L1 blockade in hepatitis B virus and HIV/hepatitis B virus coinfected patients treated with adefovir.
Topics: Adenine; Adult; Antiviral Agents; B7-H1 Antigen; CD8-Positive T-Lymphocytes; Double-Blind Method; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Immunity, Cellular; Male; Middle Aged; Organophosphonates; Programmed Cell Death 1 Receptor; Prospective Studies; T-Lymphocytes, Regulatory; Viral Load; Viremia | 2013 |
Impact of switching from zidovudine/lamivudine to tenofovir/emtricitabine on lipoatrophy: the RECOMB study.
Topics: Absorptiometry, Photon; Adenine; Adipose Tissue; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Male; Middle Aged; Organophosphonates; Prospective Studies; Tenofovir; Treatment Outcome | 2013 |
Efficacy and safety of lersivirine (UK-453,061) versus efavirenz in antiretroviral treatment-naive HIV-1-infected patients: week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, phase IIb trial.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Intention to Treat Analysis; Male; Middle Aged; Mutation; Nitriles; Organophosphonates; Pyrazoles; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Young Adult | 2013 |
A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results
Topics: Adenine; Adult; Alanine Transaminase; Anti-HIV Agents; Aspartate Aminotransferases; Atazanavir Sulfate; Bilirubin; Bone Density; Carbamates; Cobicistat; Confidence Intervals; Creatinine; Deoxycytidine; Double-Blind Method; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Quinolones; Ritonavir; RNA, Viral; Tenofovir; Thiazoles; Triglycerides | 2013 |
SWIFT: prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen.
Topics: Adenine; Adult; Aged; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Biomarkers; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Kaplan-Meier Estimate; Lamivudine; Male; Middle Aged; Organophosphonates; Prospective Studies; Protease Inhibitors; Proteinuria; Risk; Tenofovir | 2013 |
MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Cross-Over Studies; Female; HIV Infections; Humans; Middle Aged; Organophosphonates; Phosphorous Acids; Phosphorylation; Rectum; Tablets; Tenofovir; Vagina; Vaginal Creams, Foams, and Jellies; Young Adult | 2013 |
A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results.
Topics: Adenine; Adult; Anti-HIV Agents; Carbamates; Creatinine; Deoxycytidine; Double-Blind Method; Drug Combinations; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Oxazines; Quinolones; RNA, Viral; Thiazoles; Treatment Outcome; Young Adult | 2013 |
Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Atazanavir Sulfate; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Oligopeptides; Organophosphonates; Postpartum Period; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimester, Second; Pregnancy Trimester, Third; Prospective Studies; Pyridines; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Young Adult | 2013 |
A pilot study of cidofovir for progressive multifocal leukoencephalopathy in AIDS.
Topics: Adult; Antiviral Agents; Brain; Cerebrospinal Fluid; Cidofovir; Cytosine; HIV Infections; Humans; JC Virus; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Male; Middle Aged; Neurologic Examination; Organophosphonates; Organophosphorus Compounds; Pilot Projects; Polymerase Chain Reaction; Treatment Outcome | 2002 |
Once-daily quadruple-drug therapy with adefovir dipivoxil, Lamivudine, Didanosine, and efavirenz in treatment-naive human immunodeficiency virus type 1-infected patients.
Topics: Adenine; Adult; Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Kidney Diseases; Lamivudine; Male; Organophosphonates; Oxazines; Pulse Therapy, Drug; Reverse Transcriptase Inhibitors; RNA, Viral; Time Factors; Treatment Outcome | 2002 |
Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Follow-Up Studies; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir; Virus Replication | 2002 |
A randomized placebo-controlled trial of adefovir dipivoxil in advanced HIV infection: the ADHOC trial.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Antiviral Agents; Body Weight; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; Fanconi Syndrome; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Male; Organophosphonates; RNA, Viral; Treatment Outcome | 2002 |
Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; HIV Infections; Humans; Interferon-alpha; Lamivudine; Liver Cirrhosis; Middle Aged; Organophosphonates; Organophosphorus Compounds; Pilot Projects; Tenofovir; Time Factors; Viral Load | 2002 |
An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals.
Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Follow-Up Studies; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Lymphocyte Count; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2003 |
Treatment with indinavir, efavirenz, and adefovir after failure of nelfinavir therapy.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Male; Middle Aged; Nelfinavir; Organophosphonates; Oxazines; Treatment Failure | 2003 |
Determining the relative efficacy of highly active antiretroviral therapy.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies; Cyclopropanes; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Organophosphonates; Organophosphorus Compounds; Oxazines; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome | 2003 |
Extended treatment with tenofovir disoproxil fumarate in treatment-experienced HIV-1-infected patients: genotypic, phenotypic, and rebound analyses.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Mutation; Organophosphonates; Organophosphorus Compounds; Phenotype; RNA, Viral; Tenofovir | 2003 |
Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individuals.
Topics: Adenine; Adult; Anti-HIV Agents; Chronic Disease; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Prodrugs; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Viral Load | 2003 |
Evolution of lipid abnormalities in patients switched from stavudine- to tenofovir-containing regimens.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Double-Blind Method; Female; HIV Infections; Humans; Lipids; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; RNA, Viral; Stavudine; Tenofovir | 2003 |
Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Male; Mutation; Organophosphonates; Organophosphorus Compounds; Placebos; RNA; Tenofovir; Viral Load | 2003 |
Change to abacavir-lamivudine-tenofovir combination treatment in patients with HIV-1 who had complete virological suppression.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Viral Load | 2003 |
Single-dose and steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected children.
Topics: Adenine; Adolescent; Anti-HIV Agents; Area Under Curve; Child; Child, Preschool; Drug Combinations; Female; Half-Life; HIV Infections; Humans; Male; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2004 |
Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Anti-HIV Agents; CD4 Lymphocyte Count; Double-Blind Method; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Multivariate Analysis; Mutation; Organophosphonates; Organophosphorus Compounds; Phenotype; Placebos; Predictive Value of Tests; Regression Analysis; RNA, Viral; Tenofovir; Thymidine | 2004 |
Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Male; Mutation; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2004 |
Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359.
Topics: Adenine; Adult; Anti-HIV Agents; Delavirdine; Double-Blind Method; Drug Therapy, Combination; Female; HIV; HIV Infections; Humans; Male; Middle Aged; Nelfinavir; Organophosphonates; Ritonavir; RNA, Viral; Saquinavir; Sex Factors | 2004 |
Renal safety of tenofovir in HIV treatment-experienced patients.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; HIV Infections; Humans; Kidney Diseases; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir | 2004 |
Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; Area Under Curve; Atazanavir Sulfate; Chromatography, High Pressure Liquid; Drug Interactions; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Organophosphonates; Organophosphorus Compounds; Pyridines; Ritonavir; Spectrophotometry, Ultraviolet; Tenofovir | 2004 |
Tenofovir treatment in an unselected cohort of highly antiretroviral experienced HIV positive patients.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Mutation; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Treatment Outcome | 2004 |
[Treatment of cutaneous human papilloma virus, poxvirus and herpes simplex virus infections with topical cidofovir in HIV positive patients].
Topics: Administration, Topical; Adult; Antiviral Agents; Cidofovir; Cytosine; Female; Herpes Simplex; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Papillomaviridae; Papillomavirus Infections; Poxviridae Infections; Skin Diseases, Viral | 2004 |
Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Double-Blind Method; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Oxazines; Prospective Studies; Stavudine; Tenofovir; Viral Load | 2004 |
Genotypic determinants of the virological response to tenofovir disoproxil fumarate in nucleoside reverse transcriptase inhibitor-experienced patients.
Topics: Adenine; Codon; Cohort Studies; France; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Multivariate Analysis; Organophosphonates; Point Mutation; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir | 2004 |
Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approach.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-CD8 Ratio; Chemical and Drug Induced Liver Injury; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lipids; Male; Nevirapine; Organophosphonates; Pancreatitis; Patient Compliance; Quality of Life; RNA, Viral; Tenofovir | 2004 |
Selection of K65R mutation in HIV-2-infected patients receiving tenofovir-containing regimen.
Topics: Adenine; Cohort Studies; Drug Therapy, Combination; France; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-2; Humans; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Tenofovir; Time Factors | 2004 |
Ninety-six-week efficacy of combination therapy with lamivudine and tenofovir in patients coinfected with HIV-1 and wild-type hepatitis B virus.
Topics: Adenine; Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; Hepatitis B; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir | 2004 |
Patterns of resistance emerging in HIV-1 from antiretroviral-experienced patients undergoing intensification therapy with tenofovir disoproxil fumarate.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Amino Acid Substitution; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; HIV Infections; HIV-1; Humans; Organophosphonates; Phenotype; Placebos; Polymorphism, Single Nucleotide; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; RNA, Viral; Tenofovir | 2004 |
Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection.
Topics: Adenine; Adult; Drug Resistance, Viral; Female; Hepatitis B, Chronic; HIV Infections; Humans; Immunosuppressive Agents; Lamivudine; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2004 |
New once-daily HIV combination better tolerated.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Lamivudine; Organophosphonates; Oxazines; Tenofovir; Zidovudine | 2004 |
Saquinavir trough concentration before and after switching NRTI to tenofovir in patients treated with once-daily saquinavir hard gel capsule/ritonavir 1600 mg/100 mg.
Topics: Adenine; Adult; Capsules; Drug Administration Schedule; Drug Therapy, Combination; Gels; HIV Infections; HIV Protease Inhibitors; Humans; Organophosphonates; Ritonavir; Saquinavir; Tenofovir | 2004 |
Tenofovir regimen compared with Combivir.
Topics: Adenine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Europe; Female; Follow-Up Studies; HIV Infections; Humans; Lamivudine; Male; Maximum Tolerated Dose; Organophosphonates; Risk Assessment; Severity of Illness Index; Single-Blind Method; Tenofovir; Treatment Outcome; United States; Viral Load; Zidovudine | 2005 |
Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study.
Topics: Adenine; Adult; Double-Blind Method; Female; HIV Infections; HIV-1; Humans; Kidney Diseases; Male; Organophosphonates; Tenofovir; Time Factors | 2005 |
Early virological failure with a combination of tenofovir, didanosine and efavirenz.
Topics: Adenine; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Didanosine; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Mutation; Organophosphonates; Oxazines; Pyrimidinones; RNA, Viral; Tenofovir; Time Factors; Treatment Failure; Viremia | 2005 |
Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Creatinine; Female; HIV Infections; Humans; Kidney Diseases; Longitudinal Studies; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2005 |
Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine.
Topics: Adenine; Adult; Anti-HIV Agents; CD4-Positive T-Lymphocytes; Didanosine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; HIV Infections; Humans; Lymphopenia; Male; Organophosphonates; Retrospective Studies; Tenofovir; Virus Replication | 2005 |
Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Cholesterol; Drug Administration Schedule; Drug Resistance, Multiple, Viral; HIV Infections; HIV-1; Humans; Lipids; Lopinavir; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Saquinavir; Tenofovir; Viral Load | 2005 |
Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients.
Topics: Adenine; Anti-HIV Agents; Cell Count; Chromatography, Liquid; Cross-Sectional Studies; Didanosine; Half-Life; HIV Infections; HIV-1; Humans; Kinetics; Longitudinal Studies; Mass Spectrometry; Organophosphonates; Phosphorylation; Reference Standards; Tenofovir | 2005 |
The steady-state pharmacokinetics of nelfinavir in combination with tenofovir in HIV-infected patients.
Topics: Adenine; Adult; Aged; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Nelfinavir; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Time Factors | 2005 |
Long-term hepatitis B virus dynamics in HIV-hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; DNA, Viral; Epidemiologic Methods; Female; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Tenofovir; Viral Load; Virus Replication | 2005 |
Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Didanosine; Drug Combinations; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Oxazines; Tenofovir; Treatment Failure | 2005 |
Comparative selection of the K65R and M184V/I mutations in human immunodeficiency virus type 1-infected patients enrolled in a trial of first-line triple-nucleoside analog therapy (Tonus IMEA 021).
Topics: Adenine; Dideoxynucleosides; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Mutation; Organophosphonates; Pilot Projects; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; RNA, Viral; Sequence Analysis, Protein; Tenofovir; Treatment Failure; Viral Load | 2005 |
Compromised immunologic recovery in treatment-experienced patients with HIV infection receiving both tenofovir disoproxil fumarate and didanosine in the TORO studies.
Topics: Adenine; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Enfuvirtide; HIV Envelope Protein gp41; HIV Infections; Humans; Organophosphonates; Peptide Fragments; Tenofovir; Time Factors; Viral Load | 2005 |
Is tenofovir involved in hypophosphatemia and decrease of tubular phosphate reabsorption in HIV-positive adults?
Topics: Adenine; Adult; Anti-HIV Agents; Cross-Sectional Studies; Female; HIV Infections; Humans; Hypophosphatemia; Kidney Tubules, Proximal; Male; Middle Aged; Organophosphonates; Phosphates; Tenofovir | 2006 |
Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir.
Topics: Adenine; Adult; Antiviral Agents; DNA-Directed DNA Polymerase; DNA, Viral; Drug Resistance, Viral; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Models, Molecular; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; Selection, Genetic; Tenofovir | 2005 |
Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Time Factors; Treatment Failure | 2005 |
Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection.
Topics: Adenine; Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Child; Child, Preschool; Drug Resistance, Viral; Female; HIV Infections; Humans; Male; Organophosphonates; Salvage Therapy; Tenofovir; Viral Load | 2005 |
Simplification therapy with once-daily didanosine, tenofovir and efavirenz in HIV-1-infected adults with viral suppression receiving a more complex antiretroviral regimen: final results of the EFADITE trial.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Dose-Response Relationship, Drug; HIV Infections; HIV-1; Humans; Male; Middle Aged; Odds Ratio; Organophosphonates; Oxazines; Prospective Studies; RNA, Viral; Tenofovir; Treatment Outcome | 2005 |
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
Topics: Adenine; Adolescent; Adult; Aged; Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Deoxycytidine; Emtricitabine; Female; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Oxazines; Prospective Studies; RNA, Viral; Tenofovir; Zidovudine | 2006 |
Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children.
Topics: Adenine; Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Child; Cyclopropanes; Dyslipidemias; Female; HIV Infections; HIV-1; Humans; Lipids; Male; Organophosphonates; Oxazines; Protease Inhibitors; Stavudine; Tenofovir; Treatment Outcome; Viral Load | 2005 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; Organophosphonates; Patient Compliance; Sexual Abstinence; Tenofovir; Vaginal Creams, Foams, and Jellies | 2006 |
96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lipids; Lopinavir; Male; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Ritonavir; RNA, Viral; Saquinavir; Tenofovir; Time Factors; Treatment Outcome | 2006 |
Increased antiretroviral potency by the addition of enfuvirtide to a four-drug regimen in antiretroviral-naive, HIV-infected patients.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Synergism; Drug Therapy, Combination; Enfuvirtide; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; Humans; Lamivudine; Lopinavir; Organophosphonates; Oxazines; Patient Compliance; Peptide Fragments; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome | 2006 |
An open-label, randomized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapy.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Oxazines; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Zidovudine | 2006 |
Absence of clinically relevant pharmacokinetic interaction between ribavirin and tenofovir in healthy subjects.
Topics: Adenine; Adult; Antiviral Agents; Drug Interactions; Female; Hepatitis C; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Ribavirin; Tenofovir | 2006 |
Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Mutation; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Salvage Therapy; Tenofovir; Treatment Failure | 2006 |
Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Developing Countries; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; RNA, Viral; Tenofovir; Treatment Outcome; Uganda; Viral Load; Zidovudine; Zimbabwe | 2006 |
Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children.
Topics: Adenine; Adolescent; Age Factors; Anti-Retroviral Agents; Bone Density; Bone Development; Child; Female; HIV Infections; Humans; Male; Organophosphonates; Salvage Therapy; Tenofovir | 2006 |
Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903.
Topics: Adenine; Alkynes; Benzoxazines; Cyclopropanes; Double-Blind Method; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir; Treatment Outcome | 2006 |
Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection.
Topics: Adenine; Anti-HIV Agents; Chi-Square Distribution; DNA, Viral; Drug Resistance, Viral; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Lamivudine; Organophosphonates; Prospective Studies; Reverse Transcriptase Inhibitors; Statistics, Nonparametric; Tenofovir; Treatment Failure | 2006 |
A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Biomarkers; Body Fat Distribution; Dideoxynucleosides; Female; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lipids; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir; Zidovudine | 2006 |
Virologic response of zidovudine, lamivudine, and tenofovir disoproxil fumarate combination in antiretroviral-naive HIV-1-infected patients.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Pilot Projects; Tenofovir; Viral Load; Zidovudine | 2006 |
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Organophosphonates; Oxazines; RNA, Viral; Tenofovir; Time Factors; Viral Load; Zidovudine | 2006 |
Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127.
Topics: Adenine; Adult; Alanine Transaminase; Anti-HIV Agents; Antiviral Agents; DNA, Viral; Double-Blind Method; Female; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Tenofovir; Treatment Outcome | 2006 |
Renal function in patients receiving tenofovir with ritonavir/lopinavir or ritonavir/atazanavir in the HIV Outpatient Study (HOPS) cohort.
Topics: Adenine; Adult; Atazanavir Sulfate; Cohort Studies; Female; HIV Infections; Humans; Kidney; Lopinavir; Male; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Ritonavir; Tenofovir | 2006 |
Efficacy and safety of tenofovir double-dose in treatment-experienced HIV-infected patients: the TENOPLUS study.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Mutation; Organophosphonates; Pilot Projects; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Viral Load | 2007 |
Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Genotype; Hepatitis B; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir; Viral Load | 2007 |
Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients.
Topics: Adenine; Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Mutation; Organophosphonates; Pilot Projects; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure; Treatment Outcome; Zidovudine | 2006 |
Metabolic and anthropometric changes one year after switching from didanosine/stavudine to tenofovir in HIV-infected patients.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Body Weight; CD4 Lymphocyte Count; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Creatinine; Didanosine; Female; Glomerular Filtration Rate; Glycated Hemoglobin; Hemoglobins; HIV Infections; Humans; Lactic Acid; Male; Middle Aged; Organophosphonates; Phosphates; Skinfold Thickness; Stavudine; Tenofovir; Treatment Outcome; Triglycerides; Uric Acid; Viral Load | 2007 |
No change in calculated creatinine clearance after tenofovir initiation among Thai patients.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Body Weight; Creatinine; Female; HIV Infections; Humans; Kidney; Kidney Function Tests; Lamivudine; Male; Organophosphonates; Tenofovir; Thailand | 2007 |
Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression.
Topics: Adenine; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Patient Compliance; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load | 2007 |
Molecular basis of antagonism between K70E and K65R tenofovir-associated mutations in HIV-1 reverse transcriptase.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Computer Simulation; Dideoxynucleosides; Drug Resistance, Multiple, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutagenesis, Site-Directed; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2007 |
Renal function in antiretroviral-experienced patients treated with tenofovir disoproxil fumarate associated with atazanavir/ritonavir.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Creatinine; Female; France; HIV Infections; HIV Protease Inhibitors; Humans; Kidney Diseases; Male; Middle Aged; Models, Biological; Oligopeptides; Organophosphonates; Prognosis; Prospective Studies; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome | 2007 |
The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Body Composition; Cholesterol; Drug Administration Schedule; Female; HIV; HIV Infections; Humans; Leukocytes, Mononuclear; Lipodystrophy; Male; Middle Aged; Mitochondria; Organophosphonates; Oxygen Consumption; Stavudine; Tenofovir; Treatment Outcome; Triglycerides | 2007 |
The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients.
Topics: Adenine; Administration, Oral; Adult; Antiretroviral Therapy, Highly Active; Case-Control Studies; Drug Interactions; Female; Genotype; HIV Infections; HIV Protease Inhibitors; Humans; Kidney; Lopinavir; Male; Membrane Transport Proteins; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Organic Anion Transport Protein 1; Organophosphonates; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome | 2008 |
Lopinavir/Ritonavir pharmacokinetic profile: impact of sex and other covariates following a change from twice-daily to once-daily therapy.
Topics: Adenine; Adult; Area Under Curve; Capsules; Chromatography, High Pressure Liquid; Drug Administration Schedule; Drug Combinations; Drug Interactions; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Organophosphonates; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Sex Factors; Tenofovir | 2007 |
Compromised immunologic recovery in patients receiving tipranavir/ritonavir coadministered with tenofovir and didanosine in Randomized Evaluation of Strategic Intervention in multidrug-resiStant patients with tipranavir (RESIST) studies.
Topics: Adenine; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Organophosphonates; Pyridines; Pyrones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Sulfonamides; Tenofovir; Treatment Outcome; Viral Load | 2007 |
Renal safety of tenofovir in HIV-infected children: a prospective, 96-week longitudinal study.
Topics: Adenine; Adolescent; Anti-HIV Agents; Child; Child, Preschool; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Diseases; Male; Organophosphonates; Prospective Studies; Tenofovir | 2007 |
Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Area Under Curve; Atazanavir Sulfate; Chromatography, Liquid; Drug Combinations; Drug Interactions; Drug Monitoring; Female; Half-Life; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Matched-Pair Analysis; Metabolic Clearance Rate; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tandem Mass Spectrometry; Tenofovir; Time Factors; Treatment Outcome | 2007 |
Low-level K65R mutation in HIV-1 reverse transcriptase of treatment-experienced patients exposed to abacavir or didanosine.
Topics: Adenine; Alleles; Didanosine; Dideoxynucleosides; Double-Blind Method; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Organophosphonates; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2007 |
Pregnancy prevention practices among women with multiple partners in an HIV prevention trial.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Condoms; Contraception; Contraception Behavior; Contraceptive Agents, Female; Female; Health Behavior; HIV Infections; Humans; Interviews as Topic; Organophosphonates; Pregnancy; Sex Work; Tenofovir | 2007 |
Determinants of high-risk sexual behavior during post-exposure prophylaxis to prevent HIV infection.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Interviews as Topic; Lamivudine; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Risk Factors; Risk-Taking; Sexual Partners; Surveys and Questionnaires; Tenofovir; Treatment Outcome | 2008 |
Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study.
Topics: Adenine; Adolescent; Adult; Aged; Australia; Canada; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Latin America; Male; Middle Aged; Organic Chemicals; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Tenofovir; Thailand; Time Factors; Treatment Outcome; United States | 2007 |
Acceptability of tenofovir gel as a vaginal microbicide by US male participants in a Phase I clinical trial (HPTN 050).
Topics: Adenine; Administration, Intravaginal; Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Patient Satisfaction; Sexually Transmitted Diseases; Tenofovir; Treatment Outcome; Vaginal Creams, Foams, and Jellies | 2007 |
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis.
Topics: Adenine; Adult; Alkynes; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Zidovudine | 2008 |
Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial.
Topics: Adenine; Adult; Antiviral Agents; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Nevirapine; Organophosphonates; Pregnancy; Reverse Transcriptase Inhibitors; Tenofovir; Zambia | 2007 |
Observational study on HIV-infected subjects failing HAART receiving tenofovir plus didanosine as NRTI backbone.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Didanosine; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Mutation; Organophosphonates; Retrospective Studies; Reverse Transcriptase Inhibitors; Sequence Analysis, DNA; Tenofovir; Treatment Outcome | 2007 |
Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; HIV; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Linear Models; Organic Chemicals; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Statistics, Nonparametric; Tenofovir; Time Factors; Viral Load; Virus Integration; Virus Latency; Virus Replication | 2007 |
Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection.
Topics: Adenine; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Deoxycytidine; Drug Administration Schedule; Emtricitabine; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Male; Organophosphonates; Tenofovir; Thailand; Transaminases; Treatment Outcome; Viral Load | 2008 |
Effects of the change from Stavudine to tenofovir in human immunodeficiency virus-infected children treated with highly active antiretroviral therapy: studies on mitochondrial toxicity and thymic function.
Topics: Adenine; Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Blood Glucose; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Child; DNA, Mitochondrial; Female; HIV Infections; Humans; Lipids; Male; Mitochondria; Organophosphonates; Stavudine; Tenofovir; Thymus Gland; Viral Load | 2008 |
Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy.
Topics: Adenine; Adult; Drug Therapy, Combination; Female; Glomerular Filtration Rate; HIV Infections; HIV Protease Inhibitors; Humans; Kidney Diseases; Kidney Tubules; Male; Middle Aged; Nucleosides; Organophosphonates; Prospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Time | 2008 |
Plasma HIV load and proviral DNA decreases after two standard antiretroviral regimens in HIV-positive patients naïve to antiretrovirals.
Topics: Adenine; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Biomarkers; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cyclopropanes; DNA, Viral; Drug Administration Schedule; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Viral Load | 2008 |
Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load | 2008 |
Acceptability of tenofovir gel as a vaginal microbicide among women in a phase I trial: a mixed-methods study.
Topics: Adenine; Administration, Intravaginal; Adult; Anti-Infective Agents, Local; Cohort Studies; Female; HIV Infections; Humans; Middle Aged; Organophosphonates; Patient Acceptance of Health Care; Patient Satisfaction; Tenofovir; Treatment Outcome; Vaginal Creams, Foams, and Jellies | 2008 |
The effects of cotrimoxazole or tenofovir co-administration on the pharmacokinetics of maraviroc in healthy volunteers.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Anti-Infective Agents; CCR5 Receptor Antagonists; Cyclohexanes; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Organophosphonates; Receptors, CCR5; Statistics as Topic; Tenofovir; Triazoles; Trimethoprim, Sulfamethoxazole Drug Combination | 2008 |
Changes in metabolic toxicity after switching from stavudine/didanosine to tenofovir/lamivudine--a Staccato trial substudy.
Topics: Absorptiometry, Photon; Adenine; Adult; Anti-HIV Agents; Body Fat Distribution; Didanosine; DNA, Mitochondrial; HIV Infections; Humans; Lamivudine; Lipids; Liver Function Tests; Organophosphonates; Ritonavir; RNA, Viral; Saquinavir; Stavudine; Tenofovir; Thailand | 2008 |
Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients.
Topics: Adenine; Adult; Female; Gene Frequency; Genotype; HIV Infections; Humans; Kidney; Male; Membrane Transport Proteins; Metabolic Clearance Rate; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Organic Anion Transport Protein 1; Organophosphonates; Polymorphism, Single Nucleotide; Reverse Transcriptase Inhibitors; Tenofovir | 2008 |
An open-label pilot study to determine the efficacy of lopinavir/ritonavir and tenofovir DF in the treatment of HIV-infected patients experiencing first virologic failure on a non-nucleoside-based regimen.
Topics: Adenine; Adult; Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lopinavir; Middle Aged; Organophosphonates; Pilot Projects; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome | 2008 |
Risk of early virological failure of once-daily tenofovir-emtricitabine plus twice-daily nevirapine in antiretroviral therapy-naive HIV-infected patients.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Nevirapine; Oligopeptides; Organophosphonates; Pyridines; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load | 2008 |
Clinical pharmacokinetics of adefovir in human immunodeficiency virus type 1-infected patients.
Topics: Adenine; Administration, Oral; Adult; Antiviral Agents; Biological Availability; Female; Half-Life; HIV Infections; HIV-1; Humans; Injections, Intravenous; Injections, Subcutaneous; Male; Middle Aged; Organophosphonates; Protein Binding | 1995 |
Susceptibility of human cytomegalovirus to cidofovir is unchanged after limited in vivo exposure to various regimens of drug.
Topics: Adult; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Drug Resistance, Microbial; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds | 1996 |
Pharmacokinetics, safety and bioavailability of HPMPC (cidofovir) in human immunodeficiency virus-infected subjects.
Topics: Adolescent; Adult; Antiviral Agents; Biological Availability; Cidofovir; Cytosine; Double-Blind Method; Drug Administration Routes; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Zidovudine | 1996 |
Safety of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) in patients with human immunodeficiency virus infection: a pilot study.
Topics: Acquired Immunodeficiency Syndrome; Adenine; AIDS-Related Complex; Alanine Transaminase; Aspartate Aminotransferases; CD4-Positive T-Lymphocytes; HIV Infections; Humans; Immunosuppressive Agents; Injections, Intravenous; Leukocyte Count; Organophosphonates | 1996 |
Anti-human immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefovir dipivoxil (9-[2-(bis-pivaloyloxymethyl)-phosphonylmethoxyethyl]adenine) in HIV-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Carnitine; Digestive System; Double-Blind Method; Female; HIV Core Protein p24; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; RNA, Viral | 1997 |
The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial.
Topics: Adenine; Administration, Oral; Adult; Anti-HIV Agents; Carnitine; CD4 Lymphocyte Count; Cytomegalovirus; Cytomegalovirus Infections; DNA, Viral; Double-Blind Method; Female; HIV Infections; HIV-1; Humans; Lymphocyte Count; Male; Middle Aged; Mutation; Organophosphonates; Polymerase Chain Reaction; RNA, Viral; Semen; Sequence Analysis, RNA; T-Lymphocyte Subsets | 1997 |
Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; Double-Blind Method; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; RNA, Viral; T-Lymphocytes; Tenofovir | 1998 |
Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro.
Topics: Adenine; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; In Vitro Techniques; Lamivudine; Organophosphonates; Point Mutation; Reverse Transcriptase Inhibitors; Virus Replication; Zidovudine | 1999 |
Clinical pharmacokinetics of 1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl]cytosine in human immunodeficiency virus-infected patients.
Topics: Administration, Oral; Adult; Anti-HIV Agents; Biological Availability; Cidofovir; Cytosine; Female; HIV Infections; Humans; Injections, Intravenous; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Prodrugs | 1999 |
A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind Method; Female; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Male; Organophosphonates; Treatment Outcome; Viral Load; Viremia | 1999 |
Single-dose pharmacokinetics and safety of the oral antiviral compound adefovir dipivoxil in children infected with human immunodeficiency virus type 1. The Pediatrics AIDS Clinical Trials Group.
Topics: Adenine; Adolescent; Antiviral Agents; Area Under Curve; Child; Child, Preschool; Female; Half-Life; HIV Infections; HIV-1; Humans; Infant; Male; Organophosphonates | 2000 |
Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Delavirdine; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Nelfinavir; Organophosphonates; Prospective Studies; Ritonavir; RNA, Viral; Saquinavir | 2000 |
Cidofovir added to HAART improves virological and clinical outcome in AIDS-associated progressive multifocal leukoencephalopathy.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cerebrospinal Fluid; Cidofovir; Cytosine; DNA, Viral; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Seropositivity; Humans; JC Virus; Leukoencephalopathy, Progressive Multifocal; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Proteinuria; RNA, Viral; Treatment Outcome | 2000 |
Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV- infected subjects: ACTG 884.
Topics: Adenine; Adult; Anti-HIV Agents; Delavirdine; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Nelfinavir; Organophosphonates; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir | 2000 |
PMPA trials recruiting.
Topics: Adenine; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; HIV Infections; Humans; Hydroxyurea; Organophosphonates; Organophosphorus Compounds; Tenofovir; Viral Load | 1998 |
Efficacy and tolerability of topical 1% cidofovir cream for the treatment of external anogenital warts in HIV-infected persons.
Topics: Administration, Cutaneous; Adult; Antiviral Agents; Anus Diseases; Cidofovir; Cytosine; Female; Female Urogenital Diseases; HIV Infections; Humans; Male; Male Urogenital Diseases; Organophosphonates; Organophosphorus Compounds; Patient Satisfaction; Pilot Projects; Single-Blind Method; Treatment Outcome; Tumor Virus Infections; Warts | 2001 |
Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy: genotypic and phenotypic analyses of study GS-96-408.
Topics: Adenine; Anti-HIV Agents; Double-Blind Method; Genes, Viral; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Mutation; Organophosphonates; Organophosphorus Compounds; Phenotype; Reverse Transcriptase Inhibitors; Tenofovir | 2001 |
The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease: a randomized, placebo-controlled trial.
Topics: Adenine; Anti-HIV Agents; CD4 Lymphocyte Count; Cytomegalovirus Infections; Double-Blind Method; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Organophosphonates; Reverse Transcriptase Inhibitors; RNA, Viral | 2001 |
Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Drug Tolerance; Female; Genotype; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; RNA, Viral; Tenofovir | 2001 |
HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Composition; Carnitine; Dideoxynucleosides; Drug Administration Schedule; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hydroxyurea; Insulin Resistance; Lipodystrophy; Male; Middle Aged; Nevirapine; Organophosphonates; Quality of Life; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome | 2001 |
Hydroxyurea does not enhance the anti-HIV activity of low-dose tenofovir disoproxil fumarate.
Topics: Adenine; Adult; Anti-HIV Agents; Cohort Studies; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Hydroxyurea; Male; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2001 |
Combined surgery and cidofovir is an effective treatment for genital warts in HIV-infected patients.
Topics: Adult; Antiviral Agents; Cidofovir; Combined Modality Therapy; Condylomata Acuminata; Cytosine; Electrocoagulation; Female; HIV Infections; Humans; Male; Organophosphonates; Organophosphorus Compounds; Prospective Studies | 2002 |
Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF.
Topics: Adenine; Double-Blind Method; Drug Resistance, Viral; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Organophosphonates; Organophosphorus Compounds; Phenotype; RNA, Viral; Tenofovir; Time Factors | 2002 |
Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Double-Blind Method; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Organophosphorus Compounds; RNA, Viral; Tenofovir; Time Factors | 2002 |
Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Disease Progression; Double-Blind Method; Drug Resistance, Viral; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Male; Nelfinavir; Organophosphonates; Oxazines; Proportional Hazards Models; Reverse Transcriptase Inhibitors; Saquinavir; Sulfonamides; Treatment Failure; Viral Load | 2002 |
1043 other study(ies) available for organophosphonates and HIV Coinfection
| Article | Year |
|---|---|
The making of the one pill-Developing single tablet regimens for HIV and for HCV.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Hepatitis C; HIV Infections; Humans; Organophosphonates; Tablets | 2022 |
The transformation of HIV therapy: One pill once a day.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Combinations; HIV Infections; Humans; Organophosphonates; Tablets | 2022 |
The Elegance of the Acyclic Nucleoside Phosphonates (ANPs), Honorary Tribute to Antonín Holý, Who Passed Away on 16 July 2012, at the 10th Anniversary of His Death.
Topics: Anniversaries and Special Events; Anti-HIV Agents; Antiviral Agents; Cidofovir; Emtricitabine; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Nucleosides; Organophosphonates; Prodrugs; Tenofovir | 2022 |
Counterfactual estimation of efficacy against placebo for novel PrEP agents using external trial data: example of injectable cabotegravir and oral PrEP in women.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Organophosphonates; Pre-Exposure Prophylaxis | 2023 |
Synthesis and Antiviral Evaluation of 3'-Fluoro-5'-norcarbocyclic Nucleoside Phosphonates Bearing Uracil and Cytosine as Potential Antiviral Agents.
Topics: Anti-HIV Agents; Cytosine; HIV Infections; HIV-1; Humans; Nucleosides; Organophosphonates; Structure-Activity Relationship; Uracil; Virus Replication | 2020 |
Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection-authors' response.
Topics: Adenine; Anti-HIV Agents; Cobicistat; Deoxycytidine; Emtricitabine; HIV Infections; Humans; Organophosphonates; Quinolones; Tenofovir | 2017 |
The Female Genital Tract Microbiome Is Associated With Vaginal Antiretroviral Drug Concentrations in Human Immunodeficiency Virus-Infected Women on Antiretroviral Therapy.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Cohort Studies; Deoxycytidine; Emtricitabine; Female; Fumarates; Genitalia, Female; HIV Infections; Humans; Microbiota; Middle Aged; Organophosphonates; Prospective Studies; Tenofovir; Young Adult | 2017 |
Development of rectal enema as microbicide (DREAM): Preclinical progressive selection of a tenofovir prodrug enema.
Topics: Adenine; Administration, Rectal; Alanine; Animals; Anti-HIV Agents; Anti-Infective Agents; Enema; HIV Infections; HIV-1; Homosexuality, Male; Male; Mice; Organophosphates; Organophosphonates; Pre-Exposure Prophylaxis; Prodrugs; Rectum; Sexual and Gender Minorities; Tenofovir | 2019 |
Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: a pilot study.
Topics: Adenine; Aged; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Black or African American; Cyclopropanes; Data Interpretation, Statistical; Deoxycytidine; Emtricitabine; Female; Frail Elderly; HIV; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Organophosphonates; Pilot Projects; Pyridines; Ritonavir; Tenofovir; White People | 2013 |
[Tenofovir hypersensitivity to tenofovir (DRESS) syndrome in a female patient infected by HIV].
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Asthenia; Benzoxazines; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Eruptions; Drug Hypersensitivity; Drug Substitution; Emtricitabine; Female; Fever; HIV Infections; Humans; Lamivudine; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Syndrome; Tenofovir | 2013 |
Urinary beta-2 microglobulin and alpha-1 microglobulin are useful screening markers for tenofovir-induced kidney tubulopathy in patients with HIV-1 infection: a diagnostic accuracy study.
Topics: Adenine; Adult; Alpha-Globulins; Anti-Retroviral Agents; beta 2-Microglobulin; Biomarkers; Chi-Square Distribution; Female; HIV Infections; HIV-1; Humans; Kidney Diseases; Male; Middle Aged; Organophosphonates; Sensitivity and Specificity; Tenofovir | 2013 |
Prophylactic effect of antiretroviral therapy on hepatitis B virus infection.
Topics: Adenine; Adult; Alanine Transaminase; Anti-Retroviral Agents; Antibiotic Prophylaxis; Drug Resistance, Viral; Female; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Core Antigens; Hepatitis B Surface Antigens; HIV Infections; Humans; Kaplan-Meier Estimate; Lamivudine; Male; Organophosphonates; Retrospective Studies; Tenofovir | 2013 |
[Pulmonary hypertension in human immunodeficiency virus-infected patients: the role of antiretroviral therapy].
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cross-Sectional Studies; Drug Therapy, Combination; Female; HIV Infections; Humans; Hypertension, Pulmonary; Lamivudine; Male; Middle Aged; Organophosphonates; Prevalence; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Tricuspid Valve Insufficiency; Ultrasonography | 2014 |
Urine processing impacts uric acid level in HIV-infected adults: implications for diagnosing tenofovir-associated proximal tubulopathy.
Topics: Adenine; Adult; AIDS-Associated Nephropathy; Anti-HIV Agents; HIV Infections; Humans; Organophosphonates; Sensitivity and Specificity; Specimen Handling; Tenofovir; Time Factors; Uric Acid | 2013 |
Cost-effectiveness of pre-exposure prophylaxis (PrEP) in preventing HIV-1 infections in rural Zambia: a modeling study.
Topics: Adenine; Anti-HIV Agents; Cost-Benefit Analysis; Deoxycytidine; Emtricitabine; HIV Infections; HIV-1; Humans; Models, Biological; Organophosphonates; Prevalence; Primary Prevention; Rural Population; Sensitivity and Specificity; Sexual Behavior; Tenofovir; Zambia | 2013 |
Rectal transmission of transmitted/founder HIV-1 is efficiently prevented by topical 1% tenofovir in BLT humanized mice.
Topics: Adenine; Administration, Rectal; Animals; Anti-HIV Agents; Antigens, CD34; Drug Evaluation, Preclinical; Female; Hepatocytes; HIV Infections; HIV-1; Humans; Kaplan-Meier Estimate; Male; Mice; Mice, Transgenic; Organophosphonates; Rectum; Sequence Analysis, DNA; Tenofovir | 2013 |
Boosting HIV treatment options: good news, new challenges.
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Cobicistat; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir; Thiazoles | 2013 |
Cardiometabolic risk factors among HIV patients on antiretroviral therapy.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Cyclopropanes; Female; HIV; HIV Infections; Humans; Insulin Resistance; Lamivudine; Male; Middle Aged; Nevirapine; Organophosphonates; Risk Factors; Stavudine; Tenofovir; Triglycerides; Zambia; Zidovudine | 2013 |
Access to treatment for HBV infection and its consistency with 2008 European guidelines in a multicentre cross-sectional study of HIV/HBV co-infected patients in Italy.
Topics: Adenine; Adult; Anti-Retroviral Agents; Coinfection; Cross-Sectional Studies; Deoxycytidine; Emtricitabine; Europe; Female; Guideline Adherence; Health Services Accessibility; Hepatitis B; HIV Infections; Humans; Infectious Disease Medicine; Italy; Lamivudine; Male; Multivariate Analysis; Organophosphonates; Practice Guidelines as Topic; Regression Analysis; Tenofovir; Treatment Outcome | 2013 |
Drug synergy of tenofovir and nanoparticle-based antiretrovirals for HIV prophylaxis.
Topics: Adenine; Alkynes; Animals; Anti-HIV Agents; Benzoxazines; Cell Line; Cervix Uteri; Chemistry, Pharmaceutical; Cyclopropanes; Delayed-Action Preparations; Drug Carriers; Drug Synergism; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Inhibitory Concentration 50; Lactic Acid; Macaca; Models, Biological; Nanoparticles; Organophosphonates; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Saquinavir; Spectroscopy, Fourier Transform Infrared; Tenofovir; Tissue Culture Techniques | 2013 |
Left ventricular hypertrophy detected by echocardiography in HIV-infected patients.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Carbamates; Comorbidity; Cross-Sectional Studies; Cyclopropanes; Diabetes Mellitus; Drug Combinations; Dyslipidemias; Echocardiography; Female; Furans; HIV Infections; Humans; Hypertension; Hypertrophy, Left Ventricular; Lamivudine; Lopinavir; Male; Middle Aged; Nevirapine; Organophosphates; Organophosphonates; Risk Factors; Ritonavir; Smoking; Spain; Sulfonamides; Tenofovir; Zidovudine | 2013 |
Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir; Thymidine; Treatment Failure; Viral Load; Zidovudine | 2013 |
Influence of HIV infection on response to tenofovir in patients with chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Female; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Spain; Tenofovir; Treatment Outcome; Viral Load | 2013 |
Could FDA approval of pre-exposure prophylaxis make a difference? A qualitative study of PrEP acceptability and FDA perceptions among men who have sex with men.
Topics: Adenine; Adult; Anti-Retroviral Agents; Chemoprevention; Deoxycytidine; Emtricitabine; Focus Groups; Health Knowledge, Attitudes, Practice; HIV Infections; Homosexuality, Male; Humans; Interviews as Topic; Male; Organophosphonates; Patient Acceptance of Health Care; Perception; Qualitative Research; Rhode Island; Sex Workers; Tenofovir; United States; United States Food and Drug Administration | 2014 |
Oral antiretroviral drugs as public health tools for HIV prevention: global implications for adherence, drug resistance, and the success of HIV treatment programs.
Topics: Adenine; Administration, Oral; Anti-HIV Agents; Counseling; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Organophosphonates; Patient Compliance; Public Health; Tenofovir | 2013 |
Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine.
Topics: Adenine; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cyclopropanes; Databases, Factual; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; HIV Infections; HIV-1; Humans; Mutation, Missense; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine; Tenofovir; Zidovudine | 2013 |
Comparison of tenofovir, zidovudine, or stavudine as part of first-line antiretroviral therapy in a resource-limited-setting: a cohort study.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Female; Health Resources; HIV; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Residence Characteristics; RNA, Viral; Stavudine; Tenofovir; Young Adult; Zidovudine | 2013 |
Tenofovir disoproxil fumarate-associated nephrotoxicity in HIV-infected patients: a prospective controlled study.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; Humans; Incidence; Kidney Diseases; Male; Organophosphonates; Prospective Studies; Tenofovir; Zidovudine | 2013 |
Short communication: Interferon/ribavirin treatment for HCV is associated with the development of hypophosphatemia in HIV/hepatitis C virus-coinfected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; Coinfection; Drug Interactions; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Hypophosphatemia; Interferons; Kidney Diseases; Male; Middle Aged; Organophosphonates; Retrospective Studies; Ribavirin; Risk Factors; Tenofovir | 2013 |
In vivo platelet activation and platelet hyperreactivity in abacavir-treated HIV-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Blood Platelets; Case-Control Studies; CD40 Ligand; Cyclic GMP; Deoxyguanine Nucleotides; Dideoxynucleosides; Female; HIV Infections; Humans; Male; Middle Aged; Nitric Oxide; Organophosphonates; P-Selectin; Phospholipases A2, Secretory; Platelet Activation; Platelet Aggregation; Retrospective Studies; Tenofovir | 2013 |
Rates of switching antiretroviral drugs in a primary care service in South Africa before and after introduction of tenofovir.
Topics: Adenine; Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Drug Substitution; Drug-Related Side Effects and Adverse Reactions; Female; HIV; HIV Infections; Humans; Male; Organophosphonates; Primary Health Care; Retrospective Studies; Risk Factors; South Africa; Tenofovir | 2013 |
Vulnerability in research ethics: a way forward.
Topics: Adenine; Alzheimer Disease; Anti-HIV Agents; Cambodia; Community-Based Participatory Research; Ethics Committees, Research; Ethics, Research; HIV Infections; Human Experimentation; Humans; Informed Consent; Moral Obligations; Organophosphonates; Primary Prevention; Randomized Controlled Trials as Topic; Research Personnel; Research Subjects; Sex Workers; Tenofovir; Vulnerable Populations | 2013 |
Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Europe; HIV Infections; HIV Protease Inhibitors; HIV Seropositivity; HIV-1; Humans; Lamivudine; Lopinavir; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Risk Factors; Tenofovir; Time Factors; United States | 2013 |
Once-daily darunavir/ritonavir and abacavir/lamivudine versus tenofovir/emtricitabine for treatment-naïve patients with a baseline viral load of more than 100 000 copies/ml.
Topics: Adenine; Anti-HIV Agents; Darunavir; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Organophosphonates; Ritonavir; Sulfonamides; Tenofovir; Viral Load | 2013 |
Ethical considerations in determining standard of prevention packages for HIV prevention trials: examining PrEP.
Topics: Adenine; Anti-HIV Agents; Clinical Trials as Topic; Community-Based Participatory Research; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Ethics, Research; Health Services Needs and Demand; HIV Infections; Humans; Organophosphonates; Practice Guidelines as Topic; Primary Prevention; Research Design; Tenofovir; Treatment Failure; United States; United States Food and Drug Administration | 2013 |
Knowledge of and opinions on HIV preexposure prophylaxis among front-line service providers at Canadian AIDS service organizations.
Topics: Adenine; Adult; Anti-HIV Agents; Canada; Chemoprevention; Deoxycytidine; Emtricitabine; Female; Health Knowledge, Attitudes, Practice; Health Personnel; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Surveys and Questionnaires; Tenofovir | 2013 |
Peripheral T-cell apoptosis is not differentially affected by antiretroviral regimens in HIV-infected patients.
Topics: Adenine; Anti-HIV Agents; Apoptosis; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cross-Sectional Studies; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Organophosphonates; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2013 |
The significance of antiretroviral-associated acute kidney injury in a cohort of ambulatory human immunodeficiency virus-infected patients.
Topics: Acute Kidney Injury; Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; Follow-Up Studies; Glomerular Filtration Rate; HIV; HIV Infections; Humans; Kidney Function Tests; Male; Organophosphonates; Prognosis; Prospective Studies; Risk Factors; Tenofovir | 2013 |
Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Middle Aged; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; South Africa; Tenofovir; Treatment Failure; Viral Load | 2013 |
Update to Interim Guidance for Preexposure Prophylaxis (PrEP) for the Prevention of HIV Infection: PrEP for injecting drug users.
Topics: Adenine; Anti-HIV Agents; Centers for Disease Control and Prevention, U.S.; Deoxycytidine; Emtricitabine; Female; Heterosexuality; HIV Infections; Homosexuality, Male; Humans; Male; Organophosphonates; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Risk Assessment; Substance Abuse, Intravenous; Tenofovir; United States | 2013 |
Study design considerations for evaluating efficacy of systemic preexposure prophylaxis interventions.
Topics: Adenine; Anti-HIV Agents; Clinical Trials, Phase III as Topic; Delayed-Action Preparations; Deoxycytidine; Drug Combinations; Emtricitabine; HIV Infections; Humans; Medication Adherence; Organophosphonates; Randomized Controlled Trials as Topic; Research Design; Sample Size; Tenofovir; Treatment Outcome; United States | 2013 |
Ethics and pre-exposure prophylaxis for HIV infection.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Organophosphonates; Public Health; Risk-Taking; Tenofovir; United States | 2013 |
Topical microbicides--what's new?
Topics: Adenine; Anti-Infective Agents, Local; Anti-Retroviral Agents; Drug Delivery Systems; Female; Gels; HIV Infections; Humans; Male; Medication Adherence; Organophosphonates; Reproductive Health; Tenofovir; Treatment Outcome | 2013 |
HIV pre-exposure prophylaxis in injecting drug users.
Topics: Adenine; Anti-HIV Agents; Female; HIV Infections; Humans; Male; Organophosphonates; Substance Abuse, Intravenous; Tenofovir | 2013 |
Role of traditional risk factors and antiretroviral drugs in the incidence of chronic kidney disease, ANRS CO3 Aquitaine cohort, France, 2004-2012.
Topics: Adenine; Age Factors; Anti-Retroviral Agents; Cohort Studies; Contraindications; Female; France; Glomerular Filtration Rate; HIV Infections; Humans; Incidence; Kaplan-Meier Estimate; Male; Organophosphonates; Poisson Distribution; Prospective Studies; Protease Inhibitors; Regression Analysis; Renal Insufficiency, Chronic; Risk Factors; Sex Factors; Tenofovir | 2013 |
Tenofovir helps prevent HIV in drug users.
Topics: Adenine; Anti-HIV Agents; Drug Users; HIV Infections; Humans; Organophosphonates; Substance-Related Disorders; Tenofovir | 2013 |
Complera for the treatment of HIV.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine, Rilpivirine, Tenofovir Drug Combination; HIV Infections; HIV-1; Humans; Nitriles; Nurse Practitioners; Organophosphonates; Practice Guidelines as Topic; Pyrimidines | 2013 |
Human papillomavirus: the fundamentals of HPV for oral health care providers.
Topics: Antiviral Agents; Cidofovir; Cytosine; HIV Infections; Humans; Mouth Neoplasms; Organophosphonates; Papillomaviridae; Papillomavirus Infections; Papillomavirus Vaccines | 2013 |
Neutrophil gelatinase-associated lipocalin, a marker of tubular dysfunction, is not increased in long-term virologically controlled patients receiving a tenofovir/emtricitabine + nevirapine regimen.
Topics: Acute-Phase Proteins; Adenine; Adult; Anti-HIV Agents; Cross-Sectional Studies; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Lipocalin-2; Lipocalins; Male; Middle Aged; Nevirapine; Organophosphonates; Proto-Oncogene Proteins; Tenofovir | 2013 |
[Pre-exposure prophylaxis for HIV transmission? No, unless].
Topics: Adenine; Anti-HIV Agents; Chemoprevention; Deoxycytidine; Emtricitabine; HIV Infections; Humans; Organophosphonates; Tenofovir | 2013 |
Tenofovir-related Fanconi's syndrome and osteomalacia in a teenager with HIV.
Topics: Adenine; Adolescent; Anti-HIV Agents; Fanconi Syndrome; HIV Infections; Humans; Male; Organophosphonates; Osteomalacia; Tenofovir | 2013 |
[Crucial risk factors for renal function deterioration of HIV-infected patients at the AIDS Clinic in Rambam Hospital].
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Coinfection; Female; Glomerular Filtration Rate; Hepatitis C; HIV Infections; Humans; Israel; Male; Medical Records, Problem-Oriented; Middle Aged; Models, Statistical; Organophosphonates; Renal Insufficiency; Retrospective Studies; Risk Factors; Tenofovir | 2013 |
Effect of antiretroviral therapy on HIV reservoirs in elite controllers.
Topics: Adenine; Anti-HIV Agents; Asymptomatic Diseases; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Deoxycytidine; DNA, Viral; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Immunity, Innate; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Tenofovir; Viremia; Virus Replication | 2013 |
Intralesional cidofovir for treating extensive genital verrucous herpes simplex virus infection.
Topics: Antiviral Agents; Cidofovir; Coinfection; Cytosine; Hepatitis C; Herpes Genitalis; HIV Infections; Humans; Injections, Intralesional; Male; Middle Aged; Organophosphonates | 2013 |
Tenofovir-related nephrotoxicity: an ongoing clinical challenge.
Topics: Adenine; Anti-HIV Agents; Female; HIV Infections; Humans; Kidney Diseases; Male; Middle Aged; Organophosphonates; Risk Factors; Tenofovir | 2013 |
Severe recurrent rhabdomyolysis-induced acute kidney injury in a HIV-infected patient on antiretroviral therapy.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; HIV Infections; Humans; Kidney Tubular Necrosis, Acute; Male; Organophosphonates; Rhabdomyolysis; Tenofovir | 2013 |
HIV-HBV coinfection in Southern Africa and the effect of lamivudine- versus tenofovir-containing cART on HBV outcomes.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Coinfection; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B; Hepatitis B virus; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Prospective Studies; Reverse Transcriptase Inhibitors; South Africa; Tenofovir; Treatment Outcome; Zambia | 2013 |
An evaluation of polycaprolactone matrices for vaginal delivery of the antiviral, tenofovir, in preventing heterosexual transmission of HIV.
Topics: Adenine; Administration, Intravaginal; Antiviral Agents; Drug Delivery Systems; HeLa Cells; Heterosexuality; HIV Infections; Humans; Organophosphonates; Polyesters; Porosity; Powders; Tenofovir | 2013 |
Evolution of glomerular filtration rate in HIV-infected, HIV-HBV-coinfected and HBV-infected patients receiving tenofovir disoproxil fumarate.
Topics: Adenine; Adult; Antiviral Agents; Coinfection; Female; Glomerular Filtration Rate; Hepatitis B, Chronic; HIV Infections; Humans; Kidney Diseases; Male; Middle Aged; Organophosphonates; Risk Factors; Tenofovir | 2013 |
Tubular and glomerular proteinuria in HIV-infected adults with estimated glomerular filtration rate ≥ 60 ml/min per 1.73 m2.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Cross-Sectional Studies; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Glomerulus; Kidney Tubules; Male; Middle Aged; Organophosphonates; Proteinuria; Regression Analysis; Renal Insufficiency, Chronic; Risk Factors; Tenofovir | 2013 |
Preexposure prophylaxis will have a limited impact on HIV-1 drug resistance in sub-Saharan Africa: a comparison of mathematical models.
Topics: Adenine; Adolescent; Adult; Africa South of the Sahara; Aged; Anti-HIV Agents; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Models, Theoretical; Organophosphonates; Pre-Exposure Prophylaxis; Tenofovir; Young Adult | 2013 |
Antiretroviral preexposure prophylaxis for preventing HIV infection in high-risk individuals.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Female; HIV Infections; Humans; Male; Organophosphonates; Premedication | 2013 |
The impact of choice of NNRTI on short-term treatment outcomes among HIV-infected patients prescribed tenofovir and lamivudine in Johannesburg, South Africa.
Topics: Adenine; Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Reverse Transcriptase Inhibitors; South Africa; Tenofovir; Treatment Outcome; Viral Load | 2013 |
[Ophthalmological alterations at the initial diagnosis of HIV infection].
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Cyclohexanes; Deoxycytidine; Drug Therapy, Combination; Early Diagnosis; Emtricitabine; Eye Infections, Viral; HIV Infections; Humans; Lopinavir; Male; Maraviroc; Organophosphonates; Retinal Diseases; Syndrome; Tenofovir; Treatment Outcome; Triazoles; Zidovudine | 2014 |
Safety and efficacy of tenofovir/emtricitabine or abacavir/lamivudine in combination with efavirenz in treatment naïve HIV patients: a 5 year retrospective observational cohort study. (the TOKEN Study).
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cardiovascular Diseases; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Kidney Diseases; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Tenofovir; Viral Load | 2013 |
[ First integrase inhibitor based single tablet regimen].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; Cobicistat; Deoxycytidine; Drug Approval; Drug Combinations; Emtricitabine; HIV Infections; HIV Integrase Inhibitors; Humans; Organophosphonates; Quinolones; Tenofovir; Thiazoles; Treatment Outcome | 2013 |
Non-occupational HIV post-exposure prophylaxis at a Sydney metropolitan sexual health clinic.
Topics: Adenine; Adult; Anti-HIV Agents; Australia; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Middle Aged; Organophosphonates; Post-Exposure Prophylaxis; Practice Guidelines as Topic; Practice Patterns, Physicians'; Risk-Taking; Stavudine; Tenofovir | 2013 |
Hypophosphataemia with non-tenofovir-containing antiretroviral therapy.
Topics: Adenine; Adult; Anti-Retroviral Agents; Cross-Sectional Studies; Female; Glomerular Filtration Rate; HIV Infections; Hospitals, Teaching; Humans; Hypophosphatemia; Male; Middle Aged; Organophosphonates; Phosphates; Prevalence; Prospective Studies; Risk Factors; Tenofovir; Treatment Outcome; United Kingdom | 2013 |
Effect of tenofovir with and without interferon on hepatitis D virus replication in HIV-hepatitis B virus-hepatitis D virus-infected patients.
Topics: Adenine; Adult; Female; Hepatitis B virus; Hepatitis Delta Virus; HIV; HIV Infections; Humans; Interferons; Limit of Detection; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Virus Replication | 2013 |
Increased risk of dialysis and end-stage renal disease among HIV patients in Denmark compared with the background population.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Cohort Studies; Comorbidity; Denmark; Female; HIV Infections; Humans; Incidence; Kidney Failure, Chronic; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Renal Dialysis; Renal Replacement Therapy; Risk Factors; Tenofovir | 2014 |
Acute kidney injury caused by tenofovir disoproxil fumarate and diclofenac co-administration.
Topics: Acute Kidney Injury; Adenine; Adult; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Drug Interactions; Fanconi Syndrome; Female; Germany; HIV Infections; Humans; Hypophosphatemia; Male; Middle Aged; Organophosphonates; Retrospective Studies; Tenofovir | 2013 |
Preexposure prophylaxis reduces HIV risk in injection-drug users.
Topics: Adenine; Adult; Anti-HIV Agents; Centers for Disease Control and Prevention, U.S.; Comorbidity; Deoxycytidine; Drug Administration Schedule; Drug Users; Emtricitabine; Female; Follow-Up Studies; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Male; Organophosphonates; Practice Guidelines as Topic; Pregnancy; Risk Reduction Behavior; Substance Abuse, Intravenous; Tenofovir; United States | 2013 |
Comparison of cardiovascular disease risk markers in HIV-infected patients receiving abacavir and tenofovir: the nucleoside inflammation, coagulation and endothelial function (NICE) study.
Topics: Adenine; Adult; Anti-HIV Agents; Biomarkers; Blood Coagulation; Cardiovascular Diseases; Dideoxynucleosides; Endothelium, Vascular; Female; HIV Infections; Humans; Inflammation; Male; Middle Aged; Organophosphonates; Risk Factors; Tenofovir; Zidovudine | 2014 |
In vivo antiviral activity of telbivudine against HIV-1: a case report.
Topics: Acute Disease; Adenine; Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Hepatitis B; Hepatitis B virus; HIV Infections; HIV-1; Humans; Immunocompromised Host; Male; Organophosphonates; Telbivudine; Thymidine; Treatment Outcome | 2013 |
HIV antiretroviral prophylaxis for injecting drug users.
Topics: Adenine; Anti-HIV Agents; Female; HIV Infections; Humans; Male; Organophosphonates; Substance Abuse, Intravenous | 2013 |
HIV antiretroviral prophylaxis for injecting drug users.
Topics: Adenine; Anti-HIV Agents; Female; HIV Infections; Humans; Male; Organophosphonates; Substance Abuse, Intravenous | 2013 |
HIV antiretroviral prophylaxis for injecting drug users.
Topics: Adenine; Anti-HIV Agents; Female; HIV Infections; Humans; Male; Organophosphonates; Substance Abuse, Intravenous | 2013 |
HIV antiretroviral prophylaxis for injecting drug users.
Topics: Adenine; Anti-HIV Agents; Female; HIV Infections; Humans; Male; Organophosphonates; Substance Abuse, Intravenous | 2013 |
HIV antiretroviral prophylaxis for injecting drug users - Authors' reply.
Topics: Adenine; Anti-HIV Agents; Female; HIV Infections; Humans; Male; Organophosphonates; Substance Abuse, Intravenous | 2013 |
No evidence for selection of HIV-1 with enhanced gag-protease or Nef function among breakthrough infections in the CAPRISA 004 tenofovir microbicide trial.
Topics: Adenine; Anti-HIV Agents; Clinical Trials as Topic; Female; gag Gene Products, Human Immunodeficiency Virus; HIV Infections; HIV-1; Humans; nef Gene Products, Human Immunodeficiency Virus; Organophosphonates; Phylogeny; Sequence Analysis, DNA; Tenofovir; Vaginal Creams, Foams, and Jellies; Virus Replication | 2013 |
Evaluation of renal adverse effects of combination anti-retroviral therapy including tenofovir in HIV-infected patients.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Drug Combinations; Female; Glomerular Filtration Rate; HIV Infections; HIV Protease Inhibitors; Humans; Kidney; Kidney Diseases; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Retrospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir | 2013 |
Changes in bone mineral density over a 2-year period in HIV-1-infected men under combined antiretroviral therapy with osteopenia.
Topics: Absorptiometry, Photon; Adenine; Adult; Anti-HIV Agents; Anti-Retroviral Agents; Bone Density; Bone Diseases, Metabolic; Hip; HIV Infections; HIV-1; Humans; Lumbar Vertebrae; Male; Middle Aged; Organophosphonates; Risk Factors; Tenofovir | 2013 |
Multicompartmental pharmacokinetic model of tenofovir delivery by a vaginal gel.
Topics: Adenine; Anti-HIV Agents; Area Under Curve; Epithelium; Female; HIV Infections; Humans; Models, Statistical; Mucous Membrane; Organophosphates; Organophosphonates; Tenofovir; Vagina; Vaginal Creams, Foams, and Jellies | 2013 |
Prophylactic tenofovir reduced HIV infection in injectable drug users.
Topics: Adenine; Anti-HIV Agents; Female; HIV Infections; Humans; Male; Organophosphonates; Substance Abuse, Intravenous | 2013 |
Acute kidney injury as a presentation of primary renal diffuse large B-cell lymphoma in HIV.
Topics: Acute Kidney Injury; Adenine; Adult; Anti-HIV Agents; Antinematodal Agents; Biopsy; HIV Infections; Humans; Kidney; Kidney Neoplasms; Lymphoma, Large B-Cell, Diffuse; Male; Organophosphonates; Tenofovir; Treatment Outcome | 2014 |
The emergence of drug resistant HIV variants at virological failure of HAART combinations containing efavirenz, tenofovir and lamivudine or emtricitabine within the UK Collaborative HIV Cohort.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies; Cyclopropanes; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir; Treatment Failure | 2014 |
An investigation of the pattern of kidney injury in HIV-positive persons exposed to tenofovir disoproxil fumarate: an examination of a large population database (MHRA database).
Topics: Acute Kidney Injury; Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Databases, Factual; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Population Surveillance; Socioeconomic Factors; Tenofovir | 2014 |
Tenofovir-induced renal tubular dysfunction in vertically HIV-infected patients associated with polymorphisms in ABCC2, ABCC4 and ABCC10 genes.
Topics: Adenine; Anti-HIV Agents; Child; Female; HIV Infections; Humans; Kidney Diseases; Kidney Tubules; Male; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Organophosphonates; Polymorphism, Single Nucleotide; Tenofovir; Young Adult | 2013 |
Low prevalence of renal dysfunction in HIV-infected pregnant women: implications for guidelines for the prevention of mother-to-child transmission of HIV.
Topics: Adenine; Adult; Age Factors; Anti-HIV Agents; CD4 Lymphocyte Count; Contraindications; Creatinine; Female; HIV; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Kidney Diseases; Male; Mothers; Organophosphonates; Pregnancy; Pregnancy Complications; Pregnancy Complications, Infectious; Pregnant Women; Prevalence; South Africa; Tenofovir; Viral Load | 2013 |
Acceptability of pre-exposure prophylaxis among men who have sex with men and transgender women in Northern Thailand.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Female; HIV Infections; Homosexuality, Male; Humans; Male; Middle Aged; Multivariate Analysis; Organophosphonates; Outcome Assessment, Health Care; Patient Acceptance of Health Care; Self Report; Sexual Behavior; Sexual Partners; Tenofovir; Thailand; Transgender Persons; Young Adult | 2013 |
A clinical prediction score for targeted creatinine testing before initiating tenofovir-based antiretroviral treatment in Cambodia.
Topics: Adenine; Adult; Anti-HIV Agents; Cambodia; Clinical Medicine; Creatinine; Cross-Sectional Studies; Decision Support Techniques; Female; HIV Infections; Humans; Kidney Diseases; Male; Metabolic Clearance Rate; Organophosphonates; Tenofovir | 2014 |
[Efficacy and tolerability of antiretroviral therapy containing tenofovir disoproxil fumarate-emtricitabine-efavirenz in treatment-naive patients infected with HIV-1 in Bobo Dioulasso (Burkina Faso, 2009-2011)].
Topics: Adenine; Adult; Anti-Retroviral Agents; Burkina Faso; Deoxycytidine; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Oxazines; Retrospective Studies; Treatment Outcome | 2013 |
Recurrent bone fractures due to tenofovir-induced renal phosphate wasting.
Topics: Adenine; Adult; Anti-HIV Agents; Fractures, Stress; HIV Infections; Humans; Kidney Diseases; Male; Organophosphonates; Phosphates; Radiography; Tenofovir; Whole Body Imaging | 2014 |
Delayed emergence of HIV-1 variants resistant to 4'-ethynyl-2-fluoro-2'-deoxyadenosine: comparative sequential passage study with lamivudine, tenofovir, emtricitabine and BMS-986001.
Topics: Adenine; Amino Acid Sequence; Anti-HIV Agents; Deoxyadenosines; Deoxycytidine; Drug Resistance, Multiple, Viral; Emtricitabine; HIV Infections; HIV-1; Human Immunodeficiency Virus Proteins; Humans; Lamivudine; Molecular Sequence Data; Molecular Structure; Organophosphonates; Tenofovir; Thymidine | 2014 |
Urine liver-type fatty acid-binding protein and kidney injury molecule-1 in HIV-infected patients receiving combined antiretroviral treatment based on tenofovir.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cross-Sectional Studies; Fatty Acid-Binding Proteins; Female; Hepatitis A Virus Cellular Receptor 1; HIV Infections; Humans; Kidney Diseases; Male; Membrane Glycoproteins; Middle Aged; Organophosphonates; Receptors, Virus; Tenofovir | 2014 |
Increases in regimen durability associated with the introduction of tenofovir at a large public-sector clinic in Johannesburg, South Africa.
Topics: Adenine; Adult; Ambulatory Care Facilities; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Female; HIV Infections; Humans; Male; Medication Adherence; Organophosphonates; South Africa; Tenofovir | 2013 |
Common clinical conditions - age, low BMI, ritonavir use, mild renal impairment - affect tenofovir pharmacokinetics in a large cohort of HIV-infected women.
Topics: Adenine; Adult; Age Factors; Anti-HIV Agents; Body Mass Index; Cohort Studies; Female; Glomerular Filtration Rate; HIV Infections; Humans; Middle Aged; Organophosphonates; Prospective Studies; Renal Insufficiency; Ritonavir; Tenofovir; Young Adult | 2014 |
Tenofovir or zidovudine in second-line antiretroviral therapy after stavudine failure in southern Africa.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Retreatment; South Africa; Stavudine; Tenofovir; Treatment Failure; Treatment Outcome; Viral Load; Zidovudine | 2014 |
Rilpivirine, emtricitabine and tenofovir resistance in HIV-1-infected rilpivirine-naive patients failing antiretroviral therapy.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; HIV Infections; HIV-1; Humans; Nitriles; Organophosphonates; Pyrimidines; Rilpivirine; Sequence Analysis, DNA; Tenofovir; Treatment Failure | 2014 |
CD4(+) cell count, viral load, and drug resistance patterns among heterosexual breakthrough HIV infections in a study of oral preexposure prophylaxis.
Topics: Adenine; Anti-HIV Agents; Botswana; CD4 Lymphocyte Count; Chemoprevention; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Heterosexuality; HIV; HIV Infections; Humans; Organophosphonates; Plasma; Post-Exposure Prophylaxis; Tenofovir; Viral Load | 2014 |
No evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; Homosexuality, Male; Humans; Male; Middle Aged; Organophosphonates; Pregnancy; Sexual Behavior; Tenofovir; Transgender Persons; Young Adult | 2013 |
GS-8374, a prototype phosphonate-containing inhibitor of HIV-1 protease, effectively inhibits protease mutants with amino acid insertions.
Topics: Amino Acid Sequence; Binding Sites; Crystallography, X-Ray; Drug Resistance, Viral; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Models, Molecular; Mutagenesis, Insertional; Organophosphonates | 2014 |
Impact of Tenofovir gel as a PrEP on HIV infection: a mathematical model.
Topics: Adenine; Female; Gels; HIV Infections; Humans; Models, Theoretical; Organophosphonates; Reverse Transcriptase Inhibitors; South Africa; Tenofovir | 2014 |
Comparative biophysical properties of tenofovir-loaded, thiolated and nonthiolated chitosan nanoparticles intended for HIV prevention.
Topics: Adenine; Animals; Anti-HIV Agents; Caveolins; Cell Line; Chitosan; Drug Delivery Systems; Fluorometry; HIV Infections; Humans; Hydrogen-Ion Concentration; Microscopy, Electron, Scanning; Microscopy, Electron, Transmission; Nanomedicine; Nanoparticles; Organophosphonates; Sulfhydryl Compounds; Swine; Tenofovir; Thioglycolates | 2014 |
Cost-effectiveness of tenofovir gel in urban South Africa: model projections of HIV impact and threshold product prices.
Topics: Adenine; Anti-HIV Agents; Circumcision, Male; Cost-Benefit Analysis; Female; Forecasting; Herpes Genitalis; Herpesvirus 2, Human; HIV Infections; HIV Seropositivity; Humans; Incidence; Male; Models, Economic; Organophosphonates; Prevalence; South Africa; Tenofovir | 2014 |
Telaprevir therapy, renal impairment, and their effects on the pharmacokinetics of tenofovir in HIV/hepatitis C virus coinfected patients.
Topics: Adenine; Adult; Antiviral Agents; Hepatitis C; HIV Infections; Humans; Kidney Diseases; Male; Oligopeptides; Organophosphonates; Tenofovir | 2014 |
Pharmacogenetics and clinical biomarkers for subtherapeutic plasma efavirenz concentration in HIV-1 infected Thai adults.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Asian People; Benzoxazines; Biomarkers; Cyclopropanes; Cytochrome P-450 Enzyme System; Female; Gene Frequency; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Polymorphism, Single Nucleotide; Prospective Studies; Tenofovir; Young Adult | 2014 |
Factors associated with delayed hepatitis B viral suppression on tenofovir among patients coinfected with HBV-HIV in the CNICS cohort.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Tenofovir; Time Factors; Treatment Outcome; Viral Load | 2014 |
Long-term follow-up of HIV-infected patients once diagnosed with acyclovir-resistant herpes simplex virus infection.
Topics: Acyclovir; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Cytosine; Drug Resistance, Viral; Female; Follow-Up Studies; Foscarnet; Herpes Simplex; HIV Infections; Humans; Immunocompromised Host; Male; Middle Aged; Organophosphonates; Retrospective Studies; Skin Diseases, Viral; Skin Ulcer; Socioeconomic Factors; Thymidine Kinase; Treatment Outcome | 2014 |
HIV nucleoside reverse transcriptase inhibitors efavirenz and tenofovir change the growth and differentiation of primary gingival epithelium.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cell Differentiation; Cell Proliferation; Cells, Cultured; Cyclopropanes; Dose-Response Relationship, Drug; Gene Expression Regulation; Gingiva; HIV Infections; Humans; Keratin-6; Keratinocytes; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2014 |
Long-term treatment with tenofovir: prevalence of kidney tubular dysfunction and its association with tenofovir plasma concentration.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Comorbidity; Cross-Sectional Studies; Drug Monitoring; Female; HIV Infections; Humans; Kidney Diseases; Kidney Function Tests; Kidney Tubules; Male; Middle Aged; Netherlands; Organophosphonates; Prevalence; Tenofovir | 2014 |
Effect of baseline renal function on tenofovir-containing antiretroviral therapy outcomes in Zambia.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Creatinine; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney; Male; Organophosphonates; Renal Insufficiency; Tenofovir; Zambia | 2014 |
Editorial commentary: Risks and benefits of tenofovir in the context of kidney dysfunction in sub-Saharan Africa.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney; Male; Organophosphonates; Renal Insufficiency | 2014 |
Incomplete reversibility of estimated glomerular filtration rate decline following tenofovir disoproxil fumarate exposure.
Topics: Adenine; Adult; Anti-HIV Agents; Cohort Studies; Drug Administration Schedule; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Diseases; Male; Middle Aged; Organophosphonates; Proportional Hazards Models; Tenofovir; Viral Load | 2014 |
Synthesis and antiviral evaluation of novel 2',2'-difluoro 5'-norcarbocyclic phosphonic acid nucleosides as antiviral agents.
Topics: Adenosine; Anti-HIV Agents; Drug Design; HIV Infections; HIV-1; Humans; Molecular Structure; Nucleosides; Organophosphonates; Phosphorous Acids | 2014 |
Impact of choice of NRTI in first-line antiretroviral therapy: a cohort analysis of stavudine vs. tenofovir.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Female; Follow-Up Studies; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Proportional Hazards Models; Prospective Studies; South Africa; Stavudine; Survival Analysis; Survival Rate; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2014 |
Early experiences implementing pre-exposure prophylaxis (PrEP) for HIV prevention in San Francisco.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Disease Management; Emtricitabine; Female; HIV Infections; Humans; Male; Organophosphonates; San Francisco; Tenofovir | 2014 |
Incidence and risk factors for incomplete HBV DNA suppression in HIV/HBV-co-infected patients initiating tenofovir-based therapy.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Coinfection; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Incidence; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Risk Factors; Tenofovir; Viral Load; Viremia | 2014 |
Focal bone lesions in HIV-positive patient treated with tenofovir.
Topics: Adenine; Anti-HIV Agents; Bone Diseases; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Tenofovir | 2014 |
Use of hepatitis B surface and "e" antigen quantification during extensive treatment with tenofovir in patients co-infected with HIV-HBV.
Topics: Adenine; Adult; Anti-HIV Agents; Coinfection; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Male; Middle Aged; Multivariate Analysis; Organophosphonates; Prospective Studies; Sensitivity and Specificity; Tenofovir; Viral Load | 2015 |
Disclosure of microbicide gel use to sexual partners: influence on adherence in the CAPRISA 004 trial.
Topics: Adenine; Adolescent; Adult; Anti-Infective Agents; Condoms; Disclosure; Female; Gels; HIV Infections; Humans; Interviews as Topic; Medication Adherence; Organophosphonates; Sexual Behavior; Sexual Partners; Socioeconomic Factors; South Africa; Surveys and Questionnaires; Tenofovir; Young Adult | 2014 |
The rate of recovery in renal function when patients with HIV infection discontinue treatment with tenofovir.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney; Male; Organophosphonates; Prospective Studies; Tenofovir; Withholding Treatment | 2014 |
HIV-1 genital shedding is suppressed in the setting of high genital antiretroviral drug concentrations throughout the menstrual cycle.
Topics: Adenine; Adult; Anti-Retroviral Agents; Deoxycytidine; DNA, Viral; Emtricitabine; Female; Genitalia, Female; HIV Infections; HIV-1; Humans; Menstrual Cycle; Middle Aged; Organophosphonates; Plasma; Ritonavir; RNA, Viral; Tenofovir; Viral Load; Virus Shedding | 2014 |
Leveraging rapid implementation of an HIV treatment policy to reduce confounding in observational analysis of antiretroviral outcomes.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; Humans; Male; Organophosphonates; Stavudine; Tenofovir | 2014 |
Assessing adherence in the CAPRISA 004 tenofovir gel HIV prevention trial: results of a nested case-control study.
Topics: Adenine; Adult; Anti-HIV Agents; Anti-Infective Agents; Case-Control Studies; Condoms; Double-Blind Method; Female; HIV Infections; Humans; Logistic Models; Organophosphonates; Patient Compliance; Rural Population; South Africa; Tenofovir; Treatment Outcome; Urban Population; Vaginal Creams, Foams, and Jellies | 2014 |
Fanconi syndrome accompanied by renal function decline with tenofovir disoproxil fumarate: a prospective, case-control study of predictors and resolution in HIV-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Case-Control Studies; Creatinine; Fanconi Syndrome; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Diseases; Kidney Function Tests; Male; Middle Aged; Organophosphonates; Prognosis; Prospective Studies; Risk Factors; Tenofovir | 2014 |
Molecular basis of the association of H208Y and thymidine analogue resistance mutations M41L, L210W and T215Y in the HIV-1 reverse transcriptase of treated patients.
Topics: Adenine; Anti-HIV Agents; Cell Line; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Mutation, Missense; Organophosphonates; Reverse Transcription; Tenofovir; Zidovudine | 2014 |
Single-tablet, once-daily treatment regimens for HIV.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cobicistat; Cyclopropanes; Cytochrome P-450 CYP3A Inhibitors; Deoxycytidine; Drug Combinations; Emtricitabine; HIV Infections; HIV Integrase Inhibitors; HIV Reverse Transcriptase; Humans; Nitriles; Organophosphonates; Pyrimidines; Quinolones; Reverse Transcriptase Inhibitors; Rilpivirine; Tenofovir; Thiazoles | 2014 |
Higher risk of renal impairment associated with tenofovir use amongst people living with HIV in India: a comparative cohort analysis between Western India and United Kingdom.
Topics: Adenine; Adult; Anti-HIV Agents; Cohort Studies; Female; HIV Infections; Humans; India; Kidney Diseases; Male; Middle Aged; Organophosphonates; Retrospective Studies; Tenofovir; United Kingdom | 2014 |
Retention in care, resource utilization, and costs for adults receiving antiretroviral therapy in Zambia: a retrospective cohort study.
Topics: Adenine; Adult; Ambulatory Care Facilities; Anti-HIV Agents; CD4 Lymphocyte Count; Delivery of Health Care; Female; Guideline Adherence; Health Care Costs; Health Resources; HIV Infections; Humans; Male; Office Visits; Organophosphonates; Patient Dropouts; Retrospective Studies; Tenofovir; Zambia | 2014 |
PMPA and PMEA prodrugs for the treatment of HIV infections and human papillomavirus (HPV) associated neoplasia and cancer.
Topics: Adenine; Antineoplastic Agents; Antiviral Agents; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; HeLa Cells; HIV; HIV Infections; Humans; Microbial Sensitivity Tests; Molecular Structure; Organophosphonates; Papillomavirus Infections; Prodrugs; Structure-Activity Relationship; Tenofovir; Tumor Cells, Cultured | 2014 |
Increased Dapivirine tissue accumulation through vaginal film codelivery of dapivirine and Tenofovir.
Topics: Adenine; Administration, Intravaginal; Anti-HIV Agents; Anti-Infective Agents; Drug Delivery Systems; Female; HIV Infections; Humans; In Vitro Techniques; Membranes, Artificial; Organophosphonates; Pyrimidines; Tenofovir; Vagina | 2014 |
Virologic and serologic outcomes of mono versus dual HBV therapy and characterization of HIV/HBV coinfection in a US cohort.
Topics: Adenine; Adult; Antibodies, Viral; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Coinfection; Deoxycytidine; DNA, Viral; Emtricitabine; Female; Follow-Up Studies; Hepatitis B; Hepatitis B e Antigens; HIV Infections; Humans; Lamivudine; Logistic Models; Male; Middle Aged; Organophosphonates; Randomized Controlled Trials as Topic; Retrospective Studies; Tenofovir; United States | 2014 |
Fibroblast growth factor 23 is elevated in tenofovir-related hypophosphatemia.
Topics: Adenine; Adult; Anti-HIV Agents; Bone Density; Fanconi Syndrome; Fibroblast Growth Factor-23; Fibroblast Growth Factors; HIV Infections; Humans; Hypophosphatemia; Male; Organophosphonates; Osteomalacia; Osteoporosis; Tenofovir | 2014 |
Uptake of prevention of mother-to-child-transmission using Option B+ in northern rural Malawi: a retrospective cohort study.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Chemoprevention; Cohort Studies; Cyclopropanes; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Malawi; Nevirapine; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Prenatal Care; Retrospective Studies; Rural Population; Tenofovir; Young Adult | 2014 |
The preventive misconception: experiences from CAPRISA 004.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Anti-Infective Agents, Local; Female; Gels; HIV Infections; Humans; Informed Consent; Medication Adherence; Motivation; Organophosphonates; Personal Satisfaction; South Africa; Tenofovir; Young Adult | 2014 |
Successful switch to rilpivirine/tenofovir/emtricitabine in HIV-1-infected patients with an isolated K103N mutation acquired during prior nonnucleoside reverse transcriptase inhibitor therapy.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, Viral; Drug Substitution; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Mutation; Nitriles; Organophosphonates; Pilot Projects; Prospective Studies; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Tenofovir; Viral Load; Young Adult | 2014 |
HIV-1 drug resistance in the iPrEx preexposure prophylaxis trial.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Female; Genotype; HIV Infections; HIV-1; Homosexuality, Male; Humans; Male; Mutation; Organophosphonates; RNA, Viral; Tenofovir; Transgender Persons; Viral Load | 2014 |
Sustained virological response after taking crushed elvitegravir-cobicistat-emtricitabine-tenofovir tablets.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Carbamates; Cobicistat; Deoxycytidine; Emtricitabine; Female; HIV; HIV Infections; Humans; Organophosphonates; Powders; Quinolones; Tablets; Tenofovir; Thiazoles; Viral Load | 2014 |
ACOG Committee Opinion no 595: Committee on Gynecologic Practice: Preexposure prophylaxis for the prevention of human immunodeficiency virus.
Topics: Adenine; Anti-Retroviral Agents; Deoxycytidine; Emtricitabine; Female; Gynecology; HIV Infections; Humans; Medication Adherence; Organophosphonates; Risk Factors; Tenofovir | 2014 |
ABCC2*1C and plasma tenofovir concentration are correlated to decreased glomerular filtration rate in patients receiving a tenofovir-containing antiretroviral regimen.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Creatinine; Cyclopropanes; Drug Therapy, Combination; Female; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Kidney; Lamivudine; Male; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Organophosphonates; Polymorphism, Single Nucleotide; Reverse Transcriptase Inhibitors; Tenofovir | 2014 |
An interesting case of 'diabetic foot ulcer' in an HIV-positive patient.
Topics: Adenine; Aged; Antiretroviral Therapy, Highly Active; Biopsy; Deoxycytidine; Diabetes Mellitus, Type 2; Diabetic Foot; Emtricitabine; Herpesvirus 8, Human; HIV Infections; HIV Seropositivity; Humans; Male; Organophosphonates; Sarcoma, Kaposi; Skin Neoplasms; Tenofovir; Treatment Outcome; Ulcer | 2015 |
Perceptions of emtricitabine-tenofovir in HIV PrEP.
Topics: Adenine; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Organophosphonates; Sex Education; Sexual Partners; Tenofovir; United States | 2014 |
Biomarkers of CD4+ T-cell activation as risk factors for tuberculosis-associated immune reconstitution inflammatory syndrome.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Biomarkers; CD4-Positive T-Lymphocytes; Cyclopropanes; Deoxycytidine; Emtricitabine; Enzyme-Linked Immunosorbent Assay; Female; HIV Infections; Humans; Immune Reconstitution Inflammatory Syndrome; Lymphocyte Activation; Male; Middle Aged; Mycobacterium tuberculosis; Organophosphonates; Risk Factors; Tenofovir; Tuberculosis | 2014 |
In vivo effect of two first-line ART regimens on inflammatory mediators in male HIV patients.
Topics: Adenine; Adult; Alkynes; Animals; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Interleukin-10; Interleukin-6; Interleukin-8; Lamivudine; Male; Middle Aged; Organophosphonates; Platelet Activating Factor; Tenofovir; Tumor Necrosis Factor-alpha | 2014 |
Synergistic activity of tenofovir and nevirapine combinations released from polycaprolactone matrices for potential enhanced prevention of HIV infection through the vaginal route.
Topics: Adenine; Anti-HIV Agents; Drug Administration Routes; Drug Synergism; Drug Therapy, Combination; Female; HIV Infections; Humans; Microscopy, Electron, Scanning; Nevirapine; Organophosphonates; Polyesters; Tenofovir; Vagina | 2014 |
A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe.
Topics: Adenine; Adult; Anti-HIV Agents; Cohort Studies; Data Collection; Deoxycytidine; Drug Combinations; Drug Utilization; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Europe; Female; HIV Infections; Humans; Male; Organophosphonates; Oxazines; Prospective Studies | 2014 |
Switching from tenofovir/emtricitabine and nevirapine to a tenofovir/emtricitabine/rilpivirine single-tablet regimen in virologically suppressed, HIV-1-infected subjects.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Deoxycytidine; Drug Combinations; Drug Substitution; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nevirapine; Nitriles; Organophosphonates; Prospective Studies; Pyrimidines; Rilpivirine; Tenofovir; Treatment Outcome; Viral Load | 2014 |
Switching STRATEGIES in HIV treatment.
Topics: Adenine; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Emtricitabine; Female; HIV; HIV Infections; Humans; Male; Organophosphonates; Protease Inhibitors; Quinolones; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Thiazoles | 2014 |
A chronic kidney disease risk score to determine tenofovir safety in a prospective cohort of HIV-positive male veterans.
Topics: Adenine; Adult; Anti-HIV Agents; Cohort Studies; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Prospective Studies; Renal Insufficiency, Chronic; Risk Assessment; Tenofovir; Veterans | 2014 |
Tenofovir in HIV-infected children. Antiretroviral efficacy, but beware of adverse effects on bone and the kidneys.
Topics: Adenine; Anti-HIV Agents; Bone Diseases; Child; Dose-Response Relationship, Drug; HIV Infections; Humans; Kidney Diseases; Medication Errors; Organophosphonates; Tenofovir | 2014 |
An HBV-HIV co-infected patient treated with tenofovir-based therapy who achieved HBs antigen/antibody seroconversion.
Topics: Adenine; Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Coinfection; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Surface Antigens; HIV Infections; Humans; Male; Organophosphonates; Tenofovir | 2014 |
Pharmacokinetics and preliminary safety study of pod-intravaginal rings delivering antiretroviral combinations for HIV prophylaxis in a macaque model.
Topics: Adenine; Administration, Intravaginal; Animals; Anti-HIV Agents; Delayed-Action Preparations; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Macaca; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Vagina; Vaginal Creams, Foams, and Jellies | 2014 |
Pharmacokinetics of atazanavir/ritonavir among HIV-infected Thai children concomitantly taking tenofovir disoproxil fumarate.
Topics: Adenine; Adolescent; Anti-HIV Agents; Asian People; Atazanavir Sulfate; Child; Female; HIV Infections; Humans; Lamivudine; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir | 2014 |
Pre-exposure prophylaxis accessibility research and evaluation (PrEPARE Study).
Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; California; Deoxycytidine; Emtricitabine; Health Expenditures; Health Knowledge, Attitudes, Practice; Health Services Accessibility; Health Surveys; HIV Infections; Homosexuality, Male; Humans; Male; Middle Aged; Organophosphonates; Patient Acceptance of Health Care; Pre-Exposure Prophylaxis; Tenofovir; Unsafe Sex | 2014 |
Development of HIV-1 rectal-specific microbicides and colonic tissue evaluation.
Topics: Adenine; Adult; Anilides; Anti-Infective Agents, Local; Colon; Drug Evaluation, Preclinical; Drug Stability; Furans; HIV Infections; HIV-1; Humans; Hydrogels; Middle Aged; Organophosphonates; Semen; Tenofovir; Thioamides; Virus Replication; Young Adult | 2014 |
Effect of antiretroviral HIV therapy on hepatitis B virus replication and pathogenicity.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Coinfection; Deoxycytidine; Emtricitabine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV Reverse Transcriptase; HIV Seropositivity; HIV-1; Humans; Inflammation; Organophosphonates; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; tat Gene Products, Human Immunodeficiency Virus; Tenofovir; Virus Replication; vpr Gene Products, Human Immunodeficiency Virus | 2014 |
Safety and efficacy of coformulated efavirenz/emtricitabine/tenofovir single-tablet regimen in treatment-naive patients infected with HIV-1.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; Europe; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Plasma; Tablets; Tenofovir; Treatment Outcome; Viral Load | 2015 |
Formulation and characterization of polymeric films containing combinations of antiretrovirals (ARVs) for HIV prevention.
Topics: Adenine; Administration, Intravaginal; Administration, Topical; Anti-HIV Agents; Chemistry, Pharmaceutical; Drug Carriers; Drug Combinations; Drug Delivery Systems; Female; HIV Infections; HIV-1; Humans; Organophosphonates; Polymers; Pyrimidines; Tenofovir; Vagina | 2015 |
Proximal renal tubular dysfunction related to antiretroviral therapy among HIV-infected patients in an HIV clinic in Mexico.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Therapy, Combination; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Tubules, Proximal; Longitudinal Studies; Male; Mexico; Middle Aged; Organophosphonates; Prospective Studies; Protease Inhibitors; Proteinuria; Tenofovir | 2015 |
HIV pre-exposure prophylaxis: mucosal tissue drug distribution of RT inhibitor Tenofovir and entry inhibitor Maraviroc in a humanized mouse model.
Topics: Adenine; Animals; Anti-HIV Agents; Cyclohexanes; Disease Models, Animal; Female; HIV Infections; HIV-1; Humans; Maraviroc; Mice; Mucous Membrane; Organophosphonates; Pre-Exposure Prophylaxis; Reverse Transcriptase Inhibitors; Tenofovir; Triazoles; Virus Internalization | 2014 |
Efficacy of prolonged tenofovir therapy on hepatitis delta in HIV-infected patients.
Topics: Adenine; Adult; Antiviral Agents; Hepatitis D, Chronic; HIV Infections; Humans; Liver Cirrhosis; Male; Middle Aged; Organophosphonates; Retrospective Studies; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load | 2014 |
Initiation of rilpivirine, tenofovir and emtricitabine (RPV/TDF/FTC) regimen in 363 patients with virological vigilance assessment in 'real life'.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Genotype; HIV; HIV Infections; Humans; Microbial Sensitivity Tests; Nitriles; Organophosphonates; Pyrimidines; Rilpivirine; Tenofovir | 2014 |
Switching to emtricitabine, tenofovir and rilpivirine as single tablet regimen in virologically suppressed HIV-1-infected patients: a cohort study.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Cohort Studies; Deoxycytidine; Drug Combinations; Drug Substitution; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nitriles; Organophosphonates; Pyrimidines; Retrospective Studies; Rilpivirine; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load | 2015 |
A clinical prediction tool for targeted pre-antiretroviral therapy creatinine testing applied to the TREAT Asia HIV observational database cohort.
Topics: Adenine; Anti-HIV Agents; Clinical Medicine; Creatinine; Decision Support Techniques; Female; HIV Infections; Humans; Kidney Diseases; Male; Organophosphonates | 2014 |
Assessing adherence to the 2010 antiretroviral guidelines at the antiretroviral rollout clinic in 1 military hospital, South Africa: a retrospective, cross sectional study.
Topics: Adenine; Adult; Anti-Retroviral Agents; Cross-Sectional Studies; Drug Monitoring; Drug Substitution; Female; Guideline Adherence; HIV Infections; Hospitals, Military; Humans; Male; Organophosphonates; Outcome Assessment, Health Care; Practice Guidelines as Topic; Practice Patterns, Physicians'; Retrospective Studies; South Africa; Stavudine; Tenofovir | 2014 |
Enantiomerically pure phosphonated carbocyclic 2'-oxa-3'-azanucleosides: synthesis and biological evaluation.
Topics: HIV; HIV Infections; Humans; Molecular Structure; Nucleosides; Organophosphonates; Stereoisomerism; Structure-Activity Relationship; U937 Cells | 2014 |
High prevalence of signs of renal damage despite normal renal function in a cohort of HIV-infected patients: evaluation of associated factors.
Topics: Adenine; Adult; Age Factors; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Cross-Sectional Studies; Diabetes Mellitus; Female; HIV Infections; HIV Protease Inhibitors; Humans; Hypertension; Kidney; Kidney Diseases; Male; Middle Aged; Multivariate Analysis; Organophosphonates; Prevalence; Prospective Studies; Risk Factors; Socioeconomic Factors; Spain; Surveys and Questionnaires; Tenofovir; Viral Load | 2014 |
Long-term exposure to tenofovir continuously decrease renal function in HIV-1-infected patients with low body weight: results from 10 years of follow-up.
Topics: Adenine; Adult; Anti-HIV Agents; Body Weight; Cohort Studies; Female; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Longitudinal Studies; Male; Organophosphonates; Renal Insufficiency; Tenofovir; Tokyo | 2014 |
Infection with the frequently transmitted HIV-1 M41L variant has no influence on selection of tenofovir resistance.
Topics: Adenine; Adult; Amino Acid Substitution; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Evolution, Molecular; Female; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Mutation; Organophosphonates; Phenotype; Phylogeny; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2015 |
Lopinavir/r no longer recommended as a first-line regimen: a comparative effectiveness analysis.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies; Deoxycytidine; Emtricitabine; Female; France; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Organophosphonates; Prospective Studies; Tenofovir; Treatment Failure; Viral Load | 2014 |
When is good good enough for HIV-1 prophylaxis?
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Male; Organophosphonates; Pre-Exposure Prophylaxis; Tenofovir | 2014 |
Evaluation of the efficacy and safety of switching to tenofovir, emtricitabine, and rilpivirine in treatment-experienced patients.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Nitriles; Organophosphonates; Pyrimidines; Rilpivirine; Tenofovir; Young Adult | 2015 |
[To evaluate the changes in body composition in male human immunodeficiency virus-related lipodystrophy after different treatment regimens by dual-energy X-ray absorptiometry].
Topics: Absorptiometry, Photon; Adenine; Anti-HIV Agents; Antiviral Agents; Body Composition; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Male; Organophosphonates; Stavudine; Tenofovir; Zidovudine | 2014 |
Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Clinical Trials, Phase III as Topic; Coinfection; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Organophosphonates; Oxazines; Piperazines; Pyridones; Pyrrolidinones; Raltegravir Potassium; Randomized Controlled Trials as Topic; Regression Analysis; Retrospective Studies; Ritonavir; Tenofovir; Treatment Outcome; Viral Load | 2015 |
Perception of HIV risk and adherence to a daily, investigational pill for HIV prevention in FEM-PrEP.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Blood Chemical Analysis; Chemoprevention; Deoxycytidine; Disease Transmission, Infectious; Emtricitabine; Female; Health Knowledge, Attitudes, Practice; HIV Infections; Humans; Medication Adherence; Organophosphonates; Risk-Taking; Tenofovir; Young Adult | 2014 |
HIV testing in pregnancy.
Topics: Adenine; Anti-HIV Agents; Benzoxazines; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Nevirapine; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Rural Population | 2014 |
Anti-HIV drug-combination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates.
Topics: Adenine; Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Carriers; Drug Combinations; HIV Infections; HIV Protease Inhibitors; HIV-1; Indinavir; Lipids; Lopinavir; Lymph Nodes; Macaca; Nanoparticles; Organophosphonates; Ritonavir; Tenofovir; Viral Load; Virus Latency | 2015 |
Renal impairment in HIV-infected patients initiating tenofovir-containing antiretroviral therapy regimens in a Primary Healthcare Setting in South Africa.
Topics: Adenine; Adult; Age Factors; Anemia; Anti-HIV Agents; CD4 Lymphocyte Count; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney; Logistic Models; Male; Middle Aged; Organophosphonates; Prevalence; Primary Health Care; Renal Insufficiency; Reverse Transcriptase Inhibitors; South Africa; Tenofovir | 2015 |
Elvitegravir/cobicistat/emtricitabine/tenofovir DF in HIV-infected patients with mild-to-moderate renal impairment.
Topics: Adenine; Adult; Anti-HIV Agents; Carbamates; Cobicistat; Cohort Studies; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Quinolones; Renal Insufficiency; Tenofovir; Thiazoles; Treatment Outcome | 2015 |
A pharmacogenetic candidate gene study of tenofovir-associated Fanconi syndrome.
Topics: Adenine; Alleles; Anti-HIV Agents; Biomarkers, Pharmacological; Case-Control Studies; Fanconi Syndrome; Genetic Association Studies; HEK293 Cells; HIV Infections; HIV-1; Humans; Multidrug Resistance-Associated Protein 2; Organophosphonates; Pharmacogenetics; Polymorphism, Single Nucleotide; Sequence Analysis, DNA; Tenofovir | 2015 |
Development of a composite measure of product adherence, protocol compliance, and semen exposure using DNA and protein biomarkers for topical HIV prevention studies.
Topics: Adenine; Administration, Topical; Adult; Anti-HIV Agents; Biomarkers; Cellulose; DNA; Environmental Exposure; Feasibility Studies; Female; Guideline Adherence; HIV Infections; Humans; Keratin-4; Male; Middle Aged; Organophosphonates; Outcome Assessment, Health Care; Patient Compliance; Semen; Tenofovir; Vagina; Young Adult | 2014 |
High interest in preexposure prophylaxis among men who have sex with men at risk for HIV infection: baseline data from the US PrEP demonstration project.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Chemoprevention; Cohort Studies; Deoxycytidine; Disease Transmission, Infectious; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Longitudinal Studies; Male; Organophosphonates; Patient Acceptance of Health Care; Pre-Exposure Prophylaxis; Prospective Studies; Tenofovir; United States; Young Adult | 2015 |
Models for predicting effective HIV chemoprevention in women.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Cell Culture Techniques; Cell Survival; Chemoprevention; Chromatography, Liquid; Cyclohexanes; Disease Transmission, Infectious; Dose-Response Relationship, Drug; Female; HIV Infections; Humans; Maraviroc; Middle Aged; Organ Culture Techniques; Organophosphonates; Tandem Mass Spectrometry; Tenofovir; Triazoles; Vagina; Viral Load; Young Adult | 2015 |
Quiz Page January 2015: acute kidney injury in a patient with well-controlled HIV infection.
Topics: Acute Kidney Injury; Adenine; Aged, 80 and over; Anti-HIV Agents; Biopsy; CD4 Lymphocyte Count; Diagnosis, Differential; Diarrhea; HIV Infections; Humans; Hypertension; Immunologic Tests; Kidney; Kidney Function Tests; Male; Monitoring, Physiologic; Organophosphonates; Ritonavir; Tenofovir; Treatment Outcome; Viral Load; Withholding Treatment | 2015 |
Preexposure prophylaxis: a path forward.
Topics: Adenine; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Kidney Glomerulus; Male; Organophosphonates; Tenofovir | 2015 |
No relationship between drug transporter genetic variants and tenofovir plasma concentrations or changes in glomerular filtration rate in HIV-infected adults.
Topics: Adenine; Adult; Anti-HIV Agents; Cohort Studies; Female; Genotype; Glomerular Filtration Rate; HIV Infections; Humans; Male; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Organophosphonates; Plasma; Retrospective Studies; Tenofovir | 2015 |
Pregnancy and contraceptive use among women participating in the FEM-PrEP trial.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraceptive Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Incidence; Medication Adherence; Organophosphonates; Plasma; Pregnancy; Pregnancy Rate; Pregnancy, Unplanned; Tenofovir; Young Adult | 2015 |
Commentary: The place of tenofovir disoproxil fumarate in pediatric antiretroviral therapy.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Utilization; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Stavudine; Zidovudine | 2015 |
Clinical trials. Renal safety of TDF as pre-exposure prophylaxis for HIV-1 infection.
Topics: Adenine; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Kidney Glomerulus; Male; Organophosphonates | 2015 |
Diminished impact of ethnicity as a risk factor for chronic kidney disease in the current HIV treatment era.
Topics: Adenine; Adult; Africa South of the Sahara; Anti-HIV Agents; Cross-Sectional Studies; Female; HIV Infections; Humans; Male; Middle Aged; Netherlands; Organophosphonates; Prevalence; Renal Insufficiency, Chronic; Risk Factors; Tenofovir | 2015 |
Preventing HIV in women--still trying to find their VOICE.
Topics: Adenine; Anti-Retroviral Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Organophosphonates; Pre-Exposure Prophylaxis; Tenofovir | 2015 |
High prevalence of the K65R mutation in HIV-1 subtype C infected patients failing tenofovir-based first-line regimens in South Africa.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Middle Aged; Molecular Sequence Data; Mutation; Organophosphonates; Prevalence; South Africa; Tenofovir; Viral Load; Young Adult | 2015 |
Pre-exposure prophylaxis in women fails to prevent HIV infection in African study.
Topics: Adenine; Anti-Retroviral Agents; Deoxycytidine; Female; HIV Infections; HIV-1; Humans; Organophosphonates; Pre-Exposure Prophylaxis | 2015 |
Renal tubular dysfunction associated with tenofovir therapy.
Topics: Adenine; Adult; Anti-HIV Agents; Creatinine; Developing Countries; Diagnosis, Differential; Female; HIV Infections; Humans; Incidence; India; Kidney Diseases; Kidney Tubules; Long-Term Care; Male; Middle Aged; Organophosphonates; Tenofovir | 2014 |
How does weight influence tenofovir disoproxil-fumarate induced renal function decline?
Topics: Adenine; Anti-HIV Agents; Body Weight; Female; Glomerular Filtration Rate; HIV Infections; Humans; Male; Organophosphonates; Renal Insufficiency | 2015 |
Reply to 'how does weight influence tenofovir disoproxil-fumarate induced renal function decline?'.
Topics: Adenine; Anti-HIV Agents; Body Weight; Female; Glomerular Filtration Rate; HIV Infections; Humans; Male; Organophosphonates; Renal Insufficiency | 2015 |
Antibody Maturation in Women Who Acquire HIV Infection While Using Antiretroviral Preexposure Prophylaxis.
Topics: Adenine; Adult; Anti-Retroviral Agents; Antibody Affinity; Cohort Studies; Female; HIV; HIV Antibodies; HIV Infections; Humans; Immunoassay; Organophosphonates; Pre-Exposure Prophylaxis; Randomized Controlled Trials as Topic; Tenofovir; Time Factors; Young Adult | 2015 |
Efficacy, safety and pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed HIV-infected children using weight-band dosing.
Topics: Adenine; Adolescent; Alkynes; Anti-HIV Agents; Benzoxazines; Bone Density; Calcium; CD4 Lymphocyte Count; Child; Child, Preschool; Cyclopropanes; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Organophosphonates; Prospective Studies; RNA, Viral; Tenofovir; Treatment Outcome; Urinalysis; Viral Load | 2015 |
The science of being a study participant: FEM-PrEP participants' explanations for overreporting adherence to the study pills and for the whereabouts of unused pills.
Topics: Adenine; Adult; Clinical Trials as Topic; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Interviews as Topic; Kenya; Medication Adherence; Organophosphonates; South Africa; Tenofovir; Treatment Outcome | 2015 |
Antiretroviral chemoprophylaxis: new successes and questions.
Topics: Adenine; Anti-HIV Agents; Anti-Retroviral Agents; Chemoprevention; Deoxycytidine; Drug Combinations; Emtricitabine; Gels; HIV Infections; Humans; Organophosphonates; Tenofovir | 2015 |
Is zidovudine first-line therapy virologically comparable to tenofovir in resource-limited settings?
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Female; Health Resources; HIV; HIV Infections; Humans; Lamivudine; Lesotho; Logistic Models; Male; Middle Aged; Organophosphonates; Tenofovir; Viral Load; Zidovudine | 2015 |
Painless penile papule.
Topics: Adenine; Adult; Anti-Bacterial Agents; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biopsy; CD4 Lymphocyte Count; Coinfection; Deoxycytidine; Emtricitabine; HIV Infections; Humans; Male; Nevirapine; Organophosphonates; Penicillin G Benzathine; Penis; Syphilis, Cutaneous; Tenofovir; Treatment Outcome | 2015 |
Triple combination of carbosilane dendrimers, tenofovir and maraviroc as potential microbicide to prevent HIV-1 sexual transmission.
Topics: Adenine; Animals; Anti-HIV Agents; Anti-Infective Agents; Antiviral Agents; Cell Survival; Cyclohexanes; Dendrimers; Drug Combinations; Female; HIV Infections; HIV-1; Humans; Maraviroc; Mice; Mice, Inbred BALB C; Mucous Membrane; Organophosphonates; Silanes; Software; Tenofovir; Triazoles; Vagina | 2015 |
Tenofovir alafenamide for HIV infection: is less more?
Topics: Adenine; Alanine; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Male; Organophosphonates; Quinolones; Tenofovir; Thiazoles | 2015 |
Preexposure prophylaxis for HIV infection.
Topics: Adenine; Anti-Retroviral Agents; Deoxycytidine; Female; HIV Infections; HIV-1; Humans; Organophosphonates; Pre-Exposure Prophylaxis | 2015 |
Pre-exposure prophylaxis works--it's time to deliver.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Health Services Accessibility; HIV Infections; Humans; Organophosphonates; Pre-Exposure Prophylaxis; Tenofovir | 2015 |
Infectious disease: New HIV-1 prodrug shows promise in phase III trials.
Topics: Adenine; Anti-HIV Agents; Carbamates; Deoxycytidine; Female; HIV Infections; Humans; Male; Organophosphonates; Quinolones; Thiazoles | 2015 |
HIV-serodiscordant couples desiring a child: 'treatment as prevention,' preexposure prophylaxis, or medically assisted procreation?
Topics: Adenine; Anti-HIV Agents; Cost-Benefit Analysis; Deoxycytidine; Emtricitabine; Female; Fertile Period; France; Health Care Costs; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Insemination, Artificial; Male; Models, Economic; Organophosphonates; Pre-Exposure Prophylaxis; Pregnancy; Reproductive Techniques, Assisted; Semen; Tenofovir | 2015 |
Many in VOICE trial didn't use provided prevention products.
Topics: Adenine; Africa South of the Sahara; Anti-Retroviral Agents; Female; Gels; HIV Infections; Humans; Medication Adherence; Organophosphonates; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir | 2015 |
Early Initiation of Antiretroviral Therapy Can Functionally Control Productive HIV-1 Infection in Humanized-BLT Mice.
Topics: Adenine; Animals; Anti-HIV Agents; Antigens, CD34; Bone Marrow; CD8-Positive T-Lymphocytes; Disease Models, Animal; Disease Progression; DNA, Viral; Gene Dosage; HIV Infections; HIV-1; Humans; Liver; Mice; Mice, Inbred NOD; Mice, Transgenic; Organophosphonates; Pilot Projects; RNA, Viral; Spleen; Tenofovir; Thymus Gland; Viral Load; Virus Replication | 2015 |
VOICE reveals the need to improve adherence in PrEP trials.
Topics: Adenine; Anti-Retroviral Agents; Deoxycytidine; Female; HIV Infections; HIV-1; Humans; Organophosphonates; Pre-Exposure Prophylaxis | 2015 |
Preventing long-term tenofovir renal toxicity by pharmacokinetic assessment.
Topics: Adenine; Anti-HIV Agents; HIV Infections; Humans; Organophosphonates; Tenofovir | 2016 |
Uptake of PrEP and condom and sexual risk behavior among MSM during the ANRS IPERGAY trial.
Topics: Adolescent; Anti-HIV Agents; Canada; Condoms; Deoxycytidine; Double-Blind Method; Emtricitabine; Follow-Up Studies; France; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Middle Aged; Organophosphonates; Outcome Assessment, Health Care; Pre-Exposure Prophylaxis; Risk-Taking; Safe Sex; Sexual Behavior; Sexual Partners; Surveys and Questionnaires; Tenofovir | 2016 |
Tenofovir tablet not effective in preventing HIV in women.
Topics: Adenine; Anti-HIV Agents; Female; HIV Infections; Humans; Organophosphonates; Tablets; Tenofovir | 2011 |
Tenofovir alafenamide: safer, but questions remain.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; HIV Infections; HIV-1; Humans; Organophosphonates; Tenofovir | 2016 |
[CLINICAL AND PHARMACOECONOMIC RESULTS OF THE USAGE OF VARIOUS HIV REVERSE TRANSCRIPTASE INHIBITORS IN THE SCHEMES OF ANTIRETROVIRAL THERAPY OF PATIENT RECEIVING THERAPY FOR THE CHRONIC HEPATITIS C VIRUS].
Topics: Adult; Alanine Transaminase; Biomarkers; Blood Platelets; CD4-Positive T-Lymphocytes; Cell Count; Coinfection; Dideoxynucleosides; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 2016 |
First case report of renal improvement on tenofovir alafenamide in an HIV/hepatitis B virus-coinfected patient with adefovir-induced Fanconi's syndrome.
Topics: Absorptiometry, Photon; Adenine; Alanine; Coinfection; Dose-Response Relationship, Drug; Fanconi Syndrome; Hepatitis B, Chronic; HIV Infections; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Organophosphonates; Tenofovir; Treatment Outcome | 2016 |
Real-World Experiences with Tenofovir Disoproxil Fumarate: Is this the "B-Ticket"?
Topics: Adenine; HIV Infections; Humans; Organophosphonates; Tenofovir | 2016 |
Immune reconstitution inflammatory syndrome associated with dermatophytoses in two HIV-1 positive patients in rural Tanzania: a case report.
Topics: Adenine; Adult; Africa; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cyclopropanes; Deoxycytidine; Female; HIV Infections; HIV-1; Humans; Immune Reconstitution Inflammatory Syndrome; Male; Organophosphonates; Tanzania; Tinea | 2016 |
Reactions and Receptivity to Framing HIV Prevention Message Concepts About Pre-Exposure Prophylaxis for Black and Latino Men Who Have Sex with Men in Three Urban US Cities.
Topics: Adenine; Adult; Anti-HIV Agents; Black or African American; Black People; Chicago; Cities; Condoms; Deoxycytidine; Emtricitabine; Female; Focus Groups; Health Knowledge, Attitudes, Practice; Hispanic or Latino; HIV Infections; Homosexuality, Male; Humans; Male; Organophosphonates; Patient Acceptance of Health Care; Pre-Exposure Prophylaxis; Qualitative Research; Safe Sex; Tenofovir; United States; Urban Population | 2016 |
Comment on: Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection.
Topics: Adenine; Anti-HIV Agents; Cobicistat; Deoxycytidine; Emtricitabine; HIV Infections; Humans; Organophosphonates; Quinolones; Tenofovir | 2017 |
Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Bilirubin; Chromatography, High Pressure Liquid; Drug Monitoring; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Retrospective Studies; Ritonavir; Tenofovir | 2008 |
Genetic basis of variation in tenofovir drug susceptibility in HIV-1.
Topics: Adenine; Amino Acid Sequence; Anti-HIV Agents; Drug Resistance, Viral; Genetic Variation; Genotype; HIV Infections; HIV-1; Humans; Lethal Dose 50; Models, Biological; Organophosphonates; Phenotype; Predictive Value of Tests; Tenofovir | 2008 |
Human immunodeficiency virus-induced uveitis: intraocular and plasma human immunodeficiency virus-1 RNA loads.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Aqueous Humor; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Eye Infections, Viral; HIV Antibodies; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Polymerase Chain Reaction; RNA, Viral; Tenofovir; Uveitis, Anterior; Viral Load | 2008 |
FDA notifications. FDA's tentative approval for generic Tenofovir.
Topics: Adenine; Drug Approval; Drugs, Generic; HIV Infections; Humans; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; United States; United States Food and Drug Administration | 2008 |
Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects.
Topics: Adenine; Age Factors; Animals; Anti-HIV Agents; Disease Models, Animal; Female; HIV Infections; HIV-1; Humans; Macaca mulatta; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Tenofovir; Time Factors; Treatment Outcome | 2008 |
The A62V and S68G mutations in HIV-1 reverse transcriptase partially restore the replication defect associated with the K65R mutation.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Didanosine; Dideoxynucleosides; Drug Resistance, Multiple, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Organophosphonates; Point Mutation; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir; Virus Replication | 2008 |
Lack of evidence for an effect of lopinavir/ritonavir on tenofovir renal clearance.
Topics: Adenine; Creatinine; Drug Interactions; Drug Therapy, Combination; Female; Glomerular Filtration Rate; HIV Infections; HIV Protease Inhibitors; Humans; Kidney Tubules; Lopinavir; Male; Organophosphonates; Pyrimidinones; Ritonavir; Sensitivity and Specificity; Tenofovir | 2008 |
A new assay based on solid-phase extraction procedure with LC-MS to measure plasmatic concentrations of tenofovir and emtricitabine in HIV infected patients.
Topics: Adenine; Anti-HIV Agents; Calibration; Chromatography, Liquid; Deoxycytidine; Emtricitabine; HIV Infections; Humans; Organophosphonates; Reproducibility of Results; Sensitivity and Specificity; Solid Phase Extraction; Spectrometry, Mass, Electrospray Ionization; Tenofovir | 2008 |
Can a topical microbicide prevent rectal HIV transmission?
Topics: Adenine; Animals; Anti-Infective Agents, Local; HIV Infections; Macaca; Organophosphonates; Tenofovir | 2008 |
Tenofovir-associated decline in renal function.
Topics: Adenine; Adult; Anti-HIV Agents; Female; Glomerular Filtration Rate; HIV Infections; HIV Protease Inhibitors; Humans; Kidney; Kidney Diseases; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2008 |
Antiretroviral rounds. Is that "one pill" treatment enough?
Topics: Adenine; CD4 Lymphocyte Count; Deoxycytidine; Drug Combinations; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; HIV Infections; Humans; Middle Aged; Organophosphonates; Oxazines; Viral Load | 2008 |
Drug-susceptible HIV-1 infection despite intermittent fixed-dose combination tenofovir/emtricitabine as prophylaxis is associated with low-level viremia, delayed seroconversion, and an attenuated clinical course.
Topics: Adenine; Adult; Amino Acid Sequence; Anti-HIV Agents; CD4 Lymphocyte Count; Chemoprevention; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV Seropositivity; HIV-1; HLA Antigens; Humans; Intestinal Mucosa; Male; Microbial Sensitivity Tests; Molecular Sequence Data; Organophosphonates; Phylogeny; Receptors, CCR5; Sequence Alignment; Tenofovir; Time Factors; Viral Load; Viremia | 2008 |
Effect of tenofovir subtraction on HIV plasma viraemia, CD4+ T-cell count and resistance in a patient with baseline K65R and M184V mutations.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Treatment Outcome; Viremia | 2008 |
Combination antiretroviral therapy with tenofovir, emtricitabine or lamivudine, and nevirapine.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Lamivudine; Nevirapine; Organophosphonates; Tenofovir | 2008 |
The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cost-Benefit Analysis; Dideoxynucleosides; Drug Costs; Drug Hypersensitivity; Female; Genetic Testing; Health Care Costs; HIV Infections; HLA-B Antigens; Humans; Male; Middle Aged; Models, Biological; Organophosphonates; Pharmacogenetics; Quality-Adjusted Life Years; Reverse Transcriptase Inhibitors; Sensitivity and Specificity; Tenofovir; Treatment Outcome | 2008 |
Topical cidofovir for severe warts in a patient affected by AIDS and Hodgkin's lymphoma.
Topics: Administration, Topical; Adult; Antiviral Agents; Cidofovir; Cytosine; Foot; Hand; HIV Infections; Hodgkin Disease; Human papillomavirus 16; Humans; Lymphoma, AIDS-Related; Male; Organophosphonates; Papillomaviridae; Treatment Outcome; Warts | 2008 |
Effectiveness and safety of simplification from tenofovir-lamivudine (TDF-3TC) to tenofovir-emtricitabine (TDF-FTC) co-formulation (Truvada) in virologically suppressed HIV-infected patients on HAART.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Central Nervous System; Cohort Studies; Creatinine; Deoxycytidine; Drug Combinations; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; HIV Infections; HIV-1; Humans; Kidney; Lamivudine; Male; Metabolic Clearance Rate; Middle Aged; Organophosphonates; Organophosphorus Compounds; Retrospective Studies; Risk Factors; RNA, Viral; Tenofovir; Viral Load | 2009 |
Disinhibition and risk compensation: scope, definitions, and perspective.
Topics: Adenine; Anti-HIV Agents; Chemoprevention; Clinical Trials as Topic; Counseling; Female; HIV Infections; Humans; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Risk Reduction Behavior; Safe Sex; Sex Work; Sexual Behavior; Sexually Transmitted Diseases; Tenofovir | 2008 |
Adverse effects of tenofovir use in HIV-infected pregnant women and their infants.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Organophosphonates; Pregnancy; Retrospective Studies; Tenofovir | 2008 |
Regression of HIV-related diffuse large B-cell lymphoma in response to antiviral therapy alone.
Topics: Adenine; Anti-HIV Agents; Antifungal Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Drug Combinations; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Fluconazole; HIV Infections; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Organophosphonates; Oxazines; Positron-Emission Tomography; Radiography; Trimethoprim, Sulfamethoxazole Drug Combination | 2008 |
Low trough levels of tipranavir in a combination antiretroviral therapy of tipranavir/ritonavir and tenofovir require therapeutic drug monitoring.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Interactions; Drug Monitoring; Enfuvirtide; HIV Envelope Protein gp41; HIV Infections; Humans; Organophosphonates; Peptide Fragments; Pyridines; Pyrones; Retrospective Studies; Ritonavir; Sulfonamides; Tenofovir | 2008 |
[First line therapy. Tenofovir DF/emtricitabine--the potent backbone].
Topics: Adenine; Anti-HIV Agents; Clinical Trials as Topic; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Organophosphonates; Tenofovir; Viral Load | 2008 |
[Complete HAART in a single pill. New milestone for improving compliance].
Topics: Acquired Immunodeficiency Syndrome; Adenine; Antiretroviral Therapy, Highly Active; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; Humans; Organophosphonates; Oxazines; Viral Load | 2008 |
[HIV therapy and adherence].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Deoxycytidine; Drug Combinations; Drug Resistance, Viral; Drug Therapy, Combination; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; HIV-1; Humans; Organophosphonates; Oxazines; Patient Compliance; Prognosis; Pyridines; Pyrones; Sulfonamides | 2008 |
[One pill--all HAART. Complete divergent HAART in a single tablet per day].
Topics: Adenine; Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; Humans; Organophosphonates; Oxazines; Patient Compliance | 2008 |
Sensitivity of phenotypic susceptibility analyses for nonthymidine nucleoside analogues conferred by K65R or M184V in mixtures with wild-type HIV-1.
Topics: Adenine; Anti-HIV Agents; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Genetic Predisposition to Disease; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Organophosphonates; Phenotype; Plasmids; Tenofovir; Viral Load | 2009 |
The rise and fall of K65R in a Portuguese HIV-1 Drug Resistance database, despite continuously increasing use of tenofovir.
Topics: Adenine; Anti-HIV Agents; Bayes Theorem; Data Interpretation, Statistical; Databases, Nucleic Acid; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Organophosphonates; Portugal; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir | 2009 |
96-week CASTLE data show similar efficacy results.
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Lopinavir; Multicenter Studies as Topic; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome; Viral Load | 2008 |
[A case of acute renal failure involving high amounts of tenofovir after HAART start].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Kidney Failure, Chronic; Male; Middle Aged; Organophosphonates; Tenofovir | 2008 |
Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients.
Topics: Adenine; Alkynes; Alleles; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Medication Adherence; Mutation, Missense; Nevirapine; Organophosphonates; Plasma; Polymerase Chain Reaction; Selection, Genetic; Tenofovir; Treatment Failure | 2009 |
Glomerular filtration rates in HIV-infected patients treated with and without tenofovir: a prospective, observational study.
Topics: Adenine; Adult; Female; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Prospective Studies; RNA, Viral; Tenofovir; Viral Load | 2009 |
Urinary cystatin C can improve the renal safety follow-up of tenofovir-treated patients.
Topics: Adenine; Anti-HIV Agents; Biomarkers; Creatinine; Cystatin C; Fanconi Syndrome; HIV Infections; Humans; Hypophosphatemia; Organophosphonates; Retrospective Studies; Sensitivity and Specificity; Tenofovir | 2009 |
Molecular analysis of an HBsAg-negative hepatitis B virus mutant selected in a tenofovir-treated HIV-hepatitis B virus co-infected patient.
Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Gene Products, pol; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Mutation; Organophosphonates; Tenofovir; Virus Replication | 2009 |
Population pharmacokinetics of emtricitabine in human immunodeficiency virus type 1-infected pregnant women and their neonates.
Topics: Adenine; Anti-HIV Agents; Area Under Curve; Clinical Trials as Topic; Deoxycytidine; Emtricitabine; Female; Half-Life; HIV Infections; HIV-1; Humans; Infant, Newborn; Maternal-Fetal Exchange; Organophosphonates; Population Groups; Pregnancy; Pregnancy Complications, Infectious; Prenatal Exposure Delayed Effects; Tenofovir | 2009 |
HIV-1 infection of human penile explant tissue and protection by candidate microbicides.
Topics: Adenine; Antiviral Agents; CD4-Positive T-Lymphocytes; Cytokines; Foreskin; HIV Infections; HIV-1; Humans; Langerhans Cells; Male; Naphthalenesulfonates; Organophosphonates; Penis; Polymers; Tenofovir; Tissue Culture Techniques; Urethra; Virus Replication | 2009 |
Comment on: High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Lamivudine; Nevirapine; Organophosphonates; Tenofovir; Treatment Failure; Viral Load | 2009 |
Prolonged use of tenofovir in HIV/hepatitis B virus (HBV)-coinfected individuals does not lead to HBV polymerase mutations and is associated with persistence of lamivudine HBV polymerase mutations.
Topics: Adenine; Adult; Aged; Antiretroviral Therapy, Highly Active; Antiviral Agents; Cross-Sectional Studies; Drug Resistance, Viral; Female; Gene Products, pol; Genotype; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Polymerase Chain Reaction; Retrospective Studies; Tenofovir; Viral Load; Viremia | 2009 |
HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness.
Topics: Adenine; Adult; Anti-HIV Agents; Chemoprevention; Computer Simulation; Cost-Benefit Analysis; Deoxycytidine; Emtricitabine; HIV Infections; Homosexuality; Humans; Male; Organophosphonates; Risk Assessment; Tenofovir; United States | 2009 |
Tenofovir use is associated with an increase in serum alkaline phosphatase in the Swiss HIV Cohort Study.
Topics: Adenine; Adult; Alkaline Phosphatase; Anti-HIV Agents; Cohort Studies; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Switzerland; Tenofovir | 2008 |
[Introduction. Tenofovir].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2008 |
[Conclusions. Tenofovir].
Topics: Adenine; Anti-HIV Agents; Drug Resistance, Viral; HIV; HIV Infections; HIV Reverse Transcriptase; Humans; Kidney Diseases; Liver Diseases; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2008 |
A preemptive strike against HIV.
Topics: Adenine; Animals; Clinical Trials as Topic; HIV Infections; Humans; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2009 |
Long-term outcome of tenofovir disoproxil fumarate use against hepatitis B in an HIV-coinfected cohort.
Topics: Adenine; Adult; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; Hepatitis B; Hepatitis B Antigens; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Time Factors; Treatment Outcome; Virus Replication | 2009 |
Study shows people can safely switch to Atripla.
Topics: Adenine; CD4 Lymphocyte Count; Deoxycytidine; Drug Combinations; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; Humans; Organophosphonates; Oxazines | 2008 |
[Atazanavir-induced nephrolithiasis].
Topics: Adenine; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Hepatitis B, Chronic; Hepatitis C, Chronic; Hepatitis D, Chronic; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Lopinavir; Male; Nephrolithiasis; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Tenofovir | 2009 |
Reverse transcriptase inhibitors as potential colorectal microbicides.
Topics: Adenine; Anilides; Anti-HIV Agents; Anti-Infective Agents, Local; Colon; Drug Resistance, Viral; Furans; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Organophosphonates; Pyrimidines; Rectum; Reverse Transcriptase Inhibitors; Tenofovir; Thioamides; Tissue Culture Techniques; Virus Replication | 2009 |
Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir.
Topics: Adenine; Adult; Age Factors; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Creatinine; Epidemiologic Methods; Fanconi Syndrome; Female; HIV Infections; Humans; Kidney Function Tests; Kidney Glomerulus; Kidney Tubules; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2009 |
Bone pain due to fractures revealing osteomalacia related to tenofovir-induced proximal renal tubular dysfunction in a human immunodeficiency virus-infected patient.
Topics: Adenine; Bone Density Conservation Agents; Fanconi Syndrome; Female; Fractures, Bone; HIV Infections; Humans; Middle Aged; Organophosphonates; Osteomalacia; Pain; Reverse Transcriptase Inhibitors; Tenofovir | 2009 |
Highly active antiretroviral therapy-associated ptosis in patients with human immunodeficiency virus.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Blepharoptosis; Carbamates; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Middle Aged; Oculomotor Muscles; Organophosphates; Organophosphonates; Sulfonamides; Tenofovir | 2009 |
Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients.
Topics: Adenine; Antiviral Agents; Base Sequence; DNA Primers; DNA, Viral; Drug Resistance, Viral; Genetic Variation; Genotype; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Mutation; Organophosphonates; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase | 2009 |
Mitochondrial function, morphology and metabolic parameters improve after switching from stavudine to a tenofovir-containing regimen.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adenine; Adipose Tissue; Adult; Anti-HIV Agents; Body Fat Distribution; CD4 Lymphocyte Count; Deoxyguanosine; F2-Isoprostanes; Glutathione; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Lopinavir; Male; Mitochondria; Organophosphonates; Pyrimidinones; Ritonavir; Stavudine; Tenofovir; Treatment Outcome; Viral Load | 2009 |
Proximal tubular dysfunction associated with tenofovir and didanosine causing Fanconi syndrome and diabetes insipidus: a report of 3 cases.
Topics: Adenine; Adult; Anti-HIV Agents; Diabetes Insipidus; Didanosine; Drug Therapy, Combination; Fanconi Syndrome; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2009 |
Editorial comment: tenofovir nephrotoxicity--the disconnect between clinical trials and real-world practice.
Topics: Adenine; Anti-HIV Agents; Clinical Trials as Topic; Diabetes Insipidus; Didanosine; Drug Therapy, Combination; Fanconi Syndrome; HIV Infections; Humans; Kidney Function Tests; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Risk Factors; Tenofovir | 2009 |
Gilead is going strong.
Topics: Adenine; Anti-HIV Agents; California; Commerce; Drug Combinations; Drug Industry; HIV Infections; Humans; Organophosphonates; Tenofovir | 2009 |
FDA approves three generics.
Topics: Adenine; Anti-HIV Agents; Drug Approval; Drugs, Generic; HIV Infections; Humans; Lamivudine; Lopinavir; Organophosphonates; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; United States; United States Food and Drug Administration | 2009 |
Progressive renal tubular dysfunction associated with long-term use of tenofovir DF.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Drug Therapy, Combination; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Kidney Diseases; Kidney Tubules, Proximal; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Time Factors; Urinalysis; Young Adult | 2009 |
Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study.
Topics: Adenine; Adult; Anti-HIV Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carrier Proteins; Female; Gene Frequency; HIV Infections; Homozygote; Humans; Kidney Tubules; Male; Molecular Sequence Data; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Organic Anion Transporters, Sodium-Independent; Organophosphonates; Polymorphism, Genetic; Renal Insufficiency; Tenofovir | 2009 |
Rationing antiretroviral therapy in Africa--treating too few, too late.
Topics: Adenine; Africa; Anti-Retroviral Agents; CD4 Lymphocyte Count; Developing Countries; Drug Administration Schedule; Health Care Rationing; HIV Infections; Humans; Organophosphonates; Stavudine; Tenofovir; Viral Load | 2009 |
Substituting tenofovir for stavudine in resource-limited settings: there are challenges ahead.
Topics: Adenine; Anti-HIV Agents; Developing Countries; Drug Therapy, Combination; HIV Infections; Humans; Organophosphonates; Stavudine; Tenofovir; Treatment Failure | 2009 |
Initiation of antiretroviral therapy 48 hours after infection with simian immunodeficiency virus potently suppresses acute-phase viremia and blocks the massive loss of memory CD4+ T cells but fails to prevent disease.
Topics: Adenine; Amino Acid Sequence; Animals; Anti-HIV Agents; CD4-Positive T-Lymphocytes; Cells, Cultured; Disease Models, Animal; Drug Administration Schedule; HIV Antibodies; HIV Infections; Humans; Injections; Macaca mulatta; Molecular Sequence Data; Organophosphonates; Sequence Alignment; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Tenofovir; Time Factors; Viremia; Virus Replication | 2009 |
Generic Truvada approved.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Approval; Drug Combinations; Drugs, Generic; Emtricitabine; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir; United States; United States Food and Drug Administration | 2009 |
Mutations in the thumb-connection and RNase H domain of HIV type-1 reverse transcriptase of antiretroviral treatment-experienced patients.
Topics: Adenine; Alkynes; Amino Acid Substitution; Benzoxazines; Cyclopropanes; Drug Resistance, Multiple, Viral; Genetic Variation; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Organophosphonates; Protein Structure, Tertiary; Reverse Transcriptase Inhibitors; Ribonuclease H, Human Immunodeficiency Virus; Stavudine; Tenofovir | 2009 |
Prolonged exposure to tenofovir monotherapy 1 month after treatment discontinuation because of tenofovir-related renal failure.
Topics: Adenine; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Renal Insufficiency; Reverse Transcriptase Inhibitors; Tenofovir; Time Factors; Withholding Treatment | 2009 |
Emtricitabine/tenofovir disoproxil fumarate: in combination with a protease inhibitor in HIV-1 infection.
Topics: Adenine; Anti-HIV Agents; Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Organophosphonates; Tenofovir | 2009 |
Rhabdomyolysis in an HIV-infected patient on anti-retroviral therapy precipitated by high-dose pravastatin.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Deoxycytidine; Dyslipidemias; Emtricitabine; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Oligopeptides; Organophosphonates; Pravastatin; Pyridines; Rhabdomyolysis; Ritonavir; Tenofovir | 2009 |
Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only?
Topics: Adenine; Amino Acid Substitution; Anti-HIV Agents; CD4 Lymphocyte Count; Dideoxynucleosides; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation, Missense; Organophosphonates; Retrospective Studies; Salvage Therapy; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2009 |
Long-term suppressive therapy for pulmonary aspergilloma in an immunocompromised man with AIDS. Is it always necessary?
Topics: Adenine; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antifungal Agents; Aspergillosis; Didanosine; Drug Administration Schedule; Drug Interactions; Fatal Outcome; HIV Infections; Humans; Immunocompromised Host; Lung Diseases, Fungal; Male; Middle Aged; Organophosphonates; Pancreatitis; Radiography; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2009 |
Reduced glomerular filtration rate but sustained virologic response in HIV/hepatitis B co-infected individuals on long-term tenofovir.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; CD4 Lymphocyte Count; Cohort Studies; Female; Glomerular Filtration Rate; Hepatitis B; HIV Infections; Humans; Longitudinal Studies; Male; Middle Aged; Organophosphonates; Tenofovir; Treatment Outcome; Viral Load | 2009 |
Tenofovir-associated renal and bone toxicity.
Topics: Adenine; Adult; Anti-HIV Agents; Creatinine; Fanconi Syndrome; Female; Glycosuria; HIV Infections; Humans; Kidney Diseases; Kidney Function Tests; Kidney Tubules, Proximal; Male; Mass Screening; Middle Aged; Organophosphonates; Osteomalacia; Proteinuria; Radionuclide Imaging; Tenofovir | 2009 |
Tapping into combination pills for HIV.
Topics: Adenine; Anti-Retroviral Agents; Deoxycytidine; Drug Combinations; Drug Industry; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Oxazines | 2009 |
FDA notifications. Tenofovir in India receives tentative approval.
Topics: Adenine; Drug Approval; HIV Infections; India; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; United States; United States Food and Drug Administration | 2009 |
Renal function in patients with preexisting renal disease receiving tenofovir-containing highly active antiretroviral therapy in the HIV outpatient study.
Topics: Adenine; Adult; Aged; Ambulatory Care Facilities; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Diseases; Kidney Function Tests; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; United States | 2009 |
HIV clinics are halting enrolment of new patients as funding stalls, MSF warns.
Topics: Adenine; Anti-HIV Agents; Developing Countries; Drug Costs; HIV Infections; Hospitals, Special; Humans; Organophosphonates; Stavudine; Tenofovir | 2009 |
The absence of HIV mutations in cerebrospinal fluid and in peripheral blood mononuclear cells during a regimen containing Trizivir plus tenofovir.
Topics: Adenine; Anti-HIV Agents; Cohort Studies; Drug Combinations; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Leukocytes, Mononuclear; Mutation; Organophosphonates; Prospective Studies; Tenofovir; Viremia; Zidovudine | 2009 |
Virological response to initial antiretroviral regimens containing abacavir or tenofovir.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Tenofovir; Treatment Failure; Treatment Outcome; Viral Load | 2009 |
Efavirenz + emtricitabine + tenofovir: new combination. HIV infection: do not modify ongoing therapy just to use one less tablet. Better adherence than with separate dosing has not been demonstrated, while reduced efficacy is plausible.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Approval; Drug Combinations; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Emtricitabine; Europe; HIV Infections; Humans; Organophosphonates; Oxazines; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2009 |
High rates of active hepatitis B and C co-infections in HIV-1 infected Cameroonian adults initiating antiretroviral therapy.
Topics: Adenine; Adult; Age Factors; Anti-HIV Agents; Anti-Retroviral Agents; Cameroon; Comorbidity; Female; Hepacivirus; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis C; Hepatitis C Antibodies; HIV Infections; HIV-1; Humans; Male; Middle Aged; Multivariate Analysis; Organophosphonates; Pregnancy; Retrospective Studies; Tenofovir; Transaminases | 2010 |
Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: predictors of virological response and drug resistance evolution in a multi-cohort study.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Dideoxynucleosides; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Mutation, Missense; Organophosphonates; Tenofovir; Treatment Failure; Treatment Outcome; Viral Load; Viral Proteins | 2009 |
Efficacy and safety of boosted and unboosted atazanavir-containing antiretroviral regimens in real life: results from a multicentre cohort study.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Cohort Studies; Drug Administration Schedule; Drug Interactions; Female; HIV Infections; HIV Protease Inhibitors; Humans; Kaplan-Meier Estimate; Male; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome; Viral Load | 2010 |
HIV therapy may be given safely in resource-limited settings without routine laboratory monitoring.
Topics: Adenine; Anti-HIV Agents; Diagnostic Tests, Routine; Glomerular Filtration Rate; Health Resources; HIV Infections; HIV-1; Humans; Incidence; Kidney Diseases; Laboratories; Organophosphonates; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Uganda; Zimbabwe | 2009 |
Renal function with use of a tenofovir-containing initial antiretroviral regimen.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; Glomerular Filtration Rate; HIV Infections; HIV Protease Inhibitors; Humans; Kidney Diseases; Longitudinal Studies; Male; Organophosphonates; Prospective Studies; Reverse Transcriptase Inhibitors; Tenofovir | 2009 |
Hepatitis B in HIV patients: what is the current treatment and what are the challenges?
Topics: Adenine; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Therapy, Combination; Emtricitabine; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Cirrhosis; Nucleosides; Organophosphonates; Polyethylene Glycols; Pyrimidinones; Recombinant Proteins; Telbivudine; Tenofovir; Thymidine; Transaminases | 2009 |
Conserved T cell and natural killer cell function in treatment-experienced adults receiving tenofovir plus didanosine as nucleoside reverse transcription inhibitor backbone.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Cell Proliferation; Didanosine; Drug Therapy, Combination; Flow Cytometry; Fluorescent Antibody Technique; Follow-Up Studies; HIV Infections; HIV-1; Humans; Immunologic Memory; Immunophenotyping; Interferon-gamma; Killer Cells, Natural; Lamivudine; Logistic Models; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Statistics, Nonparametric; T-Lymphocytes; Tenofovir | 2009 |
[Medication change due to side effects or possible long-term complications. Side effect management with vision].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Deoxycytidine; Drug Combinations; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; HIV-1; Humans; Long-Term Care; Lopinavir; Oligopeptides; Organophosphonates; Oxazines; Pyridines; Pyrimidinones; Pyrrolidinones; Raltegravir Potassium; Randomized Controlled Trials as Topic | 2009 |
[One year with Atripla. Changeover to complete HIV therapy in a single tablet has proven successful].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Controlled Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; Humans; Medication Adherence; Organophosphonates; Oxazines; Viral Load | 2009 |
Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Area Under Curve; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Plasma; Ritonavir; RNA, Viral; Saquinavir; Tenofovir; Treatment Outcome; Viral Load | 2009 |
Subclinical tubular injury in HIV-infected individuals on antiretroviral therapy: a cross-sectional analysis.
Topics: Acetylglucosaminidase; Adenine; Adult; Aged; Albuminuria; Anti-Retroviral Agents; Creatinine; Cross-Sectional Studies; Disease Progression; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Tubules, Proximal; Male; Middle Aged; Organophosphonates; Phosphates; Proteinuria; Retinol-Binding Proteins; Risk Factors; Sensitivity and Specificity; Tenofovir | 2009 |
Lower limb high arterial flow induced by tenofovir and emtricitabine treatment.
Topics: Adenine; Adult; Blood Flow Velocity; Deoxycytidine; Edema; Emtricitabine; HIV Infections; Humans; Leg; Male; Organophosphonates; Tenofovir | 2009 |
Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Creatinine; Fanconi Syndrome; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Function Tests; Male; Middle Aged; Multivariate Analysis; Organophosphonates; Retrospective Studies; Tenofovir | 2010 |
The art of managing human immunodeficiency virus infection: a balancing act.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; HIV Infections; Humans; Lamivudine; Organophosphonates; Tenofovir; Treatment Outcome | 2009 |
Tenofovir coadministration is not associated with lower unboosted atazanavir plasma exposure in the clinical setting.
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; Drug Interactions; Drug Therapy, Combination; Female; History, 17th Century; HIV Infections; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Tenofovir | 2009 |
Safety and efficacy of once-daily nevirapine dosing: a multicohort study.
Topics: Adenine; Adult; Anti-HIV Agents; Cohort Studies; Drug Administration Schedule; Drug Hypersensitivity; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nevirapine; Organophosphonates; Retrospective Studies; Tenofovir; Treatment Outcome | 2009 |
A new drug combination therapy for treatment-naive patients with HIV-1 infection, consisting of raltegravir, emtricitabine and tenofovir disoproxil fumarate.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Tenofovir | 2009 |
Multivalent catanionic GalCer analogs derived from first generation dendrimeric phosphonic acids.
Topics: Anti-HIV Agents; Cell Line; Cell Survival; Dendrimers; Galactosylceramides; HIV Infections; HIV-1; Humans; Microbial Sensitivity Tests; Organophosphonates | 2010 |
Prevalence and factors associated with renal impairment in HIV-infected patients, ANRS C03 Aquitaine Cohort, France.
Topics: Adenine; Adult; Anti-HIV Agents; Body Mass Index; CD4 Lymphocyte Count; Creatinine; Epidemiologic Methods; Female; France; HIV Infections; Humans; Hypertension; Indinavir; Kidney; Kidney Function Tests; Male; Middle Aged; Organophosphonates; Renal Insufficiency; Tenofovir | 2010 |
Low-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovir.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Combinations; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Lamivudine; Microbial Sensitivity Tests; Middle Aged; Mutation, Missense; Organophosphonates; RNA, Viral; Tenofovir; Treatment Failure; Viremia; Young Adult; Zidovudine | 2010 |
Early clinical and programmatic outcomes with tenofovir-based antiretroviral therapy in Zambia.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; Humans; Male; Organophosphonates; Tenofovir; Treatment Outcome; Zambia | 2010 |
N348I in HIV-1 reverse transcriptase decreases susceptibility to tenofovir and etravirine in combination with other resistance mutations.
Topics: Adenine; Drug Resistance, Multiple, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutagenesis, Site-Directed; Mutation; Nitriles; Organophosphonates; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Tenofovir | 2010 |
[Protocol for the antiviral therapy of hepatitis B and D].
Topics: Adenine; Antiviral Agents; Biopsy; Guanine; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis D; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Lamivudine; Liver Cirrhosis; Nucleotides; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Tenofovir | 2010 |
Susceptibility to genital herpes as a biomarker predictive of increased HIV risk: expansion of a murine model of microbicide safety.
Topics: Adenine; Administration, Intravaginal; Animals; Anti-Infective Agents; Antiviral Agents; Biomarkers; Disease Models, Animal; Disease Susceptibility; Female; Herpes Genitalis; Herpesvirus 2, Human; HIV Infections; Mice; Mice, Inbred BALB C; Naphthalenesulfonates; Nonoxynol; Organophosphonates; Polymers; Predictive Value of Tests; Risk Assessment; Tenofovir | 2009 |
FDA notifications. Generic efavirenz/emtricitabine/fenofovir has tentative approval.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Approval; Drug Combinations; Drugs, Generic; Emtricitabine; HIV Infections; Humans; Organophosphonates; Tenofovir; United States; United States Food and Drug Administration | 2009 |
Cost-effectiveness of tenofovir as first-line antiretroviral therapy in India.
Topics: Adenine; Adult; Antifungal Agents; Antiretroviral Therapy, Highly Active; Cost-Benefit Analysis; Female; HIV Infections; Humans; India; Male; Organophosphonates; Stavudine; Survival Analysis; Tenofovir; Treatment Outcome; Zidovudine | 2010 |
Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008.
Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Nevirapine; Oligopeptides; Organophosphonates; Proportional Hazards Models; Prospective Studies; Pyridines; Pyrimidinones; Risk Factors; Switzerland; Tenofovir; Zidovudine | 2010 |
DAART for human immunodeficiency virus-infected patients: Studying subjects not at risk for nonadherence and use of untested interventions.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Aged; Anti-HIV Agents; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Viral; Emtricitabine; Female; Genotype; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Organophosphonates; Patient Compliance; Pyrimidinones; Randomized Controlled Trials as Topic; RNA, Viral; Stavudine; Tenofovir; Treatment Outcome; Young Adult | 2010 |
Microbicide research already benefiting thousands--experts.
Topics: Adenine; Anti-HIV Agents; Anti-Infective Agents; Anti-Retroviral Agents; Biomedical Research; HIV Infections; Humans; Organophosphonates; Tenofovir; Vaginal Creams, Foams, and Jellies | 2009 |
Expanded postexposure prophylaxis for simultaneous multiple source HIV exposure in a health-care worker.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Deoxycytidine; Emtricitabine; Enfuvirtide; Female; Fingers; HIV Envelope Protein gp41; HIV Infections; Humans; Infectious Disease Transmission, Patient-to-Professional; Middle Aged; Needlestick Injuries; Occupational Diseases; Organophosphonates; Peptide Fragments; Post-Exposure Prophylaxis; Ritonavir; Sulfonamides; Tenofovir | 2010 |
Incidence of proximal renal tubular dysfunction in patients on tenofovir disoproxil fumarate.
Topics: Adenine; Anti-HIV Agents; Fanconi Syndrome; HIV Infections; Humans; Incidence; Organophosphonates; Retrospective Studies; Tenofovir; United Kingdom | 2010 |
Tolerability of two different combinations of antiretroviral drugs including tenofovir used in occupational and nonoccupational postexposure prophylaxis for HIV.
Topics: Adenine; Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; Humans; Infectious Disease Transmission, Patient-to-Professional; Male; Occupational Exposure; Occupational Health Services; Organophosphonates; Patient Compliance; Tenofovir | 2010 |
Systemic administration of antiretrovirals prior to exposure prevents rectal and intravenous HIV-1 transmission in humanized BLT mice.
Topics: Adenine; Animals; Anti-HIV Agents; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; Flow Cytometry; HIV Infections; HIV-1; Mice; Organophosphonates; Rectum; Tenofovir | 2010 |
International cohort analysis of the antiviral activities of zidovudine and tenofovir in the presence of the K65R mutation in reverse transcriptase.
Topics: Adenine; Amino Acid Substitution; Anti-HIV Agents; California; Cohort Studies; Drug Resistance, Viral; France; Genes, Viral; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Multivariate Analysis; Mutation, Missense; Organophosphonates; RNA, Viral; Tenofovir; Zidovudine | 2010 |
Emerging mutations at virological failure of HAART combinations containing tenofovir and lamivudine or emtricitabine.
Topics: Adenine; Adult; Analysis of Variance; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Organophosphonates; Retrospective Studies; RNA, Viral; Tenofovir; Treatment Failure; Viral Load | 2010 |
Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case-control study.
Topics: Adenine; Adolescent; Anti-HIV Agents; Case-Control Studies; Child; Child, Preschool; England; Female; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Hypophosphatemia; Ireland; Kidney; Male; Organophosphonates; Salvage Therapy; Tenofovir; Treatment Outcome | 2010 |
Recent FDA approvals and changes.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Drug Approval; Drug Combinations; Drug Labeling; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; Humans; Organophosphonates; Oxazines; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration | 2010 |
Safety and efficacy of tenofovir/emtricitabine plus nevirapine in HIV-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Male; Nevirapine; Organophosphonates; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load | 2010 |
Incomplete reversibility of tenofovir-related renal toxicity in HIV-infected men.
Topics: Adenine; Anti-HIV Agents; Glomerular Filtration Rate; HIV Infections; Humans; Kidney; Kidney Diseases; Male; Middle Aged; Organophosphonates; Tenofovir; Withholding Treatment | 2010 |
Tenofovir and changes in renal function.
Topics: Adenine; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Diseases; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2010 |
A controlled trial of initial antiviral regimens for HIV-1 infection.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Genotype; HIV Infections; HIV-1; Homosexuality, Male; Humans; Lamivudine; Male; Organophosphonates; Tenofovir; Treatment Failure | 2010 |
Single-tablet Quad regimen achieves high rate of virologic suppression.
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Clinical Trials, Phase II as Topic; Cytochrome P-450 CYP3A Inhibitors; Deoxycytidine; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; HIV-1; Humans; Multicenter Studies as Topic; Oligopeptides; Organophosphonates; Organophosphorus Compounds; Oxazines; Pyridines; Quinolones; Randomized Controlled Trials as Topic; Ritonavir; Treatment Outcome; Viral Load | 2010 |
Disseminated bartonellosis presenting as neuroretinitis in a young adult with human immunodeficiency virus infection.
Topics: Adenine; Anti-Bacterial Agents; Anti-HIV Agents; Bartonella; Bartonella Infections; Biopsy; Deoxycytidine; Doxycycline; Drug Combinations; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; Humans; Lung; Male; Organophosphonates; Oxazines; Retinitis; Rifampin; Treatment Outcome; Young Adult | 2010 |
Efficacy of tenofovir-emtricitabine versus abacavir-lamivudine.
Topics: Adenine; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; HIV Infections; Humans; Lamivudine; Organophosphonates; Tenofovir; Treatment Outcome | 2010 |
Elvucitabine data released at CROI.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials, Phase II as Topic; Cyclopropanes; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Organophosphonates; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Viral Load; Zalcitabine | 2010 |
Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations.
Topics: Adenine; HIV Infections; Humans; Kidney Diseases; Kidney Function Tests; Kidney Tubules; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2010 |
Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Body Mass Index; CD4 Lymphocyte Count; Developing Countries; Drug Resistance, Viral; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; HIV Infections; HIV-1; Humans; Malawi; Male; Medication Adherence; Middle Aged; National Health Programs; Organophosphonates; Prospective Studies; RNA, Viral; Statistics as Topic; Tenofovir; Treatment Failure; Tuberculosis; Urban Population; Viral Load; Zidovudine | 2010 |
Tenofovir/probenecid combination in HIV/HBV-coinfected patients: how to escape Fanconi syndrome recurrence?
Topics: Adenine; Fanconi Syndrome; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Probenecid; Secondary Prevention; Tenofovir | 2010 |
Findings in humanized-mouse model suggest benefit of further studies in HIV pre-exposure prophylaxis.
Topics: Adenine; Animals; Anti-HIV Agents; Bone Marrow Transplantation; Clinical Trials as Topic; Deoxycytidine; Disease Models, Animal; Drug Combinations; Emtricitabine; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV; HIV Antibodies; HIV Infections; Humans; Infection Control; Liver Transplantation; Mice; Occupational Exposure; Organophosphonates; Organophosphorus Compounds; Tenofovir; Thymus Gland; Transplantation Chimera | 2010 |
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
Topics: Adenine; Anti-HIV Agents; Cell Survival; Cells, Cultured; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Macrophages; Nucleosides; Nucleotides; Organophosphonates; Tenofovir | 2010 |
Raltegravir, tenofovir, and emtricitabine in an HIV-infected patient with HCV chronic hepatitis, NNRTI intolerance and protease inhibitors-induced severe liver toxicity.
Topics: Adenine; Adult; Antiviral Agents; CD4-Positive T-Lymphocytes; Chemical and Drug Induced Liver Injury; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; Hepatitis C, Chronic; HIV Infections; Humans; Liver; Lymphocyte Count; Organophosphonates; Protease Inhibitors; Pyrrolidinones; Raltegravir Potassium; Tenofovir; Treatment Outcome; Viral Load | 2010 |
Report from the 17th Conference on Retroviruses and Opportunistic Infections. Randomized studies of once-daily darunavir and tenofovir/FTC + nevirapine.
Topics: Adenine; Anti-HIV Agents; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; Organophosphonates; Randomized Controlled Trials as Topic; Sulfonamides; Tenofovir | 2010 |
Recent FDA approvals and changes.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Child; Delayed-Action Preparations; Didanosine; Drug Approval; Drug Labeling; HIV Infections; Humans; Organophosphonates; Randomized Controlled Trials as Topic; Tenofovir; United States; United States Food and Drug Administration | 2010 |
[Protease inhibitor or non-nucleoside reverse transcriptase inhibitor. ACTG study 5202 in focus].
Topics: Adenine; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; Humans; Lamivudine; Multicenter Studies as Topic; Oligopeptides; Organophosphonates; Pyridines; Randomized Controlled Trials as Topic; Tenofovir | 2010 |
[HIV-therapy-associated immune reconstitution syndrome presenting as immunogenic hyperthyroidism].
Topics: Adenine; Alkynes; Anti-HIV Agents; Autoantibodies; Benzoxazines; Cyclopropanes; Deoxycytidine; Diagnosis, Differential; Drug Therapy, Combination; Emtricitabine; Graves Disease; HIV Infections; HIV-1; Humans; Immune Reconstitution Inflammatory Syndrome; Long-Term Care; Male; Middle Aged; Organophosphonates; Tenofovir; Thyroid Gland; Thyroiditis, Autoimmune | 2010 |
Prevalence and factors associated with renal dysfunction among HIV-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cross-Sectional Studies; Female; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Kidney; Kidney Diseases; Kidney Function Tests; Male; Middle Aged; Military Hygiene; Military Personnel; Organophosphonates; Prevalence; Reverse Transcriptase Inhibitors; Risk Factors; Tenofovir; Time Factors | 2010 |
Clonal resistance analyses of HIV type-1 after failure of therapy with didanosine, lamivudine and tenofovir.
Topics: Adenine; Anti-HIV Agents; Didanosine; Drug Resistance, Viral; Drug Therapy, Combination; Genome, Viral; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Organophosphonates; Phenotype; Recombination, Genetic; Reverse Transcriptase Inhibitors; Sequence Analysis, DNA; Tenofovir; Treatment Failure | 2010 |
Advantages of low-cost generic tenofovir instead of D4T for first-line antiretroviral therapy in Burma: a 2-year experience.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cost-Benefit Analysis; HIV Infections; Humans; Myanmar; Organophosphonates; Tenofovir | 2010 |
The exploitation of "Exploitation" in the tenofovir prep trial in Cameroon: Lessons learned from media coverage of an HIV prevention trial.
Topics: Adenine; Anti-HIV Agents; Cameroon; Ethics, Research; Female; HIV Infections; Human Rights; Humans; Internationality; Mass Media; Organophosphonates; Persuasive Communication; Problem Solving; Public Relations; Randomized Controlled Trials as Topic; Tenofovir; Vulnerable Populations | 2010 |
Economic efficiency of genetic screening to inform the use of abacavir sulfate in the treatment of HIV.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Computer Simulation; Cost-Benefit Analysis; Decision Trees; Dideoxynucleosides; Drug Hypersensitivity; Drug-Related Side Effects and Adverse Reactions; Genetic Testing; HIV Infections; HLA-B Antigens; Humans; Middle Aged; Models, Economic; Organophosphonates; Quality-Adjusted Life Years; Tenofovir; United States | 2010 |
FDA notifications. Updated Atripla label approved.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Drug Labeling; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; Humans; Organophosphonates; Oxazines; Viral Load | 2010 |
Rapid HIV-RNA decline following addition of raltegravir and tenofovir to ongoing highly active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancy.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; Humans; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Tenofovir; Viral Load; Viremia | 2010 |
Immunodeficiency and renal impairment are risk factors for HIV-associated acute renal failure.
Topics: Acute Kidney Injury; Adenine; Adult; Atazanavir Sulfate; CD4 Lymphocyte Count; Cohort Studies; Female; Glomerular Filtration Rate; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; London; Male; Oligopeptides; Organophosphonates; Pyridines; Risk Factors; Tenofovir | 2010 |
More research needed to find new HIV-suppressive functions of cytotoxic T cells.
Topics: Adenine; Animals; Combined Modality Therapy; Deoxycytidine; Emtricitabine; HIV Infections; Humans; Lymphocyte Depletion; Macaca mulatta; Organophosphonates; Simian Acquired Immunodeficiency Syndrome; T-Lymphocyte Subsets; T-Lymphocytes, Cytotoxic; Tenofovir; Viral Load; Viremia | 2010 |
HIV/AIDS. At last, vaginal gel scores victory against HIV.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Anti-Infective Agents, Local; Female; HIV Infections; HIV-1; Humans; Medication Adherence; Organophosphonates; Randomized Controlled Trials as Topic; South Africa; Tenofovir; Vaginal Creams, Foams, and Jellies; Young Adult | 2010 |
No changes in efavirenz plasma concentrations in HIV-infected patients who switch from Stocrin to Atripla.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Combinations; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; Humans; Organophosphonates; Oxazines; Plasma | 2010 |
Lower arterial stiffness and Framingham score after switching abacavir to tenofovir in men at high cardiovascular risk.
Topics: Adenine; Cardiovascular Diseases; Dideoxynucleosides; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Risk Assessment; Tenofovir; Vascular Resistance | 2010 |
High frequency of lamivudine resistance mutations in Brazilian patients co-infected with HIV and hepatitis B.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Brazil; Comorbidity; Cross-Sectional Studies; DNA-Directed DNA Polymerase; Drug Resistance, Viral; Female; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Mutation; Organophosphonates; Tenofovir; Viral Core Proteins; Viral Load; Viral Proteins | 2010 |
Associations of antiretroviral drug use and HIV-specific risk factors with carotid intima-media thickness.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Atherosclerosis; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Risk Factors; Tenofovir; Tunica Intima; Tunica Media | 2010 |
Tenofovir-linked hyperparathyroidism is independently associated with the presence of vitamin D deficiency.
Topics: Adenine; Adult; Female; HIV Infections; HIV-1; Humans; Hyperparathyroidism; Male; Middle Aged; Organophosphonates; Parathyroid Hormone; Tenofovir; United Kingdom; Urban Population; Vitamin D; Vitamin D Deficiency | 2010 |
Short communication: Inadequate vitamin D exacerbates parathyroid hormone elevations in tenofovir users.
Topics: Adenine; Adult; Anti-HIV Agents; Bone Density; Cross-Sectional Studies; Dose-Response Relationship, Drug; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Parathyroid Hormone; Tenofovir; Vitamin D; Vitamin D Deficiency | 2010 |
Antiretroviral vaginal gel shows promise against HIV.
Topics: Adenine; Adult; Anti-HIV Agents; Anti-Retroviral Agents; Clinical Trials as Topic; Female; Gels; HIV Infections; HIV Seropositivity; Humans; Incidence; Infectious Disease Transmission, Vertical; Medication Adherence; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors; South Africa; Tenofovir; Vagina | 2010 |
Maraviroc concentrations in cerebrospinal fluid in HIV-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Chromatography, Liquid; Cyclohexanes; Didanosine; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Organophosphonates; Polymerase Chain Reaction; Tandem Mass Spectrometry; Tenofovir; Triazoles; Viral Load | 2010 |
After CAPRISA 004: time to re-evaluate the HIV lexicon.
Topics: Adenine; Administration, Intravaginal; Administration, Oral; Anti-HIV Agents; Female; Gels; HIV Infections; Humans; Organophosphonates; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir | 2010 |
Tolerability of HIV postexposure prophylaxis with tenofovir/emtricitabine and lopinavir/ritonavir tablet formulation.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; CD4 Lymphocyte Count; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Organophosphonates; Post-Exposure Prophylaxis; Practice Guidelines as Topic; Pyrimidinones; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome; Young Adult | 2010 |
Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens.
Topics: Adaptation, Biological; Adenine; Adult; Amino Acid Substitution; Anti-HIV Agents; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation, Missense; Organophosphonates; pol Gene Products, Human Immunodeficiency Virus; RNA, Viral; Tenofovir | 2010 |
Management and treatment of chronic hepatitis B virus infection in HIV positive and negative patients: the EPIB 2008 study.
Topics: Adenine; Adult; Antiviral Agents; Female; France; Hepatitis B Antibodies; Hepatitis B Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Retrospective Studies; Surveys and Questionnaires; Tenofovir | 2010 |
Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities.
Topics: Acute Kidney Injury; Adenine; Adult; Anti-HIV Agents; Biopsy; Drug Administration Schedule; Female; Glycosuria; HIV Infections; HIV-1; Humans; Kidney Tubular Necrosis, Acute; Kidney Tubules, Proximal; Male; Microscopy, Electron; Middle Aged; Mitochondria; New York City; Organophosphonates; Proteinuria; Renal Dialysis; Renal Insufficiency; Retrospective Studies; Tenofovir; Time Factors | 2010 |
Trial results finally show potential for microbicidal HIV gel.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Anti-HIV Agents; Female; Gels; HIV; HIV Infections; Humans; Organophosphonates; South Africa; Tenofovir; Vagina | 2010 |
Still a long wait for approved HIV-protective gel.
Topics: Adenine; Antiviral Agents; Deoxycytidine; Drug Approval; Drug Combinations; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Technology Transfer; Tenofovir; Vaginal Creams, Foams, and Jellies | 2010 |
Low bone mineral density with tenofovir: does statistically significant mean clinically significant?
Topics: Adenine; Adult; Anti-HIV Agents; Bone Density; Bone Diseases; Female; Fractures, Bone; HIV Infections; Humans; Incidence; Male; Organophosphonates; Tenofovir | 2010 |
[Two cases of Fanconi's syndrome induced by tenofovir in the Ivory Coast].
Topics: Adenine; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cote d'Ivoire; Cyclopropanes; Drug Therapy, Combination; Enterobacter aerogenes; Enterobacteriaceae Infections; Fanconi Syndrome; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Malaria; Male; Middle Aged; Organophosphonates; Pyelonephritis; Pyrimidinones; Ritonavir; Tenofovir | 2011 |
Preventing HIV infection: turning the tide for young women.
Topics: Adenine; Adolescent; Africa South of the Sahara; Antiviral Agents; Female; HIV Infections; HIV-1; Humans; Motivation; Naphthalenesulfonates; Organophosphonates; Polymers; Tenofovir; Vaginal Creams, Foams, and Jellies; Young Adult | 2010 |
Changes in the renal function after tenofovir-containing antiretroviral therapy initiation in a Senegalese cohort (ANRS 1215).
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Incidence; Kidney; Kidney Function Tests; Male; Middle Aged; Organophosphonates; Renal Insufficiency; Senegal; Tenofovir | 2010 |
The impact of gender and anchor drugs on TDF renal toxicity.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Dideoxynucleosides; Emtricitabine; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney; Lamivudine; Male; Organophosphonates; Sex Factors; Tenofovir | 2010 |
A tailored dose of tenofovir could reduce its impact on bone mass in HIV Type 1-infected children and adolescents: a report from 5 years of clinical experience.
Topics: Adenine; Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone and Bones; Calcification, Physiologic; Child; Child, Preschool; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Tenofovir | 2010 |
In vitro evaluation of viability, integrity, and inflammation in genital epithelia upon exposure to pharmaceutical excipients and candidate microbicides.
Topics: Adenine; Anilides; Anti-Infective Agents; Benzofurans; Cell Line; Cell Survival; Cervix Uteri; Epithelium; Female; Furans; HIV Infections; Humans; In Vitro Techniques; Interleukin-8; Laurates; Monoglycerides; Naphthalenesulfonates; Organophosphonates; Polymers; Reverse Transcriptase Inhibitors; Tenofovir; Thioamides | 2010 |
Implications of HIV PrEP trials results.
Topics: Adenine; Anti-HIV Agents; Chemoprevention; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Randomized Controlled Trials as Topic; Tenofovir; Treatment Outcome; United States | 2011 |
Prevention. Study reveals that vaginal gel reduces HIV, herpes.
Topics: Adenine; Female; Gels; Herpes Genitalis; HIV Infections; Humans; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Vagina | 2010 |
Virologic and clinical outcomes in HIV/HBV coinfected patients on tenofovir-containing HAART.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Hepatitis B, Chronic; HIV Infections; Humans; Organophosphonates; Tenofovir | 2010 |
[Human immunodeficiency virus and Chagas disease coinfection treated successfully with benznidazole and a raltegravir-based antiretroviral regimen: a case report].
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Chagas Disease; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Nitroimidazoles; Oligopeptides; Organophosphonates; Paraguay; Pyridines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Spain; Tenofovir; Trypanocidal Agents; Zidovudine | 2011 |
Liver fibrosis changes in HIV-HBV-coinfected patients: clinical, biochemical and histological effect of long-term tenofovir disoproxil fumarate use.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies; DNA, Viral; Female; Hepacivirus; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C; Hepatitis D, Chronic; HIV Infections; Humans; Liver Cirrhosis; Male; Middle Aged; Organophosphonates; Tenofovir; Viral Load | 2010 |
Occult HBV infection in untreated HIV-infected adults in Côte d'Ivoire.
Topics: Adenine; Adult; Aged; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cote d'Ivoire; Cross-Sectional Studies; Deoxycytidine; DNA, Viral; Emtricitabine; Female; Hepatitis B Antibodies; Hepatitis B Core Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Prevalence; Tenofovir; World Health Organization; Young Adult | 2010 |
Tenofovir disoproxil fumarate and bone mineral density: a 60-month longitudinal study in a cohort of HIV-infected youths.
Topics: Adenine; Adolescent; Antiretroviral Therapy, Highly Active; Biomarkers; Bone Density; Child; Child, Preschool; Collagen Type I; Female; Follow-Up Studies; HIV; HIV Infections; Humans; Longitudinal Studies; Male; Organophosphonates; Peptides; Tenofovir; Young Adult | 2010 |
High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study.
Topics: Absorptiometry, Photon; Adenine; Aged; Antiretroviral Therapy, Highly Active; Bone Density; Cohort Studies; Cross-Sectional Studies; Disease Progression; Female; HIV Infections; Humans; Longitudinal Studies; Male; Middle Aged; Organophosphonates; Osteoporosis; Prevalence; Radionuclide Imaging; Reverse Transcriptase Inhibitors; Risk Factors; Tenofovir | 2010 |
A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Ill-Housed Persons; Male; Middle Aged; Organophosphonates; Patient Compliance; Tenofovir; Viral Load | 2010 |
[Immune reconstitution inflammatory syndrome associated with eosinophilic pustular folliculitis in an HIV-infected patient].
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Diagnosis, Differential; Emtricitabine; Eosinophilia; Folliculitis; HIV Infections; Humans; Immune Reconstitution Inflammatory Syndrome; Organophosphonates; Rosacea; Skin Diseases, Infectious; Tenofovir | 2011 |
The role of nucleoside and nucleotide analogues in nodular regenerative hyperplasia in HIV-infected patients: a case control study.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Case-Control Studies; Didanosine; Female; HIV Infections; Humans; Hyperplasia; Hypertension, Portal; Liver; Liver Regeneration; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir | 2011 |
Incidence and risk factors for tenofovir-associated renal function decline among Thai HIV-infected patients with low-body weight.
Topics: Adenine; Adult; Anti-HIV Agents; Body Mass Index; Body Weight; Cohort Studies; Drug Interactions; Female; Glomerular Filtration Rate; HIV Infections; HIV Protease Inhibitors; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Organophosphonates; Renal Insufficiency; Retrospective Studies; Risk Factors; Tenofovir; Thailand | 2010 |
Prospective study of renal function in HIV-infected pediatric patients receiving tenofovir-containing HAART regimens.
Topics: Adenine; Adolescent; Antiretroviral Therapy, Highly Active; Child; Female; HIV Infections; Humans; Kidney Diseases; Kidney Function Tests; Male; Organophosphonates; Prospective Studies; Proteinuria; Spain; Tenofovir | 2011 |
Tenofovir-induced kidney disease: an acquired renal tubular mitochondriopathy.
Topics: Acute Kidney Injury; Adenine; Animals; Anti-HIV Agents; Drug Administration Schedule; Glycosuria; HIV Infections; HIV-1; Humans; Kidney Tubular Necrosis, Acute; Kidney Tubules, Proximal; Mitochondria; Organophosphonates; Proteinuria; Renal Dialysis; Renal Insufficiency; Tenofovir; Time Factors | 2010 |
Oral preexposure prophylaxis for HIV--another arrow in the quiver?
Topics: Adenine; Administration, Oral; Anti-HIV Agents; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Organophosphonates; Patient Compliance; Tenofovir | 2010 |
[Long-term therapy for chronic hepatitis B in HIV co-infected patients].
Topics: Adenine; Antiretroviral Therapy, Highly Active; Antiviral Agents; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Guanine; Hepatitis B, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Recombinant Proteins; Telbivudine; Tenofovir; Thymidine | 2010 |
Lipid-lowering effect of tenofovir in HIV-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Anticholesteremic Agents; Female; HIV Infections; Humans; Lipids; Male; Middle Aged; Organophosphonates; Tenofovir; Treatment Outcome | 2011 |
First real success for anti-HIV gel: a new start for HIV microbicides?
Topics: Adenine; Adolescent; Adult; Anti-Infective Agents; Controlled Clinical Trials as Topic; Disease Transmission, Infectious; Female; HIV Infections; Humans; Organophosphonates; Sexually Transmitted Diseases, Viral; South Africa; Tenofovir; Treatment Outcome; Vaginal Creams, Foams, and Jellies; Young Adult | 2010 |
No impact of oral tenofovir disoproxil fumarate on herpes simplex virus shedding in HIV-infected adults.
Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Canada; Female; Herpes Simplex; Herpesvirus 1, Human; Herpesvirus 2, Human; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Tenofovir; Virus Shedding | 2011 |
Implementing a tenofovir-based first-line regimen in rural Lesotho: clinical outcomes and toxicities after two years.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Female; HIV Infections; Humans; Lesotho; Male; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Rural Population; Tenofovir; Treatment Outcome | 2011 |
Avascular necrosis of the talus in a HIV-infected patient.
Topics: Adenine; Carbamates; Deoxycytidine; Emtricitabine; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Immunocompromised Host; Male; Middle Aged; Organophosphates; Organophosphonates; Orthotic Devices; Osteonecrosis; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Talus; Tenofovir | 2010 |
The ART of preventing HIV.
Topics: Adenine; Adult; Anti-HIV Agents; Anti-Retroviral Agents; Circumcision, Male; Deoxycytidine; Emtricitabine; Female; HIV Infections; Homosexuality, Male; Humans; Male; Organophosphonates; Random Allocation; Risk Assessment; Tenofovir | 2011 |
Microbicides & their implications in HIV prevention.
Topics: Adenine; Anti-HIV Agents; Anti-Infective Agents; Clinical Trials as Topic; Female; HIV Infections; Humans; India; Organophosphonates; Risk Factors; Sex Factors; Tenofovir | 2010 |
HIV-2 goes global: an unaddressed issue in Indian anti-retroviral programmes.
Topics: Adenine; Anti-HIV Agents; HIV Infections; HIV-2; Humans; India; Organophosphonates; Prevalence; Tenofovir; Zidovudine | 2010 |
AIDS: Drugs that prevent HIV infection.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Administration, Intravaginal; Administration, Oral; Animals; Anti-HIV Agents; Condoms; Controlled Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Emtricitabine; Female; HIV Infections; Homosexuality, Male; Humans; Male; Medication Adherence; Organophosphonates; Placebos; Reverse Transcriptase Inhibitors; Safe Sex; Tenofovir; Vaginal Creams, Foams, and Jellies | 2011 |
HIV prevention in women: next steps.
Topics: Adenine; Administration, Intravaginal; Anti-HIV Agents; Clinical Trials, Phase III as Topic; Coitus; Female; HIV Infections; Humans; Organophosphonates; Tenofovir; Vaginal Creams, Foams, and Jellies | 2011 |
Cost effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in treatment-naïve human immunodeficiency virus-infected patients in the United States.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Cost-Benefit Analysis; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Markov Chains; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Quality-Adjusted Life Years; Reverse Transcriptase Inhibitors; Risk Assessment; Ritonavir; Tenofovir; United States | 2011 |
Lactic acidosis after concomitant treatment with metformin and tenofovir in a patient with HIV infection.
Topics: Acidosis, Lactic; Acute Kidney Injury; Adenine; Aged; Anti-HIV Agents; Diabetes Mellitus, Type 2; Drug Interactions; HIV Infections; Humans; Hypoglycemic Agents; Male; Metformin; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2011 |
Analysis of drug resistance during HIV RNA viraemia in the MONET trial of darunavir/ritonavir monotherapy.
Topics: Adenine; Adult; Anti-HIV Agents; Clinical Trials as Topic; Darunavir; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Molecular Typing; Mutation; Organophosphonates; Ritonavir; RNA, Viral; Sulfonamides; Tenofovir; Treatment Outcome; Virus Replication | 2011 |
Is tenofovir-related renal toxicity incompletely reversible?
Topics: Adenine; Adult; Anti-HIV Agents; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Diseases; Male; Middle Aged; Organophosphonates; Tenofovir | 2011 |
[HIV infected women with intense bone and muscular pain and general weakness].
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Fanconi Syndrome; Female; Hepatitis, Viral, Human; HIV Infections; Humans; Hypophosphatemia; Middle Aged; Muscle Weakness; Musculoskeletal Diseases; Organophosphonates; Osteomalacia; Pain; Radionuclide Imaging; Radiopharmaceuticals; Substance Abuse, Intravenous; Technetium Tc 99m Medronate; Tenofovir | 2011 |
Efficacy of intravenous cidofovir in the treatment of giant molluscum contagiosum in a patient with human immunodeficiency virus.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cidofovir; Cytosine; HIV Infections; Humans; Infusions, Intravenous; Male; Molluscum Contagiosum; Organophosphonates; Treatment Outcome | 2011 |
HIV-2 infection, end-stage renal disease and protease inhibitor intolerance: which salvage regimen?
Topics: Adenine; Adult; Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; HIV-2; Humans; Kidney Failure, Chronic; Lamivudine; Male; Organophosphonates; Protease Inhibitors; Pyrrolidinones; Raltegravir Potassium; Renal Dialysis; Salvage Therapy; Tenofovir; Treatment Outcome | 2011 |
Managing hepatitis B/HIV co-infected: adding entecavir to truvada (tenofovir disoproxil/emtricitabine) experienced patients.
Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Deoxycytidine; DNA, Viral; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; Guanine; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Prospective Studies; Tenofovir; Treatment Outcome | 2011 |
Analysis of resistance testing in South Trinidad.
Topics: Adenine; Anti-HIV Agents; Darunavir; Drug Resistance, Multiple; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; Humans; Mutation; Organophosphonates; Patient Compliance; Sulfonamides; Tenofovir; Trinidad and Tobago | 2010 |
Low incidence of renal impairment observed in tenofovir-treated patients.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Case-Control Studies; Cohort Studies; Female; HIV Infections; Humans; Incidence; Male; Middle Aged; Organophosphonates; Renal Insufficiency; Retrospective Studies; Risk Factors; Tenofovir | 2011 |
Determination of the antiretroviral drug tenofovir in plasma from HIV-infected adults by ultrafast isotope dilution MALDI-triple quadrupole tandem mass spectrometry.
Topics: Adenine; Adult; Anti-HIV Agents; HIV Infections; Humans; Isotope Labeling; Linear Models; Organophosphonates; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tandem Mass Spectrometry; Tenofovir; Triglycerides | 2011 |
[HIV and AIDS: what's new in 2010?].
Topics: Adenine; Anti-HIV Agents; Anti-Retroviral Agents; Chemoprevention; Gels; HIV Infections; Humans; Organophosphonates; Tenofovir | 2011 |
[Renal adverse reactions of antiretroviral medication: proximal tubular dysfunction associated with tenofovir].
Topics: Adenine; Anti-HIV Agents; Fanconi Syndrome; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Tenofovir | 2011 |
Formulation of tenofovir-loaded functionalized solid lipid nanoparticles intended for HIV prevention.
Topics: Adenine; Administration, Intravaginal; Anti-HIV Agents; Cell Culture Techniques; Cell Line; Cell Survival; Chemistry, Pharmaceutical; Drug Carriers; Epithelial Cells; Female; Heparin; HIV Infections; Humans; Lipids; Microscopy, Electron, Transmission; Nanoparticles; Organophosphonates; Particle Size; Phase Transition; Polylysine; Surface Properties; Tenofovir; Vagina | 2011 |
Six-year follow-up of hepatitis B surface antigen concentrations in tenofovir disoproxil fumarate treated HIV-HBV-coinfected patients.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Follow-Up Studies; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Young Adult | 2011 |
Tenofovir-induced renal toxicity in 324 HIV-infected, antiretroviral-naïve patients.
Topics: Adenine; Adult; Anti-HIV Agents; Cohort Studies; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Diseases; Male; Middle Aged; Multivariate Analysis; Organophosphonates; Tenofovir | 2011 |
Preexposure chemoprophylaxis for HIV prevention.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Organophosphonates; Risk-Taking; Sexual Behavior; Tenofovir | 2011 |
Preexposure chemoprophylaxis for HIV prevention.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Organophosphonates; Risk-Taking; Sexual Behavior; Tenofovir | 2011 |
Preexposure chemoprophylaxis for HIV prevention.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Organophosphonates; Tenofovir | 2011 |
Preexposure chemoprophylaxis for HIV prevention.
Topics: Adenine; Age Factors; Anti-HIV Agents; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Kaplan-Meier Estimate; Male; Organophosphonates; Tenofovir; Young Adult | 2011 |
Preexposure chemoprophylaxis for HIV prevention.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Costs; Drug Therapy, Combination; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Organophosphonates; Risk; Tenofovir | 2011 |
Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection.
Topics: Acute Disease; Adenine; Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Prospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2011 |
Synergistic in vitro anti-HIV type 1 activity of tenofovir with carbohydrate-binding agents (CBAs).
Topics: Adenine; Anti-HIV Agents; Cell Line; Drug Synergism; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Organophosphonates; Tenofovir | 2011 |
Clinical experience with nevirapine combined with tenofovir plus emtricitabine or lamivudine-containing regimens in HIV-infected subjects.
Topics: Adenine; Adult; Anti-HIV Agents; Australia; Deoxycytidine; Drug Administration Schedule; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lost to Follow-Up; Male; Medical Audit; Middle Aged; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2011 |
Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons.
Topics: Adenine; Anti-Retroviral Agents; Biomarkers, Pharmacological; Cardiovascular Diseases; CD4 Lymphocyte Count; Cohort Studies; Dideoxynucleosides; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Risk Factors; Tenofovir; United States; Veterans; Viral Load | 2011 |
Improvement in chronic renal impairment following the discontinuation of tenofovir in two HIV-infected patients.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biomarkers; Biopsy; Chronic Disease; Creatinine; Drug Substitution; Glomerular Filtration Rate; HIV Infections; Humans; Kidney; Kidney Diseases; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2011 |
Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors.
Topics: Adenine; Animals; Anti-HIV Agents; Chemoprevention; Deoxyadenine Nucleotides; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lymphocytes; Lymphoid Tissue; Macaca; Organophosphonates; Prodrugs; Rectum; Reverse Transcriptase Inhibitors; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Substrate Specificity; Tenofovir | 2011 |
Long-term renal safety of tenofovir disoproxil fumarate in vertically HIV-infected children, adolescents and young adults: a 60-month follow-up study.
Topics: Adenine; Adolescent; Adult; Child; Cohort Studies; Creatinine; Female; Follow-Up Studies; Glomerular Filtration Rate; HIV Infections; Humans; Kidney; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2011 |
Increased risk of abnormal proximal renal tubular function with HIV infection and antiretroviral therapy.
Topics: Adenine; Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cross-Sectional Studies; Fanconi Syndrome; Female; France; HIV Infections; HIV-1; Humans; Kidney Tubules, Proximal; Logistic Models; Male; Middle Aged; Odds Ratio; Oligopeptides; Organophosphonates; Prevalence; Pyridines; Risk Assessment; Risk Factors; Tenofovir; Time Factors | 2011 |
Tenofovir-induced Fanconi syndrome and osteomalacia in two HIV-infected patients: role of intracellular tenofovir diphosphate levels and review of the literature.
Topics: Adenine; Adult; Anti-HIV Agents; Diphosphates; Fanconi Syndrome; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Osteomalacia; Radionuclide Imaging; Tenofovir; Whole Body Imaging | 2011 |
Study halted: no benefit seen from antiretroviral pill in preventing HIV in women.
Topics: Adenine; Adult; Africa; Anti-Retroviral Agents; Deoxycytidine; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Organophosphonates; Patient Compliance; Pregnancy; Pregnancy Rate; Randomized Controlled Trials as Topic; Tenofovir; Treatment Failure | 2011 |
One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidates.
Topics: Adenine; Administration, Topical; Animals; Base Sequence; CD4-Positive T-Lymphocytes; Chimera; Disease Models, Animal; DNA Primers; Drug Evaluation, Preclinical; Female; HIV Infections; Humans; Mice; Organophosphonates; Receptors, CCR5; Reverse Transcriptase Inhibitors; Tenofovir; Vagina | 2011 |
[Efavirenz in fixed combination with tenofovir and emtricitabine. Long-term effectiveness verified in new studies].
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Deoxycytidine; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Medication Adherence; Organophosphonates; Tenofovir; Treatment Outcome; Viral Load | 2011 |
Early end for FEM-PrEP HIV prevention trial.
Topics: Adenine; Administration, Oral; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Emtricitabine; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; HIV Infections; Humans; Kenya; Organophosphonates; Organophosphorus Compounds; Patient Compliance; Randomized Controlled Trials as Topic; South Africa; Tanzania; Tenofovir | 2011 |
Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction.
Topics: Adenine; Anti-HIV Agents; Female; HIV Infections; Humans; Kidney; Kidney Diseases; Kidney Tubules; Male; Multidrug Resistance-Associated Proteins; Organophosphonates; Polymorphism, Single Nucleotide; Tenofovir | 2011 |
Synergy against drug-resistant HIV-1 with the microbicide antiretrovirals, dapivirine and tenofovir, in combination.
Topics: Adenine; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Organophosphonates; Pyrimidines; Reverse Transcriptase Inhibitors; Tenofovir | 2011 |
Relationship between renal dysfunction, nephrotoxicity and death among HIV adults on tenofovir.
Topics: Adenine; Adult; Anti-HIV Agents; Cohort Studies; Creatinine; Female; HIV Infections; Humans; Kidney; Male; Middle Aged; Organophosphonates; Renal Insufficiency; Risk Factors; South Africa; Tenofovir | 2011 |
Population pharmacokinetics of atazanavir/ritonavir in HIV-1-infected children and adolescents.
Topics: Adenine; Adolescent; Anti-HIV Agents; Atazanavir Sulfate; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Drug Monitoring; Female; Follow-Up Studies; HIV Infections; Humans; Male; Models, Biological; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir; Tissue Distribution | 2011 |
Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Female; HIV Infections; Humans; Ischemic Attack, Transient; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Organophosphonates; Proportional Hazards Models; Renal Insufficiency, Chronic; Risk Factors; Stroke; Tenofovir; United States; United States Department of Veterans Affairs | 2011 |
Epidemiological impact of tenofovir gel on the HIV epidemic in South Africa.
Topics: Adenine; Anti-HIV Agents; Cost-Benefit Analysis; Female; HIV Infections; Humans; Incidence; Models, Biological; Organophosphonates; Prevalence; South Africa; Tenofovir; Vaginal Creams, Foams, and Jellies | 2011 |
Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Antiviral Agents; Case-Control Studies; Female; Gene Products, pol; Glomerular Filtration Rate; Hepatitis B, Chronic; HIV Infections; Humans; Linear Models; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Young Adult | 2011 |
Engineering tenofovir loaded chitosan nanoparticles to maximize microbicide mucoadhesion.
Topics: Adenine; Adhesiveness; Analysis of Variance; Animals; Anti-HIV Agents; Cell Survival; Chitosan; Drug Carriers; Drug Compounding; Epithelial Cells; Epithelium; Female; HIV Infections; Humans; In Vitro Techniques; Lactobacillus; Microscopy, Electron, Transmission; Nanoparticles; Organophosphonates; Particle Size; Solubility; Surface Properties; Swine; Tenofovir; Vagina | 2011 |
Renal impairment in HIV-1 infected patients receiving antiretroviral regimens including tenofovir in a resource-limited setting.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Anti-Retroviral Agents; Female; HIV Infections; HIV-1; Humans; Kidney Function Tests; Male; Middle Aged; Organophosphonates; Protease Inhibitors; Renal Insufficiency; Retrospective Studies; Tenofovir; Thailand | 2011 |
Determination of kidney function before tenofovir initiation: four-fold difference in need of tenofovir dose reduction depending on method used.
Topics: Adenine; Adult; Anti-HIV Agents; Dose-Response Relationship, Drug; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Diseases; Male; Organophosphonates; Retrospective Studies; Tenofovir | 2011 |
Comparison of abacavir/lamivudine and tenofovir/emtricitabine among treatment-naive HIV-infected patients initiating therapy.
Topics: Adenine; Adult; Anti-HIV Agents; Canada; Cohort Studies; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug Substitution; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Tenofovir; Treatment Failure; Virus Replication | 2011 |
Tenofovir and emtricitabine cerebrospinal fluid-to-plasma ratios correlate to the extent of blood-brainbarrier damage.
Topics: Adenine; Adult; Blood-Brain Barrier; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Pilot Projects; Tenofovir | 2011 |
Membranous nephropathy in an HIV-positive patient complicated with hepatitis B virus infection.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Emtricitabine; Glomerulonephritis, Membranous; Hepatitis B; HIV Infections; Humans; Male; Nephrotic Syndrome; Organophosphonates; Prednisolone; Tenofovir | 2011 |
Synthesis and antiviral evaluation of 9-(S)-[3-alkoxy-2-(phosphonomethoxy)propyl]nucleoside alkoxyalkyl esters: inhibitors of hepatitis C virus and HIV-1 replication.
Topics: Adenine; Antiviral Agents; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Organophosphonates; Prodrugs; Virus Replication | 2011 |
pH-responsive nanoparticles releasing tenofovir intended for the prevention of HIV transmission.
Topics: Adenine; Administration, Intravaginal; Anti-HIV Agents; Cell Line; Cell Survival; Drug Carriers; Drug Compounding; Epithelial Cells; Female; HIV Infections; Humans; Hydrogen-Ion Concentration; Lactic Acid; Lactobacillus; Microscopy, Confocal; Microscopy, Electron, Transmission; Microscopy, Fluorescence; Nanoparticles; Organophosphonates; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polymethacrylic Acids; Solubility; Surface Properties; Tenofovir; Vagina | 2011 |
Acyclic nucleoside phosphonates with a branched 2-(2-phosphonoethoxy)ethyl chain: efficient synthesis and antiviral activity.
Topics: Animals; Antiviral Agents; Cell Line; Cell Survival; Herpes Simplex; HIV; HIV Infections; Humans; Mice; Nucleosides; Organophosphonates; Simplexvirus; Structure-Activity Relationship; Vaccinia; Vaccinia virus; Virus Diseases; Viruses | 2011 |
Severe acute renal failure in an HIV-infected patient after only 2 weeks of tenofovir-based antiretroviral therapy.
Topics: Acute Kidney Injury; Adenine; Anti-HIV Agents; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Tenofovir; Treatment Outcome | 2011 |
Subcellular renal proximal tubular mitochondrial toxicity with tenofovir treatment.
Topics: Adenine; Animals; Cardiomyopathies; Cell Separation; DNA, Mitochondrial; Female; HIV Infections; HIV-1; Humans; Kidney Tubules, Proximal; Lasers; Liver Failure; Male; Mice; Mice, Inbred C57BL; Microdissection; Mitochondria; Organophosphonates; Reverse Transcriptase Inhibitors; Staining and Labeling; Tenofovir | 2011 |
Recalcitrant herpetic scrotal ulcer as a manifestation of immune reconstitution inflammatory syndrome.
Topics: Administration, Topical; Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Biopsy, Needle; Cidofovir; Cytosine; Diagnosis, Differential; Follow-Up Studies; Herpes Simplex; HIV Infections; Humans; Immune Reconstitution Inflammatory Syndrome; Immunohistochemistry; Male; Organophosphonates; Scrotum; Severity of Illness Index; Skin Ulcer; Treatment Outcome; Wound Healing | 2011 |
Rilpivirine: a step forward in tailored HIV treatment.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials, Phase III as Topic; Cyclopropanes; Delavirdine; Deoxycytidine; Drug Design; Drug Resistance, Viral; Emtricitabine; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Multicenter Studies as Topic; Mutation; Nevirapine; Nitriles; Organophosphonates; Pyrimidines; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Rilpivirine; Tenofovir; Viral Load | 2011 |
Antiretrovirals for HIV prevention: translating promise into praxis.
Topics: Adenine; Administration, Cutaneous; Administration, Oral; Algorithms; Anti-HIV Agents; Anti-Retroviral Agents; Congresses as Topic; Deoxycytidine; Emtricitabine; Female; Gels; Global Health; HIV Infections; Humans; Organophosphonates; Primary Prevention; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Sexual Behavior; Tenofovir; Treatment Outcome; Women's Health | 2011 |
Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women.
Topics: Adenine; Administration, Intravaginal; Administration, Oral; Africa South of the Sahara; Anti-HIV Agents; Anti-Retroviral Agents; Coitus; Deoxycytidine; Early Termination of Clinical Trials; Emtricitabine; Female; Gels; HIV Infections; Humans; Incidence; Organophosphonates; Primary Prevention; Randomized Controlled Trials as Topic; Rectum; Reverse Transcriptase Inhibitors; Tenofovir; Time Factors; Vagina; Women's Health | 2011 |
Tenofovir works as pre-exposure prophylaxis against HIV, two studies confirm.
Topics: Adenine; Anti-HIV Agents; HIV Infections; Humans; Organophosphonates; Randomized Controlled Trials as Topic; Sexual Partners; Tenofovir | 2011 |
Cost and cost-effectiveness of switching from d4T or AZT to a TDF-based first-line regimen in a resource-limited setting in rural Lesotho.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cost-Benefit Analysis; Developing Countries; Female; Health Care Costs; HIV Infections; Humans; Lesotho; Male; Middle Aged; Organophosphonates; Pregnancy; Rural Population; Stavudine; Tenofovir; Zidovudine | 2011 |
Antiretroviral prophylaxis: a defining moment in HIV control.
Topics: Adenine; Administration, Oral; Anti-HIV Agents; Anti-Retroviral Agents; Botswana; Clinical Trials as Topic; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Kenya; Male; Organophosphonates; Tenofovir; Uganda | 2011 |
Association of osteonecrosis and osteoporosis in HIV-1-infected patients.
Topics: Absorptiometry, Photon; Adenine; Alcohol Drinking; Anti-HIV Agents; California; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Osteonecrosis; Osteoporosis; Prednisolone; Tenofovir | 2011 |
Concentrations of tenofovir and emtricitabine in saliva: implications for preexposure prophylaxis of oral HIV acquisition.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Saliva; Sexual Behavior; Tenofovir | 2011 |
Bilateral pathologic hip fractures associated with antiretroviral therapy: a case report.
Topics: Accidental Falls; Adenine; Alendronate; Anti-HIV Agents; Bone Density Conservation Agents; Comorbidity; Fanconi Syndrome; Female; Femoral Neck Fractures; Fractures, Spontaneous; Hip Fractures; HIV Infections; Humans; Magnetic Resonance Imaging; Middle Aged; Organophosphonates; Osteoporotic Fractures; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure | 2011 |
Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients.
Topics: Adenine; Adult; Anti-HIV Agents; Asian People; Body Weight; Cohort Studies; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney; Male; Middle Aged; Multivariate Analysis; Organophosphonates; Retrospective Studies; Tenofovir | 2011 |
Patient-reported outcomes and low-level residual HIV-RNA in adolescents perinatally infected with HIV-1 after switching to one-pill fixed-dose regimen.
Topics: Adenine; Adolescent; Alkynes; Anti-HIV Agents; Antiviral Agents; Benzoxazines; Child; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Patient Satisfaction; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2012 |
A case of lactic acidosis (LA) after administration of tenofovir and metformin in a diabetic patient with recently diagnosed HIV infection.
Topics: Acidosis, Lactic; Adenine; Anti-HIV Agents; Diabetes Mellitus, Type 2; HIV Infections; Humans; Hypoglycemic Agents; Male; Metformin; Organophosphonates; Reverse Transcriptase Inhibitors | 2011 |
Antiretroviral therapy alone resulted in successful resolution of large idiopathic esophageal ulcers in a patient with acute retroviral syndrome.
Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Esophageal Diseases; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Organophosphonates; Pyrimidinones; Ritonavir; RNA, Viral; Syndrome; Tenofovir; Ulcer | 2011 |
Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Cohort Studies; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Retrospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Viral Load | 2011 |
A comparison of tenofovir-associated renal function changes in HIV-infected African Americans vs Caucasians.
Topics: Adenine; Adult; Anti-HIV Agents; Black or African American; Creatinine; Drug Monitoring; Female; Glomerular Filtration Rate; HIV; HIV Infections; Humans; Kidney; Male; Middle Aged; Organophosphonates; Renal Insufficiency; Tenofovir; United States; White People; Withholding Treatment | 2011 |
HIV-HBV vaccine escape mutant infection with loss of HBV surface antibody and persistent HBV viremia on tenofovir/emtricitabine without antiviral resistance.
Topics: Adenine; Antiviral Agents; Coinfection; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Hepatitis B; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B virus; HIV Infections; HIV-1; Humans; Male; Middle Aged; Mutation; Organophosphonates; Tenofovir; Viral Load; Viremia | 2011 |
Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy.
Topics: Adenine; Anti-Retroviral Agents; Cell Line; Drug Resistance, Viral; HEK293 Cells; HIV Infections; HIV-1; Humans; Models, Biological; Organophosphonates; Tenofovir; Virus Replication | 2011 |
Impact of tenofovir versus abacavir on HIV-related endothelial dysfunction.
Topics: Adenine; Adult; Anti-HIV Agents; Case-Control Studies; Chemokine CCL2; Dideoxynucleosides; Endothelium, Vascular; Female; HIV Infections; HIV-1; Humans; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Vascular Cell Adhesion Molecule-1; Vasodilation | 2011 |
Comparative outcomes of tenofovir-based and zidovudine-based antiretroviral therapy regimens in Lusaka, Zambia.
Topics: Adenine; Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Organophosphonates; Proportional Hazards Models; Retrospective Studies; Risk Factors; Tenofovir; Zambia; Zidovudine | 2011 |
Population pharmacokinetics of tenofovir in HIV-1-infected pediatric patients.
Topics: Adenine; Adolescent; Anti-HIV Agents; Child; Child, Preschool; HIV Infections; HIV-1; Humans; Kidney; Organophosphonates; Plasma; Tenofovir | 2011 |
Modeling interventions to assess HIV epidemic impact in Africa.
Topics: Adenine; Anti-HIV Agents; Female; HIV Infections; Humans; Organophosphonates; Tenofovir | 2011 |
Persistent decline in estimated but not measured glomerular filtration rate on tenofovir may reflect tubular rather than glomerular toxicity.
Topics: Adenine; Adult; Alpha-Globulins; Anti-HIV Agents; Creatinine; Female; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Kidney Glomerulus; Kidney Tubules; Male; Middle Aged; Organophosphonates; Randomized Controlled Trials as Topic; Renal Plasma Flow, Effective; Serum Albumin; Tenofovir; Time Factors; Treatment Outcome | 2011 |
Optimizing initial therapy for HIV infection.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Tenofovir | 2011 |
Fanconi syndrome-like tubular acidosis associated with a tenofovir-containing antiretroviral regimen in a human immunodeficiency virus-1-infected Asian woman.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Fanconi Syndrome; Female; HIV Infections; HIV-1; Humans; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2012 |
Predictors of HBeAg status and hepatitis B viraemia in HIV-infected patients with chronic hepatitis B in the HAART era in Brazil.
Topics: Adenine; Adult; Alanine Transaminase; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Brazil; CD4 Lymphocyte Count; Cross-Sectional Studies; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Retrospective Studies; Risk Factors; Tenofovir; Viral Load; Viremia | 2011 |
Assessing recovery of renal function after tenofovir disoproxil fumarate discontinuation.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Drug Administration Schedule; Female; Glomerular Filtration Rate; HIV Infections; Humans; Japan; Kidney Diseases; Kidney Function Tests; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Young Adult | 2012 |
Pharmacokinetics of tenofovir following intravaginal and intrarectal administration of tenofovir gel to rhesus macaques.
Topics: Adenine; Administration, Intravaginal; Administration, Rectal; Animals; Antiviral Agents; Area Under Curve; Body Fluids; Dose-Response Relationship, Drug; Female; Gels; HIV Infections; HIV-1; Humans; Macaca mulatta; Organophosphonates; Rectum; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Tenofovir; Vagina | 2012 |
Microbicide might protect pregnant women from HIV. Susceptibility is high for them.
Topics: Adenine; Disease Susceptibility; Female; HIV Infections; Humans; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors; Tenofovir | 2011 |
Neither proteinuria nor albuminuria is associated with endothelial dysfunction in HIV-infected patients without diabetes or hypertension.
Topics: Adenine; Adult; Albuminuria; Alkynes; Anti-HIV Agents; Benzoxazines; Brachial Artery; Chi-Square Distribution; Creatinine; Cyclopropanes; Dideoxynucleosides; Endothelium, Vascular; Female; Glomerular Filtration Rate; HIV Infections; Humans; Linear Models; Male; Middle Aged; Organophosphonates; Proteinuria; Tenofovir; Ultrasonography; Vasodilation | 2011 |
Efficacy, adherence and tolerability of once daily tenofovir DF-containing antiretroviral therapy in former injecting drug users with HIV-1 receiving opiate treatment: results of a 48-week open-label study.
Topics: Adenine; Adult; Analgesics, Opioid; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Male; Maximum Tolerated Dose; Medication Adherence; Methadone; Middle Aged; Organophosphonates; Substance Abuse, Intravenous; Survival Rate; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2011 |
Bone turnover, osteoprotegerin/RANKL and inflammation with antiretroviral initiation: tenofovir versus non-tenofovir regimens.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Biomarkers; Bone Density; Bone Remodeling; CD4 Lymphocyte Count; Collagen Type I; Cytokines; Female; HIV Infections; Humans; Inflammation; Longitudinal Studies; Male; NF-kappa B; Organophosphonates; Osteoprotegerin; Protease Inhibitors; RANK Ligand; Tenofovir; Tumor Necrosis Factor-alpha; Young Adult | 2011 |
Resistance data in the ARTEN trial.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Female; HIV Infections; Humans; Male; Nevirapine; Oligopeptides; Organophosphonates; Pyridines; Ritonavir | 2011 |
Effects of HAART on platelet-activating factor metabolism in naive HIV-infected patients I: study of the tenofovir-DF/emtricitabine/efavirenz HAART regimen.
Topics: Adenine; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Deoxycytidine; Drug Combinations; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; Humans; Male; Organophosphonates; Oxazines; Platelet Activating Factor; Viral Load | 2012 |
Synthesis of novel difluoro-cyclopropyl guanine nucleosides and their phosphonate analogues as potent antiviral agents.
Topics: Antiviral Agents; Cell Line; Cyclopropanes; Cytomegalovirus; Cytomegalovirus Infections; Guanine; Halogenation; HIV Infections; HIV-1; Humans; Nucleosides; Organophosphonates | 2011 |
Pre-exposure chemoprophylaxis of HIV infection: quo vadis?
Topics: Adenine; Administration, Intravaginal; Administration, Oral; Administration, Topical; Anti-HIV Agents; Clinical Trials as Topic; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Molecular Structure; Organophosphonates; Patient Compliance; Tenofovir | 2012 |
Sustained virological response to a raltegravir-containing salvage therapy in an HIV-2-infected patient.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; CD4 Lymphocyte Count; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV Protease Inhibitors; HIV-2; Humans; Lopinavir; Male; Middle Aged; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Salvage Therapy; Tenofovir; Treatment Outcome; Viral Load | 2011 |
The price of tenofovir-emtricitabine undermines the cost-effectiveness and advancement of pre-exposure prophylaxis.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Cost-Benefit Analysis; Deoxycytidine; Drug Costs; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Models, Economic; Organophosphonates; Tenofovir | 2011 |
Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue.
Topics: Adenine; Animals; Anti-HIV Agents; Cells, Cultured; Drug Stability; Female; Half-Life; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Longitudinal Studies; Organophosphonates; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Tenofovir; Vagina; Vaginal Creams, Foams, and Jellies | 2012 |
Acceptability of an "on-demand" pre-exposure HIV prophylaxis trial among men who have sex with men living in France.
Topics: Adenine; Adult; Anti-HIV Agents; Chemoprevention; Deoxycytidine; Drug Combinations; Educational Status; Emtricitabine; France; HIV Infections; HIV Serosorting; Homosexuality, Male; Humans; Male; Organophosphonates; Patient Acceptance of Health Care; Patient Selection; Post-Exposure Prophylaxis; Research Subjects; Risk Reduction Behavior; Self Administration; Tenofovir; Unsafe Sex | 2012 |
Re.: Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
Topics: Adenine; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Organophosphonates; Pregnancy | 2011 |
Re.: Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; HIV Infections; Homosexuality, Male; Humans; Male; Organophosphonates | 2011 |
Long-term outcome of primary non-responders to tenofovir therapy in HIV/HBV-co-infected patients: impact of HBV genotype G.
Topics: Adenine; Adult; Anti-HIV Agents; Coinfection; Deoxycytidine; DNA Mutational Analysis; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; Genotype; Hepatitis B; Hepatitis B virus; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Retrospective Studies; Tenofovir; Time Factors; Treatment Outcome | 2012 |
Different baseline characteristics and different outcomes of HIV-infected patients receiving HAART through clinical trials compared with routine care in Mexico.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Clinical Trials as Topic; Deoxycytidine; Emtricitabine; Epidemiologic Methods; Female; HIV Infections; Humans; Kaplan-Meier Estimate; Lopinavir; Male; Mexico; Nevirapine; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir | 2012 |
Tenofovir induced acute kidney injury in a patient with unilateral renal agenesis despite initially non-impaired renal function.
Topics: Acute Kidney Injury; Adenine; Adult; Anti-HIV Agents; Congenital Abnormalities; HIV Infections; Humans; Kidney; Kidney Diseases; Male; Organophosphonates; Tenofovir | 2011 |
Pregnancy-related effects on tenofovir pharmacokinetics: a population study with 186 women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Drug Monitoring; Female; HIV Infections; HIV-1; Humans; Middle Aged; Models, Biological; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimester, Second; Pregnancy Trimester, Third; Reverse Transcriptase Inhibitors; Tenofovir; Young Adult | 2012 |
Simultaneous delivery of tenofovir and acyclovir via an intravaginal ring.
Topics: Acyclovir; Adenine; Administration, Intravaginal; Animals; Anti-HIV Agents; Antiviral Agents; Delayed-Action Preparations; Disease Models, Animal; Drug Combinations; Drug Delivery Systems; Equipment Design; Female; Herpes Genitalis; Herpesvirus 2, Human; HIV Infections; HIV-1; Humans; Organophosphonates; Rabbits; Sexually Transmitted Diseases, Viral; Tenofovir; Treatment Outcome | 2012 |
In vitro resistance profile of the candidate HIV-1 microbicide drug dapivirine.
Topics: Adenine; Anti-HIV Agents; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Mutation; Organophosphonates; Pyrimidines; Reverse Transcriptase Inhibitors; Tenofovir | 2012 |
Early markers of tubular dysfunction in antiretroviral-experienced HIV-infected patients treated with tenofovir versus abacavir.
Topics: Adenine; Anti-HIV Agents; Biomarkers; Cohort Studies; Cytochromes c; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Glomerular Filtration Rate; Glutathione Transferase; HIV Infections; Humans; Kidney Diseases; Kidney Tubules, Proximal; Lamivudine; Male; Middle Aged; Mitochondria; Organophosphonates; Tenofovir; Time Factors | 2012 |
Evaluating the extent of potential resistance to pre-exposure prophylaxis within the UK HIV-1-infectious population of men who have sex with men.
Topics: Adenine; Anti-HIV Agents; Cohort Studies; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Homosexuality, Male; Humans; Logistic Models; Male; Organophosphonates; Prevalence; Tenofovir; United Kingdom; Viral Load | 2012 |
In utero exposure to tenofovir disoproxil fumarate does not impair growth and bone health in HIV-uninfected children born to HIV-infected mothers.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone and Bones; Child; Child, Preschool; Cohort Studies; Cross-Sectional Studies; Female; Fetus; HIV; HIV Infections; HIV Seropositivity; Humans; Infant; Infectious Disease Transmission, Vertical; Italy; Male; Observation; Organophosphonates; Pregnancy; Reverse Transcriptase Inhibitors; Tenofovir | 2011 |
Abacavir, didanosine and tenofovir do not induce inflammatory, apoptotic or oxidative stress genes in coronary endothelial cells.
Topics: Adenine; Anti-HIV Agents; Apoptosis; Cardiovascular Diseases; Cell Adhesion Molecules; Coronary Vessels; Cytokines; Didanosine; Dideoxynucleosides; Endothelial Cells; Gene Expression; Gene Expression Profiling; HIV Infections; HIV-1; Humans; Inflammation; NADPH Oxidases; Organophosphonates; Oxidative Stress; Primary Cell Culture; Proto-Oncogene Proteins; Tenofovir | 2011 |
Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Area Under Curve; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Male; Organophosphonates; Tenofovir | 2011 |
FDA notifications. Complera approved.
Topics: Adenine; Deoxycytidine; Drug Approval; Drug Combinations; Drug Labeling; Emtricitabine; HIV Infections; Humans; Nitriles; Organophosphonates; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Tenofovir; United States; United States Food and Drug Administration | 2011 |
Recent HIV-1 infection: to treat or not to treat, that is the question.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Organophosphonates; Ritonavir; Tenofovir; Viral Load | 2012 |
Comparison between Elecsys HBsAg II and architect HBsAg QT assays for quantification of hepatitis B surface antigen among patients coinfected with HIV and hepatitis B virus.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Coinfection; Female; Genotype; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Reagent Kits, Diagnostic; Tenofovir | 2012 |
Tenofovir-induced nephrotoxicity: myths and facts.
Topics: Adenine; Animals; Anti-HIV Agents; Evidence-Based Medicine; HIV Infections; HIV-1; Humans; Kidney Diseases; Organophosphonates; Reverse Transcriptase Inhibitors; Risk Factors; Tenofovir | 2012 |
Renal function declines more in tenofovir- than abacavir-based antiretroviral therapy in low-body weight treatment-naïve patients with HIV infection.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Body Weight; Demography; Dideoxynucleosides; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kaplan-Meier Estimate; Male; Multivariate Analysis; Organophosphonates; Risk Factors; Tenofovir | 2012 |
Combination of antiretroviral drugs as microbicides.
Topics: Adenine; Anti-Infective Agents, Local; Anti-Retroviral Agents; Drug Therapy, Combination; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Organophosphonates; Receptors, HIV; Tenofovir | 2012 |
Quasispecies analysis and in vitro susceptibility of HBV strains isolated from HIV-HBV-coinfected patients with delayed response to tenofovir.
Topics: Adenine; Adult; Antiviral Agents; Cloning, Molecular; Coinfection; DNA, Viral; Drug Resistance, Viral; Female; Genotype; Hep G2 Cells; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Sequence Analysis, DNA; Tenofovir; Transfection | 2012 |
Renal function in HIV-infected children and adolescents treated with tenofovir disoproxil fumarate and protease inhibitors.
Topics: Adenine; Adolescent; Anti-HIV Agents; Child; Female; HIV Infections; HIV Protease Inhibitors; Humans; Kidney; Kidney Diseases; Kidney Function Tests; Male; Organophosphonates; Prospective Studies; Tenofovir | 2012 |
HIV preexposure prophylaxis: new data and potential use.
Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Deoxycytidine; Emtricitabine; Evidence-Based Medicine; Female; HIV Infections; HIV-1; Homosexuality, Male; Humans; Male; Organophosphonates; Tenofovir | 2011 |
Effect of abacavir on acute changes in biomarkers associated with cardiovascular dysfunction.
Topics: Adenine; Adult; Anti-HIV Agents; Biomarkers; Cardiovascular Diseases; Case-Control Studies; Dideoxynucleosides; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Risk Factors; Tenofovir | 2012 |
Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; Hip Fractures; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Organophosphonates; Osteoporotic Fractures; Retrospective Studies; Risk; Risk Factors; Ritonavir; Spinal Fractures; Tenofovir; Time Factors; Treatment Outcome; Wrist Injuries; Young Adult | 2012 |
An unrecognised case of tenofovir-associated Fanconi syndrome.
Topics: Adenine; Adolescent; Anti-HIV Agents; Fanconi Syndrome; HIV Infections; Humans; Male; Organophosphonates; Tenofovir | 2012 |
Association of tenofovir exposure with kidney disease risk in HIV infection.
Topics: Adenine; Adult; Anti-HIV Agents; Female; Follow-Up Studies; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Failure, Chronic; Male; Middle Aged; Organophosphonates; Proteinuria; Risk Factors; Tenofovir; Time Factors; Treatment Outcome | 2012 |
Standardized comparison of the relative impacts of HIV-1 reverse transcriptase (RT) mutations on nucleoside RT inhibitor susceptibility.
Topics: Adenine; Algorithms; Anti-HIV Agents; Dideoxynucleosides; Drug Resistance, Multiple, Viral; Genomics; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Least-Squares Analysis; Mutation; Nucleosides; Organophosphonates; Phenotype; Reverse Transcriptase Inhibitors; Tenofovir; Thymidine; Zidovudine | 2012 |
Kinetics of hepatitis B surface and envelope antigen and prediction of treatment response to tenofovir in antiretroviral-experienced HIV-hepatitis B virus-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Male; Organophosphonates; Prospective Studies; Tenofovir; Treatment Outcome | 2012 |
Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention.
Topics: Adenine; Administration, Oral; Anti-HIV Agents; Antiviral Agents; Clinical Trials as Topic; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Patient Compliance; Risk Factors; Tenofovir; Treatment Outcome; Vaginal Creams, Foams, and Jellies | 2012 |
Increase in serum mitochondrial creatine kinase levels induced by tenofovir administration.
Topics: Adenine; Adult; Analysis of Variance; Anti-HIV Agents; Antibodies, Monoclonal; Antiretroviral Therapy, Highly Active; Cohort Studies; Creatine Kinase, Mitochondrial Form; Electrophoresis, Agar Gel; Enzyme-Linked Immunosorbent Assay; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Tenofovir | 2012 |
Least among equals.
Topics: Adenine; Anti-HIV Agents; HIV Infections; Humans; Organophosphonates; Tenofovir | 2012 |
Reduced quantitative ultrasound bone mineral density in HIV-infected patients on antiretroviral therapy in Senegal.
Topics: Adenine; Adult; Anti-HIV Agents; Anti-Retroviral Agents; Body Mass Index; Bone Density; Case-Control Studies; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Protease Inhibitors; Senegal; Tenofovir; Viral Load | 2012 |
Preservation HIV-1-specific IFNγ+ CD4+ T-cell responses in breakthrough infections after exposure to tenofovir gel in the CAPRISA 004 microbicide trial.
Topics: Adenine; Adult; Anti-HIV Agents; Anti-Infective Agents; CD4-Positive T-Lymphocytes; Female; HIV Infections; HIV-1; Humans; Interferon-gamma; Organophosphonates; South Africa; Tenofovir; Vaginal Creams, Foams, and Jellies | 2012 |
The British HIV Association/British Association for Sexual Health and HIV Position Statement on pre-exposure prophylaxis in the UK.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Tenofovir; United Kingdom | 2012 |
Immune reconstitution renal-limited sarcoidosis presenting as acute kidney injury.
Topics: Acute Kidney Injury; Adenine; Adult; AIDS-Associated Nephropathy; Anti-Retroviral Agents; Atazanavir Sulfate; Female; HIV Infections; Humans; Oligopeptides; Organophosphonates; Prednisone; Pyridines; Ritonavir; Sarcoidosis; Tenofovir; Young Adult | 2012 |
Adverse drug reactions to antiretroviral therapy (ARVs): incidence, type and risk factors in Nigeria.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cohort Studies; Cyclopropanes; Drug-Related Side Effects and Adverse Reactions; Exanthema; Female; HIV Infections; Humans; Incidence; Lamivudine; Male; Middle Aged; Nevirapine; Nigeria; Organophosphonates; Pain; Retrospective Studies; Risk Factors; Stavudine; Tenofovir; Zidovudine | 2012 |
Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Female; France; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Mutation, Missense; Organophosphonates; Retrospective Studies; RNA, Viral; Selection, Genetic; Tenofovir; Treatment Failure; Viral Load | 2012 |
Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants.
Topics: Adenine; Anti-HIV Agents; Body Size; Child Development; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant; Infant, Low Birth Weight; Infant, Newborn; Infant, Small for Gestational Age; Male; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Prospective Studies; Risk Factors; Tenofovir | 2012 |
L-selectin and P-selectin are novel biomarkers of cervicovaginal inflammation for preclinical mucosal safety assessment of anti-HIV-1 microbicide.
Topics: Adenine; Animals; Anti-Infective Agents; Benzalkonium Compounds; Biomarkers; Carboxymethylcellulose Sodium; Cervix Uteri; Chemokine CCL2; Female; HIV Infections; Inflammation; Interleukin-6; L-Selectin; Mice; Mice, Inbred C57BL; Mucous Membrane; Nonoxynol; Organophosphonates; P-Selectin; Sodium Dodecyl Sulfate; Tenofovir | 2012 |
Pharmacokinetics and topical vaginal effects of two tenofovir gels in rabbits.
Topics: Adenine; Administration, Intravaginal; Administration, Rectal; Animals; Anti-HIV Agents; Body Fluids; Female; HIV Infections; Lymph Nodes; Organophosphonates; Rabbits; Tenofovir; Vagina; Vaginal Creams, Foams, and Jellies | 2012 |
Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir.
Topics: Adenine; Adult; Alkynes; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; Glomerular Filtration Rate; HIV Infections; HIV Protease Inhibitors; Humans; Kidney; Lopinavir; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome | 2012 |
Characterization of UC781-tenofovir combination gel products for HIV-1 infection prevention in an ex vivo ectocervical model.
Topics: Adenine; Anilides; Anti-HIV Agents; Anti-Retroviral Agents; Cervix Uteri; Chromatography, High Pressure Liquid; Female; Furans; Gels; HIV Infections; Humans; In Vitro Techniques; Organophosphonates; Tandem Mass Spectrometry; Tenofovir; Thioamides | 2012 |
Development of polylactide and polyethylene vinyl acetate blends for the manufacture of vaginal rings.
Topics: Adenine; Anti-Infective Agents; Antiviral Agents; Biocompatible Materials; Body Fluids; Contraceptive Devices, Female; Diffusion; Drug Delivery Systems; Female; HIV Infections; Humans; Microscopy, Electron, Scanning; Organophosphonates; Polyesters; Polymers; Polyvinyls; Tenofovir; Vagina | 2012 |
Intravaginal ring delivery of tenofovir disoproxil fumarate for prevention of HIV and herpes simplex virus infection.
Topics: Adenine; Antiviral Agents; Cell Culture Techniques; Chemoprevention; Contraceptive Devices, Female; Female; Herpes Genitalis; HIV; HIV Infections; Humans; Organ Culture Techniques; Organophosphonates; Simplexvirus; Tenofovir | 2012 |
The cost-effectiveness of pre-exposure prophylaxis for HIV infection in South African women.
Topics: Adenine; Adult; Anti-HIV Agents; Chemoprevention; Cost-Benefit Analysis; Female; HIV Infections; Humans; Incidence; Middle Aged; Organophosphonates; Survival Analysis; Tenofovir; Treatment Outcome | 2012 |
Cutaneous CD8+ T-cell infiltrates associated with human immunodeficiency virus.
Topics: Adenine; Alopecia; Anti-HIV Agents; Antigens, Differentiation, T-Lymphocyte; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD8-Positive T-Lymphocytes; Deoxycytidine; Diagnosis, Differential; Emtricitabine; HIV Infections; Humans; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Oligopeptides; Organophosphonates; Prednisone; Pseudolymphoma; Pyridines; Ritonavir; Skin; Tenofovir | 2012 |
Truncated phosphonated C-1'-branched N,O-nucleosides: a new class of antiviral agents.
Topics: Anti-HIV Agents; Antiviral Agents; Cells, Cultured; Drug Evaluation, Preclinical; HIV Infections; Human T-lymphotropic virus 1; Humans; Inhibitory Concentration 50; Leukocytes, Mononuclear; Molecular Structure; Nitrogen Oxides; Nucleosides; Organic Chemistry Phenomena; Organophosphonates; Structure-Activity Relationship; Zidovudine | 2012 |
Renal toxicity of long-term therapy with tenofovir in HIV-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Dideoxynucleosides; Disease Progression; Female; Follow-Up Studies; Glomerular Filtration Rate; HIV Infections; Hospitals, Veterans; Humans; Incidence; Kidney; Male; Middle Aged; New York City; Organophosphonates; Outpatient Clinics, Hospital; Pilot Projects; Proportional Hazards Models; Renal Insufficiency, Chronic; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir | 2012 |
The elvitegravir Quad pill: the first once-daily dual-target anti-HIV tablet.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; Clinical Trials as Topic; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; Humans; Organophosphonates; Quinolones; Tablets; Thiazoles | 2012 |
Reformulated tenofovir gel for use as a dual compartment microbicide.
Topics: Adenine; Anti-HIV Agents; Anti-Infective Agents; Disease Transmission, Infectious; Female; HIV Infections; HIV-1; Humans; Organ Culture Techniques; Organophosphonates; Rectum; Tenofovir; Treatment Outcome; Vagina; Vaginal Creams, Foams, and Jellies | 2012 |
Does maternal use of tenofovir during pregnancy affect growth of HIV-exposed uninfected infants?
Topics: Adenine; Anti-HIV Agents; Body Size; Female; HIV Infections; Humans; Infant, Newborn; Male; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Tenofovir | 2012 |
Case report of cytomegalovirus retinitis in an HIV-positive patient with a CD4-count nadir of 254 cells per μl.
Topics: Adenine; Administration, Oral; Adult; Alkynes; Anti-HIV Agents; Aqueous Humor; Benzoxazines; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cyclopropanes; Cytomegalovirus; Cytomegalovirus Retinitis; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Male; Organophosphonates; Polymerase Chain Reaction; Tenofovir; Visual Acuity | 2012 |
Antiretroviral prophylaxis for HIV prevention reaches a key milestone.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Emtricitabine; HIV Infections; Humans; Organophosphonates; Tenofovir | 2012 |
Pharmacokinetic profiling of efavirenz-emtricitabine-tenofovir fixed dose combination in pregnant and non-pregnant rats.
Topics: Adenine; Administration, Oral; Amniotic Fluid; Animals; Anti-HIV Agents; Chromatography, High Pressure Liquid; Deoxycytidine; Dose-Response Relationship, Drug; Drug Combinations; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; Fetus; HIV Infections; Infectious Disease Transmission, Vertical; Maternal-Fetal Exchange; Organophosphonates; Oxazines; Placenta; Pregnancy; Rats, Sprague-Dawley; Tissue Distribution | 2012 |
Patient-reported symptoms on the antiretroviral regimen efavirenz/emtricitabine/tenofovir.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cohort Studies; Cross-Sectional Studies; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; Health Status; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Quality of Life; Severity of Illness Index; Tenofovir; Treatment Outcome; Veterans | 2012 |
An intravaginal ring for the simultaneous delivery of multiple drugs.
Topics: Acyclovir; Adenine; Administration, Intravaginal; Animals; Antiviral Agents; Delayed-Action Preparations; Drug Delivery Systems; Equipment Design; Female; HIV; HIV Infections; Humans; Organophosphonates; Reverse Transcriptase Inhibitors; Silicon; Tenofovir; Tensile Strength | 2012 |
The deleterious influence of tenofovir-based therapies on the progression of atherosclerosis in HIV-infected patients.
Topics: Adenine; Atherosclerosis; Chemokine CCL2; HIV Infections; Interleukin-6; Organophosphonates; Prospective Studies; Reverse Transcriptase Inhibitors; Tenofovir | 2012 |
Impact of antiretroviral dosing frequency and pill burden on adherence among newly diagnosed, antiretroviral-naive HIV patients.
Topics: Adenine; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies; Cyclopropanes; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Male; Medication Adherence; Middle Aged; Organophosphonates; Prospective Studies; Tenofovir | 2012 |
How good is "good enough"? The case for varying standards of evidence according to need for new interventions in HIV prevention.
Topics: Adenine; Administration, Intravaginal; Administration, Oral; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Emtricitabine; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Ethical Analysis; Ethical Theory; Ethics, Research; Evidence-Based Medicine; Female; Gels; Guidelines as Topic; Health Services Accessibility; Health Services Needs and Demand; HIV Infections; Homosexuality, Male; Humans; Male; Organophosphonates; Organophosphorus Compounds; Primary Prevention; Randomized Controlled Trials as Topic; Research Subjects; Sex Work; Tenofovir; Therapeutic Equipoise; United States; United States Food and Drug Administration | 2012 |
Renal function and incidence of chronic kidney disease in HIV patients: a Danish cohort study.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cohort Studies; Denmark; Female; Glomerular Filtration Rate; HIV Infections; Humans; Incidence; Kidney; Linear Models; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Renal Insufficiency, Chronic; Tenofovir | 2012 |
Efavirenz and psychosis: is there a link?
Topics: Adenine; Adult; Alkynes; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Combinations; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; Humans; Male; Organophosphonates; Oxazines; Psychoses, Substance-Induced; Reverse Transcriptase Inhibitors | 2012 |
Sustained local delivery of structurally diverse HIV-1 microbicides released from sublimation enthalpy controlled matrices.
Topics: Adenine; Animals; Anti-HIV Agents; Cells, Cultured; Contraceptive Devices, Female; Delayed-Action Preparations; Deoxycytidine; Drug Delivery Systems; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Macrophages; Monocytes; Organophosphonates; Sheep; Structure-Activity Relationship; Sublimation, Chemical; T-Lymphocytes; Tenofovir | 2012 |
Tenofovir in second-line ART in Zambia and South Africa: collaborative analysis of cohort studies.
Topics: Adenine; Adult; Africa South of the Sahara; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; South Africa; Tenofovir; Treatment Outcome; Viral Load; Zambia | 2012 |
Long-term hepatitis B virus surface antigen decay in HIV-1/hepatitis B virus-coinfected adults initiating a tenofovir-containing regimen.
Topics: Adenine; Adult; Anti-HIV Agents; Coinfection; Hepatitis B Surface Antigens; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Middle Aged; Organophosphonates; Tenofovir; Treatment Outcome; Viral Load | 2012 |
Preexposure prophylaxis for HIV--where do we go from here?
Topics: Adenine; Anti-Retroviral Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Pregnancy; Tenofovir | 2012 |
Clinical decisions. Preexposure prophylaxis for HIV prevention.
Topics: Adenine; Adolescent; Anti-Retroviral Agents; Deoxycytidine; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Safe Sex; Tenofovir | 2012 |
Five-year review of HIV-hepatitis B virus (HBV) co-infected patients in a New York City AIDS center.
Topics: Adenine; Adult; Anti-HIV Agents; Coinfection; Female; Hepatitis B; Hepatitis B e Antigens; HIV Infections; Humans; Liver Cirrhosis; Male; Middle Aged; New York City; Organophosphonates; Retrospective Studies; Tenofovir | 2012 |
The introduction of new antiretroviral-based HIV prevention methods into health systems: an update.
Topics: Adenine; Africa South of the Sahara; Anti-Retroviral Agents; Deoxycytidine; Drug Combinations; Emtricitabine; HIV Infections; Humans; Organophosphonates; Tenofovir; Vaginal Creams, Foams, and Jellies | 2012 |
Prevention. Using PrEP cost-effective in high-risk MSM groups.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Drug Costs; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Organophosphonates; Risk Factors; Tenofovir | 2012 |
Research. Fetuses unaffected by tenofovir, 1-year-olds appear slightly smaller.
Topics: Adenine; Female; Fetus; Growth; HIV Infections; Humans; Infant; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors; Tenofovir | 2012 |
Lamivudine or emtricitabine (XTC)/protease inhibitor dual therapy as a harm-reduction strategy in patients with tenofovir-related renal toxicity: a case-control study.
Topics: Adenine; Adult; Aged; Case-Control Studies; CD4 Lymphocyte Count; Chi-Square Distribution; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Kidney Diseases; Kidney Function Tests; Lamivudine; Male; Middle Aged; Organophosphonates; Protease Inhibitors; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2012 |
Pharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infection.
Topics: Adenine; Administration, Oral; Dose-Response Relationship, Drug; HIV Infections; HIV-1; Humans; Intracellular Space; Kinetics; Models, Biological; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Viral Load | 2012 |
Case report: management and HBV sequencing in a patient co-infected with HBV and HIV failing tenofovir.
Topics: Adenine; Anti-HIV Agents; Coinfection; Drug Resistance, Viral; Gene Products, pol; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Sequence Analysis, DNA; Tenofovir; Viral Load; Young Adult | 2012 |
Innate immune activation enhances hiv acquisition in women, diminishing the effectiveness of tenofovir microbicide gel.
Topics: Adenine; Adult; Anti-HIV Agents; Avian Proteins; Case-Control Studies; Coinfection; Cytokines; Disease Susceptibility; Female; Herpes Genitalis; Herpesvirus 2, Human; HIV Infections; Humans; Immunity, Innate; Logistic Models; Lymphocyte Activation; Organophosphonates; Platelet Count; Principal Component Analysis; Randomized Controlled Trials as Topic; Risk Factors; Tenofovir; Vaginal Creams, Foams, and Jellies; Young Adult | 2012 |
Trends in HIV-1 reverse transcriptase resistance-associated mutations and antiretroviral prescription data from 2003-2010.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Prescriptions; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Organophosphonates; Prevalence; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure; Zidovudine | 2012 |
FDA paves the way for pre-exposure HIV prophylaxis.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Deoxycytidine; Drug Combinations; Emtricitabine; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Primary Prevention; Tenofovir; United States; United States Food and Drug Administration | 2012 |
Tenofovir-associated proteinuria.
Topics: Adenine; Anti-HIV Agents; Creatine; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Proteinuria; Renal Insufficiency, Chronic; Tenofovir | 2013 |
Interim guidance for clinicians considering the use of preexposure prophylaxis for the prevention of HIV infection in heterosexually active adults.
Topics: Adenine; Administration, Oral; Adult; Anti-Retroviral Agents; Centers for Disease Control and Prevention, U.S.; Contraindications; Deoxycytidine; Drug Labeling; Emtricitabine; Female; Heterosexuality; HIV Infections; Homosexuality; Humans; Male; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Randomized Controlled Trials as Topic; Risk; Sexual Behavior; Tenofovir; United States | 2012 |
Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Sequence Data; Mutation, Missense; Organophosphonates; Selection, Genetic; Sequence Analysis, DNA; Tenofovir; Treatment Failure | 2012 |
High rate of reversibility of renal damage in a cohort of HIV-infected patients receiving tenofovir-containing antiretroviral therapy.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Female; HIV Infections; Humans; Kidney; Kidney Diseases; Kidney Function Tests; Male; Middle Aged; Organophosphonates; Tenofovir; Time Factors; Withholding Treatment | 2012 |
[A single tablet against HIV: new combination preparation improves therapy].
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Clinical Trials, Phase III as Topic; Cobicistat; Cyclopropanes; Deoxycytidine; Double-Blind Method; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Glomerular Filtration Rate; HIV Infections; Humans; Oligopeptides; Organophosphonates; Pyridines; Quinolones; Randomized Controlled Trials as Topic; Ritonavir; Tenofovir; Thiazoles; Viral Load | 2012 |
Macro CK2 accumulation in tenofovir-treated HIV patients is facilitated by CK oligomer stabilization but is not predictive for pathology.
Topics: Adenine; Anti-HIV Agents; Catalysis; Creatine Kinase, Mitochondrial Form; Enzyme Stability; Follow-Up Studies; Glomerular Filtration Rate; HIV Infections; Humans; Hypophosphatemia; Organophosphonates; Protein Multimerization; Tenofovir | 2013 |
Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoring.
Topics: Adenine; Adult; Africa South of the Sahara; Anti-Retroviral Agents; Cost-Benefit Analysis; Drug Resistance, Viral; Epidemics; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Stochastic Processes; Tenofovir; Treatment Outcome; Zidovudine | 2012 |
Preexposure prophylaxis for the prevention of HIV transmission to women.
Topics: Adenine; Anti-HIV Agents; Chemoprevention; Cost-Benefit Analysis; Deoxycytidine; Directive Counseling; Emtricitabine; Family Characteristics; Female; HIV Infections; Humans; Male; Medication Adherence; Organophosphonates; Primary Health Care; Primary Prevention; Reproductive Behavior; Risk-Taking; Tenofovir; United States; United States Food and Drug Administration | 2013 |
Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort.
Topics: Adenine; Alkynes; Anti-Retroviral Agents; Atazanavir Sulfate; Benzoxazines; Cohort Studies; Cyclopropanes; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Italy; Longitudinal Studies; Lopinavir; Oligopeptides; Organophosphonates; Prospective Studies; Pyridines; Retrospective Studies; Ritonavir; Tenofovir; Time Factors | 2013 |
Emtricitabine/rilpivirine/tenofovir disoproxil fumarate single-tablet regimen: a guide to its use in HIV-1 infection.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Nitriles; Organophosphonates; Patient Compliance; Pyrimidines; Rilpivirine; RNA, Viral; Tenofovir; Time Factors; Treatment Outcome | 2012 |
FDA treads carefully with PrEP.
Topics: Adenine; Anti-HIV Agents; Chemoprevention; Deoxycytidine; Drug Approval; Drug Combinations; Drug Resistance, Viral; Emtricitabine; HIV Infections; Humans; Medication Adherence; Organophosphonates; Tenofovir; United States; United States Food and Drug Administration | 2012 |
Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure.
Topics: Adenine; Adult; Anti-HIV Agents; Blood Chemical Analysis; Chromatography, Liquid; Deoxycytidine; Desiccation; Emtricitabine; Erythrocytes; Female; Half-Life; HIV Infections; Humans; Leukocytes, Mononuclear; Male; Medication Adherence; Middle Aged; Organophosphonates; Plasma; Specimen Handling; Tandem Mass Spectrometry; Tenofovir; Young Adult | 2013 |
Safety and efficacy of tenofovir/IQP-0528 combination gels - a dual compartment microbicide for HIV-1 prevention.
Topics: Adenine; Administration, Mucosal; Anti-Infective Agents; Cell Line; Cell Survival; Chemoprevention; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Organophosphonates; Pyrimidinones; Tenofovir; Tissue Culture Techniques; Vaginal Creams, Foams, and Jellies | 2012 |
Antiretroviral medications as prevention: will the new paradigm reverse the HIV epidemic?
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Epidemics; Female; HIV Infections; Homosexuality, Male; Humans; Male; Organophosphonates; Randomized Controlled Trials as Topic; Risk Factors; Tenofovir | 2012 |
Differential effects of tenofovir/emtricitabine and abacavir/lamivudine on human leukocyte recruitment.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Cell Adhesion; Cell Adhesion Molecules; Cell Communication; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Endothelial Cells; HIV Infections; Humans; Lamivudine; Leukocytes; Organophosphonates; Tenofovir | 2012 |
Single nucleotide polymorphisms in ABCC2 associate with tenofovir-induced kidney tubular dysfunction in Japanese patients with HIV-1 infection: a pharmacogenetic study.
Topics: Adenine; Adult; Cohort Studies; Cross-Sectional Studies; Female; Genetic Predisposition to Disease; HIV Infections; HIV-1; Humans; Japan; Kidney Diseases; Kidney Tubules; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Organophosphonates; Polymorphism, Single Nucleotide; Tenofovir | 2012 |
Quantification of tenofovir in human plasma by solid-phase extraction and high-performance liquid chromatography coupled with UV detection.
Topics: Adenine; Calibration; Chromatography, High Pressure Liquid; Drug Monitoring; Female; HIV Infections; Humans; Male; Organophosphonates; Reference Standards; Reproducibility of Results; Solid Phase Extraction; Spectrophotometry, Ultraviolet; Tenofovir | 2012 |
A perspective on progress and gaps in HIV prevention science.
Topics: Adenine; Administration, Oral; Administration, Topical; Anal Canal; Anti-HIV Agents; Chemoprevention; Deoxycytidine; Drug Combinations; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; HIV Infections; Humans; Immunity, Innate; Male; Medication Adherence; Mouth Mucosa; Mucous Membrane; Organophosphonates; Organophosphorus Compounds; Sexual Partners; Tenofovir; Vagina; Vaginal Creams, Foams, and Jellies | 2012 |
Risk factors and outcome of HIV-associated idiopathic noncirrhotic portal hypertension.
Topics: Adenine; Adult; Anti-HIV Agents; Case-Control Studies; Chemical and Drug Induced Liver Injury; Didanosine; Drug Therapy, Combination; Female; HIV Infections; Humans; Hypertension, Portal; Liver; Male; Middle Aged; Multivariate Analysis; Netherlands; Organophosphonates; Risk Factors; Stavudine; Tenofovir; Young Adult | 2012 |
Drug-induced acute interstitial nephritis mimicking acute tubular necrosis after initiation of tenofovir-containing antiretroviral therapy in patient with HIV-1 infection.
Topics: Acute Disease; Adenine; Aged; Anti-Retroviral Agents; Biopsy; Diagnosis, Differential; HIV Infections; HIV-1; Humans; Kidney; Kidney Tubular Necrosis, Acute; Male; Nephritis, Interstitial; Organophosphonates; Tenofovir | 2012 |
The effect of tenofovir on vitamin D metabolism in HIV-infected adults is dependent on sex and ethnicity.
Topics: Adenine; Adult; Anti-HIV Agents; Bone Density; Calcium; Cohort Studies; Ethnicity; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Parathyroid Hormone; Phosphates; Prospective Studies; Regression Analysis; Sex Factors; Tenofovir; Vitamin D | 2012 |
Incidence of renal toxicity in HIV-infected, antiretroviral-naïve patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavir.
Topics: Adenine; Adult; Alkynes; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Emtricitabine; Female; Glomerular Filtration Rate; Glycosuria; HIV Infections; HIV Protease Inhibitors; Humans; Kidney Diseases; Lopinavir; Male; Middle Aged; Oligopeptides; Organophosphonates; Proteinuria; Pyridines; Retrospective Studies; Ritonavir; Tenofovir | 2013 |
Number of daily pills, dosing schedule, self-reported adherence and health status in 2010: a large cross-sectional study of HIV-infected patients on antiretroviral therapy.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Carbamates; CD4 Lymphocyte Count; Cross-Sectional Studies; Deoxycytidine; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; Furans; HIV Infections; Humans; Italy; Lamivudine; Male; Medication Adherence; Middle Aged; Nevirapine; Oligopeptides; Organophosphates; Organophosphonates; Oxazines; Pyridines; Self Report; Sulfonamides; Surveys and Questionnaires; Viral Load | 2013 |
A 90-day tenofovir reservoir intravaginal ring for mucosal HIV prophylaxis.
Topics: Adenine; Administration, Intravaginal; Animals; Anti-HIV Agents; Chromatography, High Pressure Liquid; Delayed-Action Preparations; Equipment Design; Female; HIV Infections; Irritants; Organophosphonates; Polyurethanes; Sheep; Tenofovir; Vagina; Vaginal Creams, Foams, and Jellies | 2012 |
Clinical decisions. Preexposure prophylaxis for HIV prevention--polling results.
Topics: Adenine; Anti-Retroviral Agents; Deoxycytidine; Female; HIV Infections; Humans; Male; Organophosphonates | 2012 |
Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation, Missense; Organophosphonates; Selection, Genetic; Tenofovir; Time Factors; Treatment Failure | 2013 |
Raltegravir central nervous system tolerability in clinical practice: results from a multicenter observational study.
Topics: Adenine; Anti-HIV Agents; Central Nervous System; Drug Administration Schedule; Drug Interactions; Female; HIV Infections; Humans; Male; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Tenofovir; Treatment Outcome; Viral Load | 2012 |
Age-related differences in plasma and intracellular tenofovir concentrations in HIV-1-infected children, adolescents and adults.
Topics: Adenine; Adolescent; Adult; Age Factors; Anti-HIV Agents; Biological Availability; Child; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Tandem Mass Spectrometry; Tenofovir | 2013 |
The influence of HLA supertype on thymidine analogue associated with low peripheral fat in HIV.
Topics: Adenine; Anti-HIV Agents; Australia; Biomarkers; Blood Glucose; Body Fat Distribution; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Female; Genotype; HIV Infections; HIV-Associated Lipodystrophy Syndrome; HLA Antigens; HLA-A1 Antigen; HLA-B8 Antigen; HLA-DQ Antigens; Humans; Lamivudine; Linkage Disequilibrium; Male; Middle Aged; Multicenter Studies as Topic; Organophosphonates; Predictive Value of Tests; Randomized Controlled Trials as Topic; Tenofovir; Thymidine | 2012 |
Increased time exposure to tenofovir is associated with a greater decrease in estimated glomerular filtration rate in HIV patients with kidney function of less than 60 ml/min/1.73 m2.
Topics: Adenine; Anti-HIV Agents; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Failure, Chronic; Kidney Function Tests; Male; Middle Aged; Organophosphonates; Risk Factors; Tenofovir; Time Factors | 2012 |
Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Coinfection; Deoxycytidine; Emtricitabine; Female; Hepatitis B; Hepatitis B e Antigens; Hepatitis B virus; HIV Infections; HIV-1; Humans; Lamivudine; Male; Organophosphonates; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Load; Virus Replication | 2012 |
Coadministration of tenofovir decreased atazanavir plasma concentration after unilateral nephrectomy.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Drug Interactions; HIV Infections; Humans; Liver Function Tests; Male; Nephrectomy; Oligopeptides; Organophosphonates; Pyridines; Tenofovir | 2013 |
Microbicides are promoted as offering a 'female-controlled' HIV prevention method: so can they revolutionize the HIV crisis of young women in Kenya?
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Anti-Infective Agents; Awards and Prizes; Chemoprevention; Condoms; Condoms, Female; Female; HIV Infections; Humans; Incidence; Kenya; Middle Aged; Negotiating; Organophosphonates; Prevalence; Sexual Partners; Spouse Abuse; Tenofovir; Women's Health; Women's Rights; Young Adult | 2012 |
[Preexposure prophylaxis for HIV infection--current data and recommendations].
Topics: Adenine; Africa; Anti-HIV Agents; Controlled Clinical Trials as Topic; Deoxycytidine; Drug Resistance, Viral; Early Termination of Clinical Trials; Emtricitabine; Female; HIV Infections; Humans; Male; Organophosphonates; Risk Factors; Tenofovir | 2012 |
Tenofovir diphosphate and emtricitabine triphosphate concentrations in blood cells compared with isolated peripheral blood mononuclear cells: a new measure of antiretroviral adherence?
Topics: Adenine; Adult; Anti-HIV Agents; Blood Cells; Deoxycytidine; Diphosphates; Emtricitabine; Female; HIV Infections; Humans; Leukocytes, Mononuclear; Male; Medication Adherence; Middle Aged; Organophosphonates; Polyphosphates; Tenofovir | 2013 |
Inefficient vaginal transmission of tenofovir-resistant HIV-1.
Topics: Adenine; Animals; Anti-HIV Agents; Disease Models, Animal; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Mice; Mucous Membrane; Mutation, Missense; Organophosphonates; Suppression, Genetic; Tenofovir; Vagina | 2013 |
Lower healthcare costs associated with the use of a single-pill ARV regimen in the UK, 2004-2008.
Topics: Adenine; Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Deoxycytidine; Drug Combinations; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; Health Care Costs; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Oxazines; Proportional Hazards Models; United Kingdom; Viral Load | 2012 |
Association between tenofovir exposure and reduced kidney function in a cohort of HIV-positive patients: results from 10 years of follow-up.
Topics: Adenine; Adult; Anti-HIV Agents; Canada; Cohort Studies; Female; Follow-Up Studies; Glomerular Filtration Rate; HIV Infections; HIV Seropositivity; Humans; Kidney Diseases; Male; Organophosphonates; Proportional Hazards Models; Tenofovir | 2013 |
FDA approves new 4-drug once-a-day HIV treatment.
Topics: Adenine; Carbamates; Cobicistat; Deoxycytidine; Drug Administration Schedule; Drug Approval; Drug Combinations; Emtricitabine; HIV Infections; Humans; Organophosphonates; Quinolones; Tenofovir; Thiazoles; United States; United States Food and Drug Administration | 2012 |
A 4-drug combination (Stribild) for HIV.
Topics: Adenine; Anti-HIV Agents; Carbamates; Clinical Trials as Topic; Cobicistat; Deoxycytidine; Double-Blind Method; Drug Approval; Drug Combinations; Drug Interactions; Drug Resistance, Multiple, Viral; Emtricitabine; HIV; HIV Infections; Humans; Organophosphonates; Quinolones; Randomized Controlled Trials as Topic; Tenofovir; Thiazoles; United States; United States Food and Drug Administration | 2012 |
HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir.
Topics: Adenine; Adult; Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genetic Variation; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Male; Middle Aged; Molecular Sequence Data; Organophosphonates; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Tenofovir | 2013 |
Absence of liver steatosis in HIV-HCV co-infected patients receiving regimens containing tenofovir or abacavir.
Topics: Adenine; Adult; Anti-HIV Agents; Coinfection; Dideoxynucleosides; Fatty Liver; Female; Genotype; Hepatitis C; HIV Infections; Humans; Liver; Male; Multivariate Analysis; Organophosphonates; Prevalence; Retrospective Studies; Reverse Transcriptase Inhibitors; Risk Factors; Tenofovir | 2013 |
Elvitegravir/cobicistat, mirabegron, and linaclotide.
Topics: Acetanilides; Adenine; Anti-Retroviral Agents; Carbamates; Constipation; Deoxycytidine; Drug Combinations; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; HIV-1; Humans; Organophosphonates; Peptides; Quinolones; Thiazoles; Urinary Bladder, Overactive | 2012 |
Novel HIV-1 treatment Stribild™ gains regulatory approval.
Topics: Adenine; Anti-HIV Agents; Carbamates; Deoxycytidine; Drug Approval; Drug Combinations; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV; HIV Infections; Humans; Organophosphonates; Quinolones; Thiazoles | 2012 |
Improved adherence expected with new HIV combo treatment.
Topics: Adenine; Aged; Aged, 80 and over; Anti-HIV Agents; Carbamates; Deoxycytidine; Drug Combinations; Drug Labeling; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; Humans; Medication Adherence; Middle Aged; Organophosphonates; Quinolones; Randomized Controlled Trials as Topic; Thiazoles; United States | 2012 |
[Efficacy and tolerance of tenofovir-lamivudine-efavirenz combination in HIV-1 patients in Fann Teaching Hospital in Dakar].
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Hospitals, Teaching; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Senegal; Tenofovir; Treatment Outcome | 2013 |
Tenofovir treatment duration predicts proteinuria in a multiethnic United States Cohort of children and adolescents with perinatal HIV-1 infection.
Topics: Adenine; Adolescent; Anti-HIV Agents; Black or African American; Child; Cohort Studies; Female; Hispanic or Latino; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Male; Multivariate Analysis; Odds Ratio; Organophosphonates; Prevalence; Prospective Studies; Proteinuria; Renal Insufficiency, Chronic; Statistics, Nonparametric; Tenofovir; United States | 2013 |
Tenofovir use and urinary biomarkers among HIV-infected women in the Women's Interagency HIV Study (WIHS).
Topics: Acetylglucosaminidase; Acute-Phase Proteins; Adenine; Adult; beta 2-Microglobulin; Biomarkers; Female; HIV Infections; Humans; Lipocalin-2; Lipocalins; Middle Aged; Organophosphonates; Prospective Studies; Proto-Oncogene Proteins; Reverse Transcriptase Inhibitors; Tenofovir | 2013 |
Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Interactions; Ethambutol; Female; Genotype; HIV Infections; Humans; Isoniazid; Lamivudine; Male; Middle Aged; Organophosphonates; Oxidoreductases, N-Demethylating; Pharmacogenetics; Polymorphism, Single Nucleotide; Pyrazinamide; Reverse Transcriptase Inhibitors; Rifampin; Tenofovir; Tuberculosis; Young Adult | 2013 |
Coverage, context and targeted prevention: optimising our impact.
Topics: Adenine; Anti-HIV Agents; Circumcision, Male; Deoxycytidine; Emtricitabine; Female; Health Priorities; HIV Infections; Humans; Male; Organophosphonates; Sexual Behavior; Tenofovir; United States; Vaginal Creams, Foams, and Jellies | 2013 |
Spray drying tenofovir loaded mucoadhesive and pH-sensitive microspheres intended for HIV prevention.
Topics: Adenine; Cell Survival; Chemistry, Pharmaceutical; Drug Carriers; HIV Infections; Humans; Hydrogen-Ion Concentration; Microspheres; Organophosphonates; Particle Size; Tenofovir | 2013 |
Tenofovir, emtricitabine intracellular and plasma, and efavirenz plasma concentration decay following drug intake cessation: implications for HIV treatment and prevention.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Combinations; Emtricitabine; Female; Half-Life; HIV Infections; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Organophosphonates; Tandem Mass Spectrometry; Tenofovir; Young Adult | 2013 |
Antiretroviral preexposure prophylaxis for HIV prevention.
Topics: Adenine; Anti-Retroviral Agents; Deoxycytidine; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates | 2013 |
Antiretroviral preexposure prophylaxis for HIV prevention.
Topics: Adenine; Anti-Retroviral Agents; Deoxycytidine; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates | 2013 |
Antiretroviral preexposure prophylaxis for HIV prevention.
Topics: Adenine; Anti-Retroviral Agents; Deoxycytidine; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Pregnancy | 2013 |
Antiretroviral preexposure prophylaxis for HIV prevention.
Topics: Adenine; Anti-Retroviral Agents; Deoxycytidine; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Pregnancy | 2013 |
Antiretroviral preexposure prophylaxis for HIV prevention.
Topics: Adenine; Anti-Retroviral Agents; Deoxycytidine; Female; HIV Infections; HIV-1; Humans; Organophosphonates | 2013 |
Tenofovir plasma concentrations in post-menopausal versus pre-menopausal HIV-infected women.
Topics: Adenine; Adult; Anti-HIV Agents; Attention; Female; HIV Infections; Humans; Middle Aged; Organophosphonates; Plasma; Postmenopause; Premenopause; Tenofovir | 2013 |
Inhibition of telomerase activity by human immunodeficiency virus (HIV) nucleos(t)ide reverse transcriptase inhibitors: a potential factor contributing to HIV-associated accelerated aging.
Topics: Adenine; Adult; Aging; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Case-Control Studies; Cells, Cultured; Deoxycytidine; Dideoxynucleosides; Emtricitabine; Enzyme Activation; Female; HIV; HIV Infections; Humans; Lamivudine; Leukocytes, Mononuclear; Male; Middle Aged; Organophosphonates; Polymerase Chain Reaction; Regression Analysis; Reverse Transcriptase Inhibitors; Risk Factors; Telomerase; Telomere; Telomere Shortening; Tenofovir; Time Factors; Young Adult; Zidovudine | 2013 |
Low prevalence of transmitted K65R and other tenofovir resistance mutations across different HIV-1 subtypes: implications for pre-exposure prophylaxis.
Topics: Adenine; Anti-HIV Agents; Drug Resistance, Viral; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Viral; Global Health; HIV Infections; HIV-1; Humans; Mutation; Organophosphonates; Population Surveillance; RNA-Directed DNA Polymerase; Tenofovir | 2012 |
Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus.
Topics: Adenine; Adult; Aged; Antiretroviral Therapy, Highly Active; Antiviral Agents; Australia; Coinfection; Deoxycytidine; DNA, Viral; Emtricitabine; Female; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Male; Medication Adherence; Middle Aged; Organophosphonates; Tenofovir; Thailand; Treatment Failure; United States | 2013 |
Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cost-Benefit Analysis; Cyclopropanes; Deoxycytidine; Drug Combinations; Drugs, Generic; Emtricitabine; Female; HIV Infections; Humans; Male; Models, Theoretical; Organophosphonates; Quality-Adjusted Life Years; Reverse Transcriptase Inhibitors; Tenofovir; United States | 2013 |
Prophylactic antiretroviral HIV therapy prevents infection in heterosexual men and women.
Topics: Adenine; Anti-Retroviral Agents; Deoxycytidine; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Pregnancy | 2013 |
HIV transmission may be prevented by intravaginal tenofovir ring.
Topics: Adenine; Administration, Intravaginal; Anti-HIV Agents; Drug Delivery Systems; Female; HIV Infections; Humans; Organophosphonates; Tenofovir | 2012 |
Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Genotype; HIV Infections; HIV-1; Humans; Mutation; Nitriles; Organophosphonates; Prevalence; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Tenofovir | 2013 |
Treatment of anal intraepithelial neoplasia: has it come of age?
Topics: Antiviral Agents; Anus Neoplasms; Carcinoma in Situ; Cidofovir; Cytosine; Female; HIV Infections; Humans; Male; Ointments; Organophosphonates; Papillomavirus Infections | 2013 |
ASN clinical pathological conference. Tenofovir-related ATN (severe).
Topics: Adenine; Anti-HIV Agents; Biopsy; Diagnosis, Differential; Glomerulonephritis, IGA; HIV Infections; Humans; Kidney Tubular Necrosis, Acute; Male; Middle Aged; Organophosphonates; Predictive Value of Tests; Risk Factors; Severity of Illness Index; Staphylococcal Infections; Tenofovir | 2013 |
Combination therapy efavirenz/emtricitabine/tenofovir disoproxil fumarate associated with hepatic failure.
Topics: Adenine; Adult; Deoxycytidine; Drug Combinations; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; Humans; Liver Failure; Male; Organophosphonates; Oxazines; Reverse Transcriptase Inhibitors | 2012 |
Synthesis and biological evaluation of phosphonate analogues of nevirapine.
Topics: HIV Infections; HIV-1; Humans; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2013 |
A model of HIV drug resistance driven by heterogeneities in host immunity and adherence patterns.
Topics: Adenine; Anti-HIV Agents; Computer Simulation; Drug Resistance, Viral; HIV Infections; Humans; Medication Adherence; Models, Immunological; Organophosphonates; Tenofovir; Viral Load | 2013 |
Tenofovir plasma concentrations according to companion drugs: a cross-sectional study of HIV-positive patients with normal renal function.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Chromatography, Liquid; Cross-Sectional Studies; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Mass Spectrometry; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir | 2013 |
Promising new agents on the horizon.
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Clinical Trials as Topic; HIV Infections; HIV Protease Inhibitors; Humans; Nitriles; Oligopeptides; Organophosphonates; Organophosphorus Compounds; Pyridazines; Pyridines; Pyrimidines; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2002 |
Tenofovir DF expanded access. Criteria for U.S. program.
Topics: Adenine; Drug Approval; Europe; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir; United States; United States Food and Drug Administration | 2001 |
Antiretroviral news from ICAAC 2000.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Drug Administration Schedule; Drug Resistance; HIV Infections; Humans; Lopinavir; Organophosphonates; Organophosphorus Compounds; Pyrimidinones; Ritonavir; Tenofovir | 2000 |
Tenofovir gel studied.
Topics: Adenine; Anti-HIV Agents; Clinical Trials, Phase I as Topic; Female; Gels; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Tenofovir; United States | 2002 |
Highlights of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).
Topics: Adenine; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Drug Resistance, Microbial; Drug Therapy; Epoetin Alfa; Erythropoietin; Hepatitis C; HIV Infections; Humans; Lamivudine; Organophosphonates; Organophosphorus Compounds; Recombinant Proteins; Saquinavir; Tenofovir; Zidovudine | 2002 |
The prevalence and determinants of the K65R mutation in HIV-1 reverse transcriptase in tenofovir-naive patients.
Topics: Adenine; Anti-HIV Agents; Databases, Factual; Dideoxynucleosides; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Mutation; Organophosphonates; Organophosphorus Compounds; Prevalence; Reverse Transcriptase Inhibitors; Tenofovir | 2002 |
[First nucleotide analog against HIV. Lowers viral load also in drug resistance].
Topics: Adenine; Anti-HIV Agents; Clinical Trials, Phase II as Topic; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir | 2002 |
[Tenofovir in Study 903. Also effective and tolerable in first-line therapy].
Topics: Adenine; Anti-HIV Agents; Clinical Trials as Topic; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir; Treatment Outcome; Viral Load | 2002 |
Marked elevation of the creatine phosphokinase level in a patient receiving tenofovir.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Creatine Kinase; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2002 |
Phenotypic and genotypic HIV-1 drug resistance assays provide complementary information.
Topics: Adenine; Anti-HIV Agents; Carbamates; Didanosine; Dideoxynucleosides; Drug Resistance, Viral; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Microbial Sensitivity Tests; Organophosphonates; Organophosphorus Compounds; Phenotype; Reverse Transcriptase Inhibitors; Sulfonamides; Tenofovir; Zalcitabine | 2002 |
Editorial comment: a tale of two viruses.
Topics: Adenine; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B; Hepatitis B Vaccines; HIV Infections; Humans; Lamivudine; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir | 2002 |
Would switching the protease inhibitors (PI) to tenoforvir be an option in controlling hypertriglyceridaemia secondary to PIs? A case report.
Topics: Adenine; HIV Infections; HIV Protease Inhibitors; Humans; Hypertriglyceridemia; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir | 2002 |
Tenofovir DF trial announced by Gilead.
Topics: Adenine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir | 2000 |
Prevention: new approach will test tenofovir for persons at high risk.
Topics: Adenine; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Risk Factors; Tenofovir | 2002 |
Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity.
Topics: Acute Kidney Injury; Adenine; Adult; Anti-HIV Agents; Chronic Disease; HIV Infections; Humans; Kidney; Kidney Diseases; Male; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2002 |
Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus.
Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2003 |
Tenofovir (Viread(R)) access for poor countries.
Topics: Adenine; Developing Countries; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir | 2002 |
Tenofovir helps beat hepatitis B.
Topics: Adenine; Antiviral Agents; CD4 Lymphocyte Count; Hepatitis B; Hepatitis B virus; HIV; HIV Infections; Humans; Male; Organophosphonates; Organophosphorus Compounds; Tenofovir; Viral Load | 2003 |
Rapid hepatitis B virus-DNA decay in co-infected HIV-hepatitis B virus 'e-minus' patients with YMDD mutations after 4 weeks of tenofovir therapy.
Topics: Adenine; Adult; Anti-HIV Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2003 |
New uses for tenofovir: more questions about d4T.
Topics: Adenine; Drug Therapy, Combination; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir | 2003 |
Renal lesions in HIV-1-positive patient treated with tenofovir.
Topics: Acute Kidney Injury; Adenine; Anti-HIV Agents; Fanconi Syndrome; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2003 |
Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus.
Topics: Acidosis; Adenine; Adult; Anti-HIV Agents; Creatinine; Diabetes Insipidus, Nephrogenic; Drug Monitoring; Fanconi Syndrome; Glycosuria; HIV Infections; Humans; Middle Aged; Organophosphonates; Organophosphorus Compounds; Proteinuria; Renal Insufficiency; Tenofovir | 2003 |
Cidofovir and surgery for genital warts.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Cidofovir; Combined Modality Therapy; Condylomata Acuminata; Cytosine; Female; HIV Infections; Humans; Male; Organophosphonates; Organophosphorus Compounds | 2002 |
Manufacturer end adefovir development.
Topics: Adenine; HIV Infections; Humans; Organophosphonates; Reverse Transcriptase Inhibitors | 2000 |
[96-week treatment outcome confirms long term efficacy of tenofovir DF].
Topics: Adenine; Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; Humans; Multicenter Studies as Topic; Organophosphonates; Organophosphorus Compounds; Randomized Controlled Trials as Topic; Tenofovir; Time Factors; Treatment Outcome | 2003 |
Liquid chromatographic assay for the antiviral nucleotide analogue tenofovir in plasma using derivatization with chloroacetaldehyde.
Topics: Acetaldehyde; Adenine; Chromatography, Liquid; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Reproducibility of Results; Reverse Transcriptase Inhibitors; Sensitivity and Specificity; Spectrometry, Fluorescence; Tenofovir | 2003 |
Pancreatitis in an HIV-infected person on a tenofovir, didanosine and stavudine containing highly active antiretroviral treatment.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Didanosine; Drug Interactions; Female; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Pancreatitis; Ritonavir; Stavudine; Tenofovir | 2003 |
Antiviral Research--16th Annual International Conference. Satellite symposium: clinical update on antiviral drugs. 27 April-1 May 2003, Savannah, GA, USA.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Clinical Trials as Topic; Enfuvirtide; Ganciclovir; Hepatitis B; HIV Envelope Protein gp41; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Peptide Fragments; Tenofovir; Valganciclovir | 2003 |
[The first nucleotide analog permitted. New hepatitis B therapy helps the problem patients, too].
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Drug Resistance; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Liver Transplantation; Organophosphonates; Placebos; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors | 2003 |
Fatal lactic acidosis and mimicking Guillain-Barré syndrome in an adolescent with human immunodeficiency virus infection.
Topics: Acidosis, Lactic; Adenine; Adolescent; Antiretroviral Therapy, Highly Active; Carbamates; Diagnosis, Differential; Didanosine; Disease Progression; Drug Therapy, Combination; Fatal Outcome; Female; Furans; Guillain-Barre Syndrome; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Organophosphonates; Organophosphorus Compounds; Risk Assessment; Severity of Illness Index; Stavudine; Sulfonamides; Tenofovir | 2003 |
Tenofovir disoproxil fumarate.
Topics: Adenine; Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Kidney Diseases; Mutation; Organophosphonates; Organophosphorus Compounds; Tenofovir; Time Factors | 2003 |
Tenofovir disoproxil fumarate.
Topics: Adenine; Anti-HIV Agents; Drug Resistance, Viral; Drug Synergism; Gastrointestinal Diseases; HIV Infections; HIV-1; Humans; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2003 |
Preemptive use of antiretroviral drugs to prevent sexual transmission of HIV to high-risk uninfected MSM.
Topics: Adenine; Anti-HIV Agents; Centers for Disease Control and Prevention, U.S.; Clinical Trials as Topic; HIV Infections; Homosexuality, Male; Humans; Male; Organophosphonates; Organophosphorus Compounds; Politics; Research Support as Topic; Tenofovir; United States | 2003 |
Sensitive determination of tenofovir in human plasma samples using reversed-phase liquid chromatography.
Topics: Adenine; Chromatography, High Pressure Liquid; Drug Monitoring; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Reproducibility of Results; Reverse Transcriptase Inhibitors; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Tenofovir | 2003 |
Pancreatitis with didanosine and tenofovir disoproxil fumarate [corrected].
Topics: Adenine; Adult; Didanosine; Drug Interactions; Fatal Outcome; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Pancreatitis; Tenofovir | 2003 |
[HIV therapy: tenofir DF is available in 68 developing countries at production costs price].
Topics: Adenine; Administration, Oral; Anti-HIV Agents; Developing Countries; Drug Costs; Drug Industry; Health Services Accessibility; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2003 |
Role of baseline human immunodeficiency virus genotype as a predictor of viral response to tenofovir in heavily pretreated patients.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Female; HIV; HIV Infections; Humans; Male; Organophosphonates; Organophosphorus Compounds; RNA, Viral; Tenofovir | 2003 |
Summaries for patients. Treatment for resistant HIV-1 infection.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Male; Mutation; Organophosphonates; Organophosphorus Compounds; Placebos; RNA; Tenofovir; Viral Load | 2003 |
Tenofovir disoproxil fumarate.
Topics: Adenine; Anti-HIV Agents; Drug Interactions; Drug Resistance, Viral; Hepatitis B virus; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2003 |
Cambodia: can a drug provide some protection?
Topics: Adenine; Animals; Anti-HIV Agents; Cambodia; Controlled Clinical Trials as Topic; Female; Haplorhini; HIV Infections; Humans; International Cooperation; Male; Organophosphonates; Organophosphorus Compounds; Sex Work; Simian Acquired Immunodeficiency Syndrome; Tenofovir | 2003 |
[Further indications for tenofovir].
Topics: Adenine; Anti-HIV Agents; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Tenofovir; Viral Load | 2003 |
Management of chronic hepatitis B in an HIV-positive patient with 3TC-resistant hepatitis B virus.
Topics: Adenine; Adult; Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Interferon-alpha; Lamivudine; Liver Cirrhosis; Male; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2003 |
Warning issued on non-response rates.
Topics: Adenine; Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; HIV Infections; Humans; Lamivudine; Multicenter Studies as Topic; Organophosphonates; Organophosphorus Compounds; Randomized Controlled Trials as Topic; Tenofovir | 2003 |
Acute tubular necrosis in a patient receiving tenofovir.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Creatinine; HIV Infections; Humans; Kidney Tubular Necrosis, Acute; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2003 |
Triple combinations regimens for HIV.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Multicenter Studies as Topic; Organophosphonates; Organophosphorus Compounds; Oxazines; Randomized Controlled Trials as Topic; Tenofovir; Treatment Failure | 2003 |
Complex patterns of viral load decay under antiretroviral therapy: influence of pharmacokinetics and intracellular delay.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; HIV Infections; HIV-1; Humans; Models, Biological; Organophosphonates; Organophosphorus Compounds; Ritonavir; Tenofovir; Time Factors; Viral Load; Virus Replication | 2004 |
Meeting notes from the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Exploring once-daily tenofovir + 3TC + abacavir: an argument for clinical-trials-based data.
Topics: Adenine; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Organophosphonates; Organophosphorus Compounds; Pilot Projects; Reverse Transcriptase Inhibitors; Tenofovir | 2003 |
BMS issues PK notice regarding ATV + TDF.
Topics: Adenine; Anti-HIV Agents; Area Under Curve; Atazanavir Sulfate; Clinical Trials as Topic; Drug Industry; HIV Infections; Humans; Oligopeptides; Organophosphonates; Organophosphorus Compounds; Pyridines; Tenofovir; United States; United States Food and Drug Administration | 2003 |
Failure of combination abacavir + tenofovir + lamivudine (3TC).
Topics: Adenine; Dideoxynucleosides; HIV Infections; Humans; Lamivudine; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir | 2003 |
Meeting notes from the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Suboptimal response to once-daily abacavir + 3TC + tenofovir.
Topics: Adenine; Anti-HIV Agents; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Multicenter Studies as Topic; Organophosphonates; Organophosphorus Compounds; Randomized Controlled Trials as Topic; Tenofovir | 2003 |
Treatment of chronic hepatitis B in the human immunodeficiency virus-infected patient: present and future.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Forecasting; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Interferon-alpha; Lamivudine; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir | 2003 |
Tenofovir: a nucleotide analogue reverse-transcriptase inhibitor for treatment of HIV infection.
Topics: Adenine; Aged; Child; Clinical Trials as Topic; Counseling; Education, Continuing; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Safety; Tenofovir; Treatment Outcome; United States | 2004 |
The renal tolerance of low-dose adefovir dipivoxil by lamivudine-resistant individuals co-infected with hepatitis B and HIV.
Topics: Adenine; Administration, Oral; Adult; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Viral; Female; Follow-Up Studies; Hepatitis B, Chronic; HIV Infections; Humans; Kidney; Kidney Function Tests; Lamivudine; Male; Maximum Tolerated Dose; Middle Aged; Organophosphonates; Prospective Studies; Risk Assessment; Treatment Outcome | 2004 |
Early nonresponse for tenofovir regimen.
Topics: Adenine; Anti-HIV Agents; Dideoxynucleosides; HIV Infections; Humans; Lamivudine; Organophosphonates; Organophosphorus Compounds; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure | 2003 |
Can AIDS drug also prevent HIV infection?
Topics: Adenine; Anti-HIV Agents; Clinical Trials as Topic; Female; HIV Infections; HIV-1; Homosexuality, Male; Humans; Male; Organophosphonates; Organophosphorus Compounds; Primary Prevention; Sex Work; Tenofovir; Virus Replication | 2004 |
Molecular mechanisms of tenofovir resistance conferred by human immunodeficiency virus type 1 reverse transcriptase containing a diserine insertion after residue 69 and multiple thymidine analog-associated mutations.
Topics: Adenine; Adenosine Triphosphate; Cells, Cultured; DNA Primers; DNA Transposable Elements; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Kinetics; Models, Molecular; Mutation; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; Serine; Tenofovir; Thymidine | 2004 |
Antiretroviral therapy and HIV/hepatitis B virus coinfection.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Antiviral Agents; Hepatitis B; Hepatitis B virus; HIV; HIV Infections; Humans; Lamivudine; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2004 |
High rate of virologic failure with once-daily ddI/3TC/TDF.
Topics: Adenine; Didanosine; HIV Infections; Humans; Lamivudine; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2003 |
Progressive multifocal leukoencephalopathy successfully treated with highly active antiretroviral therapy and cidofovir in an adolescent infected with perinatal human immunodeficiency virus (HIV).
Topics: Adolescent; AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Cidofovir; Cytosine; Diagnosis, Differential; Follow-Up Studies; HIV Infections; HIV-1; Humans; Image Enhancement; Infectious Disease Transmission, Vertical; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Male; Neurologic Examination; Neuropsychological Tests; Organophosphonates; Organophosphorus Compounds; Treatment Outcome; Viral Load | 2004 |
Hepatitis B infection in an HIV-positive man treated with tenofovir: a case of re-infection or reactivation?
Topics: Adenine; Adult; Hepatitis B Antibodies; Hepatitis B virus; HIV Infections; Humans; Male; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir; Virus Activation | 2004 |
French investigators warn of LPV/TDF/ddI interaction.
Topics: Adenine; CD4 Lymphocyte Count; Didanosine; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Organophosphonates; Organophosphorus Compounds; Pyrimidinones; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2003 |
Which nucleoside and nucleotide backbone combinations select for the K65R mutation in HIV-1 reverse transcriptase.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Didanosine; Dideoxynucleosides; Drug Resistance, Multiple, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Nucleosides; Nucleotides; Organophosphonates; Organophosphorus Compounds; Prevalence; Tenofovir | 2004 |
Tenofovir-related nephrotoxicity in HIV-infected patients.
Topics: Acute Kidney Injury; Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Didanosine; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Oxazines; Tenofovir | 2004 |
The management of oral human papillomavirus with topical cidofovir: a case report.
Topics: Administration, Topical; Adult; Antiviral Agents; Cidofovir; Cytosine; Diagnosis, Differential; Gels; HIV Infections; Humans; Male; Mouth Diseases; Organophosphonates; Organophosphorus Compounds; Papillomavirus Infections | 2004 |
EU issues warning about HAART regimen.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Didanosine; Dideoxynucleosides; Drug Resistance, Viral; European Union; HIV Infections; Humans; Lamivudine; Organophosphonates; Organophosphorus Compounds; Patient Selection; Pilot Projects; Safety; Tenofovir; Treatment Failure; Viral Load | 2004 |
Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load.
Topics: Adenine; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Didanosine; Drug Interactions; Drug Therapy, Combination; Follow-Up Studies; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2004 |
Didanosine-associated toxicity: a predictable complication of therapy with tenofovir and didanosine?
Topics: Adenine; Adult; Anti-HIV Agents; Creatinine; Didanosine; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; Humans; Kidney Diseases; Male; Middle Aged; Organophosphonates; Tenofovir | 2004 |
Failure of cidofovir in HIV-associated multicentric Castleman disease.
Topics: Anti-HIV Agents; Castleman Disease; Cidofovir; Cytosine; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Treatment Failure | 2004 |
Improvement of dyslipidemia in patients switching from stavudine to tenofovir: preliminary results.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; Humans; Hyperlipidemias; Male; Organophosphonates; Organophosphorus Compounds; Prospective Studies; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir | 2004 |
Atazanavir (Reyataz): new recommendations if combined with tenofovir (Viread) -- and warning on Viagra, Cialis, and Levitra.
Topics: Adenine; Atazanavir Sulfate; Carbolines; Drug Information Services; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Imidazoles; Oligopeptides; Organophosphonates; Organophosphorus Compounds; Piperazines; Purines; Pyridines; Reverse Transcriptase Inhibitors; Sildenafil Citrate; Sulfones; Tadalafil; Tenofovir; Triazines; Vardenafil Dihydrochloride | 2004 |
Virologic outcome after switching from a nucleoside reverse transcriptase inhibitor to tenofovir in patients with undetectable HIV-1 RNA plasma level.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Organophosphonates; Retrospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Treatment Outcome; Viremia | 2004 |
Haemolytic anaemia after nucleotide antiretroviral treatment discontinuation in a chronic hepatitis B-virus co-infected AIDS patient.
Topics: Adenine; Adult; Anemia, Hemolytic; Antiretroviral Therapy, Highly Active; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Tenofovir | 2004 |
The K65R mutation in HIV-1 reverse transcriptase.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Organophosphonates; Point Mutation; Reverse Transcriptase Inhibitors; Tenofovir | 2004 |
In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
Topics: Adenine; Adult; Antiviral Agents; Cell Line; DNA-Directed DNA Polymerase; DNA, Viral; Dose-Response Relationship, Drug; Drug Resistance, Viral; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Middle Aged; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Transfection; Virus Replication | 2004 |
Phenotypic impact of HIV reverse transcriptase M184I/V mutations in combination with single thymidine analog mutations on nucleoside reverse transcriptase inhibitor resistance.
Topics: Adenine; Algorithms; Anti-HIV Agents; Databases, Genetic; Didanosine; Dideoxynucleosides; Drug Resistance, Multiple, Viral; HIV; HIV Infections; Humans; Mutation; Organophosphonates; Organophosphorus Compounds; Phenotype; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir; Thymidine; Zalcitabine; Zidovudine | 2004 |
Proximal tubular kidney damage and tenofovir: a role for mitochondrial toxicity?
Topics: Adenine; Adult; Anti-HIV Agents; DNA, Mitochondrial; HIV Infections; HIV-1; Humans; Kidney Diseases; Kidney Tubules, Proximal; Male; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2004 |
Tubulopathy consecutive to tenofovir-containing antiretroviral therapy in two patients infected with human immunodeficiency virus-1.
Topics: Adenine; Anti-HIV Agents; Drug Therapy, Combination; Fanconi Syndrome; HIV Infections; HIV-1; Humans; Hypophosphatemia; Kidney Tubules; Organophosphonates; Organophosphorus Compounds; Polyuria; Reverse Transcriptase Inhibitors; Tenofovir | 2004 |
Lichenoid drug eruption to tenofovir in an HIV/hepatitis B virus co-infected patient.
Topics: Adenine; Anti-HIV Agents; Drug Eruptions; Hepatitis B, Chronic; HIV Infections; Humans; Lichenoid Eruptions; Male; Middle Aged; Organophosphonates; Tenofovir | 2004 |
Nephrolithiasis and hydronephrosis in an HIV-infected man receiving tenofovir.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Hydronephrosis; Kidney Calculi; Male; Organophosphonates; Tenofovir | 2004 |
AIDS research. Cambodian leader throws novel prevention trial into limbo.
Topics: Adenine; Anti-HIV Agents; Cambodia; Controlled Clinical Trials as Topic; Female; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Sex Work; Tenofovir | 2004 |
Fatal lactic acidosis associated with coadministration of didanosine and tenofovir disoproxil fumarate.
Topics: Acidosis, Lactic; Adenine; Anti-HIV Agents; Area Under Curve; Comorbidity; Didanosine; Drug Interactions; Fatal Outcome; Female; HIV Infections; Humans; Lactates; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2004 |
Acute onset of pancreatitis with concomitant use of tenofovir and didanosine.
Topics: Acute Disease; Adenine; Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Pancreatitis; Tenofovir | 2004 |
Correlation between rules-based interpretation and virtual phenotype interpretation of HIV-1 genotypes for predicting drug resistance in HIV-infected individuals.
Topics: Adenine; Amino Acid Substitution; Anti-HIV Agents; Didanosine; Dideoxynucleosides; Drug Resistance, Viral; Genotype; HIV Infections; HIV-1; Humans; Microbial Sensitivity Tests; Mutation; Nucleosides; Organophosphonates; Phenotype; Protease Inhibitors; Reverse Transcriptase Inhibitors; Tenofovir | 2004 |
Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Blood-Testis Barrier; Cyclopropanes; Enfuvirtide; Genitalia, Male; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Oxazines; Peptide Fragments; Tenofovir | 2004 |
[3 years' data of tenofovir. Confirmed as a valuable building block].
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; HIV Reverse Transcriptase; Humans; Lamivudine; Organophosphonates; Oxazines; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir | 2004 |
[5 years' data are convincing. Lopinavir as primary therapy is effective and safe in the long term].
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Clinical Trials as Topic; Cyclopropanes; Drug Synergism; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Long-Term Care; Lopinavir; Organophosphonates; Oxazines; Pyrimidinones; Ritonavir; Tenofovir; Viral Load | 2004 |
Prevention trials starting.
Topics: Adenine; Adult; Africa; Clinical Trials as Topic; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir; United States | 2004 |
Cambodia stops important tenofovir prevention trial.
Topics: Adenine; Cambodia; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir | 2004 |
Trial of antiretroviral for HIV prevention on hold.
Topics: Adenine; Anti-HIV Agents; Cambodia; Controlled Clinical Trials as Topic; Double-Blind Method; Ethics Committees, Research; Ethics, Research; Female; HIV Infections; Humans; Insurance, Health; International Cooperation; National Institutes of Health (U.S.); Organophosphonates; Organophosphorus Compounds; Research Design; Sex Work; Tenofovir; United States; Women, Working | 2004 |
Intracellular pharmacology of emtricitabine and tenofovir.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Half-Life; HIV Infections; Humans; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2004 |
[Active prevention and treatment of superinfection with HBV, HCV and HIV].
Topics: Adenine; Antiretroviral Therapy, Highly Active; Hepatitis B, Chronic; Hepatitis C, Chronic; HIV Infections; Humans; Lamivudine; Organophosphonates | 2004 |
Tenofovir, equivalence, and noninferiority.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Tenofovir; Viral Load | 2004 |
Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Nelfinavir; Oligopeptides; Organophosphonates; Oxazines; Pregnancy; Pyrimidinones; Ritonavir; Stavudine; Sulfonamides; Treatment Outcome; Viral Load; Zidovudine | 2004 |
Increasing prevalence of HIV-1 reverse transcriptase mutation K65R correlates with tenofovir utilization.
Topics: Adenine; Anti-HIV Agents; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Organophosphonates; Prevalence; Reverse Transcriptase Inhibitors; Tenofovir | 2004 |
Tenofovir use in a patient with a severe renal impairment.
Topics: Adenine; Adult; Diabetic Nephropathies; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2004 |
Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatment.
Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Chronic Disease; DNA-Directed DNA Polymerase; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Viral Load | 2004 |
Predictors of selection of K65R: tenofovir use and lack of thymidine analogue mutations.
Topics: Adenine; Anti-HIV Agents; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Thymidine | 2004 |
Impact of a treatment including tenofovir plus didanosine on the selection of the 65R mutation in highly drug-experienced HIV-infected patients.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Databases, Genetic; Didanosine; DNA, Viral; Drug Resistance, Multiple, Viral; Gene Deletion; Genotype; HIV Infections; HIV-1; Humans; Mutation; Organophosphonates; Tenofovir | 2004 |
Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control study.
Topics: Adenine; Albuminuria; Antiretroviral Therapy, Highly Active; Case-Control Studies; Cohort Studies; Creatinine; Follow-Up Studies; HIV Infections; Humans; Organophosphonates; Proteinuria; Renal Insufficiency; Tenofovir | 2004 |
Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects.
Topics: Adenine; Adult; Anti-HIV Agents; Area Under Curve; Drug Combinations; Drug Interactions; Gels; Half-Life; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Middle Aged; Organophosphonates; Ritonavir; Saquinavir; Tenofovir | 2005 |
Prevalence and conditions of selection of the K65R mutation in the reverse transcriptase gene of HIV-1.
Topics: Adenine; Amino Acid Substitution; Anti-HIV Agents; Drug Resistance, Viral; Gene Frequency; Genes, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Organophosphonates; Point Mutation; Reverse Transcriptase Inhibitors; Selection, Genetic; Tenofovir | 2005 |
Warning on two specific 3-drug regimens: Viread + Didanosine + either Sustiva or Viramune.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; Organophosphonates; Oxazines; Tenofovir; United States; United States Food and Drug Administration | 2004 |
CD4 cell decline with didanosine and tenofovir and failure of triple nucleoside/nucleotide regimens may be related.
Topics: Adenine; Anti-HIV Agents; CD4-Positive T-Lymphocytes; Didanosine; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Lymphopenia; Organophosphonates; Purine-Nucleoside Phosphorylase; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure | 2004 |
Antiretroviral therapy with tenofovir is associated with mild renal dysfunction.
Topics: Adenine; Anti-HIV Agents; Creatinine; Cross-Sectional Studies; Cystatin C; Cystatins; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Diseases; Organophosphonates; Proteinuria; Tenofovir | 2005 |
Low rate of treatment failure on antiretroviral therapy with tenofovir, lamivudine and zidovudine.
Topics: Adenine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Organophosphonates; Retrospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Treatment Failure; Zidovudine | 2005 |
The experts speak. Studying the potential of tenofovir to prevent sexual transmission of HIV: first steps. Interview by Vicki Glaser.
Topics: Adenine; Communicable Disease Control; Female; HIV Infections; Humans; Male; Organophosphonates; Primary Prevention; Risk Assessment; Sensitivity and Specificity; Sexually Transmitted Diseases; Tenofovir; Treatment Outcome | 2005 |
Early virological failure in treatment-naive HIV-infected adults receiving didanosine and tenofovir plus efavirenz or nevirapine.
Topics: Adenine; Adult; Aged; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Didanosine; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nevirapine; Organophosphonates; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir | 2005 |
Tenofovir-induced acute renal failure in an HIV patient with normal renal function.
Topics: Acute Kidney Injury; Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Male; Organophosphonates; Renal Dialysis; Tenofovir | 2005 |
Tenofovir: a pill to prevent HIV?
Topics: Adenine; Anti-HIV Agents; Drugs, Investigational; HIV Infections; Humans; Organophosphonates; Tenofovir | 2005 |
Meeting notes from ICAAC. Tenofovir + ddI: a combination to avoid.
Topics: Adenine; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2005 |
Meeting notes from ICAAC. Tenofovir + emtricitabine vs. AZT + 3TC.
Topics: Adenine; CD4 Lymphocyte Count; Deoxycytidine; Emtricitabine; HIV Infections; Humans; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load; Zidovudine | 2005 |
Delivery of antiviral agents in liposomes.
Topics: Antiviral Agents; beta-Cyclodextrins; CD4 Antigens; Cross-Linking Reagents; Drug Delivery Systems; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Hydrogen-Ion Concentration; Liposomes; Macrophages; Microbial Sensitivity Tests; Oligonucleotides, Antisense; Organophosphonates; Protease Inhibitors; Purines; Pyrimidines; RNA, Catalytic; Succinimides; Sulfides | 2005 |
Selection of a rare resistance profile in an HIV-1-infected patient exhibiting a failure to an antiretroviral regimen including tenofovir DF.
Topics: Adenine; Adult; Anti-HIV Agents; Didanosine; Dideoxynucleosides; Drug Resistance, Viral; Female; Gabon; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Lopinavir; Microbial Sensitivity Tests; Mutation; Organophosphonates; Pyrimidinones; Tenofovir; Viral Load | 2005 |
Serum hypophosphatemia in tenofovir disoproxil fumarate recipients is multifactorial in origin, questioning the utility of its monitoring in clinical practice.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Blood Chemical Analysis; Creatinine; Fanconi Syndrome; Female; HIV Infections; Humans; Hypophosphatemia; Lopinavir; Male; Organophosphonates; Phosphates; Prospective Studies; Pyrimidinones; Reproducibility of Results; Tenofovir; Urea | 2005 |
Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; DNA, Viral; Female; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Multivariate Analysis; Organophosphonates; Oxazines; RNA, Viral; Stavudine; Tenofovir; Viremia | 2005 |
Women testing tenofovir for HIV prevention.
Topics: Adenine; Anti-HIV Agents; Clinical Trials as Topic; Female; HIV Infections; Humans; Nigeria; Organophosphonates; Sex Work; Tenofovir | 2005 |
Tubular cell apoptosis and cidofovir-induced acute renal failure.
Topics: Acute Kidney Injury; Adult; Annexin A5; Antiviral Agents; Apoptosis; Caspase 3; Caspases; Cells, Cultured; Cidofovir; Cytomegalovirus Retinitis; Cytosine; HIV Infections; Humans; Kidney Tubules, Proximal; Male; Organophosphonates | 2005 |
AIDS clinical trials. More woes for novel HIV prevention approach.
Topics: Adenine; Anti-HIV Agents; Centers for Disease Control and Prevention, U.S.; Clinical Trials as Topic; HIV Infections; Humans; Nigeria; Organophosphonates; Patient Selection; Sex Work; Substance Abuse, Intravenous; Tenofovir; Thailand; United States | 2005 |
Early virologic failure in a pilot study evaluating the efficacy of therapy containing once-daily abacavir, lamivudine, and tenofovir DF in treatment-naive HIV-infected patients.
Topics: Adenine; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Organophosphonates; Pilot Projects; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure; Viral Load | 2005 |
Switching from protease inhibitors to a single-class regimen of abacavir/lamivudine/zidovudine plus tenofovir in patients with HIV load suppression.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load; Zidovudine | 2005 |
The durability of virological success of tenofovir and didanosine dosed at either 400 or 250 mg once daily.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Didanosine; Drug Administration Schedule; HIV Infections; HIV-1; Humans; Organophosphonates; Retrospective Studies; Survival Rate; Tenofovir; Treatment Failure; Viral Load | 2005 |
The use of a triple nucleoside-nucleotide regimen for nonoccupational HIV post-exposure prophylaxis.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Chi-Square Distribution; HIV Infections; Humans; Lamivudine; Male; Nelfinavir; Organophosphonates; Reverse Transcriptase Inhibitors; Risk Assessment; Risk-Taking; Stavudine; Tenofovir; Zidovudine | 2005 |
Resistance mutations before and after tenofovir regimen failure in HIV-1 infected patients.
Topics: Adenine; Amino Acid Substitution; Anti-HIV Agents; Drug Resistance, Viral; France; HIV Infections; HIV-1; Humans; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure | 2005 |
Fatal lactic acidosis associated with tenofovir and abacavir.
Topics: Acidosis, Lactic; Adenine; Anti-HIV Agents; Dideoxynucleosides; Fatal Outcome; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Tenofovir | 2005 |
[Acute renal failure, Fanconi syndrome and insipidus diabetes in a HIV-infected patient treated with Tenofovir].
Topics: Acute Kidney Injury; Adenine; Adult; Diabetes Insipidus; Fanconi Syndrome; HIV Infections; Humans; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2005 |
Tenofovir helpful for patients with HBV.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Hepatitis B; HIV Infections; Humans; Organophosphonates; Randomized Controlled Trials as Topic; Tenofovir | 2005 |
Risk factors for CD4 lymphopenia in patients treated with a tenofovir/didanosine high dose-containing highly active antiretroviral therapy regimen.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Didanosine; Female; HIV Infections; Humans; Lymphopenia; Male; Organophosphonates; Risk Factors; Tenofovir | 2005 |
The risk of adefovir monotherapy in human immunodeficiency virus (HIV) and hepatitis B virus (HBV) co-infected patients.
Topics: Adenine; Antiviral Agents; DNA, Viral; Hepatitis B; Hepatitis B virus; HIV; HIV Infections; Humans; Organophosphonates; Treatment Outcome | 2005 |
Severe efavirenz-induced hypersensitivity syndrome (not-DRESS) with acute renal failure.
Topics: Acute Kidney Injury; Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Hypersensitivity; Ghana; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Mycobacterium tuberculosis; Organophosphonates; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Tuberculosis | 2006 |
We must not let protestors derail trials of pre-exposure prophylaxis for HIV.
Topics: Adenine; Health Knowledge, Attitudes, Practice; HIV Infections; Humans; Organophosphonates; Public Opinion; Public Policy; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir | 2005 |
The abandoned trials of pre-exposure prophylaxis for HIV: what went wrong?
Topics: Adenine; Global Health; Health Knowledge, Attitudes, Practice; HIV Infections; Humans; Organophosphonates; Patient Advocacy; Public Opinion; Randomized Controlled Trials as Topic; Research Design; Reverse Transcriptase Inhibitors; Tenofovir | 2005 |
Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Cytidine Triphosphate; Dideoxynucleosides; Dideoxynucleotides; Drug Interactions; Female; HIV Infections; Humans; Lamivudine; Leukocytes, Mononuclear; Male; Middle Aged; Organophosphonates; Prospective Studies; Tenofovir | 2005 |
Incidence of and risk factors for tenofovir-induced nephrotoxicity: a retrospective cohort study.
Topics: Adenine; Adult; Anti-HIV Agents; Creatinine; Female; HIV Infections; Humans; Hypophosphatemia; Kidney; Kidney Diseases; Male; Metabolic Clearance Rate; Middle Aged; Organophosphonates; Proteinuria; Retrospective Studies; Risk Factors; Tenofovir; Urinalysis | 2005 |
Tenofovir and changes in renal function.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Kidney Diseases; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2005 |
Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Area Under Curve; Bayes Theorem; Female; HIV Infections; HIV-1; Humans; Kidney Function Tests; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2005 |
Progression of renal impairment under therapy with tenofovir.
Topics: Adenine; Anti-HIV Agents; Case-Control Studies; Disease Progression; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Diseases; Organophosphonates; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir | 2005 |
Low frequency of renal function impairment during one-year of therapy with tenofovir-containing regimens in the real-world: a case-control study.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Case-Control Studies; Creatinine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; HIV Infections; Humans; Incidence; Kidney; Kidney Diseases; Kidney Function Tests; Male; Organophosphonates; Probability; Prognosis; Reference Values; Retrospective Studies; Reverse Transcriptase Inhibitors; Risk Assessment; Severity of Illness Index; Tenofovir | 2005 |
HIV/AIDS. Prevention cocktails: combining tools to Stop HIV's spread.
Topics: Acyclovir; Adenine; Anti-HIV Agents; Antidepressive Agents, Second-Generation; Antiviral Agents; Bupropion; Circumcision, Male; Clinical Trials as Topic; Contraceptive Devices, Female; Female; Herpes Genitalis; Herpesvirus 2, Human; HIV; HIV Infections; Humans; Hygiene; Male; Organophosphonates; Sexual Behavior; Tenofovir; Viral Load | 2005 |
Protests may slow down trials.
Topics: Adenine; Bisexuality; Clinical Trials as Topic; Europe; HIV Infections; Homosexuality, Male; Humans; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Thailand; Time Factors; United States | 2005 |
Tenofovir-induced renal tubular dysfunction presenting with hypocalcaemia.
Topics: Adenine; Anti-HIV Agents; Bone Density Conservation Agents; Fanconi Syndrome; HIV Infections; Humans; Hydroxycholecalciferols; Hypocalcemia; Male; Middle Aged; Organophosphonates; Phosphates; Tenofovir; Treatment Outcome | 2006 |
The development of hypophosphataemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Fanconi Syndrome; Female; HIV Infections; Humans; Hypophosphatemia; Male; Middle Aged; Muscular Diseases; Organophosphonates; Osteomalacia; Reverse Transcriptase Inhibitors; Tenofovir | 2005 |
High rate of virological failure in maintenance antiretroviral therapy with didanosine and tenofovir.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Didanosine; Drug Resistance, Multiple, Viral; HIV Infections; HIV-1; Humans; Mutation; Organophosphonates; Tenofovir; Treatment Failure | 2005 |
Protease inhibitors and non-nucleoside reverse transcriptase inhibitors have a comparable effect on the CD4 cell change after switching to tenofovir-based regimens.
Topics: Adenine; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2005 |
Absence of new thymidine-associated mutations and evidence of an immune virologic response over a 12-month period in a cohort of antiretroviral-experienced HIV-1-infected subjects treated with tenofovir combination therapy.
Topics: Adenine; Cohort Studies; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Thymidine; Viral Load | 2005 |
Fatal HHV-6 associated encephalitis in an HIV-1 infected patient treated with cidofovir.
Topics: Antiviral Agents; Biopsy; Brain; Cidofovir; Cytosine; Encephalitis, Viral; Fatal Outcome; Female; Herpesvirus 6, Human; HIV Infections; HIV-1; Humans; Magnetic Resonance Imaging; Middle Aged; Organophosphonates; Polymerase Chain Reaction; Roseolovirus Infections; Viral Load | 2006 |
AIDS. Promote HIV chemoprophylaxis research, don't prevent it.
Topics: Adenine; Africa; Anti-HIV Agents; Asia; Community Participation; Controlled Clinical Trials as Topic; Counseling; Developing Countries; Drug Costs; Female; Health Services Accessibility; HIV Infections; Humans; Latin America; Male; Organophosphonates; Patient Selection; Tenofovir | 2005 |
The tenofovir pre-exposure prophylaxis trial in Thailand: researchers should show more openness in their engagement with the community.
Topics: Adenine; Anti-HIV Agents; Clinical Trials as Topic; Community Networks; HIV Infections; Human Rights; Humans; Needle-Exchange Programs; Organophosphonates; Patient Advocacy; Research Design; Substance-Related Disorders; Tenofovir; Thailand | 2005 |
Response to Joep M. A. Lange.
Topics: Adenine; Cambodia; Clinical Trials as Topic; Health Services Accessibility; HIV Infections; Humans; Organophosphonates; Patient Advocacy; Research Design; Sex Work; Tenofovir | 2005 |
Antiviral potential of a new generation of acyclic nucleoside phosphonates, the 6-[2-(phosphonomethoxy)alkoxy]-2,4-diaminopyrimidines.
Topics: Adenoviridae; Adenoviridae Infections; Animals; Anti-HIV Agents; Antiviral Agents; Cell Line; Cidofovir; Cytosine; HIV Infections; Humans; Mice; Mice, Nude; Models, Chemical; Moloney murine sarcoma virus; Organophosphonates; Papillomaviridae; Papillomavirus Infections; Poxviridae; Poxviridae Infections; Purines; Pyrimidines; Vaccinia; Vaccinia virus | 2005 |
HIV Pathogenesis and Treatment - Third International AIDS Society Conference.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Chemistry, Pharmaceutical; Clinical Trials as Topic; Congresses as Topic; Darunavir; Drugs, Investigational; Enfuvirtide; HIV Envelope Protein gp41; HIV Infections; HIV-1; Humans; Nitriles; Organophosphonates; Peptide Fragments; Pyrimidines; Receptors, CCR5; Reverse Transcriptase Inhibitors; Rilpivirine; Societies, Scientific; Sulfonamides; Tenofovir; Zalcitabine | 2005 |
Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Didanosine; Dose-Response Relationship, Immunologic; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Retrospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Treatment Outcome | 2005 |
Renal tubular toxicity associated with tenofovir assessed using urine-beta 2 microglobulin, percentage of tubular reabsorption of phosphate and alkaline phosphatase levels.
Topics: Absorption; Adenine; Adult; Alkaline Phosphatase; Antiretroviral Therapy, Highly Active; beta 2-Microglobulin; Creatinine; HIV Infections; HIV-1; Humans; Kidney Tubules; Middle Aged; Organophosphonates; Phosphates; Phosphorus; Reverse Transcriptase Inhibitors; Tenofovir; Uric Acid | 2005 |
Risk of selecting K65R in antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir.
Topics: Adenine; Antiviral Agents; DNA, Viral; Genes, Viral; Genotype; Hepatitis B e Antigens; Hepatitis B, Chronic; HIV Infections; Humans; Mutation; Organophosphonates; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral | 2005 |
Less than the sum of its parts: failure of a tenofovir-abacavir-Lamivudine triple-nucleoside regimen.
Topics: Adenine; Anti-HIV Agents; Dideoxynucleosides; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Organophosphonates; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure | 2005 |
Sensitive assay for determining plasma tenofovir concentrations by LC/MS/MS.
Topics: Adenine; Calibration; Chromatography, High Pressure Liquid; HIV Infections; Humans; Mass Spectrometry; Organophosphonates; Reference Standards; Reverse Transcriptase Inhibitors; Sensitivity and Specificity; Tenofovir | 2006 |
Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; DNA, Viral; Drug Resistance, Viral; Evolution, Molecular; Female; Genes, pol; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Tenofovir; Viral Load; Viremia; Virus Replication | 2005 |
Stakeholder consultation to address issues related to tenofovir prophylactic research.
Topics: Adenine; Anti-HIV Agents; HIV Infections; Humans; Organophosphonates; Referral and Consultation; Research; Tenofovir | 2005 |
A 12-month treatment with tenofovir does not impair bone mineral accrual in HIV-infected children.
Topics: Absorptiometry, Photon; Adenine; Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Density; Child; HIV Infections; Humans; Organophosphonates; Stavudine; Tenofovir | 2005 |
Improved lipid profiles and maintenance of virologic control in heavily pretreated HIV-infected patients who switched from stavudine to tenofovir treatment.
Topics: Adenine; Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Lipid Metabolism; Male; Middle Aged; Organophosphonates; Retrospective Studies; Stavudine; Tenofovir | 2006 |
Assessment of drug-drug interactions between tenofovir disoproxil fumarate and the nonnucleoside reverse transcriptase inhibitors nevirapine and efavirenz in HIV-infected patients.
Topics: Adenine; Administration, Oral; Alkynes; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Nevirapine; Organophosphonates; Oxazines; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir | 2006 |
Tenofovir trials raise ethical issues.
Topics: Adenine; Clinical Trials as Topic; Ethics, Medical; HIV Infections; Humans; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2005 |
[Simply convincing. New fixed combination for HIV therapy].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Patient Compliance; Practice Guidelines as Topic; Survival Rate; Tenofovir | 2005 |
Should tenofovir ever be used in association with didanosine?
Topics: Adenine; Anti-HIV Agents; Contraindications; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure; Viral Load | 2005 |
Wild type and YMDD variant of hepatitis B virus: no difference in viral kinetics on lamivudine/tenofovir therapy in HIV-HBV co-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; DNA, Viral; Drug Resistance, Viral; Genetic Variation; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Kinetics; Lamivudine; Male; Middle Aged; Organophosphonates; RNA, Viral; Tenofovir | 2006 |
Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy.
Topics: Acid-Base Equilibrium; Acute Kidney Injury; Adenine; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Creatinine; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Kidney; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2006 |
Case study: an active, 24-year-old woman positive for HIV.
Topics: Adenine; Adult; Anti-Retroviral Agents; Deoxycytidine; Disease Progression; Emtricitabine; Female; HIV Infections; Humans; Organophosphonates; Ritonavir; Tenofovir | 2006 |
Longitudinal study on mitochondrial effects of didanosine-tenofovir combination.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Didanosine; DNA, Mitochondrial; Drug Therapy, Combination; Electron Transport Complex IV; HIV Infections; HIV-1; Humans; Longitudinal Studies; Organophosphonates; Oxidative Phosphorylation; Prospective Studies; Retrospective Studies; Tenofovir | 2006 |
Retrovirus meeting. Novel attacks on HIV move closer to reality.
Topics: Adenine; Animals; Anti-HIV Agents; Evolution, Molecular; HIV Infections; HIV-1; Humans; Organic Chemicals; Organophosphonates; Primates; Pyrrolidinones; Raltegravir Potassium; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Tenofovir | 2006 |
Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients.
Topics: Adenine; Adult; Antiviral Agents; Cohort Studies; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Tenofovir; Treatment Outcome | 2006 |
Serum creatinine changes in HIV-seropositive patients receiving tenofovir.
Topics: Acute Kidney Injury; Adenine; Creatinine; Cross-Sectional Studies; HIV Infections; Humans; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2006 |
Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biopsy; Didanosine; DNA, Mitochondrial; Drug Therapy, Combination; Female; HIV Infections; Humans; Kidney; Male; Microscopy, Electron; Middle Aged; Mitochondria; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2006 |
Registration problems for antiretrovirals in Africa.
Topics: Adenine; Africa; Anti-Retroviral Agents; Developing Countries; Drug and Narcotic Control; HIV Infections; Humans; Organophosphonates; Tenofovir | 2006 |
Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Didanosine; Drug Interactions; HIV Infections; Humans; Mitochondria; Organophosphonates; Purine-Nucleoside Phosphorylase; Tenofovir | 2006 |
Clinical and genotypic correlates of mutation K65R in HIV-infected patients failing regimens not including tenofovir.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Male; Middle Aged; Multivariate Analysis; Mutation; Organophosphonates; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure | 2006 |
Virological response to HIV-1 nucleoside/nucleotide reverse transcriptase inhibitors-based, tenofovir DF-including regimens in the ANRS Aquitaine Cohort.
Topics: Adenine; Cohort Studies; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; France; HIV Infections; HIV Reverse Transcriptase; HIV-1; Hospitals, University; Humans; Lamivudine; Mutation; Organophosphonates; Retrospective Studies; Reverse Transcriptase Inhibitors; Species Specificity; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2006 |
Improvement of dyslipidemia during different HAART regimens: tenofovir- versus stavudine-containing antiretroviral combinations.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dyslipidemias; HIV Infections; Humans; Organophosphonates; Stavudine; Tenofovir | 2006 |
Tenofovir for chronic hepatitis B virus infection in HIV-coinfected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Clinical Trials as Topic; Hepatitis B e Antigens; Hepatitis B, Chronic; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Tenofovir | 2006 |
Short-term safety and tolerability of didanosine combined with high- versus low-dose tenofovir disproxil fumarate in ambulatory HIV-1-infected persons.
Topics: Adenine; Adult; Anti-HIV Agents; Didanosine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Organophosphonates; Retrospective Studies; Tenofovir | 2006 |
Higher risk of hyperglycemia in HIV-infected patients treated with didanosine plus tenofovir.
Topics: Adenine; Adult; Anti-HIV Agents; Blood Glucose; Didanosine; Drug Therapy, Combination; Fasting; Female; Follow-Up Studies; HIV Infections; Humans; Hyperglycemia; Linear Models; Male; Organophosphonates; Retrospective Studies; Risk Factors; RNA, Viral; Tenofovir; Time Factors; Treatment Outcome; Virus Replication | 2006 |
Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biological Evolution; Drug Administration Schedule; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Retrospective Studies; RNA, Viral; Stavudine; Tenofovir; Treatment Failure; Viral Load | 2006 |
Tenofovir-associated kidney diseases and interactions between tenofovir and other antiretrovirals.
Topics: Acute Kidney Injury; Adenine; Adult; Anti-HIV Agents; Drug Interactions; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Tenofovir | 2006 |
The role of drug interactions and monitoring in the prevention of tenofovir-associated kidney disease.
Topics: Acute Kidney Injury; Adenine; Anti-HIV Agents; Drug Interactions; HIV Infections; Humans; Organophosphonates; Tenofovir | 2006 |
Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Prospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load; Viremia; Zidovudine | 2006 |
Investigating new antiretroviral combinations.
Topics: Adenine; Anti-HIV Agents; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Organophosphonates; Pilot Projects; Randomized Controlled Trials as Topic; Tenofovir | 2006 |
Comment on: suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir.
Topics: Adenine; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; HIV Infections; Humans; Organophosphonates; Purine-Nucleoside Phosphorylase; Tenofovir | 2006 |
Report from the 13th retrovirus conference. Renal tenofovir debate continues.
Topics: Adenine; Glomerular Filtration Rate; HIV Infections; Humans; Kidney; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2006 |
Truvada trials hold promise for new HIV prevention strategy. Once-a-day might keep HIV away.
Topics: Adenine; Centers for Disease Control and Prevention, U.S.; Clinical Trials as Topic; Female; HIV Infections; HIV Seronegativity; Humans; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; United States | 2006 |
FDA makes final approvals.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Approval; Drug Combinations; Emtricitabine; HIV Infections; Humans; Organophosphonates; Tenofovir; United States; United States Food and Drug Administration | 2006 |
Tenofovir DF and emtricitabine vs. zidovudine and lamivudine.
Topics: Adenine; Anti-Retroviral Agents; Bias; Data Interpretation, Statistical; Deoxycytidine; Emtricitabine; HIV Infections; Humans; Lamivudine; Organophosphonates; Research Design; Tenofovir; Zidovudine | 2006 |
Renal safety of tenofovir disoproxil fumarate in HIV-1 treatment-experienced patients with adverse events related to prior NRTI use: data from a prospective, observational, multicenter study.
Topics: Adenine; Adult; HIV Infections; HIV-1; Humans; Kidney; Middle Aged; Organophosphonates; Prospective Studies; Reverse Transcriptase Inhibitors; Tenofovir | 2006 |
Virologic and immunologic efficacy of the tenofovir/didanosine/lamivudine regimen.
Topics: Adenine; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2006 |
Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients.
Topics: Adenine; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Interactions; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Nevirapine; Oligopeptides; Organophosphonates; Oxazines; Pyridines; Retrospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir | 2006 |
Tenofovir DF and emtricitabine vs. zidovudine and lamivudine.
Topics: Adenine; Bone Density; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; HIV; HIV Infections; Humans; Lamivudine; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Zidovudine | 2006 |
Nephrotoxicity in a child with perinatal HIV on tenofovir, didanosine and lopinavir/ritonavir.
Topics: Adenine; Anti-HIV Agents; Child; Diabetes Insipidus, Nephrogenic; Didanosine; Drug Therapy, Combination; Fanconi Syndrome; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Kidney; Kidney Diseases; Lopinavir; Organophosphonates; Pregnancy; Pregnancy Complications; Pyrimidinones; Ritonavir; Tenofovir | 2006 |
Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Dyslipidemias; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Prospective Studies; Risk Factors; Stavudine; Tenofovir | 2006 |
FDA notifications. Two tenofovir containing products are approved.
Topics: Adenine; Drug Approval; Drug Therapy, Combination; HIV Infections; Humans; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; United States; United States Food and Drug Administration | 2006 |
Moving toward assured access to treatment in microbicide trials. Global Campaign for Microbicides.
Topics: Adenine; Anti-HIV Agents; Cambodia; Cameroon; Clinical Trials as Topic; Consensus Development Conferences as Topic; Global Health; Health Policy; Health Services Accessibility; HIV Infections; HIV Seropositivity; Humans; International Agencies; Nigeria; Organophosphonates; Patient Rights; Political Systems; Politics; Randomized Controlled Trials as Topic; Refusal to Treat; Risk-Taking; Social Justice; Tenofovir; United Nations | 2006 |
Impact of modelling intra-subject variability on tests based on non-linear mixed-effects models in cross-over pharmacokinetic trials with application to the interaction of tenofovir on atazanavir in HIV patients.
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; Bias; Cross-Over Studies; Drug Interactions; France; HIV Infections; Humans; Likelihood Functions; Nonlinear Dynamics; Oligopeptides; Organophosphonates; Pyridines; Tenofovir | 2007 |
[Pure alexia secondary to progressive multifocal leukoencephalopathy as first manifestation of HIV infection].
Topics: Alexia, Pure; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Brain; Cidofovir; Cytosine; HIV Infections; Humans; JC Virus; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Organophosphonates | 2006 |
AIDS drug trial turned away; protests by prostitutes in Cambodia ended Tenofovir testing.
Topics: Adenine; Anti-HIV Agents; Cambodia; Clinical Trials as Topic; Developing Countries; Female; HIV Infections; Humans; Internationality; Organophosphonates; Refusal to Participate; Reverse Transcriptase Inhibitors; Sex Work; Tenofovir; Women | 2006 |
Hypokalemia in HIV patients on tenofovir.
Topics: Adenine; Adolescent; Adult; Body Weight; Child; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Hypokalemia; Kidney Diseases; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Risk Factors; Ritonavir; Tenofovir; Time Factors | 2006 |
Alkoxyalkyl esters of (S)-9-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine are potent inhibitors of the replication of wild-type and drug-resistant human immunodeficiency virus type 1 in vitro.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Cell Count; Cell Line; Cell Survival; DNA, Viral; Drug Resistance, Viral; Esters; Fibroblasts; Genetic Variation; HIV Infections; HIV-1; Humans; In Vitro Techniques; Microbial Sensitivity Tests; Molecular Structure; Mutation; Organophosphonates; Virus Replication | 2006 |
Rapid improvement of liver function in a patient with HIV and hepatitis B coinfection treated with lamivudine and tenofovir.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; Hepatitis; HIV Infections; Humans; Lamivudine; Liver Function Tests; Organophosphonates; Tenofovir; Zidovudine | 2006 |
Chronic hypertrophic acyclovir-resistant genital herpes treated with topical cidofovir and with topical foscarnet at recurrence in an HIV-positive man.
Topics: Acyclovir; Administration, Topical; Antiretroviral Therapy, Highly Active; Antiviral Agents; Chronic Disease; Cidofovir; Cytosine; Drug Resistance, Viral; Drug Therapy, Combination; Foscarnet; Herpes Genitalis; HIV Infections; Humans; Male; Middle Aged; Organophosphonates | 2006 |
Efavirenz/emtricitabine/tenofovir disoproxil fumarate: triple combination tablet.
Topics: Adenine; Alkynes; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Deoxycytidine; Drug Combinations; Emtricitabine; HIV Infections; Humans; Organophosphonates; Oxazines; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2006 |
Urinary beta2-microglobulin as a possible sensitive marker for renal injury caused by tenofovir disoproxil fumarate.
Topics: Adenine; Adult; Anti-HIV Agents; beta 2-Microglobulin; Biomarkers; Creatinine; Female; HIV Infections; HIV-1; Humans; Kidney Tubules; Lopinavir; Male; Middle Aged; Organophosphonates; Pyrimidinones; Tenofovir; Thinness | 2006 |
Evaluation of hypophosphataemia in tenofovir disoproxil fumarate (TDF)-exposed and TDF-unexposed HIV-infected out-patients receiving highly active antiretroviral therapy.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Female; HIV Infections; Humans; Hypophosphatemia; Incidence; Male; Organophosphonates; Prospective Studies; Reverse Transcriptase Inhibitors; Risk Factors; Tenofovir; Treatment Outcome; United States | 2006 |
Estimating renal function in patients on tenofovir disoproxil fumarate: suggestions for safer use.
Topics: Adenine; Creatinine; Dose-Response Relationship, Drug; Fanconi Syndrome; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Diseases; Organophosphonates; Osteomalacia; Reverse Transcriptase Inhibitors; Tenofovir | 2006 |
Acute renal failure in HIV patients with liver cirrhosis receiving tenofovir: a report of two cases.
Topics: Acute Kidney Injury; Adenine; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Liver Cirrhosis; Male; Organophosphonates; Tenofovir | 2006 |
Change to a once-daily combination including boosted atazanavir in HIV-1-infected children.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Atazanavir Sulfate; Child; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Oligopeptides; Organophosphonates; Prospective Studies; Pyridines; Ritonavir; Tenofovir; Virus Replication | 2006 |
Hepatitis delta virus super-infection in a co-infected patient with the human immunodeficiency virus type 1 and a surface antigen-negative hepatitis B virus variant.
Topics: Adenine; Alanine Transaminase; Amino Acid Sequence; Anti-HIV Agents; Follow-Up Studies; Hepatitis B; Hepatitis B virus; Hepatitis D; HIV Infections; HIV-1; Homosexuality, Male; Humans; Male; Middle Aged; Molecular Sequence Data; Organophosphonates; RNA, Viral; Superinfection; Tenofovir; Time Factors; Viral Load | 2006 |
Chemoprophylaxis of HIV infection: moving forward with caution.
Topics: Adenine; Animals; Antiviral Agents; Chemoprevention; Disease Models, Animal; HIV Infections; HIV-1; Humans; Macaca mulatta; Organophosphonates; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Tenofovir | 2006 |
Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges.
Topics: Adenine; Animals; Anti-HIV Agents; Chemoprevention; Disease Models, Animal; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Macaca mulatta; Male; Organophosphonates; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Tenofovir | 2006 |
Short communication metabolic and mitochondrial effects of switching antiretroviral-experienced patients to enfuvirtide, tenofovir and saquinavir/ritonavir.
Topics: Adenine; Adult; Aged; Antiretroviral Therapy, Highly Active; DNA, Mitochondrial; Electron Transport Complex III; Electron Transport Complex IV; Enfuvirtide; Female; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV Protease Inhibitors; Humans; Insulin; Leukocytes, Mononuclear; Male; Middle Aged; Mitochondria; Organophosphonates; Oxygen Consumption; Peptide Fragments; Prospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Tenofovir | 2006 |
Temporary HBV resolution in an HIV-coinfected patient during HBV-directed combination therapy followed by relapse of HBV.
Topics: Adenine; Adult; Antiviral Agents; CD4 Lymphocyte Count; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Surface Antigens; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Male; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Secondary Prevention; Viral Load | 2006 |
Suppression of HIV-1 protease inhibitor resistance by phosphonate-mediated solvent anchoring.
Topics: Atazanavir Sulfate; Binding Sites; Drug Design; Drug Resistance, Multiple, Viral; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Models, Molecular; Molecular Structure; Oligopeptides; Organophosphonates; Pyridines; Solvents; Thermodynamics | 2006 |
Long-term follow-up of patients with initial early virologic failure after being treated with once-daily tenofovir/abacavir/lamivudine.
Topics: Adenine; Anti-HIV Agents; Dideoxynucleosides; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Follow-Up Studies; HIV; HIV Infections; Humans; Lamivudine; Organophosphonates; RNA, Viral; Tenofovir; Treatment Failure | 2006 |
The role of tenofovir in the prevention of HIV infections.
Topics: Adenine; Anti-HIV Agents; HIV Infections; Humans; Organophosphonates; Tenofovir | 2006 |
Virological outcome of chronic hepatitis B virus infection in HIV-coinfected patients receiving anti-HBV active antiretroviral therapy.
Topics: Adenine; Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Chi-Square Distribution; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Regression Analysis; RNA, Viral; Statistics, Nonparametric; Tenofovir; Treatment Outcome | 2006 |
One pill, once daily: now an option for HIV patients.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug Combinations; HIV Infections; Humans; Organophosphonates; Oxazines; Tenofovir | 2006 |
A once-daily combination tablet (Atripla) for HIV.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Combinations; Drug Interactions; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Emtricitabine; HIV Infections; Humans; Organophosphonates; Oxazines; Tenofovir | 2006 |
Once-daily dosing and the treatment of HIV disease.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Emtricitabine; HIV Infections; Humans; Organophosphonates; Oxazines; Tenofovir | 2006 |
Pre-exposure prophylaxis effective.
Topics: Adenine; Anti-HIV Agents; Clinical Trials as Topic; Drug Administration Schedule; Female; Ghana; HIV Infections; Humans; Organophosphonates; Tenofovir | 2006 |
Toward a pharmacogenetic understanding of nucleotide and nucleoside analogue toxicity.
Topics: Adenine; Anti-HIV Agents; Fanconi Syndrome; Haplotypes; HIV Infections; Humans; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Organophosphonates; Pharmacogenetics; Polymorphism, Single Nucleotide; Tenofovir | 2006 |
Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Case-Control Studies; Fanconi Syndrome; Female; Gene Frequency; Genetic Predisposition to Disease; Haplotypes; HIV Infections; Humans; Male; Membrane Transport Proteins; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Organophosphonates; Point Mutation; Polymorphism, Single Nucleotide; Statistics as Topic; Tenofovir | 2006 |
A novel hepatitis B virus mutation with resistance to adefovir but not to tenofovir in an HIV-hepatitis B virus-co-infected patient.
Topics: Adenine; Adult; Drug Resistance, Viral; Gene Products, pol; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2006 |
HIV prophylaxis still has no clear cut answer.
Topics: Adenine; Centers for Disease Control and Prevention, U.S.; Female; HIV Infections; Humans; National Institutes of Health (U.S.); Organophosphonates; Placebos; Reverse Transcriptase Inhibitors; Risk Factors; Tenofovir; United States | 2006 |
Report from the XVI International AIDS Conference. Preexposure prophylaxis studies move forward.
Topics: Adenine; Adolescent; Adult; Condoms; Double-Blind Method; Female; HIV Infections; Humans; Organophosphonates; Placebos; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir | 2006 |
A novel diketo phosphonic acid that exhibits specific, strand-transfer inhibition of HIV integrase and anti-HIV activity.
Topics: Acetoacetates; Anti-HIV Agents; Cell Line; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Inhibitory Concentration 50; Ketones; Organophosphonates; Structure-Activity Relationship | 2007 |
Aminotransferase elevation in HIV/hepatitis B virus co-infected patients treated with two active hepatitis B virus drugs.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; DNA, Viral; Female; Hepatitis B; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir; Transaminases | 2006 |
K65R development among subtype C HIV-1-infected patients in tenofovir DF clinical trials.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Mutation; Organophosphonates; Tenofovir; Treatment Failure | 2007 |
Rate of virologic failure and selection of drug resistance mutations using different triple nucleos(t)ide analogue combinations in HIV-infected patients.
Topics: Adenine; Adult; Anti-Retroviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Proportional Hazards Models; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure; Viral Load; Zidovudine | 2006 |
Anti-HIV agents. Trying times for tenofovir and abacavir.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Organophosphonates; Tenofovir; Viral Load | 2003 |
Five-year data out on Viread.
Topics: Adenine; Anti-HIV Agents; Double-Blind Method; Drug Administration Schedule; HIV Infections; Humans; Organophosphonates; Randomized Controlled Trials as Topic; Stavudine; Tenofovir | 2006 |
Anti-HIV agents. Low rate of early virologic failure seen with a combination of Trizivir and tenofovir.
Topics: Adenine; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Organophosphonates; Tenofovir; Viral Load; Zidovudine | 2004 |
Workshop explores racial PK differences, TDF-PI interaction.
Topics: Adenine; HIV Infections; HIV Protease Inhibitors; Humans; Organophosphonates; Racial Groups; Reverse Transcriptase Inhibitors; Tenofovir | 2006 |
Macroenzyme creatine kinase (CK) type 2 in HIV-infected patients is significantly associated with TDF and consists of ubiquitous mitochondrial CK.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Cohort Studies; Creatine Kinase, Mitochondrial Form; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Tenofovir | 2006 |
Editorial comment: tenofovir-related nephrotoxicity--who's at risk?
Topics: Adenine; Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Kidney Diseases; Organophosphonates; Reverse Transcriptase Inhibitors; Risk Factors; Tenofovir | 2007 |
Induction therapy with enfuvirtide-based highly active antiretroviral therapy in a patient with acute HIV-1 infection.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Emtricitabine; Enfuvirtide; HIV Envelope Protein gp41; HIV Infections; HIV-1; Humans; Lopinavir; Male; Organophosphonates; Peptide Fragments; Pyrimidinones; Ritonavir; Tenofovir; Viral Load; Viremia | 2007 |
No response to first-line tenofovir+lamivudine+efavirenz despite optimization according to baseline resistance testing: impact of resistant minority variants on efficacy of low genetic barrier drugs.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Multiple, Viral; HIV Infections; HIV-1; Humans; Lamivudine; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2007 |
Prevention. Anti-HIV drug could prevent transmission in women.
Topics: Adenine; Administration, Topical; Female; HIV Infections; Humans; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2007 |
Human immunodeficiency virus-associated progressive multifocal leucoencephalopathy: epidemiology and predictive factors for prolonged survival.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cidofovir; Cytosine; Female; HIV Infections; Humans; Immunocompromised Host; Leukoencephalopathy, Progressive Multifocal; Male; Middle Aged; Organophosphonates; Prognosis; Retrospective Studies; Survival Analysis | 2007 |
Unlikely association of multidrug-resistance protein 2 single-nucleotide polymorphisms with tenofovir-induced renal adverse events.
Topics: Adenine; Anti-HIV Agents; Confounding Factors, Epidemiologic; HIV Infections; Humans; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Organophosphonates; Point Mutation; Polymorphism, Single Nucleotide; Renal Insufficiency; Tenofovir | 2007 |
Long-term follow-up of patients taking tenofovir DF with low-level HIV-1 viremia and the K65R substitution in HIV-1 RT.
Topics: Adenine; Anti-HIV Agents; Anti-Retroviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Long-Term Care; Longitudinal Studies; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load | 2007 |
Response to Schmutz et al., 'Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection'.
Topics: Adenine; Drug Therapy, Combination; Hepatitis B; HIV Infections; Humans; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure | 2007 |
Response to Blaas et al., 'Acute renal failure in HIV patients with liver cirrhosis receiving tenofovir: a report of two cases'.
Topics: Acute Kidney Injury; Adenine; HIV Infections; Humans; Liver Cirrhosis; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2007 |
CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load.
Topics: Adenine; Adult; Aging; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cohort Studies; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Italy; Male; Middle Aged; Organophosphonates; Risk Factors; Sex Characteristics; Tenofovir; Treatment Outcome; Viral Load | 2007 |
Evidence and possible consequences of the phosphorylation of nucleoside reverse transcriptase inhibitors in human red blood cells.
Topics: Adenine; Anti-HIV Agents; Drug Interactions; Drug Therapy, Combination; Erythrocytes; HIV Infections; Humans; Lamivudine; Nucleosides; Organophosphonates; Phosphorylation; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Zidovudine | 2007 |
Medicines Control Council and registration backlog of antiretrovirals.
Topics: Adenine; Anti-Retroviral Agents; Deoxycytidine; Drug Approval; Drug Combinations; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; Humans; Organophosphonates; Oxazines; South Africa | 2007 |
Possible allergic cross-reaction to didanosine and tenofovir in an HIV-1-infected woman.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Didanosine; Drug Hypersensitivity; Drug Interactions; Female; HIV Infections; HIV-1; Humans; Organophosphonates; Tenofovir | 2007 |
Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Black People; Cholesterol; Cross-Sectional Studies; Cyclopropanes; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Fasting; Female; Hispanic or Latino; HIV Infections; HIV Protease Inhibitors; HIV Seronegativity; HIV Seropositivity; HIV-1; Humans; Indinavir; Lamivudine; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Multivariate Analysis; Nelfinavir; Nevirapine; Organophosphonates; Ritonavir; Stavudine; Tenofovir; Triglycerides; United States; White People | 2007 |
Acute interstitial nephritis of HIV-positive patients under atazanavir and tenofovir therapy in a retrospective analysis of kidney biopsies.
Topics: Acute Kidney Injury; Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Female; Fluorescent Antibody Technique; HIV Infections; Humans; Immunohistochemistry; Kidney; Male; Microscopy, Electron; Middle Aged; Nephritis, Interstitial; Oligopeptides; Organophosphonates; Pyridines; Retrospective Studies; Tenofovir | 2007 |
Virologic characterization of HIV type 1 with a codon 70 deletion in reverse transcriptase.
Topics: Adenine; Antiviral Agents; Cell Line, Transformed; Codon; Deoxycytidine; Didanosine; Dideoxynucleosides; Drug Resistance, Viral; Emtricitabine; HeLa Cells; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Organophosphonates; Point Mutation; Reassortant Viruses; Reverse Transcriptase Inhibitors; Tenofovir | 2007 |
Relevance of a combined UV and single mass spectrometry detection for the determination of tenofovir in human plasma by HPLC in therapeutic drug monitoring.
Topics: Adenine; Calibration; Drug Monitoring; HIV Infections; Humans; Mass Spectrometry; Organophosphonates; Reference Standards; Reverse Transcriptase Inhibitors; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Tenofovir | 2007 |
Chronic renal failure among HIV-1-infected patients.
Topics: Adenine; Adult; Aged; Anti-Retroviral Agents; CD4 Lymphocyte Count; Creatinine; Female; Glomerular Filtration Rate; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hypertension; Indinavir; Kidney; Kidney Failure, Chronic; Male; Middle Aged; Organophosphonates; Prospective Studies; Reverse Transcriptase Inhibitors; Tenofovir | 2007 |
Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration's Adverse Event Reporting System.
Topics: Adenine; Adult; Adverse Drug Reaction Reporting Systems; Atazanavir Sulfate; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Hospitalization; Humans; Male; Middle Aged; Nephrolithiasis; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; United States | 2007 |
Reversibility of cirrhosis in HIV/HBV coinfection.
Topics: Adenine; Adult; Alanine Transaminase; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; DNA, Viral; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Liver Cirrhosis; Male; Organophosphonates; Platelet Count; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Viral Load; Virus Replication | 2007 |
Does tenofovir influence efavirenz pharmacokinetics?
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Interactions; Drug Therapy, Combination; Female; Genotype; HIV Infections; Humans; Liver; Longitudinal Studies; Male; Middle Aged; Models, Biological; Organophosphonates; Oxidoreductases, N-Demethylating; Phenotype; Reverse Transcriptase Inhibitors; Switzerland; Tenofovir | 2007 |
Improvements in parameters of end-stage liver disease in patients with HIV/HBV-related cirrhosis treated with tenofovir.
Topics: Adenine; CD4 Lymphocyte Count; DNA, Viral; Follow-Up Studies; Hepatitis B; Hepatitis B e Antigens; Hepatitis B virus; HIV Infections; Humans; Liver Cirrhosis; Liver Failure; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Severity of Illness Index; Tenofovir; Time Factors; Treatment Outcome; Viral Load | 2007 |
Assessment of adverse events associated with antiretroviral regimens for postexposure prophylaxis for occupational and nonoccupational exposures to prevent transmission of human immunodeficiency virus.
Topics: Adenine; Adult; Anti-HIV Agents; Chemoprevention; Drug Combinations; Female; HIV Infections; Humans; Lamivudine; Logistic Models; Male; Middle Aged; New York; Occupational Exposure; Occupational Health Services; Organophosphonates; Patient Compliance; Public Health Administration; Retrospective Studies; Risk Factors; Sex Factors; Student Health Services; Tenofovir; Universities; Zidovudine | 2007 |
The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years.
Topics: Adenine; Adult; Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Anti-Retroviral Agents; Antiviral Agents; Body Weight; CD4 Lymphocyte Count; Creatinine; Drug Therapy, Combination; Female; HIV Infections; Humans; Kidney; Kidney Diseases; Male; Organophosphonates; Product Surveillance, Postmarketing; Reverse Transcriptase Inhibitors; Risk Factors; Tenofovir | 2007 |
Transmission of multidrug-resistant HIV-1: 5 years of immunological and virological survey.
Topics: Adenine; Anti-Retroviral Agents; CD4 Lymphocyte Count; Drug Resistance, Multiple, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Mutation; Organophosphonates; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Viral Load | 2007 |
Cutaneous reactions with tenofovir disoproxil fumarate: a report of nine cases.
Topics: Adenine; Adult; Drug Eruptions; Drug Therapy, Combination; Exanthema; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Skin; Tenofovir | 2007 |
Pharmacokinetics of once-daily tenofovir, emtricitabine, ritonavir and fosamprenavir in HIV-infected subjects.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; Carbamates; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Organophosphates; Organophosphonates; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Sulfonamides; Tenofovir; Treatment Outcome | 2007 |
Tenofovir renal safety in HIV-infected patients: results from the SCOLTA Project.
Topics: Adenine; Adult; Age Factors; Anti-HIV Agents; Cohort Studies; Comorbidity; Female; Follow-Up Studies; HIV Infections; Humans; Incidence; Italy; Kidney Diseases; Male; Middle Aged; Organophosphonates; Prevalence; Prospective Studies; Risk Factors; Severity of Illness Index; Sex Factors; Tenofovir | 2008 |
Renal function in Tenofovir-exposed and Tenofovir-unexposed patients receiving highly active antiretroviral therapy in the HIV Outpatient Study.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Creatinine; HIV Infections; Humans; Organophosphonates; Outpatients; Tenofovir | 2007 |
Molecular mechanisms of bidirectional antagonism between K65R and thymidine analog mutations in HIV-1 reverse transcriptase.
Topics: Adenine; DNA Repair; Drug Resistance, Multiple, Viral; Genetic Engineering; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Models, Molecular; Mutation; Organophosphonates; Protein Binding; Reverse Transcriptase Inhibitors; Tenofovir; Thymidine | 2007 |
Amprenavir and didanosine are associated with declining kidney function among patients receiving tenofovir.
Topics: Adenine; Adult; Age Factors; Analysis of Variance; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Weight; Carbamates; Creatinine; Didanosine; Drug Interactions; Female; Furans; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Kidney; Linear Models; Male; Middle Aged; Organophosphonates; Sulfonamides; Tenofovir; Time Factors | 2007 |
Causes and consequences of hypokalemia in patients on tenofovir disoproxil fumarate.
Topics: Adenine; Adult; Cause of Death; Drug Monitoring; Drug Synergism; Fanconi Syndrome; Female; Guideline Adherence; HIV Infections; HIV-1; Humans; Hypokalemia; Male; Middle Aged; Organophosphonates; Product Surveillance, Postmarketing; Reverse Transcriptase Inhibitors; Tenofovir | 2007 |
Effect of tenofovir on renal glomerular and tubular function.
Topics: Adenine; Anti-Retroviral Agents; Case-Control Studies; Cross-Sectional Studies; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Kidney Diseases; Kidney Glomerulus; Kidney Tubules; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2007 |
Porphyria cutanea tarda in an HIV-1-infected patient after the initiation of tipranavir/ritonavir: case report.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Middle Aged; Organophosphonates; Porphyria Cutanea Tarda; Pyridines; Pyrones; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Tenofovir | 2007 |
HPV oral infection. Case report of an HIV-positive Nigerian sex worker.
Topics: Adenine; Adult; Alphapapillomavirus; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Dideoxynucleosides; Emtricitabine; Female; HIV Infections; Humans; Italy; Lamivudine; Lopinavir; Mouth Mucosa; Nigeria; Organophosphonates; Papillomavirus Infections; Pyrimidinones; Ritonavir; Sex Work; Stomatitis; Tenofovir; Treatment Refusal; Zidovudine | 2007 |
A second chance for microbicides.
Topics: Adenine; Adult; Anti-HIV Agents; Anti-Infective Agents; Clinical Trials as Topic; Female; HIV Infections; Humans; Organophosphonates; Prevalence; Rural Health Services; Sex Work; South Africa; Tenofovir; Vaginal Creams, Foams, and Jellies | 2007 |
Bone disease and pathologic fractures in a patient with tenofovir-induced Fanconi syndrome.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Diseases; Fanconi Syndrome; Female; Femoral Neck Fractures; HIV Infections; Humans; Middle Aged; Organophosphonates; Tenofovir | 2007 |
Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections.
Topics: Adenine; Animals; Anti-HIV Agents; Antiviral Agents; Cell Line; Female; Hepatitis B; Hepatitis B virus; HIV Core Protein p24; HIV Infections; HIV-1; Humans; Magnetic Resonance Spectroscopy; Male; Organophosphonates; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Inhibitors; Tenofovir | 2007 |
Early onset of tenofovir-induced renal failure: case report and review of the literature.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Antiretroviral Therapy, Highly Active; Biopsy; HIV Infections; Humans; Liver; Male; Organophosphonates; Renal Insufficiency; Tenofovir; Time Factors; Treatment Outcome | 2007 |
Adverse events experienced by three children taking tenofovir and didanosine in combination.
Topics: Adenine; Anti-HIV Agents; Child; Child, Preschool; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Male; Organophosphonates; Tenofovir; Viral Load | 2007 |
[Hypophosphatemia and multiple fractures in patient with human immunodeficiency virus infection treated with tenofovir].
Topics: Adenine; Adult; Fractures, Bone; HIV Infections; Humans; Hypophosphatemia; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2007 |
Hepatitis B virus and HIV coinfection: results of a survey on treatment practices and recommendations for therapy.
Topics: Adenine; Adult; Anti-Retroviral Agents; Antiviral Agents; Drug Therapy, Combination; Female; Guideline Adherence; Health Care Surveys; Hepatitis B Vaccines; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Practice Guidelines as Topic; Practice Patterns, Physicians'; Tenofovir; United States | 2007 |
Predictors and kinetics of occult hepatitis B virus infection in HIV-infected persons.
Topics: Adenine; Adult; Alanine Transaminase; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biomarkers; Carrier State; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cohort Studies; DNA, Viral; Female; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Core Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; HIV Infections; HIV-1; Humans; Lamivudine; London; Male; Organophosphonates; Prevalence; Tenofovir | 2007 |
Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Antineoplastic Agents, Phytogenic; Antiretroviral Therapy, Highly Active; Area Under Curve; Camptothecin; Drug Therapy, Combination; HIV Infections; Humans; Irinotecan; Lamivudine; Lopinavir; Male; Middle Aged; Organophosphonates; Pyrimidinones; Ritonavir; Sarcoma, Kaposi; Tenofovir; White People | 2008 |
Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis.
Topics: Adenine; Administration, Oral; Adult; Alkynes; Anti-Retroviral Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; Genitalia, Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Tenofovir; Zidovudine | 2007 |
Variations in reverse transcriptase and RNase H domain mutations in human immunodeficiency virus type 1 clinical isolates are associated with divergent phenotypic resistance to zidovudine.
Topics: Adenine; Amino Acid Sequence; Deoxycytidine; Drug Resistance, Multiple, Viral; Genetic Variation; HIV Infections; HIV-1; Humans; Molecular Sequence Data; Mutation; Organophosphonates; Phenotype; Ribonuclease H; RNA-Directed DNA Polymerase; Sequence Homology, Amino Acid; Tenofovir; Zidovudine | 2007 |
Diverse approaches useful for microbicide trials.
Topics: Adenine; Animals; Anti-HIV Agents; Anti-Infective Agents; Bias; Clinical Trials as Topic; Female; HIV Infections; Humans; Male; Organophosphonates; South Africa; Tenofovir | 2007 |
Is phosphatemia the best tool to monitor renal tenofovir toxicity?
Topics: Adenine; Biomarkers; Creatinine; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Diseases; Kidney Tubules; Organophosphonates; Phosphates; Tenofovir | 2007 |
Semen quality and drug concentrations in seminal plasma of patients using a didanosine or didanosine plus tenofovir containing antiretroviral regimen.
Topics: Adenine; Adult; Anti-HIV Agents; Cross-Sectional Studies; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Semen; Sperm Motility; Spermatozoa; Tenofovir | 2007 |
Increased beta-2 microglobulinuria in human immunodeficiency virus-1-infected children and adolescents treated with tenofovir.
Topics: Adenine; Adolescent; Adult; beta 2-Microglobulin; Child; Child, Preschool; Cross-Sectional Studies; Female; HIV Infections; Humans; Male; Organophosphonates; Proteinuria; Reverse Transcriptase Inhibitors; Tenofovir; Urine | 2007 |
CD4+ T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Tenofovir; Time Factors; Viral Load | 2007 |
Specificity enhancement with LC-positive ESI-MS/MS for the measurement of nucleotides: application to the quantitative determination of carbovir triphosphate, lamivudine triphosphate and tenofovir diphosphate in human peripheral blood mononuclear cells.
Topics: Adenine; Anti-HIV Agents; Cytidine Triphosphate; Deoxyguanine Nucleotides; Dideoxynucleosides; Dideoxynucleotides; HIV Infections; Humans; Lamivudine; Leukocytes, Mononuclear; Organophosphonates; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Tenofovir | 2008 |
Female-initiated prevention strategies key to tackling HIV.
Topics: Adenine; Africa South of the Sahara; Anti-HIV Agents; Condoms, Female; Diaphragm; Female; HIV Infections; Humans; Organophosphonates; Primary Prevention; Reverse Transcriptase Inhibitors; Rwanda; Tenofovir; Women | 2007 |
Tenofovir resistance among HIV-infected patients failing a fixed-dose combination of stavudine, lamivudine, and nevirapine in a resource-limited setting.
Topics: Adenine; Adult; Anti-HIV Agents; Cohort Studies; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Nevirapine; Organophosphonates; Stavudine; Tenofovir; Thailand; Treatment Outcome | 2007 |
Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Area Under Curve; Atazanavir Sulfate; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Male; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir | 2008 |
Selection of L74V mutation in reverse transcriptase of HIV-1 subtype D by a tenofovir DF-lamivudine based regimen.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Female; Follow-Up Studies; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2007 |
Reply to Crane et al., 'Amprenavir and didanosine are associated with declining kidney function among patients receiving tenofovir'.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney; Male; Organophosphonates; Retrospective Studies; Tenofovir | 2007 |
Congenital pyelectasis in children born from mothers on tenofovir containing therapy during pregnancy: report of two cases.
Topics: Adenine; Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Italy; Kidney; Male; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Tenofovir | 2007 |
Comparison of the induction of P-glycoprotein activity by nucleotide, nucleoside, and non-nucleoside reverse transcriptase inhibitors.
Topics: Adenine; Anti-HIV Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cell Proliferation; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Nucleosides; Nucleotides; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Up-Regulation | 2008 |
Intracellular metabolism of the nucleotide prodrug GS-9131, a potent anti-human immunodeficiency virus agent.
Topics: Adenine; Anti-HIV Agents; Diphosphates; Guanosine; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Lymphocyte Activation; Organophosphonates; Prodrugs; Reverse Transcriptase Inhibitors; Tenofovir | 2008 |
Acute renal failure after initiation of tenofovir disoproxil fumarate.
Topics: Acute Kidney Injury; Adenine; Anti-HIV Agents; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Tenofovir | 2007 |
Tenofovir nephrotoxicity: focusing research questions and putting them into clinical context.
Topics: Adenine; HIV Infections; Humans; Kidney Diseases; Kidney Tubules; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2008 |
Tenofovir DF plus lamivudine or emtricitabine for nonoccupational postexposure prophylaxis (NPEP) in a Boston Community Health Center.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Boston; Clinical Trials, Phase IV as Topic; Community Health Centers; Deoxycytidine; Disease Transmission, Infectious; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir; Treatment Outcome | 2008 |
Tenofovir-based rescue therapy for advanced liver disease in 6 patients coinfected with HIV and hepatitis B virus and receiving lamivudine.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Homosexuality, Male; Humans; Lamivudine; Liver Diseases; Male; Organophosphonates; Tenofovir; Transaminases; Viral Load | 2008 |
Can the new humanized mouse model give HIV research a boost.
Topics: Adenine; Administration, Intravaginal; Animals; Deoxycytidine; Disease Models, Animal; Disease Susceptibility; Drug Evaluation, Preclinical; Emtricitabine; Female; Hematopoietic Stem Cell Transplantation; HIV Infections; HIV-1; Humans; Liver Transplantation; Macaca mulatta; Mice; Mice, Inbred NOD; Mice, Inbred Strains; Mice, SCID; Organophosphonates; Radiation Chimera; Species Specificity; Tenofovir; Thymus Gland; Transplantation, Heterologous | 2008 |
Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice.
Topics: Adenine; Administration, Intravaginal; Animals; Anti-HIV Agents; Deoxycytidine; Disease Models, Animal; Drug Evaluation, Preclinical; Emtricitabine; Female; Fetal Tissue Transplantation; Genitalia, Female; Hematopoietic Stem Cell Transplantation; HIV Infections; HIV-1; Humans; Immunity, Mucosal; Liver Transplantation; Mice; Mice, Inbred Strains; Mice, SCID; Organophosphonates; Radiation Chimera; Species Specificity; Tenofovir; Thymus Gland; Transplantation, Heterologous | 2008 |
Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Female; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Kidney; Male; Organophosphonates; Switzerland; Tenofovir | 2007 |
Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system.
Topics: Adenine; Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Anti-HIV Agents; Child; Fanconi Syndrome; Female; HIV Infections; Humans; Incidence; Male; Middle Aged; Organophosphonates; Registries; Retrospective Studies; Risk Assessment; Survival Analysis; Tenofovir; United States; United States Food and Drug Administration | 2008 |
European CHMP issues positive opinion for Atripla.
Topics: Adenine; Adult; Anti-HIV Agents; Canada; Deoxycytidine; Drug Approval; Drug Combinations; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Europe; HIV Infections; HIV-1; Humans; Organophosphonates; Oxazines; United States | 2007 |
Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cost-Benefit Analysis; Cyclopropanes; Decision Trees; Deoxycytidine; Drug Costs; Emtricitabine; Health Care Costs; Health Resources; HIV Infections; HIV-1; Humans; Lamivudine; Models, Economic; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Time Factors; Treatment Outcome; Zidovudine | 2008 |
Urolithiasis under atazanavir boosted and tenofovir therapy: a case report.
Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; Atazanavir Sulfate; HIV Infections; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir; Urolithiasis; Viral Load | 2008 |
[Resolution of recalcitrant condyloma acuminata in a patient with human immunodeficiency virus treated with cidofovir].
Topics: Adult; Antiviral Agents; Cidofovir; Condylomata Acuminata; Cytosine; HIV Infections; Humans; Male; Organophosphonates; Penile Diseases | 2008 |
Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus.
Topics: Absorptiometry, Photon; Adenine; Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Density; Child; Female; HIV; HIV Infections; Humans; Male; Organophosphonates; Tenofovir | 2008 |
Syncope as a probable side effect to combination antiretroviral therapy initiated during primary HIV-1 infection.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Emtricitabine; HIV Infections; Humans; Male; Nevirapine; Organophosphonates; Syncope; Tenofovir | 2008 |
[Extensive oral condylomas treated by in situ cidofovir injection in an HIV patient].
Topics: Adult; Antiviral Agents; Cidofovir; Condylomata Acuminata; Cytosine; HIV Infections; Humans; Injections, Intralesional; Male; Mouth Diseases; Organophosphonates | 2008 |
Changing patterns in HIV reverse transcriptase resistance mutations after availability of tenofovir.
Topics: Adenine; Anti-HIV Agents; Didanosine; Drug Resistance, Multiple, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Organophosphonates; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir | 2008 |
Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Female; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Logistic Models; Male; Middle Aged; Organophosphonates; Point Mutation; Tenofovir | 2008 |
FDA grants tentative approval to first generic version of antiretroviral Viread.
Topics: Adenine; Anti-HIV Agents; Drug Approval; Drugs, Generic; HIV Infections; Humans; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; United States; United States Food and Drug Administration | 2008 |
European Commission approves Atripla.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Approval; Drug Combinations; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Emtricitabine; European Union; HIV Infections; Humans; Organophosphonates; Oxazines; Reverse Transcriptase Inhibitors; Tenofovir | 2008 |
Does tenofovir increase efavirenz hepatotoxicity?
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Chemical and Drug Induced Liver Injury; Cyclopropanes; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Tenofovir | 2008 |
[Acute renal failure associated with the use of tenofovir combined with atazanavir in patients with HIV infection].
Topics: Acute Kidney Injury; Adenine; Anti-HIV Agents; Atazanavir Sulfate; Drug Therapy, Combination; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Tenofovir | 2008 |
[Severe hypokalemia and tenofovir].
Topics: Adenine; Anti-HIV Agents; HIV Infections; Humans; Hypokalemia; Male; Middle Aged; Organophosphonates; Severity of Illness Index; Tenofovir | 2008 |
Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV-1-infected patients with multidrug-resistant virus: a multicentre pilot study.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Resistance, Multiple, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Pilot Projects; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Thymidine; Viral Load; Zidovudine | 2008 |
Partial immunological and mitochondrial recovery after reducing didanosine doses in patients on didanosine and tenofovir-based regimens.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Dose-Response Relationship, Drug; Drug Therapy, Combination; HIV Infections; Humans; Male; Mitochondria; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2008 |
K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenine.
Topics: Adenine; Antiviral Agents; Cell-Free System; Cloning, Molecular; Culture Techniques; Drug Resistance, Microbial; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Organophosphonates; RNA-Directed DNA Polymerase | 1995 |
AIDS research. New drug shows promise in monkeys.
Topics: Adenine; Animals; Antiviral Agents; HIV; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Macaca fascicularis; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Tenofovir | 1995 |
Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine.
Topics: Adenine; Animals; Antibodies, Viral; Antiviral Agents; Base Sequence; Cells, Cultured; HIV Infections; Humans; Injections, Subcutaneous; Leukocytes, Mononuclear; Lymph Nodes; Macaca fascicularis; Molecular Sequence Data; Organophosphonates; Organophosphorus Compounds; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Tenofovir | 1995 |
Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cytosine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; HIV Infections; Humans; Immunocompromised Host; Kidney; Kidney Function Tests; Male; Metabolic Clearance Rate; Middle Aged; Organophosphonates; Organophosphorus Compounds; Probenecid | 1995 |
Inhibitory effect of 9-(2-phosphonylmethoxyethyl)adenine on visna virus infection in lambs: a model for in vivo testing of candidate anti-human immunodeficiency virus drugs.
Topics: Adenine; Animals; Antibodies, Viral; Antiviral Agents; Brain; Cytopathogenic Effect, Viral; Disease Models, Animal; Drug Evaluation, Preclinical; HIV Infections; Leukocytes, Mononuclear; Organophosphonates; Sheep; Visna; Visna-maedi virus | 1995 |
Anticytomegaloviral activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viruria.
Topics: Adult; Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cytosine; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Urine | 1995 |
MDL 74,968, a new acyclonucleotide analog: activity against human immunodeficiency virus in vitro and in the hu-PBL-SCID.beige mouse model of infection.
Topics: Adenine; Animals; Antiviral Agents; Cell Line; Cells, Cultured; Didanosine; DNA, Viral; Guanine; HIV Infections; HIV-1; HIV-2; Humans; Male; Mice; Mice, SCID; Monocytes; Organophosphonates; Spleen; T-Lymphocytes; Zidovudine | 1996 |
More new drugs for HIV and associated infections.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Anti-Bacterial Agents; Antiviral Agents; Cidofovir; Clinical Trials as Topic; Cytomegalovirus Retinitis; Cytosine; HIV Infections; Humans; Isoquinolines; Nelfinavir; Nevirapine; Organophosphonates; Organophosphorus Compounds; Protease Inhibitors; Pyridines; Ritonavir; Sulfonic Acids | 1997 |
Resolution of recalcitrant molluscum contagiosum virus lesions in human immunodeficiency virus-infected patients treated with cidofovir.
Topics: Adult; Antiviral Agents; Cidofovir; Cytosine; HIV Infections; Humans; Male; Molluscum Contagiosum; Organophosphonates; Organophosphorus Compounds; Remission Induction | 1997 |
New treatments for progressive multifocal leukoencephalopathy in HIV-1-infected patients.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Cidofovir; Cytosine; Drug Therapy, Combination; HIV Infections; Humans; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Treatment Outcome | 1998 |
Administration of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) for prevention of perinatal simian immunodeficiency virus infection in rhesus macaques.
Topics: Adenine; Animals; Animals, Newborn; Anti-HIV Agents; Antibodies, Viral; Cesarean Section; Chimera; Drug Administration Schedule; Female; HIV; HIV Infections; Humans; Macaca mulatta; Organophosphonates; Organophosphorus Compounds; Pregnancy; RNA, Viral; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Tenofovir; Treatment Outcome | 1998 |
Three new drugs for HIV infection.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System Diseases; Cyclopropanes; Dideoxynucleosides; Dizziness; Drug Therapy, Combination; Headache; HIV Infections; Humans; Organophosphonates; Oxazines; Reverse Transcriptase Inhibitors | 1998 |
Hydroxyurea potentiates the antiherpesvirus activities of purine and pyrimidine nucleoside and nucleoside phosphonate analogs.
Topics: Animals; Antiviral Agents; Cell Division; Cell Survival; Chlorocebus aethiops; Drug Synergism; Herpesvirus 1, Human; HIV Infections; Humans; Hydroxyurea; Nucleic Acid Synthesis Inhibitors; Nucleosides; Organophosphonates; Purine Nucleosides; Pyrimidine Nucleosides; Vero Cells; Virus Replication | 1999 |
Adefovir dipivoxil. Bis-POM PMEA, GS 0840, GS 840, Piv2PMEA.
Topics: Adenine; Animals; Anti-HIV Agents; Biological Availability; Cytomegalovirus; Cytomegalovirus Infections; Double-Blind Method; Drugs, Investigational; HIV Infections; Humans; Macaca fascicularis; Male; Organophosphonates; Protein Binding; Randomized Controlled Trials as Topic; Semen | 1999 |
Compassionate use for tenofovir.
Topics: Adenine; Anti-HIV Agents; Clinical Trials as Topic; Drug Approval; HIV Infections; Humans; Organophosphonates; Patient Selection; Tenofovir | 2000 |
NDA submitted for adefovir.
Topics: Adenine; Carnitine; Drug Approval; Drug Packaging; Drug Therapy, Combination; HIV Infections; Humans; Organophosphonates; Reverse Transcriptase Inhibitors; United States; United States Food and Drug Administration | 1999 |
Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: clinical and genotypic predictors of virologic response.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiviral Agents; Benzoxazines; Codon; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; HIV Infections; Humans; Logistic Models; Male; Middle Aged; Mutation; Organophosphonates; Oxazines; Protease Inhibitors; Retrospective Studies; Reverse Transcriptase Inhibitors; Salvage Therapy; Treatment Outcome; Viral Load | 2000 |
Early HIV infection in vivo: branching-process model for studying timing of immune responses and drug therapy.
Topics: Adenine; Animals; Anti-HIV Agents; Computer Simulation; Disease Progression; HIV; HIV Infections; Humans; Macaca; Macrophages; Models, Immunological; Organophosphonates; Organophosphorus Compounds; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Soman; Stochastic Processes; Tenofovir; Time Factors; Viral Load | 2000 |
Promising results for tenofovir.
Topics: Adenine; Clinical Trials, Phase II as Topic; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2000 |
Progressive multifocal leukoencephalopathy treated with cidofovir in HIV-infected patients receiving highly active anti-retroviral therapy.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Antiviral Agents; Cidofovir; Cytosine; Female; HIV Infections; HIV-1; Humans; Leukoencephalopathy, Progressive Multifocal; Male; Organophosphonates; Organophosphorus Compounds | 2000 |
The treatment pipeline: new therapies are on the way.
Topics: Adenine; AIDS Vaccines; Anti-HIV Agents; Enfuvirtide; Granulocyte-Macrophage Colony-Stimulating Factor; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV Protease Inhibitors; Humans; Interleukin-2; Organophosphonates; Peptide Fragments; Ritonavir | 1999 |
Post-exposure chemoprophylaxis (PECP) against SIV infection of macaques as a model for protection from HIV infection.
Topics: Adenine; Animals; Disease Models, Animal; DNA, Viral; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Macaca fascicularis; Organophosphonates; Organophosphorus Compounds; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Tenofovir | 2000 |
Severe irreversible proximal renal tubular acidosis and azotaemia secondary to cidofovir.
Topics: Acidosis, Renal Tubular; Adult; Anti-HIV Agents; Cidofovir; Cytosine; HIV Infections; Humans; Male; Organophosphonates; Organophosphorus Compounds; Uremia | 2000 |
Failure of cidofovir therapy in progressive multifocal leukoencephalopathy unrelated to human immunodeficiency virus.
Topics: Anti-HIV Agents; Brain; Cidofovir; Cytosine; Female; HIV Infections; Humans; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Middle Aged; Organophosphonates; Organophosphorus Compounds; Treatment Failure | 2001 |
Resolution of recalcitrant human papillomavirus gingival infection with topical cidofovir.
Topics: Anti-Infective Agents, Local; Antiviral Agents; Cidofovir; Cytosine; Gingival Diseases; HIV Infections; Humans; Inclusion Bodies, Viral; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Papillomaviridae; Papillomavirus Infections | 2000 |
Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): Implications for HIV-1 infections of humans.
Topics: Adenine; Animals; Anti-HIV Agents; CD4 Lymphocyte Count; Chimera; Digestive System; Disease Progression; Drug Resistance, Microbial; HIV Infections; HIV-1; Lentivirus Infections; Lymphoid Tissue; Macaca mulatta; Macrophages; Organ Specificity; Organophosphonates; Reverse Transcriptase Inhibitors; RNA, Viral; Simian Immunodeficiency Virus; Tenofovir; Viral Load; Virus Replication | 2001 |
Mechanistic study on the cytostatic and tumor cell differentiation-inducing properties of 9-(2-phosphonylmethoxyethyl)adenine (PMEA, adefovir)-collected publications.
Topics: Adenine; Animals; Antineoplastic Agents; Antiviral Agents; Cell Differentiation; Cell Division; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Hepatitis B; HIV Infections; Humans; Neoplasms; Organophosphonates; Rats; Tumor Cells, Cultured | 2000 |
Development of virus-specific immune responses in SHIV(KU)-infected macaques treated with PMPA.
Topics: Adenine; Animals; Anti-HIV Agents; Antibodies, Viral; Disease Models, Animal; HIV Antibodies; HIV Infections; HIV-1; Humans; Macaca mulatta; Neutralization Tests; Organophosphonates; Organophosphorus Compounds; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Helper-Inducer; Tenofovir; Virus Replication | 2001 |
Topical cidofovir for bowenoid papulosis in an HIV-infected patient.
Topics: Adult; Antineoplastic Agents; Antiviral Agents; Anus Neoplasms; Carcinoma in Situ; Carcinoma, Squamous Cell; Cidofovir; Cytosine; HIV Infections; Humans; Male; Organophosphonates; Organophosphorus Compounds | 2001 |
CDC to revisit AZT, post-exposure guidelines. Centers for Disease Control and Prevention.
Topics: Adenine; Antiviral Agents; Blood-Borne Pathogens; Centers for Disease Control and Prevention, U.S.; Guidelines as Topic; Health Personnel; HIV Infections; Humans; Macaca; Needlestick Injuries; Occupational Exposure; Organophosphonates; Zidovudine | 1996 |
Update on other antivirals.
Topics: Adenine; Antiviral Agents; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Organophosphonates; Stavudine; Zalcitabine; Zidovudine | 1996 |
Anti-HIV agents at ICAAC.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; CD4 Lymphocyte Count; Cidofovir; Cytomegalovirus Retinitis; Cytosine; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Isoquinolines; Kidney; Mutation; Nelfinavir; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sulfonic Acids; Treatment Failure; Viral Load | 1996 |
Update on antivirals.
Topics: Adenine; Anti-HIV Agents; Brazil; CD4 Lymphocyte Count; Clinical Trials as Topic; Dosage Forms; Drug Resistance, Microbial; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Infusions, Intravenous; Organophosphonates; Organophosphorus Compounds; Saquinavir; Tenofovir; Viral Load | 1997 |
Scientific basis for PEP rests in animal trials.
Topics: Adenine; Animals; Anti-HIV Agents; Centers for Disease Control and Prevention, U.S.; Health Personnel; HIV; HIV Infections; Humans; Macaca; Nevirapine; Occupational Diseases; Organophosphonates; Organophosphorus Compounds; Pan troglodytes; Pyridines; Reverse Transcriptase Inhibitors; Simian Immunodeficiency Virus; Tenofovir; United States; Zidovudine | 1997 |
Looking down the drug pipeline.
Topics: Adenine; Animals; Anti-HIV Agents; Biological Availability; Chlorobenzenes; Clinical Trials as Topic; Codon; Dideoxyadenosine; Drug Resistance, Microbial; Drugs, Investigational; Granulocyte-Macrophage Colony-Stimulating Factor; HIV Infections; HIV Protease Inhibitors; Humans; Naphthalenes; Organophosphonates; Pyrimidinones; Receptors, CCR5; Receptors, CXCR4; Reverse Transcriptase Inhibitors; Tenofovir | 1998 |
A rocky road for nucleotide analogs.
Topics: Adenine; AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Clinical Trials as Topic; Cytomegalovirus Retinitis; Cytosine; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds | 1998 |
Neurology update.
Topics: AIDS Dementia Complex; Anti-HIV Agents; Antiviral Agents; Brain; Cerebrospinal Fluid; Chicago; Cidofovir; Clinical Trials as Topic; Cohort Studies; Congresses as Topic; Cytosine; HIV Infections; Humans; Leukoencephalopathy, Progressive Multifocal; Mutation; Organophosphonates; Organophosphorus Compounds; RNA, Viral; Viral Load | 1999 |
Lower doses of adefovir dipivoxil (Preveon).
Topics: Adenine; Anti-HIV Agents; CD4 Lymphocyte Count; Dose-Response Relationship, Drug; Drug Therapy, Combination; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 1999 |
Expanded access.
Topics: Adenine; Anti-HIV Agents; Carbamates; Drug Approval; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Organophosphonates; Reverse Transcriptase Inhibitors; Sulfonamides; Treatment Failure; United States; United States Food and Drug Administration | 1999 |
Upcoming compassionate use programs for two new antiretrovirals will begin this fall.
Topics: Adenine; Anti-HIV Agents; Clinical Trials as Topic; Drug Approval; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Organophosphonates; Organophosphorus Compounds; Patient Selection; Pyrimidinones; Reverse Transcriptase Inhibitors; Tenofovir | 1999 |
Expanded access.
Topics: Adenine; Anti-HIV Agents; Drug Approval; Drugs, Investigational; Health Services Accessibility; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Organophosphonates; Organophosphorus Compounds; Pyrimidinones; Reverse Transcriptase Inhibitors; Tenofovir | 1999 |
CRIA clinical trials.
Topics: Adenine; Alkynes; Anabolic Agents; Anti-HIV Agents; Benzoxazines; Blood Glucose; Clinical Trials as Topic; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Male; Organophosphonates; Oxandrolone; Oxazines; Patient Selection; Reverse Transcriptase Inhibitors; Weight Loss | 1998 |
[Once daily administration improves therapy adherence in HAART. New substance class with more powerful reserves against virus resistance].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Administration Schedule; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2001 |
Tenofovir ready for approval.
Topics: Adenine; Anti-HIV Agents; Drug Approval; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Tenofovir; United States; United States Food and Drug Administration | 2001 |
Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion.
Topics: Acute Kidney Injury; Adenine; Adult; Antiviral Agents; Cytochrome-c Oxidase Deficiency; Dissection; DNA, Mitochondrial; Drug Therapy, Combination; Electron Transport Complex IV; HIV Infections; Humans; Immunoenzyme Techniques; Kidney Tubules, Proximal; Male; Micromanipulation; Mitochondria; Necrosis; Organophosphonates; Polymerase Chain Reaction; Succinate Dehydrogenase | 2001 |
Tenofovir, adefovir, and zidovudine susceptibilities of primary human immunodeficiency virus type 1 isolates with non-B subtypes or nucleoside resistance.
Topics: Adenine; Anti-HIV Agents; Drug Resistance, Microbial; HIV Infections; HIV-1; Humans; Microbial Sensitivity Tests; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir; Zidovudine | 2001 |
Encouraging results for tenofovir.
Topics: Adenine; Clinical Trials, Phase III as Topic; HIV Infections; HIV-1; Humans; Organophosphonates; Organophosphorus Compounds; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2001 |
Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study.
Topics: Adenine; Adult; Alanine Transaminase; Anti-HIV Agents; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Drug Resistance, Microbial; Female; Hepatitis B; Hepatitis B virus; HIV Infections; HIV-1; Humans; Lamivudine; Male; Organophosphonates; Pilot Projects; Viral Load | 2001 |
Tenofovir: Gilead applies for approval; expanded access liberalized.
Topics: Adenine; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Approval; Drug Industry; Health Services Accessibility; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir; United States; United States Food and Drug Administration; Viral Load | 2001 |
Tenofovir: FDA hearing October 3, public comment deadlines September 26.
Topics: Adenine; Anti-HIV Agents; Drug Approval; Drug Resistance, Microbial; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Patient Compliance; Reverse Transcriptase Inhibitors; Tenofovir; United States; United States Food and Drug Administration | 2001 |
Tenofovir: FDA hearing on important new antiretroviral.
Topics: Adenine; Drug Approval; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir; United States; United States Food and Drug Administration | 2001 |
Tenacious tenofovir struts its stuff in a virtual ICAAC.
Topics: Adenine; Clinical Trials as Topic; Drug Interactions; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir | 2001 |
From the Food and Drug Administration.
Topics: Adenine; Administration, Oral; Anti-HIV Agents; Cathartics; Defibrillators, Implantable; HIV Infections; HIV-1; Humans; Monitoring, Ambulatory; Organophosphonates; Organophosphorus Compounds; Pacemaker, Artificial; Pharmaceutical Solutions; Phosphates; Tenofovir; United States; United States Food and Drug Administration; Viral Load; Water-Electrolyte Imbalance | 2001 |
Expanded access to tenofovir.
Topics: Adenine; Canada; Europe; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir; United States | 2001 |
Cidofovir for KS lesions.
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Cidofovir; Cytosine; Dose-Response Relationship, Drug; Herpesvirus 8, Human; HIV Infections; Humans; Italy; Male; Organophosphonates; Organophosphorus Compounds; Sarcoma, Kaposi | 2001 |
Tenofovir approved: broad indication.
Topics: Adenine; Drug Approval; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir; United States; United States Food and Drug Administration | 2001 |
Prodrug of tenofovir diphosphate approved for combination HIV therapy.
Topics: Adenine; Anti-HIV Agents; Biological Availability; Drug Approval; Drug Therapy, Combination; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Prodrugs; Tenofovir; United States; United States Food and Drug Administration | 2002 |
More uses for tenofovir?
Topics: Adenine; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir | 2001 |
Nutrient deficiency associated with new HIV medication.
Topics: Adenine; HIV Infections; Humans; Nutrition Disorders; Organophosphonates; Organophosphorus Compounds; Phosphorus; Reverse Transcriptase Inhibitors; Tenofovir | 2002 |
Gilead sciences releases Viread.
Topics: Adenine; Drug Approval; Drug Industry; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir; United States; United States Food and Drug Administration | 2002 |
New antiretroviral for HIV infection.
Topics: Adenine; Anti-HIV Agents; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2002 |
Herpes simplex virus isolates with reduced adefovir susceptibility selected in vivo by foscarnet therapy.
Topics: Adenine; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Foscarnet; Herpes Genitalis; Herpes Simplex; Herpesvirus 1, Human; Herpesvirus 2, Human; HIV Infections; Humans; Organophosphonates; Reverse Transcriptase Inhibitors | 2002 |
Human immunodeficiency virus (HIV) Type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors | 2002 |
[Tenofovir--a new option for combination therapy].
Topics: Adenine; Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2002 |
[No comparison with NRTI. Tenofovir is robust against resistance trouble].
Topics: Acquired Immunodeficiency Syndrome; Adenine; Anti-HIV Agents; Drug Resistance, Viral; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2002 |
[Nucleotide analog shows effectiveness in previously treated patients. The new kind of HAART].
Topics: Acquired Immunodeficiency Syndrome; Adenine; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Clinical Trials as Topic; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Tenofovir; Viral Load | 2002 |
[First nucleotide analog on the market. New drug for the pretreated patient].
Topics: Acquired Immunodeficiency Syndrome; Adenine; Anti-HIV Agents; Drug Approval; Drug Therapy, Combination; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2002 |
Drugs in development.
Topics: Adenine; Anti-HIV Agents; Clinical Trials as Topic; Cyclic N-Oxides; HIV Infections; Humans; Nitriles; Organophosphonates; Organophosphorus Compounds; Oximes; Piperidines; Pyridazines; Pyridines; Pyrimidines; Tenofovir | 2002 |
8th European Conference on Clinical Aspects and Treatment of HIV Infection, Athens, 28-31 October 2001.
Topics: Adenine; Anti-HIV Agents; Greece; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2002 |
A case of flare syndrome.
Topics: Acute Disease; Adult; AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Cidofovir; Cytomegalovirus Retinitis; Cytosine; Drug Therapy, Combination; Ganciclovir; HIV Infections; Humans; Indinavir; Lamivudine; Male; Organophosphonates; Organophosphorus Compounds; Zidovudine | 2001 |
Adefovir nephrotoxicity and mitochondrial DNA depletion.
Topics: Adenine; Antiviral Agents; Clinical Trials, Phase III as Topic; Cyclooxygenase Inhibitors; DNA, Mitochondrial; Drug Therapy, Combination; HIV Infections; Humans; Hydroxyurea; Kidney Tubules; Mitochondria; Organophosphonates; Renal Insufficiency; Stavudine | 2002 |
Different pattern of activity of inhibitors of the human immunodeficiency virus in lymphocytes and monocyte/macrophages.
Topics: Adenine; Antibodies, Viral; Antiviral Agents; Benzodiazepines; CD4 Antigens; Cytokines; Didanosine; Doxorubicin; Drug Interactions; HIV; HIV Infections; Humans; Imidazoles; Leukocytes, Mononuclear; Lymphocytes; Macrophages; Monocytes; Organ Specificity; Organophosphonates; Zalcitabine; Zidovudine | 1992 |